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Abstract 
To develop targeted brain tumour therapies that carry fewer side effects it is essential to 
understand brain tumour histogeneiss and identify the cell of origin. It has been 
suggested that neoplastic transformation of neural stem/progenitor cells in the adult 
brain can result in the development of intrinsic brain tumours. Using the Cre-LoxP 
system we have developed a model that allows us to inactivate tumour suppressor genes 
Rb, p53 and PTEN in neural stem/progenitor cells both in vivo and in vitro. 
In vivo recombination of these tumour suppressor genes in neural stem/progenitor cells 
resulted in the formation of intrinsic brain tumours, with the phenotype depending on 
the combination of recombined genes. Intracerebral engraftment of in vitro recombined 
neural stem/progenitor cells produced a similar tumour phenotype pattern. However, 
while in vivo recombination of Rb and p53 frequently caused brain tumours, in vitro 
recombined and engrafted Rb-/-; p53-/- neurospheres rarely generated tumours. The 
converse was true following in vivo recombination of Rb and PTEN. These results 
suggest that microenvironment influences tumour formation. 
An increased number of tumourigenic neural stem/progenitor cells expressed the cancer 
stem cell marker CD133 when compared to control cells. In vivo engraftment of purified 
CD133+ Rb-/-; p53-/-; PTEN-/- neural stem/progenitor cells resulted in the preferential 
development of gliomas. We also showed that astrocytes are not capable of forming 
tumours following either orthotopic recombination or in vitro recombination and 
engraftment. 
In conclusion, we found that (i) certain phenotypes of brain tumours develop from 
neural stem/progenitor cells in the subventricular zone, (ii) the combination of 
inactivated tumour suppressor genes is the most significant but not sole determinant of 
in vitro functional profile and behaviour in vivo, (iii) the cellular microenvironment of 
neural stem/progenitor cells influences their tumourigenic profile, and (iv) terminally 
differentiated astrocytes do not contribute to tumour development in this model. 
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1 Introduction 
Cancers of the central nervous system (CNS) globally account for 189,000 new cases 
and 142,000 deaths annually. These figures represent 1.7% of all new cancer cases and 
2.1% of the total number of cancer deaths (Parkin et al., 2005). Despite these relatively 
low percentages, they carry a disproportionate and devastating level of morbidity and 
mortality. To put this into perspective, around 43,800 new brain tumour cases are 
diagnosed in the United States every year, and one in four of these patients will die 
(Buckner et al., 2007). The incidence of brain tumours in the United States is 14.8 per 
100,000 person-years, and is increasing year on year (Central Brain Tumor Registry of 
the United States, 2006). Malignant primary brain tumours remain the leading cause of 
death from solid tumours in children, and the third leading cause of death from cancer in 
adolescents (Jemal et al., 2007). Cancer Research UK estimates that in 2005 in the 
United Kingdom there were around 3500 deaths from brain tumours, which accounted 
for 2% of all cancer deaths (Office for national statistics UK, 2008). Brain tumours are 
estimated to represent 1.4% of all cancers, 2.4% of all cancer deaths, ~20% of paediatric 
cancers, and are the commonest tumour-related cause of death in children. In addition to 
this, the tumour incidence is increasing by 2.7% per year in UK children (Office for 
national statistics UK, 2008). The survival rate in UK children is 60%, and although 
there is no specific clinical symptom or sign for brain tumours, slowly progressive focal 
neurologic signs and signs of elevated intracranial pressure can be symptomatic (Clark 
et al., 1985). 
Brain tumours represent the most common form of solid malignancy in children and due 
to often innocuous sub-clinical symptoms, difficulties in diagnosis, limited treatment 
options, unpredictable treatment efficacy, and tumour recurrence, they remain a major 
cause of morbidity and mortality in adults. Despite the variation between the different 
tumour phenotypes they are generally extremely difficult to treat and their diagnosis 
often carries a poor prognosis. This is due in part to their ability to grow insidiously and 
diffusely throughout the brain parenchyma and to the fact they often clinically present 
with non-specific symptoms. The most common malignant brain tumour is glioblastoma 
(WHO grade IV glioma), which also accounts for 40% of all primary malignant CNS 
tumours (Miller and Perry, 2007). Glioblastoma patients have a median survival rate of 
approximately 12 months (Laks et al., 2010) despite aggressive surgical resection, 
chemotherapy and local radiotherapy (Krex et al., 2007; Smith and Jenkins, 2000). In 
order to develop effective therapeutic treatment regimens it is important to identify the 
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“cell of origin” from which brain tumours arise, and to define the cellular and molecular 
events that occur during tumourigenesis. Despite detailed genetic and morphological 
studies, the cell of origin of most CNS tumours is not known or has been previously 
assumed based on indirect inferences such as anatomical location. The differentiation 
stage at which a cell undergoes transformation may have important implications for the 
phenotype of brain tumours and it may also give important clues about the histogenesis 
and molecular pathogenesis of the tumours. It remains unclear as to whether brain 
tumour phenotype is influenced more greatly by the combination of genetic mutations a 
neoplastic cell contains or by the type of cell in which these mutations occur. Only a 
small number of models have been established in which early stages of tumourigenesis 
can be studied, and for which the histogenesis of brain tumours has been described. 
To this end, we developed a mouse model that allows us to conditionally knock-out 
different combinations of the tumour suppressor genes (TSGs) Rb, p53, and PTEN in a 
variety of cell types both in vivo and in vitro in the aim of generating tumour-initiating 
cells and characterising their functional profiles. This was achieved using the Cre-LoxP 
system through which Adenovirus-Cre-mediated recombination allowed us to study the 
downstream effects of conditionally knocking-out the different TSGs with regards to 
tumourigenesis. 
 
1.0  Neurogenesis 
Adult neurogenesis results in the production of new functional neurons in the adult 
brain, produced from asymmetric cell division of neural stem and progenitor cells. After 
such asymmetric division, various factors such as migration, differentiation, and the 
cellular expression profile determine the fate of the cell. Neurogenesis applies 
specifically to the production of new neurons but is a term that is often used to 
encompass the production of glia (gliogenesis) and oligodendrocytes (oligogenesis). 
The work of Peter Eriksson in 1998 dispelled the dogma surrounding the lack of 
credibility of adult neurogenesis when he reported and characterised the birth of new 
neurons within the hippocampus of adult humans (Eriksson et al., 1998). At the turn of 
the 21st century, the heightened interest in stem cell biology, coined by many as the 
“stem cell revolution”, drove research into developmental neurobiology and brain 
plasticity. Neurogenesis is fundamental to both of these topics and hence the pioneering 
work of Altman and Eriksson was further validated throughout the first decade of the 
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21st century. Although the vast majority of pioneering research into neurogenesis 
studied the process in vivo, some groups perfected the ability to study it in vitro 
(Wichterle et al., 2002) by recapitulating and characterising the regulatory processes 
that drive embryonic stem cells toward a neuronal phenotype. Understanding 
neurogenesis not only provides us with insight into neuroplastic and stem cell disorders 
of the brain, it potentially paves the way towards understanding the ultimate therapeutic 
target of the brain in neuroregeneration. 
The work of His, Cajal, and Spielmeyer had never alluded to the presence of precursor 
cells in the brain or the ability of neurons to divide. Hence, Altman’s autoradiagraphical 
suggestions of neurogenesis in the 1960’s were met with considerable scepticism 
(Altman, 1963). It took additional experiments by Altman, supplemented with electron 
microscopy data from Kaplan (Kaplan and Hinds, 1977) before the notion of 
neurogenesis began to gather momentum. Despite this, scepticism remained throughout 
the 1980’s and until the late 1990’s. As interest in stem cell research grew so did the 
level of unorthodox research, as demonstrated by the proposal of neural 
transdifferentiation (Anderson et al., 2001). This concept suggested that stem cells could 
cross organ and germ layer borders so that NSCs could in fact migrate and divide into 
non-CNS cells (i.e. non-region-specific pluripotency); a hypothesis that continues to be 
disputed. 
To be considered neurogenic, a brain region must possess a) sufficient neural stem and 
progenitor cells from which new neuronal cells can develop, and b) a microenvironment 
conducive for neurogenesis. Confirmation of the second point was first achieved in the 
hippocampus and the olfactory system through verifying neurogenesis following in vivo 
implantation of neural precursor cells (Gage et al., 1995; Herrera et al., 1999; Lie et al., 
2002). However, it should also be noted that neurogenesis has been observed in ‘non-
neurogenic’ areas of the brain in response to damage, such as ischemic stroke 
(Arvidsson et al., 2002). 
 
1.1 Brain Tumours 
A brain tumour is any intracranial neoplasm created by abnormal and uncontrolled cell 
division. Primary brain tumours are derived from neural cells intrinsic to the brain (i.e. 
neurons, astrocytes, ependymal cells, oligodendrocytes and their progenitors), the brain 
envelopes (meninges), skull, pituitary or pineal gland, or even the from the portion of 
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cranial nerves that are myelinated by Schwann cells. Secondary brain tumours are those 
that have metastasised from cancers primarily located in other organs (Louis et al., 
2007). Brain tumours are named and classified according to the cell type that the tumour 
mass most closely resembles. For example, most primary brain tumours share features 
with glial cells (globally termed ‘gliomas’) and can be further classified as 
astrocytomas, oligodendrogliomas, or ependymomas depending on the cell they most 
closely resemble (e.g. astrocytes, oligodendrocytes, or ependymal cells). There are also 
mixed forms with, for example, both an astrocytic and an oligodendroglial cellular 
resemblance (an oligoastrocytoma). 
 
1.1.1 Classification of human brain neoplasms 
In 2007, the World Health Organisation (WHO) published a collaborative classification 
of tumours of the nervous system (Louis et al., 2007). This classification provides 
histopathological, immunohistochemical, and anatomical criteria to classify and grade 
brain tumours and predict their biological behaviour thus allowing for a standardised 
means of diagnosis/prognosis. This WHO classification grades tumours based on their 
malignancy in a scale from I to IV (Louis et al., 2007; Kleihues et al., 1993). For 
example, grade I glioma lesions are generally benign tumours with a low proliferative 
potential and can typically be cured with surgical resection alone. Grade II gliomas also 
proliferate slowly but show abnormal nuclei (atypia) and in case of intrinsic tumours, 
often grow infiltrativey. These tumours tend to recur after surgical resection, often 
transforming to higher grades. Patients exhibiting grade II tumours typically survive for 
more than 5 years. Grade III gliomas show histological signs of malignancy including 
enhanced mitotic activity and nuclear atypia, with a median survival rate of 2-3 years. 
Grade IV gliomas are of the most malignant grade and are histologically defined by 
atypical nuclei, highly enhanced mitotic activity as well as necrosis and/or 
microvascular proliferation (Kleihues and Sobin, 2000). These tumours are rapidly fatal 
if untreated and the projected survival rate can be as little four months depending on the 
available treatment regimens (Louis et al., 2007). 
The most common intrinsic tumours of the CNS are gliomas. They occur in a variety of 
different tumour forms ranging from grade I to IV (Daumasduport et al., 1988). 
Astrocytic tumours represent the most common form of glioma and comprise pilocytic 
astrocytoma (grade I), diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III) 
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and glioblastoma (grade IV). Glioblastomas account for 12-15% of all intracranial 
neoplasms and 60-75% of all astrocytic tumours. They can arise de novo (95%) or from 
the malignant progression of a lower grade glioma (5%) (Ohgaki et al., 2004). The 
incidence rate in the USA is 2.96 new cases per 100,000 population per year and 
slightly higher in Europe with 3.55 new cases. Glioblastomas are highly infiltrative and 
completely resection risks serious brain damage. The same is true for grade II and III 
gliomas which are also diffusely infiltrative but just to a lesser extent. 
Ependymomas (WHO grade I–III) are primarily composed of glial tumour cells but are 
distinct from gliomas. They are relatively rare (accounting for 2-9% of all 
neuroepithelial tumours) and typically occur within the posterior fossa in children under 
4 years of age, while in adults they usually arise in the spinal canal. The five-year 
survival is 60%, however, the prognosis is much worse in children as the location is 
mostly intracranial (Auguste and Gupta, 2006). 
Medulloblastoma (WHO grade IV) is the most common malignant brain tumour of 
childhood, affecting 1 in 200,000 children less than 15 years old (Central Brain Tumor 
Registry of the United States, 1995). Medulloblastomas are referred to as embryonal 
tumours as they are comprised of undifferentiated cells that amass to resemble 
embryonic brain structures. It typically arises in the cerebellum and has a tendency to 
metastasise along the craniospinal axis (but not systemically). There have been 
significant advances in the treatment of childhood medulloblastoma which have seen 5-
year survival rise from 30% to 60-70% in recent years, but most patients suffer from 
severe long-term side effects (Central Brain Tumor Registry of the United States, 2005), 
mostly as a consequence of radiotherapy. 
There has been progress (albeit limited) in the treatment of brain tumours over the last 
ten years, with the introduction of concomitant adjuvant temozolomide into the 
established chemo/radiotherapy treatment regimes being the most notable advancement 
in glioma treatment. And as a result, the overall 3 year survival rate of newly diagnosed 
glioblastoma patients has increased four-fold from ~4% to ~16% (Scott et al., 1998; 
Stupp et al., 2009). However, surgical resection in combination with chemotherapy and 
radiotherapy remains the mainstay for many types of brain tumour. And although such a 
treatment stragtegy may provide the patient with a period of clinical remittance, ranging 
from 5 years in the case of diffuse astrocytoma (grade II) to as little as 4 months in 
glioblastoma (grade IV), clinically progressive relapse remains inevitable in many 
cases. This issue highlights the high levels of morbidity and mortality associated with 
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brain tumours and the current socio-economic burden they place on the healthcare 
systems around the world as “the fourth greatest impacting cancer” (Royds and 
Iacopetta, 2006). 
Hostorically, brain tumours were thought to derive from the neoplastic transformation 
of mature cell types such as astrocytes and oligodendrocytes. This was a result of the 
belief that the brain was a mitotically quiescent tissue with negligible neurogenesis. 
This model however failed to adequately explain the development of some tumours i.e. 
the mixed gliomas. There is now a growing body of evidence suggesting that brain 
tumours potentially originate from neoplastically transformed populations of 
stem/precursor cells that persist within the adult brain (Dirks, 2008; Zheng et al., 2008). 
This may ultimately explain why certain brain neoplasms show reproducible patterns of 
genetic mutations or why alterations in specific pathways are often associated with 
certain histological types of tumour. 
 
1.2 Stem Cells 
All of the organs in the body are primarily composed of terminally differentiated cells 
that perform specialised functions. These cells can stop functioning if they enter 
senescence or undergo apoptosis in response to stress. An homeostatic mechanism 
exists to regulate the replacement of these lost cells in order to maintain the 
functionality of the particular organ (Miller et al., 2005). This mechanism is governed 
by primitive progenitor cells, which are able to reproduce for the life of the organ. 
These cells can be characterised by several hallmark features: stem cells are (i) localised 
to specific niches capable of cell genesis, (ii) represent a very small subpopulation of 
cells within an organ, (iii) are undifferentiated and ultrastructurally unspecialised, (iv) 
are capable of self-renewal, (v) mostly multipotent (the ability to generate a diversity of 
differentiated cells), (vi) are slow cycling and divide infrequently, and (vii) have a 
proliferative capacity that exceeds the life of the organ (Miller et al., 2005). 
Stem cells must maintain their own population in addition to those of the terminally 
differentiated cell type lineages (Watt and Hogan, 2000). This can be achieved through 
symmetrical (producing two clonal stem cells) or asymmetrical (producing one clonal 
stem cell and one daughter cell programmed to differentiate into a non-stem cell fate) 
cell division. Asymmetrical cell division allows stem cells to both self-renew and 
regulate the different cell populations of the stem cell niche. It involves the stepwise 
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generation of daughter cells that are progressively and irreversibly committed to 
differentiation along non-stem cell lineages. In a simplified model system, a stem cell 
will typically divide to produce two daughter cells, one of which will remain as a true 
stem cell in the stem cell niche, and the other may leave the niche as a more 
differentiated progenitor cell. This progenitor may not be capable of self-renewal but is 
highly proliferative and can undergo further reproductive divisions through which an 
exponentially increasing number of increasingly differentiated daughter cells can be 
generated (Figure 1). These daughter cells progressively lose their stem cell 
characteristics and acquire lineage-specific fates until they become terminally 
differentiated mature cells (Vescovi et al., 2006).  
 
 
Figure 1: Stem cell compartment hierarchy. S: neural stem cell, P1: early transient-amplifying 
progenitor cell, P2: late transient-amplifying progenitor cell, T: terminally differentiated cell. 
 
Mounting evidence suggests that extrinsic factors, such as microenvironment (e.g. 
growth factors), play a critical role in the regulation and coordination of asymmetrical 
stem cell division, rather than the intrinsic properties of the cells themselves (Alvarez-
Buylla and Lim, 2004). 
Embryonic stem (ES) cells are pluripotent (the ability to generate all the cells of the 
body) and exist within the inner cell mass of the blastocyst. ES cells can be propagated 
in vitro and would provide an excellent cellular model for human disease but their 
derivation from human embryos raises ethical concerns. However, the pluripotency of 
ES cells means that they can generate tumours containing cells of all three germ layers 
such as teratomas and teratocarcinomas in vivo (Reubinoff et al., 2000; Asano et al., 
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2003). Neural precursor cells have been successfully generated from ES cells in vitro 
(Brustle et al., 1999; Lee et al., 2000; Zhang et al., 2001). These precursor cells behave 
like NSCs in vivo as they are capable of developing into functioning neurons and glia 
(Brustle et al., 1999). The restricted neural differentiation portfolio (e.g. neurons, glia, 
and oligodendrocytes) makes NSCs multipotent rather than pluripotent. 
 
1.3 Neural Stem Cells 
In recent times, the opinion over the regenerative capacity of the adult mammalian brain 
has changed dramatically. Historically the brain was thought of as an end-point in 
neurodevelopment whereby it was composed of postmitotic, fully differentiated cells. 
Although a few reports in the 1950s – 1970s described mitotic activity as a hypothetical 
measure of neurogenesis in the postnatal rodent brain (Messier et al., 1958; Altman and 
Das, 1965; Dacey and Wallace, 1974), it wasn’t until the 1990’s that it was 
convincingly proven that neurogenesis occurs in the adult brain of rats (Luskin, 1993; 
Lois and Alvarezbuylla, 1993), canaries  (Alvarez-Buylla et al., 1998), monkeys (Gould 
et al., 1998), and humans (Kirschenbaum et al., 1994; Eriksson et al., 1998; Kukekov et 
al., 1999). The brain is therefore no more an exception to general rules governing most 
of the other adult tissues, where reservoirs of self-renewing and multipotent cells are 
involved in the generation and repair of differentiated cells (Merkle and Alvarez-Buylla, 
2006). 
Neural stem cells (NSCs) can be defined by their unlimited ability to self-renew and 
give rise to at least one identical copy of the mother cells and/or daughter cells that are 
more determined for a particular differentiation lineage (Weissman et al., 2001), and by 
their multipotency. NSCs properties can be investigated in vitro by growing them in 
non-adherent conditions in medium rich in mitogens such as EGF and FGF-II (Gritti et 
al., 1996; Gritti et al., 1999; Doetsch et al., 2002). An interesting property of NSCs 
when grown in vitro is their propoensity to grow as spherical aggregates, termed 
neurospheres (NS). NSCs can be serially passaged and upon the removal of growth 
factors NSCs they differentiate into neurons, astrocytes and oligodendrocytes. These 
respective self-renewal and multipotency capacities are the primary indicators that a cell 
possesses stem-like characteristics. 
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1.3.1 Anatomical location of neural stem cells in the adult brain 
To date, five separate populations of NSCs have been characterised within the adult 
brain (Figure 2). They remain localised to specific regions, principally around the lateral 
ventricles (Alvarez-Buylla et al., 2002). The primary neural stem cell compartment 
(NSCC) is the subventricular zone (SVZ), a subependymal layer of cells (3-4 cells deep) 
that lines the walls of the lateral ventricles (Doetsch et al., 1999). The other germinal 
zones are located in the subcallosal zone (SCZ) between the corpus callosum and the 
hippocampus (Seri et al., 2006), the subgranular zone (SGZ) within the dentate gyrus of 
the hippocampus (Seri et al., 2001), between the internal granular layer (IGL) and the 
white matter of the cerebellum (Lee et al., 2005), and along the length of the rostral 
migratory stream (Pencea et al., 2001) (Figure 2). 
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Figure 2: Anatomical location of NSCs in the adult mouse brain (adapted from (Sutter et al., 2007). 
(1) The subventricular zone (SVZ) of the rostral portion of the lateral ventricles. (2) The subcallosal zone 
(SCZ) found between the corpus callosum and the hippocampus, and the subgranular zone (SGZ) within 
the dentate gyrus of the hippocampus. (3) Between the internal granular layer (IGL) and the white matter 
of the cerebellum (red dots).  
 
The largest of these areas is the SVZ (Figure 3) within which a structural hierarchy of 
NSC sub-classes has been characterised according to a proposed pinwheel architecture 
(Doetsch et al., 1999; Mirzadeh et al., 2008). 
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Figure 3: Hierarchical cellular organisation of the subventricular zone in the adult mouse. (A) 
Coronal cross-section of the mouse brain: NSCs (shown as blue circles) are located in the SVZ and can 
undergo neoplastic transformation resulting in the development of a brain tumour (shown as red circles). 
(B) Differentiation hierarchy of the NSC sub-classes within the SVZ. (C) Schematic representation of the 
spatial organisation of the NSC sub-classes within the SVZ (Alvarez-Buylla and Lim, 2004). (D) H&E 
stain of the wild-type mouse SVZ depicting the spatial organisation of the NSC sub-classes. H&E image 
was taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 
40x objective and using the AnalySIS software package. E: ependymal cells, A: Type A neuroblasts, B: 
Type B astrocytes, C: Type C transient-amplifying progenitor cells, LV: lateral ventricles. 
 
The type B astrocytes represent the least differentiated form of NSC and are thought to 
be slow-growing, derived from radial glia (Merkle et al., 2004), and responsible for the 
generation of all neuroblasts and new neurons in the adult mouse forebrain (Denise et 
al., 2004). Although their specific origin remains unclear it has been postulated that they 
could originate from radial glial cells (Vescovi et al., 2006; Doetsch, 2003). These type 
B type cells divide slowly and can undergo asymmetric division to differentiate into 
highly proliferative transiently amplifying type C progenitor cells, which proliferate 
rapidly and can in turn can differentiate into type A young neuroblasts (Alvarez-Buylla 
et al., 2002). Type A cells are restricted to a neuronal fate and migrate along the rostral 
migratory stream (RMS) until they reach the olfactory bulb where they differentiate into 
interneurons (Kornack and Rakic, 2001; Lois and Alvarez-Buylla, 1994). 
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1.3.2 Parallels between neural stem cells and central nervous system 
tumour cells 
Brain tumours have been shown to a) exhibit histological features similar to 
undifferentiated neural stem/progenitor cells (Zaidi et al., 2009), and b) originate from 
the SVZ (Quinones-Hinojosa and Chaichana, 2007; Chaichana et al., 2008; Jacques et 
al., 2010). In addition, the cellular and molecular mechanisms relevant to early brain 
development can also contribute to tumourigenesis when functioning aberrantly. Also, 
brain tumours are often heterogeneous and can contain immature, undifferentiated cells 
that resemble neural progenitor-like cells (Sutter et al., 2007). Therefore, it is somewhat 
paradoxical to think that brain tumours could arise from fully differentiated postmitotic 
cells, as the likelihood of them accumulating enough genetic mutations by chance to 
undergo neoplastic transformation is exceptionally low. Nevertheless, this remains an 
alternative hypothesis to that of NSCs being the brain tumour cell of origin. 
There are numerous examples of the parallels between NSCs and CNS tumour cells. 
Firstly, many CNS tumours exhibit differentiation along several neural lineages, 
suggestive of a multipotent cell of origin (Zaidi et al., 2009). Also, CNS tumourigenesis 
involves many of the same pathways as NSC regulation (sonic hedgehog, notch, Akt), 
and many CNS tumours express known NSC markers (e.g. GFAP, Nestin, Sox-2, 
Notch, Olig-2) (Dirks, 2008). Targeted overexpression of oncogenes in Nestin-positive 
cells leads to the development of malignant glial tumours (Sutter et al., 2007). And cells 
with stem-like characteristics have been identified in biopsies of glioblastoma and 
medulloblastoma grown in mitogen-enriched medium in vitro (Ignatova et al., 2002; 
Hemmati et al., 2003). These cells also formed neurospheres that could be serially 
passaged and differentiated along neuronal and glial lineages. Furthermore, 
intracerebral engraftment of these in vitro grown glioblastoma cells into nude mice 
reproduced the original tumour (Galli et al., 2004). Notably, neurosphere-forming cells 
could once again be isolated from these secondary tumours and serially re-grafted to 
recapitulate the original glioblastoma, illustrating the in vivo self-renewal potential of 
these cells. The intrinsic behavioural similarities between NSCs and CNS tumour cells, 
however, are a good indication that similar growth, survival and proliferation pathways 
are active in both types of cells. 
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1.3.3 Parallels between neural stem cells and astrocytes 
Historically, glial cells and neurons were thought to be derived from two separate pools 
of progenitor cells. However, when the primary progenitor cells of the SVZ were first 
identified they were shown to exhibit both structural and biological markers of 
astrocytes (Doetsch et al., 1999). Subsequent cytoarchitectural analysis of the brain’s 
germinal regions including its pattern of NSC sub-population division has raised 
fundamental questions about the mechanism of adult neurogenesis. Astrocytic NSCs 
belong to a developmental lineage that includes the neuroepithelium, radial glia and 
germinal astrocytes. There is mounting evidence to suggest that adult NSCs are strongly 
influenced by their local microenvironment (Calabrese et al., 2007). To this end, non-
germinal astrocytes can be oncogenically induced to de-differentiate into a stem-like 
state (Lee et al., 2008b), but environmental factors alone seem to be insufficient to 
inducing astrocytes to behave like NSCs (Alvarez-Buylla and Lim, 2004). Further 
characterisation of these cells may reveal a role in brain development and disease. We 
aim to test this hypothesis by examining whether non-germinal terminally differentiated 
astrocytes can contribute towards tumour development. 
 
1.4 Cancer Stem Cells 
Historically, two hypotheses have existed to explain how tumours arise and develop; the 
stochastic model and the hierarchical model (Figure 4). The stochastic model predicts 
that tumour cells are heterogeneous and can all induce tumour formation due to a 
combination of intrinsic and/or extrinsic variables. The hierarchical model predicts that 
only a small subset of cells in a tumour is capable of re-generating the bulk of the 
tumour, with the rest being more differentiated (Vescovi et al., 2006). 
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Figure 4: A schematic representation of the (a) stochastic vs. (b) hierarchical model of 
tumourigenesis (adapted from (Vescovi et al., 2006). The stochastic model proposes that all tumour 
cells can sustain the growth of a tumour whereas the hierarchical model proposes that only a small subset 
of tumour cells possess this ability. 
 
The latter model has received more attention and resulted in the coining of the “cancer 
stem cell hypothesis” (Bonnet and Dick, 1997). This hypothesis suggests that tumours 
are initiated and maintained by a subpopulation of cells, with similar properties to adult 
stem cells, termed cancer stem cells (CSC). The first of these cells to be described was 
the SCID leukaemia-initiating cell (SL-IC) in 1997 (Bonnet and Dick, 1997). However, 
the fact that only a few blood cells isolated from leukemic patients had the ability to 
proliferate in vivo was noted some 40 years earlier (Bruce and Vanderga.H, 1963). 
Similarly CSCs have been identified in breast, pancreatic, and colon cancer and it is 
widely thought that the same may be true for most if not all cancers (Al Hajj et al., 
2003; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Esposito et al., 2002).  
Assuming the hierarchical model for tumour development, cancer stem cells (CSCs) are 
believed to represent a sub-population of neoplastic cells found within tumours or 
haematological cancers that possess characteristics normally associated with stem cells 
(Bao et al., 2006). They can account for 3% of cancerous cells in leukaemia and up to 
30% in glioblastoma (Miller et al., 2005). It is hypothesised that only the CSCs within a 
tumour bulk drive tumourigenesis and are responsible for repopulating the bulk of the 
tumour stroma following surgical resection and/or chemo/radiotherapy (Zaidi et al., 
2009; Huntly and Gilliland, 2005) (Figure 5). 
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Figure 5: Schematic representation of the cancer stem cell hypothesis. According to the hierarchical 
model, only a small subset of tumour cells has the ability, as cancer stem cells, to drive tumour 
repopulation following surgical resection and chemo/radiotherapy. The phenotype of the repopulated 
tumour does not always perfectly recapitulate that of the original tumour. 
  
CSCs typically persist in a variety of tumours as a distinct and very small subpopulation 
of cells (1-5%). They are responsible for initiating and maintaining the growth of 
neoplastic tissue as it has been repeatedly shown that they can induce tumourigenesis 
when transplanted into a receptive host (Lowry and Temple, 2009). In one extreme 
example, only around 1 in 1,000,000 cells in some human acute myeloid leukemia 
(AML) samples can seed tumour growth when transplanted into severe combined 
immunodeficient (scid) mice (Hope et al., 2004). In the other extreme, it has been 
shown that primary pre-B/B lymphoma cells isolated from Eμ-myc transgenic mice 
induced lymphoma development when injected into congenic mice regardless of cell 
number (Kelly et al., 2007). However, this finding is not representative of the 
heterogeneity of tumours observed in the majority of cancers. 
The properties of CSC can sometimes be used to deduce their origin. For example, both 
epithelial tissue stem cells and their CSC counterparts contain lower levels of reactive 
oxygen species (ROS) than their terminally differentiated progeny; an essential 
requirement for maintaining their proliferative capacity, and a similarity that reinforces 
a theoretical step-wise link between the two cell types (Diehn et al., 2009). Low levels 
of ROS have also been observed in CNS stem/progenitor cells (Tsatmali et al., 2005) 
perhaps due to endogenously elevated levels of the antioxidant enzyme copper/zinc 
superoxide dismutase (SOD1), which is a known correlate of NSC proliferation 
(Takemura et al., 2006). Enhanced antioxidant levels and increased expression of free 
radical scavenging systems is one mechanism by which both normal and cancer stem 
cells can protect themselves against DNA damage (i.e. become radioresistant) and 
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maintain their stem-related proliferative capacity. And indeed, pharmacologicalical 
depletion of free radical scavenging systems in CSCs makes them more radiosensitive 
and reduces their proliferative capacity (Diehn et al., 2009). It is therefore plausible that 
the enhanced activity/protection against ROS observed in CSCs is a retained property 
from their origins as CNS stem/progenitor cells. A second mechanism by which cells 
can demonstrate radioresistance against ionising radiation is through enhanced DNA 
damage repair. And glioma CSCs have been shown to possess such a hyperactivated 
DNA damage response mechanism as a result of preferential phosphorylation activation 
of the Chk1 and Chk2 checkpoint proteins and subsequent prevention of G2-S cell cycle 
progression (Bao et al., 2006; Ward, 1985). And once again, pharmacological inhibition 
of Chk1/2 with debromohymenaildisine enhanced the radiosensitivity of the CSCs, but 
this time without affecting their proliferative capacity (Bao et al., 2006). The presence 
of these two separate pathways by which CSCs protect themselves against cytotoxic 
therapy highlights the need to identify further disease-specific CSC resistance 
mechanisms in order to develop effective therapeutic regimens.  
CSCs are known to characteristically resemble normal stem cells of the corresponding 
tissue of origin. For example, neural CSCs express the neural stem cell markers GFAP, 
Nestin, and CD133 (Galli et al., 2004; Singh et al., 2004). Until recently it was also not 
known whether CSCs remain dependent upon the same niche microenvironments that 
regulate normal NSCs. However, endothelial cells interact selectively with neural CSCs 
in order to maintain them in stem cell-like state (Sneddon and Werb, 2007). Also, 
increasing the vascularity within brain tumour xenografts expands the number of CSCs 
and accelerates tumour growth. Disruption of this vascular niche microenvironment 
ablated CSC numbers and arrested tumour growth (Calabrese et al., 2007). These data 
suggest that brain tumours orchestrate niche microenvironments that maintain CSCs. 
We know that CSCs can resemble normal tissue stem cells based on their expression 
profile, ability to self-renew, and ability to differentiate into all of the appropriate 
cellular lineages. However, it remains unknown as to whether CSCs arise from normal 
stem cells that have lost their growth control or from later-stage progenitor cells that 
have de-differentiated and acquired stem-like characteristics. In the case of intestinal 
cancer the former has been proven to be the case as stem-cell-specific loss of APC 
induced neoplasia (Barker et al., 2009). Despite this finding, it is likely that CSCs will 
have to be characterised in a tissue-dependant manner as this scenario may not be 
applicable to all cancer types. 
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The identity of the neural CSC has yet to be defined; a question that we aim to address 
with our model system. The potential therapeutic value of defining the CSC is enormous 
as (i) treatments could be designed to specifically target tumour growth thus minimising 
the cytotoxic side-effects seen with traditional chemo/radiotherapy methods, and (ii) it 
would allow us to understand the aetiology of tumourigenesis and develop ways to 
prevent tumour formation/recurrence. 
 
1.4.1 Brain Tumour Initiating Cells (BTICs) 
With the exception of hematopoeitic stem cells, more is known about the development 
of embryonic and adult NSCs than any other tissue-specific stem cell. CNS 
malignancies have become widely studied to test the CSC hypothesis. None more so 
than gliomas, from which glioblastoma-initiating cells (GICs) have been identified 
(Singh et al., 2004). GICs have been shown to possess a number of parallels with 
normal adult NSCs from their self-renewal and multi-lineage differentiation potential to 
their similar transcriptomic profiles (Lee et al., 2008a). Further comparisons of NSCs 
and GICs will provide us with an insight into the mechanism of fate determination and 
tumourigenesis. A linear relationship of NSC progression to GIC seems unlikely when 
considering the heterogeneity of gliomas. A more likely scenario of fate determination 
would be a contextually dependent progression whereby NSCs can give rise to an array 
of GIC sub-types (all of which could have different response to the same signalling 
pathway) based on the spatial and developmental qualities of the target NSC. 
It has long been thought that the regulatory cytokine transforming growth factor beta 
(TGF-$		-suppressing signals that must be avoided for a cell to become 
cancerous. However, TGF-			#					*	
been variously implicated in glioma cell proliferation, migration, immune regulation, 
and microenvironment modulation (Bodmer et al., 1989). As such, the TGF-		
has been highlighted as a potentially promising therapeutic target. TGF-	*	
	
shown to induce increased self-renewal, whilst preventing the differentiation, of GICs 
but not normal human neuroprogenitors. It does so through the Smad-dependent 
activation of leukemia inhibitory factor (LIF) and the subsequent downstream activation 
of the JAK-STAT pathway, and ultimately promotes tumourigenesis (Penuelas et al., 
2009). The Smad complex also has a range of cofactors with which it can interact to 
achieve differential gene expression/repression in a cell context-dependent manner 
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(Fine, 2009). TGF-			<=		*
	-mediated self-renewal and 
proliferation in midbrain-derived NSCs but to have no effect on forebrain-derived NSCs 
(Falk et al., 2008). This is further proof of the contextual nature of stem cell signalling. 
In addition, a distance of 1mm between NSCs of the adult SVZ is sufficient to impart a 
spatial restriction between the cells in terms of their fate determination. 
This supports our previous statement that fate determination may be influenced by 
NSCs microenvironment, and that the resulting heterogeneous pool of GICs may 
preclude the efficacy of single pathway therapeutics such as in the case of the TGF-	
receptor. For example, there is a sub-population of BMPR1b-methylated GICs that are 
unresponsive to LIF as they cannot mediate the phosphorylation of STAT3 (Lee et al., 
2008a). Conversely, during development STAT3 inhibition is required for cells to stop 
proliferating and differentiate, meaning that TGF-	*
		*	
>	
activation of STAT3 would counter-intuitively expand the GIC pool (Fine, 2009). It is 
plausible that targeting of stem cell pathways may hold therapeutic promise but a 
combination therapy / surgery approach tailored to each patient and specific to the 
tumour remains the best option currently available. 
In the case of medulloblastomas, the most common paediatric brain tumour, an 
association has been identified between the aberrant activation of Shh signalling and 
loss of function in the Ptch gene (Vorechovsky et al., 1997; Stone et al., 1996). The 
neural progenitor cells of Ptc+/- mice exhibit an increased rate of proliferation and 
around 20% of the mice themselves develop medulloblastomas (Goodrich et al., 1997; 
Galvin et al., 2007). Medulloblastomas derived from these mice are propagated by cells 
expressing the progenitor markers Math1 and CD15, and interestingly not by cells 
expressing the NSC marker CD133. These CD15+ cells were not able to form 
neurospheres in vitro, and were incapable of multilineage differentiation. CD15 has 
since been found to be expressed in a subset of human medulloblastomas and is 
associated with poor prognosis (Read et al., 2009). This suggests that BTICs do not 
have to exclusively belong to the NSC lineage and can also lack CD133 expression 
(Wang et al., 2008). 
Much work has focussed on attempting to identify and characterise BTIC, with nestin 
(Dahlstrand et al., 1992) and CD133 receiving much of the attention based on the 
association of their expression with increased tumour malignancy (Thon et al., 2010). 
Nestin is an intermediate filament produced by both neural stem and progenitor cells 
during embryongenesis (Zimmerman et al., 1994; Galli et al., 2004; Hemmati et al., 
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2003). Its expression is thought to correlate with the “stemness” of NSCs with a 
decrease in its expression correlated with a progression towards a more differentiated 
cell phenotype (Vescovi et al., 1993). Elevated nestin immunoreactivity has also been 
observed across a large number of brain tumours including astrocytomas, 
oligodendrogliomas, and glioblastomas (Almqvist et al., 2002). This finding was taken 
further by Calabrese et al who went on to show that nestin-positive brain tumour cells 
were located significantly closer to tumour vasculature than nestin-negative cells, with 
the greatest association observed in oligodendrogliomas and glioblastomas (Calabrese et 
al., 2007). The same group also showed that nestin-positive/CD133-positive tumour 
cells include the self-renewing tumourigenic CSC fraction and interact selectively with 
the endothelial cells of the tumour vasculature. The importance of this interaction was 
highlighted by treatment with antiangiogenic therapies, which were shown to arrest 
tumour growth as a result of depleting tumour vasculature and its associated pool of 
nestin-positive/CD133-positive cells (Calabrese et al., 2007). This was the first study to 
suggest a perivascular niche for the BTIC. CD133 itself has had a wealth of interest as a 
stand-alone and co-expressed marker of BTIC. Another less well studied potential BTIC 
marker is Musashi-1, an RNA-binding protein expressed by proliferating and 
multipotent neural progenitor cells of the SVZ (Sakakibara and Okano, 1997; Okano et 
al., 2002). Similarly to nestin and CD133, elevated Musashi-1 expression has been 
correlated with increased tumour malignancy and grade in human glioma (Toda et al., 
2001). 
We aim to address the relative likelihoods of BTIC originating from: a) NSCs which 
undergo neoplastic transformation, b) neural progenitor cells which have acquired 
mutations that cause them to de-differentiate into a stem-like state with unregulated 
growth control, or c) terminally differentiated cells (e.g. glia) which have acquired 
mutations that cause them to de-differentiate into a stem-like state with unregulated 
growth control. 
 
1.4.2 CD133 (Prominin-1) as a marker of cancer stem cells 
Human CD133 belongs to a family of 5-transmembrane (5-TM) proteins with 
extracellular N-termini and cytoplasmic C-termini. It is a single chain polypeptide of 
856 amino acids and a molecular weight of 120kD and its precise function remains 
relatively unclear (Miraglia et al., 1997). In 1997, a monoclonal antibody was developed 
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which recognised the glycosylation-dependent epitope of CD133 (AC133) and was used 
to show that AC133 protein expression was restricted to CD34+ haemapoietic stems 
cells (Yin et al., 1997). However, it was later shown that AC133 mRNA expression was 
present in the adult brain, heart, kidney, liver, lung, and placenta (Miraglia et al., 1997). 
In a similar manner, a monoclonal antibody developed against murine CD133 
(prominin-1) was later used to identify murine CD133 as a 5-TM protein with the same 
topology as human CD133 (Weigmann et al., 1997). However, they only share 60% 
amino acid sequence homology with murine CD133 being an 858 amino acid, 115kD 
glycoprotein with an even more diverse distribution of expression (Corbeil et al., 1998). 
Both CD133 epitopes are present as plasma membrane protrusions on epithelial 
microvilli and are thought to act as regulators of the plasma membrane (Mizrak et al., 
2008). CD133-containing membrane particles are present in the ventricular fluid of the 
developing mouse neural tube in a temporal relationship with the development of 
protuberances on the embryonic neuroepithelium (Marzesco et al., 2005). Furthermore, 
CD133 has been shown to be downregulated in the plasma membrane of Caco2 human 
epithelial cells in response to enterocytic differentiation (Corbeil et al., 2000). Taking 
both of these findings into account it appears that CD133 may actively play a role in 
maintaining the phenotype of the NSC niche. 
CD133 antibodies have been used to isolate human NSCs from fetal brain (Uchida, 
2000), and more recently putative CSCs from glioblastomas (Singh et al., 2003). This 
finding has caused much excitement in the field of cancer research with CD133 
expression often being associated with multipotent and self-renewing BTICs (Gunther 
et al., 2008). This statement was initially validated by two separate publications that 
respectively showed that CD133+ cells contribute to radioresistance and tumour 
repopulation, and that in vivo delivery of bone morphogenetic proteins block tumour 
growth by depleting the pool of CD133+ BTICs (Bao et al., 2006; Piccirillo et al., 
2006). However, there have been several recent studies in which CD133- cells have also 
been found to be tumourigenic (Shmelkov et al., 2008; Wang et al., 2008; Ogden et al., 
2008). The argument becomes even less clear-cut when we consider the dynamic nature 
of CD133 expression and the fact that CD133- cells may reflect a loss of expression 
rather than derivation from a CD133- cell. In addition to this, increased CD133 
expression has been associated with bioenergetic stress induced by hypoxia and 
mitochondrial dysfunction and may therefore simply be a marker of tumour 
microenvironment rather than tumourigenicity (Griguer et al., 2008). These 
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contradictory findings highlight the current lack of understanding in the behaviour of 
CSCs. We aim to further characterise CD133+/- NSCs in terms of their relative 
contributions to tumourigenesis. 
Since the implication of CD133 expression as a marker of CSCs in brain tumours, its 
potential as a marker of CSCs in other tumour types have been exhaustively 
investigated. Using a range of isolation techniques, such as cell sorting, CD133+ CSCs 
have been identified in a range of different cancers including breast cancer (Wright et 
al., 2008). However, the unpredictable variability in CD133 expression leaves the field 
open for debate. An assumption of the CSC hypothesis is that the clinical behaviour of a 
brain tumour should correlate with the relative presence and biological state of the CSC 
population. Despite growing ambiguity, increased CD133 expression in glioma has in 
fact been found to correlate with decreased survival independent of tumour grade, 
extent of resection, and patient age. And interestingly, the proportion of CD133+ cells 
was also found to be associated with an increased risk of tumour re-growth (Zeppernick 
et al., 2008). This is a particularly important finding considering that it fits with the 
CSC hypothesis in that it implies the ability of CD133+ cells to proliferate and re-
populate the tumour. A similar finding has been made in neuroblastoma and 
ganglioneuroblastoma where patients with CD133- tumours had an increased chance of 
survival over those with CD133+ tumours, and increased CD133 expression was found 
to correlate with increased malignancy (Tong et al., 2008). Similarly, CD133 expression 
has been used to predict decreased survival in glioblastoma patients treated with 
concomitant chemo/radiotherapy, suggesting that a CD133+ CSC population is 
responsible for the treatment resistance of glioblastoma (Murat et al., 2008). These 
correlations between increased CD133 expression and decreased survival and/or 
increased malignancy have also been observed in astrocytomas (Ma et al., 2008; Rebetz 
et al., 2008) and oligodendroglioma (Beier et al., 2008). 
 
1.5 Cell Cycle Regulation and Tumourigenesis 
Uncontrolled cellular proliferation is a hallmark feature of almost all malignant cancers, 
including brain tumours, and typically results from the neoplastic transformation of cells 
following loss of regulatory control over the cell cycle. This can lead to a decrease in 
apoptosis and/or an increase in cellular proliferation that may clinically manifest as a 
tumour mass. The cell cycle is regulated by four categories of genes/proteins: proto-
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oncogenes, tumour suppressor genes, DNA repair enzymes, and cyclins / cyclin-
dependent kinases (CDKs). Mutations in these genes, leading to a loss/gain of function, 
can result in deregulation of the cell cycle and subsequently lead to tumourigenesis. 
Proto-oncogenes can positively regulate the cell cycle upon activation by mediating the 
transduction of mitogenic signals which lead to an increase in cell proliferation (e.g. 
EGF signalling cascade). Aberrant oncogenic gain of function effects can be brought 
about by: (i) mutation in the gene coding sequence leading to a constitutively active 
protein made in normal amounts, (ii) gene amplification leading to the over production 
of normal protein or (iii) by chromosomal rearrangement resulting in the over 
production of a protein via by gene fusion with a strong and constitutively active 
promoter (Lozano, 2010). 
Under normal conditions, progression through the cell cycle is regulated by the protein 
kinase activities of CDKs. However, the catalytic capability of a CDK is only activated 
when in the form of a heterodimer with a bound cyclin molecule. These activated 
heterodimers have the ability to regulate key substrates through phosphorylation and 
facilitate the passage of a cell through the cell cycle. Cyclins are classified according to 
the phase of the cell cycle they regulate. For example, transition through the G1-S-G2-
M phases is controlled by cyclins D, E, A and B respectively (Obaya et al., 2002). 
Cyclins are regulatory proteins and must form an active heterodimer with a CDK in 
order to exert a catalytic function. Cyclin D is a G1 phase cyclin that couples with 
CDK4 and CDK6 to regulate the tranition of cells from G0 to G1. Cyclin D levels are 
controlled through the Ras GTPase signaling pathway and when present it binds to 
existing CDK4 to form the active heterodimer cyclin D-CDK4. This complex 
hypophosphorylates pRb, which subsequently binds to and inhibits E2F transcription 
factors resulting in the downstream facilitation of cyclin E expression (Zhang et al., 
2000). Cyclin E (and cyclin A) is then able to bind to CDK2 and facilitate transition 
from G1 to S-phase. This is achieved through cyclin E-CDK2 / cyclin A-CDK2-
mediated hyperphosphorylation, and subsequent inactivation, of pRb in late G1 phase 
(Akiyama et al., 1992). Hyperphosphorlyated (inactivated) pRb has an altered molecular 
conformation and is no longer able to inhibit the E2F transcription factors (Weinberg, 
1995). The resulting increase in E2F levels results in the transcription of a range of 
essential proteins involved in cell prolieration (e.g. cyclins E/A and DNA polymerases), 
which ultimately shunt the cell from G1 into S-phase. During S-phase cyclin E interacts 
with Cdc6 to stimulate replication complex assembly and cyclin A activates the 
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complex to promote DNA synthesis. The final transition of the cell cycle from G2 to 
mitosis is regulated by the complex formed between cyclins B1/ B2 and CDK1 (cdc2). 
Cyclin B-cdc2 forms part of the M-phase maturation promoting factor (MPF) that 
mediates assembly of the mitotic spindle, and conversely, deactivation of this complex 
results in the cell exiting mitosis (O’Farrell, 2001). Uncontrolled cellular proliferation 
and tumourigenesis can result when the above mechanism begins to function aberrantly. 
In addition to gene amplification / mutation (as described above), abnormal CDK 
activity can also be achiebed through inactivation of inhibitors. The cip/kip and 
INK4a/ARF families of genes downregulate progression through the cell cycle by 
inactivating cyclin-CDK complexes, and their loss-of-function is frequently observed in 
human tumours (Ivanchuk et al., 2001). To this end, many of the current cancer 
therapies in development focus on cell cycle regulation through the use of small 
molecule inhibitors and gene therapy. For example, although most interphase CDKs are 
dispensable for mouse development, their inhibition may prevent DNA replication in 
some types of tumour cells (Vermeulen et al., 2003). 
 
1.5.1 The role of Rb, p53, and PTEN in CNS tumourigenesis 
Our model reproduces known mechanisms of CNS tumourigenesis by conditionally 
knocking out the tumour suppressor genes (TSGs) Rb, p53, and PTEN. This allows us 
to examine the putative interactions between these pathways as well as the ways in 
which they may differentially influence tumourigenesis both in vitro and in vivo. One 
particular function of tumour suppressor genes is to negatively regulate progression 
through the cell cycle. The majority of TSGs are haplosufficient, i.e. as long as one 
allele remains unaffected then there is no overall effect on the function of the gene. In 
relation to our work there are three particular TSGs whose function in which we are 
interested. 
The retinoblastoma gene (RB1) was the first TSG identified in humans and Rb1 the first 
TSG to be knocked-out by targeted deletion in mice (Jacks et al., 1992; Clarke et al., 
1992; Lee et al., 1992). It is ubiquitously expressed and its protein product, pRb, binds 
and inhibits many cellular proteins implicit in the regulation of cell cycle progression 
(Friend et al., 1986). Rb tumour suppressor function was originally thought to be 
exclusively attributed the ability of hypophosphorylated pRb to arrest cells in G1 by 
inhibiting the activity of E2F transcription factors. E2F transcription factors positively 
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regulate genes whose activation is required for entry into the S-phase of the cell cycle 
(Hanahan and Weinberg, 2000). However, it is now known that Rb binds to over 100 
protein partners resulting in the transcriptional regulation of hundreds of target genes 
which in turn mediate a vast array of downstream effects ranging from cell cycle arrest 
to apoptosis, differentiation, angiogenesis, and metastasis (Burkhart and Sage, 2008). 
As such, homozygous knockout of Rb (Rb-/-) in mice results in embryonic lethality 
(Zhang et al., 2004). Rb was originally identified in families with a history of 
retinoblastoma and it is accepted that Rb loss is the most common initiating genetic 
event in retinoblastoma (Knudson, 1984). Rb inactivation/loss has also been implicated 
as a major contributing factor in a many other cancers such as osteosarcomas in children 
(Friend et al., 1986), and various carcinomas in adults (Burkhart and Sage, 2008). It is 
now known that Rb is directly or indirectly inactivated in nearly all human cancers. 
However, it is still unclear as to which cell type (stem cells, progenitors, differentiated 
cells) is responsible for cancer initiation following Rb loss. It is postulated that Rb loss 
could induce cell cycle re-entry and subsequent differentiation in type B NSCs, 
hyperproliferation in progenitors, and de-differentiation in differentiated cell types 
(Burkhart and Sage, 2008). All of these mechanisms could potentially contribute 
towards tumourigenesis. Rb loss is relatively rare in human gliomas (15-30%), and as of 
yet there has been no mouse model developed to specifically examine the consequence 
of Rb loss alone in brain tumour progression (Burkhart and Sage, 2008). In our model 
we aim to address this current knowledge gap. 
p53 was first described in 1979 by Arnold Levine, David Lane, and Lloyd Old and was 
originally considered to be an oncogene based on the finding that over 50% of all cancer 
cells were observed to exhibit increased p53 levels (Deleo et al., 1979; Lane, 1992). 
However, this elevation was later found to be due to increased levels of a mutant p53 
isoform that was interacting with, and inhibiting, the function of the endogenous p53. It 
was not until 1989 that p53 was revealed as a TSG (Nigro et al., 1989), with subsequent 
work leading to the identification of the p53 gene (TP53) as a critical element in the 
signal transduction pathway of DNA damage repair (Kastan et al., 1991). Described as 
the “guardian of the genome”, p53 is a ubiquitously expressed transcription factor that 
negatively regulates the cell cycle (Lane, 1992). Under unperturbed conditions p53 is 
expressed at low levels (Bourdon, 2007). However activation by phosphorylation, 
resulting from various genotoxic stress factors such as oncogene activation, hypoxia and 
DNA damage causes p53 to target and regulate genes that induce apoptosis and cell 
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cycle arrest (Maltzman and Czyzyk, 1984). p53 mutations have been implicated in brain 
tumour progression. Specifically, germ line mutations of the gene encoding p53 (TP53), 
located at 17p13.1 cause a rare familiar cancer disorder called Li-Fraumeni syndrome. 
This disorder includes 55 different inherited mutations of TP53 because of which the 
subsequently altered p53 isoform cannot bind to DNA and therefore loses its function. 
These mutations typically occur within the sequence-specific DNA-binding domain 
which contains a zinc ion and is responsible for DNA binding. Those affected are 
predisposed to the development of brain tumours such as astrocytomas (Srivastava et 
al., 1990). TP53 mutations have been reported in 28% of primary glioblastomas (WHO 
grade IV) and in 59% of low grade astrocytomas (WHO grade II) (Ohgaki and 
Kleihues, 2007). In the mouse, disruption of TP53 alone is not sufficient to result in 
astrocytoma formation, suggesting that additional genetic events are required (Zhu et 
al., 2002). Although it cannot be considered haploinsufficient, p53 heterozygosity 
predisposes the carrier to a vastly increased chance of developing tumours in early life. 
This is because loss of heterozygosity (LOH), or the loss of both alleles, confers this 
cancerous predisposition. 
Following the identification of Rb as the most common initiating genetic event in 
retinoblastoma in the 1980’s, genetic evidence suggested the presence of an additional 
TSG on chromosome 10, as loss of heterozygosity (LOH) at this location had been seen 
in a variety of cancers (Li et al., 2003). The subsequent characterisation of Cowden 
disease, caused by a germline mutation in 10q23, validated this finding (Liaw et al., 
1997). Sequence analysis revealed a phosphatase domain and a large region of 
homology to chicken tensin at this chromosomal location, hence PTEN (Phosphatase 
and Tensin homologue). In 1997, Li et al. confirmed the existence of PTEN at 10q23 
when screening 12 primary breast tumours. They also showed that PTEN was absent in 
31% of glioblastoma (GB) cell lines and 17% of primary glioblastomas, and that LOH 
is also a frequent event in the progression of low-grade to high grade glioma (Li et al., 
1997). PTEN is now known to be a dual lipid and protein phosphatase involved in the 
regulation of apoptosis, metabolism, cell proliferation, and cell growth through the 
PI3K/AKT pathway. As a phosphatidylinositol phosphate (PIP) phosphatase, PTEN can 
de-phosphorylate PI(3)P and PI(3,4)P2 but its main substrate is thought to be PIP3 
which is the product of PI3K (Blanco-Aparicio et al., 2007; Maehama and Dixon, 
1998). The activity of PTEN antagonises that of PI3K by lowering the levels of PIP3, 
therefore decreasing Akt activity, and subsequently enhancing the rate of apoptosis and 
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lowering cell motility/migration through a series of downstream effectors (i.e. PDK1, 
AKT/PKB, Rac1/cdc42, small G proteins, FAK) (Datta et al., 1999; Liliental et al., 
2000; Tamura et al., 1998; Blanco-Aparicio et al., 2007). PTEN activation promotes cell 
cycle arrest at G1, and increases the level of apoptosis. For example, exogenous PTEN 
causes GB cells to arrest at G1 (enhanced by G2 blocker nocodazole) and can be 
rescued by p-Akt expression. Also involved in PTEN-mediated cell death is an up-
regulation of p27 and down regulation of cyclin D1 (Weng et al., 2001). Homozygous 
knockout of PTEN (PTEN-/-) in mice results in embryonic lethality with the mice 
exhibiting abnormal differentiation and poor cellular organisation in all of the three 
germ layers. Mice heterozygous for PTEN (PTEN+/-) are viable but have a reduced rate 
of Fas-mediated apoptosis and a high incidence of lethal polyclonal autoimmune 
disorder (Di Cristofano et al., 1998; Di Cristofano et al., 1999). Mice in which PTEN is 
conditionally knocked out in neural precursor cells by using the Cre-LoxP system and a 
nestin promoter driven Cre transgene demonstrate a profound phenotype in which they 
are born with open eyes and enlarged brains, and die shortly after birth. Cell migration 
is impaired in these mice and an increased level of proliferation can be seen in cells of 
the SVZ (Groszer et al., 2001). In addition to this model, PTEN has also been 
conditionally knocked out under the control of a GFAP, En2, or L7 promoters in which 
neural precursor cells, cells of the midbrain-hindbrain junction at embryonic day 9.5, 
and mature Purkinje cells were targeted respectively. All of these mice, with the 
exception of the L7-Cre mice, exhibited cellular disorganisation, increased proliferation, 
decreased apoptosis, and increased cell/brain size in the affected tissues with seizures, 
ataxia, and death (Backman et al., 2001; Marino et al., 2002a). The L7-Cre mice had 
almost normal appearing Purkinje cells, but which showed signs of chronic 
neurodegeneration. Taken together these findings suggest that PTEN is does not play a 
major role in lineage determination but is implicitly involved in the regulation of cell 
motility, migration, and regulation of the SVZ neural stem cell compartment. 
 
1.6 Model System 
There are many well-established animal model systems that enable the studying of CNS 
tumourigenesis and its molecular aetiology. However, they vary enormously depending 
on the research topic being investigated, e.g. the tumour cell of origin, the role of 
specific signalling pathways and/or the role of the cell cycle, or therapeutic strategies. A 
selection of the most commonly used such model systems are summarised below:
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1.6.1 Modelling gene loss-of-function through the generation of knock-out 
mice 
Mice are widely used to model human diseases due to their genetic similarity and large 
array of genetic techniques available. One of the greatest breakthroughs in disease 
modelling was the cellular targeting of genes to ablate their function. This was achieved 
by ‘homologous recombination’, which involves the recombination between two 
homologous DNA sequences. In this manner, targeting vectors can recombine with 
homologous sequences in the genome to replace key exons or to disrupt expression 
through the insertion of mutations. 
 Embryonic stem cells (see section 1.2 for a description) cells can be maintained in an 
undifferentiated state in vitro, therefore retaining their pluripotency when returned to the 
environment of the early embryo. In this manner, ES cells in which genes have been 
ablated / inserted can be injected into the inner cell mass of murine blastocysts where 
they contribute to the development of the embryo (Figure 6). Incorporation of these 
cells into the germline allows the gene deletions / insertions to be inherited so that stable 
knock-out mouse lines can be established. 
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Figure 6: Generation of knock-out mice. Embryonic stem (ES) cells are derived from the blastocyst 
inner cell mass and expanded in vitro. The required genetic material (gene) is then introduced into the ES 
cells, along with the neomycin resistance gene (NeoR), by homologous recombination. The in vitro 
culture is then treated with neomycin to positively select those ES cells containing the required genetic 
material, which are then transplanted back into the inner cell mass of a blastocyst. This blastocyst is then 
implanted in a surrogate mother who produces chimaeric (mice that developed from both genetically 
manipulated and normal ES cells) offspring. These chimaeras are then crossed against one another to 
achieve germline transmission so that the artificially inserted genetic material is expressed by all cells of 
the body (used with permission from Pedro Cuadrado). 
 
1.6.2 Modelling conditional gene loss-of-function using the Cre-LoxP 
system  
Conditional gene inactivation enables the inactivation of genes in a time/tissue-specific 
manner (Gu et al., 1993). This process uses enzymes that recombine specific DNA 
sequences with high fidelity. The most commonly used system for conditional gene 
inactivation is the Cre-LoxP system, first identified within yeast (Sauer and Henderson, 
1988). Cre-recombinase is a bacteriophage P1 enzyme that belongs to a large family of 
DNA recombinases. It recognises sequences called ‘locus of crossover in P1’ (LoxP), 
which consist of two palindromic 13 base pair inverted repeats separated by an 8 base 
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pair asymmetric spacer. Cre-recombinase binds to these two LoxP sites and mediates 
strand cleavage, exchange and ligation (homologous recombination) at the asymmetric 
spacer (Hoess et al., 1982). 
By controlling Cre-recombinase expression it is therefore possible to conditionally 
inactivate gene function in a time-specific manner. The most common method for 
controlling Cre-recombinase expression is by generating mice that express the enzyme 
under the control of a specific promoter. As a result, only the cells in which the 
promoter is active will express Cre-recombinase and subsequently undergo 
recombination. The limitation of this approach is the requirement of multiple tissue-
specific Cre-recombinase-expressing mice in order to study the effect of gene 
inactivation in different cell populations. 
Cre-recombinase expression can also be controlled by inducible systems such as the 
Cre-tamoxfin system. This system relies on the synthetic oestrogen receptor antagonist 
tamoxifen (commonly used to treat early breast cancer) to achieve inducible 
recombination. In this model system, the transgenic mice express a Cre-recombinase-
oestrogen receptor binding-domain fusion protein (Cre-ER), rather than just Cre-
recombinase. When tamoxifen (however administered) binds to these oestrogen 
receptors the Cre-ER protein is translocated into the nucleus where it targets LoxP sites 
for recombination. This method is highly versatile as the timing and route of tamoxifen 
administration can be used to achieve temporal and spatial recombination specificity. 
Adenoviral vectors expressing Cre-recombinase can also be used to mediate inducible 
LoxP site recombination. In this system, Adenoviral vectors can be administered (in 
vitro and in vivo) in a time/tissue-specific manner whereby all the infected cells 
transiently express Cre-recombinase and undergo irreversible recombination at the 
target LoxP sites. It is this method that our model system uses to model the loss-of-
function of the tumour suppressor genes (TSGs) Rb, p53, and PTEN. 
 
1.6.3 Creation of a novel mouse model system 
The selection of a model system, or the creation of a new one, depends on the research 
aims being addressed. For example, although human xenograft model systems most 
accurately reproduce the human clinical condition, and are the most robust models for 
pre-clinical therapeutic testing, they are less suitable when attempting to investigate the 
molecular events of early tumourigenesis. And conversely, although there are a wealth 
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of transgenic mouse models that recapitulate the tumourigenic process for a variety of 
tumour phenotypes, they carry the risk of reduced homology to the human condition as 
signalling pathways are often unequally represented between the endogenous biologies 
of mice and humans. In addition, the vast majority of transgenic mouse models of CNS 
tumourigenesis are oncogenically driven (Table 1) in the aim of expediting the 
tumourigenic process by reducing tumour latencies allowing for more cost/time-
effective research. 
In our research we aim, amongst other things (refer to section 1.8), to characterise the 
brain tumour initiating cell (BTIC) by delineating and defining the early molecular 
events of tumourigenesis in relation to phenotype commitment. For this reason, we must 
use a model system that: a) accurately and naturally reproduces the full tumourigenic 
process, b) allows for the development of multiple tumour phenotypes and c) allows for 
the identification, isolation, and functional characterisation of potential BTICs. 
No existing model sufficiently addresses all of these requirements. And to this end, we 
developed a new mouse model that uses tumour suppressor gene (TSG) ablation, rather 
than one that is actively driven by oncogenic processes, to subtely predispose mice to 
developing intrinsic tumours. Although this means that the tumour latencies in our 
model are often considerably longer than those seen in other similar models, our model 
more naturally reproduces the early stages of tumourigenesis and allows for multiple 
phenotype determination as the mice must accrue additional (chance) mutations to the 
initial genetic lesion before neoplastic transformation can take place. This controls 
against the concern that oncogenically driven models force the tumour phenotype and 
render genotype-phenotype relationship analysis null and void. As previously discussed, 
we selected the three TSGs (Rb, p53, PTEN) based on their widespread loss of function 
in a variety of brain tumours. However, as homozygous deletion of Rb and PTEN is 
embryonically lethal (and all are haplosufficient) we incorporated the Cre-LoxP system 
in order to allow for conditional knock-out of the genes (refer to sections 1.6.1 and 
1.6.2). In addition to the Cre-LoxP system allowing for temporal control of gene loss we 
can also control the spatial perspective through targeted delivery of Cre-recombinase or 
by putting it under the control of a regionally-specific promoter. For example, we can 
target the NSC compartment in vivo by injecting Adenovirus-Cre into the lateral 
ventricles of the “conditional knock-out” mice. And finally, the Cre-LoxP system also 
allows for gene ablation (with subsequent functional profiling) to be conducted in vitro 
following ex vivo isolation of target neural cells. We can derive primary NSC or other 
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specific cell cultures (i.e. astrocytes) from the brains of conditional knock-out mice, and 
induce in vitro recombination of the TSGs by transduction with Adenovirus-Cre. This 
model system allows us not only to study which cell types possess tumourigenic 
potential, but also the downstream effects of knocking-out these particular TSGs in 
relation to tumourigenesis. 
 
1.6.4 Generation of transgenic mouse lines 
The TSGs Rb, p53 and PTEN were each modified in the germline by inserting a 34 base 
pair sequence termed a LoxP site into an intron either side of one or more exons of the 
coding sequence. These LoxP sites have no effect on gene function but serve as 
recognition sites for the enzyme Cre-recombinase. Cells infected with an adenovirus 
expressing Cre-recombinase synthesise the enzyme, which binds to the nuclear LoxP 
recognition sequences and results in the excision, or “conditional knock-out”, of the 
genetic material in between; a process termed “floxing”. Mice carrying LoxP sites 
flanking Rb, p53 or PTEN alone were bred together in order to produce various 
genotype combinations. In addition, a so-called “reporter” gene was crossed into the 
background of the mice, termed ROSA26RLox/Lox. This allows for Cre-mediated 
recombination, and subsequent LacZ expression (Figure 7$@		
	#	=*		-
Galactosidase assay. 
 
 
Figure 7: Cre-mediated recombination of the stop codon in between the LoxP sites results in the 
expression of LacZ, which can be detected by -galactosidase staining. 
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1.6.5 In vivo model system 
Using the Adenovirus-mediated Cre-LoxP system we are able to model the loss-of-
function of the tumour suppressor genes (TSGs) Rb, p53, and PTEN in the 
subventricular zone (SVZ) of adult mice. This is achieved by intracerebroventricular 
(i.c.v.) injection of Adenovirus expressing Cre-recombinase (Adenovirus-Cre), which 
infects SVZ cells and targets them for recombination (Figure 8). This method can be 
used to study whether in vivo recombination of TSGs in SVZ cells results in the 
development of brain tumours. 
 
 
Figure 8: Schematic of the experimental procedure used to achieve in vivo recombination of the 
TSGs. I.c.v. administration of Adenovirus-Cre targets SVZ cells for LoxP site recombination and 
subsequent TSG loss. 
 
1.6.6 In vitro model system 
NSCs and astrocytes are derived from the brains of 5-12 week and two day old mice 
respectively. NSCs are derived from microdissection and dissociation of the SVZ, and 
astrocytes are derived from dissociation of the cortices. NSCs are grown as free-floating 
aggregates, termed “neurospheres” (NS) in vitro, whereas astrocytes are grown as an 
adherent monolayer. Prior to splitting for passage two these cells are separated into 
three treatment groups: untreated, Adenovirus-GFP-infected (control), and Adenovirus-
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Cre-infected and recombined (experimental). The cells are then expanded for further 
passages until sufficient cells are yielded for a) in vitro functional characterisation 
(usually passage three or four), and b) intracerebral engraftment into recipient mice to 
characterise their ability to form tumours in vivo (Figure 9). 
 
Figure 9: Schematic of the experimental procedure used for the derivation and generation of in 
vitro recombined NSCs and astrocytes. NSCs (A) and astrocytes (B) are derived from the SVZ or 
cortices, respectively of mice and grown in vitro. Prior to splitting for passage two these cells are 
separated into three treatment groups: untreated, Adenovirus-GFP-infected (control), and Adenovirus-
Cre-recombined (experimental). They are then further expanded to allow for functional characterisation 
and testing of their tumourigenicity through intracerebral engraftment. 
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1.7 Model Validation 
 
1.7.1 Intracerebroventricular Adenovirus-Cre administration targets 
neurosphere-forming subventricular zone cells for recombination 
ROSA26RLox/Lox reporter mice (R26R), which express LacZ upon Cre-mediated 
recombination, were given an intra-cerebroventricular (i.c.v.) injection of 5μl 
Adenovirus-Cre. The subsequent localisation and distribution of the cells targeted for 
recombination was 	
	-galactosidase staining in situ. As a control, wild-type 
mice were injected with Adenovirus-GFP. Both the Cre/GFP-infected mice were culled 
at 7 days post-injection@	*	
	#				-galactosidase or GFP 
respectively. I.c.v. Adenovirus-Cre administration induced recombination, and 

>	-galactosidase expression, in cells within the SVZ of the lateral ventricles 
(Figure 10: A,B). This SVZ-targeted effect was validated by GFP-expression in an 
equivalent population in the control mice (Figure 10: C). Furthermore, SVZ cells 
(containing NSCs) derived from the brains of R26R mice at 7 days post-infection were 
observed to form neurospheres (NS) in vitro. Some of these NS 	-
galactosidase, suggesting that i.c.v. Adenovirus-Cre injection target NS-forming SVZ 
cells for recombination. 
 
 
Figure 10: R26R mice given an intra-cerebroventricular (i.c.v.) injection of Adenovirus-Cre exhibit 
a reproducible pattern of recombination in the 4-5 cell thick periventricular layer that includes the 
SVZ and ependymal layer (A,B). These cells include NS-			#	
	*	-
galactosidase-positivity (D). An equivalent population of cells was targeted in control wild-type mice 
injected with Adenovirus-GFP (C) (adapted from (Jacques et al., 2010). 
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Using confocal microscopy and immunofluorescence staining we examined the SVZs of 
the Adenovirus-GFP infected control mice to identify the types of cells targeted for 
recombination. The GFP-expression of infected SVZ cells was observed to co-localise 
with GFAP and nestin. This suggests that Adenvirus infection targets both the GFAP+ / 
nestin+ type B astrocytes and GFAP- / nestin+ transiently amplifying type C progenitor 
cells of the SVZ (Doetsch et al., 1999) (Figure 11: A-D). 
 
 
Figure 11: The GFP-expression of infected SVZ cells was observed to co-localise with GFAP (A,C) 
and nestin (B,D), suggesting that Adenovirus infection targets the NSCs of the SVZ (adapted from 
(Jacques et al., 2010). Representative images of R26R wild-type SVZ 7 days post-i.c.v. Adenovirus-GFP 
administration immunofluorescently stained for  GFP and GFAP (A-C) or nestin (B,D) with a Hoechst 
33342 (DAPI) counterstain. Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 
546nm. Images were taken using a 10x objective on a Zeiss LSM510 META confocal laser scanning 
microscope with the LSM software. 
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1.7.2 Inactivation of tumour suppressor genes in the stem cell compartment 
of the subventricular zone causes brain tumours 
In order to determine whether tumours could arise from SVZ cells, i.c.v. Adenovirus-
Cre was administered into R26R mice carrying further homozygous LoxP alleles for 
three different combinations of the tumour suppressor genes Rb, p53, and PTEN. These 
different combinations were RbLox/Lox; p53Lox/Lox, RbLox/Lox; p53Lox/Lox; PTENLox/Lox, and 
PTENLox/Lox; p53Lox/Lox. Each of these genotypes exhibited foci of atypical pre-
neoplastic lesions as shown by time culls performed at 14-18 weeks post-injection 
(Figure 12: A-C). Mice that were left for a longer time post-injection exhibited intrinsic 
tumours that manifested clinically with phenotypes (Figure 12: D-R) and latencies 
(Figure 12: S) that were dependent on the genotype and highly reproducible. 
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Figure 12: In vivo recombination of NSCs induces tumour formation. The development of 
microneoplasias were observed in the RbLox/Lox; p53Lox/Lox (A), RbLox/Lox; p53Lox/Lox; PTENLox/Lox (B), and 
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PTENLox/Lox; p53Lox/Lox (C) genotypes at 112, 104, and 126 days post i.c.v. Adenovirus-Cre administration 
respectively. Fully developed large intrinsic tumours were observed to develop in the same genotypes 
(D,E,F) at 194, 182, and 209 days respectively, with means of 190, 95, and 210 (S). In the case of the 
RbLox/Lox; p53Lox/Lox genotype the tumour appeared to clinically resemble that of a PNET (G,J,M,P), this 
was also the case for the RbLox/Lox; p53Lox/Lox; PTENLox/Lox genotype (H,K,N,Q). However, the 
PTENLox/Lox; p53Lox/Lox genotype appeared to give rise to a glioma-like tumour (I,L,O,R) (adapted from 
(Jacques et al., 2010). 
 
The RbLox/Lox; p53Lox/Lox mice developed solid malignant tumours, which 
morphologically resembled that of human primitive neuroectodermal tumours (PNET), 
after a latency of 6 months (Figure 12: S). RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice also 
developed PNETs but after a significantly reduced latency of 3 months. Confirmation of 
the PNET-like phenotype of the tumours was observed from the synaptophysin-positive 
and GFAP-negative staining patterns (Figure 12: M,N,P,Q) (Louis et al., 2007). The 
PTENLox/Lox; p53Lox/Lox mice developed highly malignant infiltrative tumours that 
morphologically resembled human high-grade gliomas, as also seen in the literature 
(Llaguno et al., 2009), and confirmed by their synaptophysin-negative and GFAP-
positive expression profile (Figure 12: O,R) (Louis et al., 2007). The latency of tumour 
development in these mice was 6 months, similar to that of the RbLox/Lox; p53Lox/Lox 
mice. 
 
1.7.3 Microneoplasia arises from recombined subventricular zone cells and 
precedes brain tumours 
To trace the origin of the tumours observed following i.c.v. Adenovirus-Cre 
administration1 4x Rb-/-; p53-/-, 6x Rb-/-; p53-/-; PTEN-/-, and 14x PTEN-/-; p53-/- mice 
were culled prior to the expected the expected latency of tumour formation and their 
brains processed for haematoxylin and eosin paraffin immunohistochemistry. Small 
clusters of morphologically atypical cells were observed in areas that contained the 
neural stem and progenitor cells (Figure 13). These neoplastic lesions were observed to 
be -galactosidase-positive, thereby confirming their development as a result of Cre-
mediated recombination. 
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Figure 13: In vivo inactivation of TSGs results in the development of small neoplastic lesions in the 
SVZ prior to tumour formation. The location of precursor lesions from 14x Rb-/-; p53-/-, 6x Rb-/-; p53-/-; 
PTEN-/-, and 14x PTEN-/-; p53-/- were identified using haematoxylin and eosin paraffin 
immunohistochemistry and schematically plotted to verify their origin. 
 
The predominant location of the precursor lesions in the lateral and rostral portion of the 
SVZ suggests that this area contains the stem / progenitor cells that initiate 
tumourigenesis in our model. 
 
1.7.4 In vitro recombined and engrafted neural stem / progenitor cells 
generate tumours that resemble those induced by 
intracerebroventricular Adenovirus-Cre administration 
In order to confirm that the in vivo generated tumours were derived from neural stem / 
progenitor cells of the SVZ we derived and expanded SVZ cells in vitro, recombined 
the TSGs using Adenovirus-Cre, and engrafted them into the striata of non-recombined 
mice of a similar genetic background. 
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Figure 14: In vitro recombined and engrafted NS generate tumours. As with i.c.v. Adenvirus-Cre 
administration, in vitro recombined Rb-/-; p53-/-; PTEN-/- NS were observed to generate synaptophysin-
positive (G) and GFAP-negative (I) PNET-like tumours (A,C,E) whereas the PTEN-/-; p53-/- NS were 
observed to generate synaptophysin-negative (H) and GFAP-positive (J) glioma-like tumours (B,D,F) 
(adapted from (Jacques et al., 2010). 
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The engrafted Rb-/-; p53-/-; PTEN-/- (13/13), and to a lesser extent the Rb-/-; p53-/- (2/32), 
NS gave rise to tumours (Figure 14: A,C,E) that resembled PNETs similar to the 
coprresponding i.c.v. Adenovirus-Cre-induced tumours (Figure 12), and also displayed 
the same synaptophysin-positive and GFAP-negative expression profile (Figure 12: 
G,I). Likewise, the engrafted PTEN-/-; p53-/- NS gave rise to infiltrative gliomas (8/23) 
(Figure 14: B,D,F) that displayed the same synaptophysin-negative and GFAP-positive 
expression profile as those tumours observed after i.c.v. Adenovirus-Cre-mediated 
recombination of the same TSGs (Figure 12 and Figure 14: H,J). These findings 
demonstrate that in vitro recombined and grafted neural stem/progenitor cells, grown as 
NS, generate tumours that are phenocopies of those generated following i.c.v. in vivo 
recombination. This suggests that SVZ NSCs may represent the brain tumour initiating 
cell (BTIC). However, these results do not exclude the possibility that other more 
mature cell types (e.g. terminally differentiated astrocytes) were ectopically targeted for 
recombination during i.c.v. Adenvirus-Cre delivery and contributed toward the observed 
tumourigenesis. 
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1.8 Model System Aims 
1. Characterise the in vitro functional profiles of neural stem cells and their 
transformed counterparts based on the combination of tumour suppressor genes 
inactivated; 
a. Verify that in vitro NSCs cultures contain the same SVZ NSCs that are 
targeted by i.c.v. Adenovirus-Cre administration. 
b. Characterise the effect of Rb, p53, and PTEN loss on the growth rate, 
self-renewal, multipotency and biomarker expression of NSCs in vitro. 
c. Examine whether the in vitro functional properties of NSCs correlate 
with in vivo tumour hit rate and/or latency. 
d. Identify surrogate markers of tumour phenotype. 
 
2. Characterise the brain tumour initiating cell; 
a. Verify that brain tumour development following i.c.v. Adenovirus-Cre 
administration is initiated and driven by SVZ NSCs. 
b. Examine whether NSCs exist in the brain tumour bulk as brain tumour 
initiating cells (BTICs). 
c. Refine the BTIC to a more specific sub-type of SVZ NSC. 
d. Identify whether NSCs exist in different states dependent on their 
environment and whether these have altered tumour hit rates, latencies, 
and phenotype propensities. 
e. Functionally characterise these different states in vitro. 
 
3. Investigate CD133 (Prominin-1) as a marker brain tumour initiating cells; 
a. Verify that SVZ NSCs express CD133 both in vivo and in vitro. 
b. Characterise the CD133 expression pattern in wild-type and recombined 
tumourigenic NSCs. 
c. Characterise the functional differences of tumourigenic CD133+ and 
CD133- NSCs in vitro. 
d. Characterise the in vivo tumour hit rates, latencies, and phenotype 
propensities of tumourigenic CD133+ and CD133- NSCs and assess 
whether CD133 expression can be used as a predictive indicator. 
e. Identify novel markers of BTICs. 
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4. Assess the relative contribution of terminally differentiated astrocytes to the 
development of brain tumours in our model system. 
a. Verify whether i.c.v. Adenovirus-Cre administration targets terminally 
differentiated astrocytes, outside of the SVZ, for TSG recombination. 
b. Assess whether TSG loss in terminally differentiated astrocytes induces a 
transformation in function and/or differentiation state of the cells. 
c. Examine whether these hypothetically transformed astrocytes can 
generate tumours in vivo. 
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2 Materials and Methods 
 
2.1 In Vivo Experimental Procedures 
 
2.1.1 Mice 
The following mouse genotypes were used: RbLoxP/LoxP; p53LoxP/LoxP; R26RLoxP/LoxP 
(short: Rb/p53), PTENLoxP/LoxP; p53LoxP/LoxP; R26RLoxP/LoxP (short: PTEN/p53), 
RbLoxP/LoxP; PTENLoxP/LoxP; R26RLoxP/LoxP (short: Rb/PTEN), or RbLoxP/LoxP; p53LoxP/LoxP; 
PTENLoxP/LoxP; R26RLoxP/LoxP (short: Rb/p53/PTEN). All mice were inter-crossed from 
single mutant conditional knockout mice generated with the same strain ES cells (129 
Ola). After generating double, triple, or quadruple homozygous mouse lines, they were 
kept homozygous for all alleles and in-bred within the same colony. Further description 
of PTENLoxP/LoxP mice is given in (Marino et al., 2002b), RbLoxP/LoxP, and p53LoxP/LoxP 
mice in (Marino et al., 2000) and R26RLoxP/LoxP reporter mice are described in (Soriano, 
1999). Genotyping was carried out from tail DNA using standard PCR reactions. 
Primers are as published: Rb18 and Rb19, p53–int10–fwd and p53 int10–rev (Marino et 
al., 2000), PTEN A and S (Marino et al., 2002b), ROSA26-1, 2 3 (Soriano, 1999), LZ1 
and LZ2 (Marino et al., 2000). The mice were kept, and all procedures were carried out, 
according to institutional and UK Home Office guidelines (Project license 70/5540 and 
70/6603). All mice were housed and maintained in the MRC Biological Services 
Facility (BSF), Wakefield Street, London under specific pathogen-free conditions in 
accordance with the UK Animals (Scientific Procedures) Act 1986. They were kept on a 
12hr light-dark cycle and given food and water ad libitum. 
 
2.1.2 Anaesthesia 
Prior to all stereotaxic surgery mice were anaesthetised intraperitoneally (i.p.) using 
Hypnorm / Hypnovel (Hypnorm : Hypnovel : H2O; 1:1 :3) at 10μl/g bodyweight with 
the males receiving a slightly lower dose of ca. 8μl/g, or with Ketaset / Rompun at 
100mg/kg bodyweight / 16mg/kg body weight (150-200μl). 
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2.1.3 Preparation and administration of Adenovirus-Cre for i.c.v. delivery 
The HindIII fragment of pBS185 containing the Cre ORF under control of the hCMV 
immediate early promoter and the metallothionein I polyadenylation signal was inserted 
into the HindIII site of pdE1spIA and co-transfected with pJM17 into HEK293 cells. 
The viruses were plaque purified and re-analysed prior to preparation of large scale 
stocks. The recombinant adenoviral vector was propagated in HEK293 cells and the 
titre was determined by a plaque formation assay. 
Viral infection of SVZ cells was achieved by unilateral stereotaxic injections of 109 
plaque-forming units (5μl) of Adenovirus-Cre in 10mMTris-HCl directly through the 
skull into the left cerebral hemisphere of anaesthetised mice placed in a stereotaxic 
frame (Narishige SR 6N). The coordinates of the injection site in relation to bregma 
were: anterior 0 mm; lateral 0.5 mm, ventral 2.5 mm and was performed with a 
Hamilton syringe (701RN) and 26G needle. 
 
2.1.4 Intracerebral engraftment of cells 
NS and astrocytes were taken for engraftment/transplantation at passage 3-5. NS were 
collected in a 15/50ml tube and allowed to settle before being resuspended in 0.5ml 
DMEM/HAM F12 (BioWhittaker) NS growth medium. Astrocytes were trypsinised 
with trypsin-EDTA solution (Invitrogen), spun at 300 x g for 5 min (room temperature) 
and collected in 100l DMEM high glucose astrocyte growth medium (BioWhittaker). 
Intracerebral engraftment of NS/astrospheres was performed by injecting 5-15X		
concentrated NS/astrosphere suspension sediment into the left striatum of genetic 
background-matched adult mice (bregma, 1.5 mm lateral, 2 mm ventral) using a 22G 
	*			[\X			]^!_?[$`	{	\X	|	=			
contain 1202 +/- 147 NS/astrospheres or 1.38x106 +/- 0.12x106 NSCs. 
Intracerebral injection of astrocytes was achieved by injecting 5-12.5μl glial cell 
suspension sediment (1x105 - 1x106 cells) into the left striatum (bregma, 1.5 mm lateral, 
2 mm ventral) genetic background-matched or nude adult mice using a 22G needle 
attached to a 25l Hamilton syringe (RN1702). 
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2.1.5 BrdU injections 
To label proliferating cells, mice were given intraperitoneal (i.p.) injections of BrdU at a 
		\?X			f body weight. Being a base analogue of thymidine, 
BrdU substitutes for thymidine during DNA synthesis and incorporates into the newly 
synthesized DNA. Therefore by BrdU administration, dividing (stem) cells are labelled. 
BrdU positive cells can be detected on brain sections by immunohistochemical 
techniques using an antibody detecting the BrdU residues incorporated into nuclear 
DNA. 
 
2.1.6 Culling and brain removal 
For the purposes of primary cell culture the mice were culled by cervical dislocation, 
their brains removed under sterile conditions, collected in ice-cold HEPES buffer and 
subsequently processed in accordance with the required protocol. 
For histology purposes the mice were culled by asphyxiation in rising levels of CO2 in 
order to retain the structural integrity of the entire brain. Following this the brains were 
removed and left to fix in 10% buffered formalin for 30 minutes at room temperature 
	=**	*	=	*			-galactosidase or processed for paraffin 
histology. 
 
2.2 Cell Culture 
 
2.2.1 Derivation and growth of neural stem cells 
All surgical instruments were surgically sterilised. A minimum of four mice were used 
and were killed by cervical dislocation. The brain was removed and placed in a 10cm 
dish containing ice-cold HEPES buffer in order to preserve the tissue. Each brain was 
transferred out of the HEPES buffer and onto the sterile side of a dry petri dish lid and 
processed sequentially. Using a stereo microscope, along with surgical forceps and a 
razor blade, the anterior portion (bregma 2 to -2) of the SVZ-containing lateral 
ventricles was microdissected (Figure 15). 
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Figure 15: Bregma coordinates of the brain region microdissected for lateral ventricle acquisition. 
 
This 4mm coronal slice was then trimmed further (Figure 16), using micro-scissors, to 
eliminate surplus tissue leaving an area that specifically encompassed the lateral 
ventricles. 
 
 
Figure 16: Coronal schematic showing the two lateral SVZ-containing lateral ventricle regions 
(yellow) targeted for microdissection. Black line: first plane used to trim tissue, dashed red line: second 
plane used to trim tissue, green lines: third planes used to trim tissue. 
 
The two resulting segments of tissue were transferred back into ice-cold HEPES buffer. 
These SVZ-containing tissue segments were transferred onto a sterile Teflon disk and 
minced using a Tissue Chopper (McIlwain) set to 400μm and cut in 5 planes. The tissue 
was then dissociated by treatment with Papain (Worthington, USA), and mechanically 
dissociated into a single cell suspension. The cells were pelleted by centrifugation at 
300 x g for 5min (room temperature). In order to purify the sample and remove debris 
the cell pellet was reconstituted in a DNAse-albumin-inhibitor mixture and spun in a 
discontinuous density dependant gradient over an albumin-inhibitor mixture at 70g for 
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6min (room temperature). The purified cell pellet was then resuspended in the pro-
mitogenic Dulbecco’s modified Eagle’s medium/Ham F12 medium (DMEM/Ham F12, 
Sigma) supplemented with 1 ml B27, 500ml P/S, EGF and bFGF (both 20ng/ml). The 
cells were plated out and initially left for five days before replacing the medium. 
Following this media changes were performed every three days. The cells grew as free-
floating aggregates (neurospheres) and were passaged when deemed large enough (ca. 
12 days) by incubation in Accumax (Chemicon) for 45 minutes at 37C followed by 
mechanical dissociation into single cells at which point they could be re-plated. 
All cultures were maintained at 37C in an atmosphere of 5.0% CO2 and 95% rH 
(Hareaeus), and all experiments were performed between passages 2 and 4. 
 
2.2.2 Derivation and growth of glial cells 
Neonatal mice (P2-P5) were killed by decapitation. The brain was removed and placed 
in cold (4C) HEPES buffer on ice. Using a dissecting stereo-microscope, meninges and 
blood vessels were separated from the cortex, which were then collected in 6cm sterile 
dishes containing cold HEPES buffer. The tissue was minced with a mechanical tissue 
shopper (400m thickness) and digested for 12 minutes at 37C in a solution of HEPES 
buffer and trypsin containing trypsin-EDTA and Dnase I. The digestion was terminated 
by adding a Trypsin stopper solution containing trypsin-inhibitor soybean (Boehringer 
Mannheim), MgSO4 7H2O and Dnase I. Subsequently, tissue suspension was 
fractionated by centrifugation for 30 seconds at 3300 rpm (room temperature). The 
fraction was resuspended in a small volume of pre-warmed trypsin solution, triturated 
with an 18G syringe and spun once more for 12 minutes at 1000 rpm (room 
temperature). The cell suspension was plated out in 10cm dishes (NUNC) with growth 
medium (DMEM high glucose with L-glutamine supplement (BioWhittaker), 10% FCS 
(Invitrogen, #10106-169) and 1% P/S (Invitrogen). Medium was replaced every 3 days. 
Prior to infection, the cells were passaged once confluent using trypsin-EDTA solution 
(Invitrogen) and re-plated at half of their original density (1 in 2 dilution) in growth 
medium. 
All cultures were maintained at 37C in an atmosphere of 5.0% CO2 and 95% relative 
humidity (Heraeus), and all experiments were performed between passages 2 and 3. In 
order to calculate cell numbers for the purpose of experiments, astrocytes were 
trypsinised with trypsin-EDTA solution (Invitrogen), spun for 5 min at 1000rpm and 
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resuspended in 5ml fresh medium. A 20μl aliquot was taken from this cell suspension to 
perform the cell count (as described in section 2.2.3). 
 
2.2.3 Adenovirus-Cre/GFP-infection of neurospheres and astrocytes 
NS were collected in a 15/50ml tube and allowed to settle. All but 1ml media was 
aspirated and a 50μl aliquot was taken, incubated in 350μl AccuMax (Chemicon, 
#SCR006) at 370C for 20 minutes (as the NS are smaller), and then mechanically 
dissociated into single cells. A 20μl aliquot was taken from these single cells and mixed 
1:1 with 20μl of Trypan Blue (Sigma, T8154) so that the cells could be visualised. The 
solution was then loaded onto a haemocytometer where a cell count was performed. 
Using a multiplicity of infection (MOI) of 5, the required volume of Adenovirus-Cre / 
Adenovirus-GFP required for infection was calculated (both viral titres were ~2.5x109 
pfu/ml). The original population of NS were separated with a ratio of 0.1 : 0.55 : 0.35 
for Adenovirus-Cre : Adenovirus-GFP : Untreated and placed in separate 10cm plates. 
The NS were then infected with the required volume of Adenovirus-Cre / Adenovirus-
GFP virus.  The NS medium was changed 2 days after infection, and then the NS were 
passaged after 3 days. Infection efficacy was determined by examining and recording 
the 509nm emission of the Adenovirus-GFP treated cells 2 days post-infection under a 
Zeiss Axiovert 200 fluorescence microscope (excitation wavelength 488nm). Pictures 
were obtained using a Nikon Coolpix 995 3 Megapixel digital camera mounted on the 
microscope. 
In contrast to NS, astrocytes were grown as an adherent culture. Using the same 
multiplicity of infection (MOI) of 5, the required volume of Adenovirus-Cre / 
Adenovirus-GFP required for the infection of astrocytes was calculated. Based on both 
viral titres being ~2.5x109 pfu/ml this volume was ~2μl per 80-90% confluent 10cm 
plate. As the number of cells in an 80-90% confluent 10cm plate was highly repeatable, 
a standardised volume of 2μl Adenovirus-Cre/GFP was used for the infection of each 
10cm plate for all astrocytic cultures. Six 10cm plates were infected with a ratio of 1 : 3 
: 2 for Adenovirus-Cre : Adenovirus-GFP : Untreated astrocytes. The medium was 
changed 2 days after infection, and then the astrocytes were passaged after 3 days.  
Infection efficacy was determined by examining and recording the 509nm emission of 
the Adenovirus-GFP treated cells 2 days post-infection under a Zeiss Axiovert 200 
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fluorescence microscope (excitation wavelength 488nm). Pictures were obtained on a 
Nikon Coolpix 995 3 Megapixel digital camera mounted on the microscope. 
 
2.3 In vitro Functional Characterisation Assays 
 
2.3.1 -Galactosidase staining 
Upon Cre-recombination, the LacZ reporter gene in the ROSA26 locus expresses -
Galactosidase and can therefore be used as a marker to estimate the efficiency of Cre-
recombination. 
This technique can be performed in situ on ex vivo brain slices, i.e. to macroscopically 
observe any Adenovirus-Cre-mediated recombination. Mice were culled by CO2, their 
brains removed and left to fix in 10% formaldehyde (formalin) for 30 minutes at room 
temperature. Using a razor blade, brain slices encompassing the necessary regions 
(rostral section of the LV and SVZ) were cut and further fixed in formalin for 30 
minutes (room temperature) on an orbital shaker. The brain slices were then 
permeabilised by incubation in permeabilisation buffer (10mM Phosphate buffer, 
150mM NaCl, 3mM MgCl2, 3.3mM K4Fe(Cn)6 x 3H2O, 3.3 K3Fe(CN)6, 0.02% NP40, 
0.01% sodium deoxycholate) for 30 minutes (room temperature) on an orbital shaker. 
The buffer was then changed to permeabilisation buffer containing 1mg/ml BlueGal 
(Merck) and the slices were left to incubate o/n at 37C on an orbital shaker. BlueGal is 
#	
	-galactosidase expressed by the LacZ gene yielding galactose and 5-bromo-
4-chloro-3-hydroxyindole. This compound is then oxidized into 5,5'-dibromo-4,4'-
dichloro-indigo, an insoluble blue product. Once successfully stained, these slices were 
then post-fixed for 24 hours in formalin and either immediately imaged or processed for 
paraffin immunohistochemistry. 
For NS, a 1ml aliquot of was taken directly from a NS culture at around 10 days post-
infection. In contrast, astrocytes which had been trypsinised at confluence and plated 
out at 0.3x105 cells/ml in a 4-well plate, were once again allowed to grow to confluence 
prior to being stained. Both preparations were washed once with PBS followed by 
fixation with 0.5% Glutaraldehyde for 5 minutes at room temperature. After two more 
PBS washing steps the cells were incubated with staining solution (10mM Phosphate 
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buffer, 150mM NaCl, 1mM MgCl2, 3.3mM K4Fe(CN)6 x 3H2O, 3.3 K3Fe(CN)6) 
containing 1mg/ml BlueGal (Merck) overnight at 37C. 
*	
			*		=	*<		-galactosidase staining using a Zeiss 
Stemi SV11 microscope or a Zeiss Axiovert 200 microscope respectively, and images 
were captured using a mounted Nikon Coolpix 995 3.34 mega pixels digital camera. 
 
2.3.2 WST-1 proliferation assay 
The WST-1 assay is used to measure the relative proliferation of cells in vitro. The 
assay principle is based on the conversion of the tetrazolium salt WST-1 into an orange 
coloured dye (formazan salt) by mitochondrial dehydrogenase enzymes. Over time this 
reaction produces a colour change of the medium which is directly proportional to the 
amount of mitochondrial dehydrogenase, and therefore cell number/activity, in a given 
culture.   
This analysis was performed in a 96-well plate. NS were dissociated by Accumax and 
seeded at 6x104 cells/well in 10 wells each containing 100μl medium. Astrocytes were 
trypsinised at confluence and seeded at 5x103 cells/well in 10 wells each containing 
100μl. NS were left for 3 days, and astrocytes for 2, before the addition of 10μl WST-1 
reagent per well and taking readings at 0, 4, 6 and 8 hours. 
Samples were run in groups of 10 repeats, and corrected against background 
fluorescence, on a Tecan Sunrise microplate reader with XFluor 4 software using a 
detection wavelength of 440nm and a reference of 620nm. 
 
2.3.3 Neurosphere size and neurosphere-forming clonogenicity assay 
For the NS size assay, NSCs were taken at passage 3 were seeded at 0.5x106 cells/well 
in 1 well of a 6-well plate containing 3ml NS media. On day 3 an additional 4ml of 
media was added to the well, and full media changes (4ml) were carried out on days 5 
and 7. On day 8 the diameter of the cells was visualised using a Zeiss Axiovert 135 
microscope and recorded using the Openlab 5 software. An average was calculated from 
??		=*	*			
		=		` 
For the NS-forming clonogenicity assay NSCs taken at passage 3 were seeded at 
0.5x106 cells/well in 1 well of a 6-well plate containing 3ml NS media and the number 
of neurospheres that formed was measured after 8 days. To measure the NS-forming 
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ability of the NSCs a representative 0.5ml aliquot was taken from the NS culture and 
transferred into a 4-well plate for counting. Two NS counts were performed and the 
average was extrapolated, depending on the total volume of the NS culture, in order to 
generate an estimation of the total number of NS in the culture. 
 
2.3.4 Self-renewal assay 
Neurospheres were collected and, if these were non-in vitro recombined, the percentage 
of recombined neurospheres was calculated by staining for -Galactosidase activity and 
counting the number of positive (blue) neurospheres. The neurospheres were then 
dissociated into single NSCs by complete aspiration of any media (including a wash of 
the cells in PBS) and incubation in 500μl (per half 10cm plate) Accumax (Chemicon) 
for 45mins at 37C followed by mechanical dissociation. The Accumax was diluted out 
by transferral into NS medium at a ratio of 1:3. The NSC-containing medium was then 
passed through a sterile 40μm nylon mesh to remove any multi-cell aggregates, 
collected in an Eppendorf tube and transferred onto ice. The single cells were then 
adjusted to a concentration of 1x106 cells/ml, transferred to the Flow Cytometry Core 
Facility (UCL Institute of Child Health) for single cell sorting into individual wells of 
96-well plates (2x plates per genotype) using the MoFlo XDP FACS machine 
(Beckman Coulter) with IntelliSort software. 200μl of NS medium was added to each of 
the wells of the 96-well plates for cell collection (less liquid causes NSCs to be reflected 
out of the wells and lost). The forward/side scatter gating and both forward scatter and 
side scatter height-width plots were respectively used to exclude dead cells and for 
doublet discrimination to maximise efficient single cell sorting (Figure 17). One well of 
each 96-well plate used was designated to receive 100 cells as a positive control. Once 
the single NSCs had been collected in the 96-well plates they were kept on ice until they 
could be transferred back into an incubator maintained at 37C in an atmosphere of 
5.0% CO2 and 95% relative humidity. As a post-hoc measure of verifying the viability 
of the NSCs used for sorting the DNA binding dye Hoechst 33342 (Sigma) was added 
at a concentration of 5μg/ml to the original NSC samples and left to incubate for 5 
minutes before being re-run through the FACS machine. 
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Figure 17: 95% of NSCs used for single cell sorting (self-renewal assay) were viable. Representative 
DAPI fluorescence (y-axis) vs. side scatter (x-axis) FACS plot of a NSC sample used for single cell 
sorting into individual wells of a 96-well plate using a MoFlo XDP FACS machine. 
 
The number of cells present in each of the wells was then counted to verify the success 
and accuracy of the single cell sorting process and to record the starting number of 
single cells. The plates were then incubated for nine days with medium changes of 
250μl taking place after four and seven days (only 80% of the medium was removed 
with each change to prevent aspirating the neurospheres). The self-renewal and growth 
of the single NSCs into neurospheres was monitored over the nine days by taking 
images with a Nikon Coolpix 995 3 Megapixel digital camera mounted on a Zeiss 
Axiovert 200 fluorescence microscope. After nine days the number of neurospheres that 
had grown from single NSCs in both 96-well plates was counted and the percentage of 
NSCs capable of self-renewal was calculated. If the percentage of recombined 
neurospheres calculated at the start of the assay was less than 100% then a repeat -
Galactosidase activity stain was performed in situ on all the neurospheres in one of the 
two 96-well plates so that the self-renewal data could be split into non-recombined vs. 
recombined NSCs. 
If desired, the secondary self-renewal of the NSCs could be tested for by repeating the 
protocol described above (minor changes detailed below) on the neurospheres yielded 
from the primary self-renewal assay (Figure 18). Special care was taken for the 
secondary self-renewal assay with respect to dissociating the neurospheres as they had 
to be dealt with individually to maintain the clonal identity of the neurospheres. The 
neurospheres were therefore randomly selected and dissociated into single NSCs in the 
individual wells of the 96-well plates in situ by complete aspiration of any media and 
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incubation in 100μl Accumax (Chemicon) for 20mins at 37C followed by gentle 
mechanical dissociation. The Accumax was diluted out by transferral into 300μl NS 
medium. The NSC-containing medium was then passed through a sterile 40μm nylon 
mesh to remove any multi-cell aggregates, collected in an Eppendorf tube and 
transferred onto ice. The final concentration was calculated but not adjusted as the 
estimated ~1000 cells/neurosphere (0.25x104 cells/ml) is already below the optimum 
concentration of cells for sorting with the MoFlox XDP FACS machine. To compensate 
for this, only half of a 96-well plate was used to receive the sorted single NSCs from 
each of the secondary neurospheres, with a single designated well receiving 10 cells as a 
positive control. A minimum of six individual neurospheres totalling three 96-well 
plates were used for the secondary self-renewal assay. 
 
 
Figure 18: Schematic representation of the primary and secondary phases of the self-renewal assay 
protocol. 
 
2.3.5 Neurosphere differentiation 
Neurosphere differentiation was induced by plating NS on laminin-coated (1mg/ml) 
glass coverslips (13mm) contained in 24-well plates or chamber slides in DMEM/Ham 
F12 (Sigma) with 1% FCS for 5 days. A partial medium change was carried out after 3 
days. The differentiated cells were then washed in PBS and fixed in 4% formaldehyde 
for 30 minutes (room temperature) before being processed for immunohistochemistry. 
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2.3.6 Plating glia on coverslips 
To prepare for immunohistochemistry, cells were trypsinised using trypsin-EDTA 
solution (Invitrogen) and plated at a density of 1x105cells/ ml on sterile 13mm glass 
cover slips contained in the wells of 24-well plates in DMEM high glucose with L-
glutamine (Sigma) with 10% FCS for 5 days. The differentiated cells were then washed 
in PBS and fixed in 4% formaldehyde for 30 minutes (room temperature) before being 
processed for immunohistochemistry. 
 
2.4 Expression Analysis 
 
2.4.1 cDNA Expression analysis with Superarray RT2 Profiler 
Total RNA was extracted from samples using the Qiagen RNeasy Mini Kit in 
accordance with the manufacturer’s instruction. The yield and purity of a 1μl sample of 
the total RNA was assessed using the UV/VIS NanoDrop spectrophotometer (ND-3300, 
NanoDrop Technologies, USA) to measure the concentration (A260: ng/μl), the level of 
protein contamination (A260:A280), and the level of general contamination (A260:A230). 
Only samples with concentrations greater than 500 ng/μl, A260:A280 ratios greater than 
2.0, and A260:A230 ratios greater than 1.7 were considered suitable for downstream use. 
The ribosomal RNA band integrity of these samples was then assessed using a 2100 
BioAnalyzer (Agilent Technologies, USA) to verify that that had been no 18s or 28s 
ribosomal RNA (rRNA) degradation. All the samples that passed the NanoDrop purity 
test were found to have high quality non-degraded rRNA as shown by the presence of 
two well-defined peaks without any smearing corresponding to 18S and 28S rRNA on 
the electropherograms (Figure 19). 
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Figure 19: All samples that passed the NanoDrop purity test were found to have high quality non-
degraded rRNA. (A) Representative BioAnalyzer electropherogram of a total RNA sample taken from in 
vitro neurospheres showing well-defined sharp peaks for both the 18S and 28S ribosomal RNA. (B) 
Sharp pseudo-agarose gel electrophoresis bands demonstrate minimal degradation. 
 
A quantitative RT-PCR was performed using the manufacturer's protocols for the 
Mouse Cancer PathwayFinder RT2 Profiler PCR Superarray (APMM-033C, SA 
Biosciences, USA). The Mouse Cancer PathwayFinder PCR Superarray is a 96-well 
plate containing RT2 qPCR Primers for a set of 84 genes representative of six cancer 
pathways (cycle control and DNA damage repair, apoptosis and cell senescence, signal 
transduction molecules and transcription factors, adhesion, angiogenesis, invasion and 
$@		#	*<		]-glucuronidase, hypoxanthine guanine 
phosphoribosyl transferase 1, heat shock protein 1 beta, glyceraldehydes-3-phosphate 
*@	-actin), a mouse genomic DNA contamination control, three reverse 
transcription controls, and three positive PCR controls. 
First strand cDNAs were prepared from 1μg of total RNA from each sample using the 
RT2 First Strand Kit according to the maunfacturer’s instructions (C-03, SA 
Biosciences, USA). Following this, the cDNA for each sample was added to the ready-
to-use RT2 SYBR green qPCR mastermix and, with one sample corresponding to one 
96-well PCR Superarray plate, 25μl of the experimental cocktail was added to each well 
(containing the predispensed gene-specific primer sets) of the plate. The plate was 
sealed with optical adhesive film and a two-step cycling program (Figure 20) was 
loaded onto the ABI 7500 FAST Real-Time PCR System (Applied Biosystems). 
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Figure 20: Two-step cycling program used to run the Mouse Cancer PathwayFinder RT2 Profiler 
PCR Superarray on the ABI 7500 FAST Real-Time PCR System. 
 
The instrument’s software was used to automatically set the baseline (start cycle: 3, end 
cycle: 15) and the threshold cycle (Ct) was set manually by adjusting it above the 
background signal but within the lower half to one-third of the linear phase on the log 
view of the amplification plot. The resulting Ct values for all the genes across each of 
the four experimental genotypes (n=2 each) were exported into the Superarray ‘Data 
Analysis Template Excel File’ for analysis against the control genotype (n=2). 
Relative gene expressions were calculated using the 2 method (Pfaffl, 2001) and an 
average of all five of the housekeeping genes for normalisation. Any Ct values greater 
than 35 were considered to be negative and only samples that were passed for all the 
internal/external controls were analysed (none failed). Fold change values were then 
presented as average fold change = 2(average ) for each of the genes relative to the 
control samples and converted into fold changes (up- or down-regulation). The 
statistical significance of differences in gene expression between the experimental 
samples (n=2) and the controls (n=2) was calculated using a two-tailed student's t-test 
(P < 0.05). 
The Superarray assay was carried out for a total of two experimental repeat samples for 
each of the non-recombined Adenvirus-GFP-infected control, Rb-/-; p53-/-, PTEN-/-; p53-
/-, Rb-/-; p53-/-; PTEN-/-, and Rb-/-; PTEN-/- genotypes (n=10 overall). 
 
2.4.2 Reverse-transcriptase polymerase chain reaction analysis of CD133 
RNA expression 
Total RNA was extracted from samples using the Qiagen RNeasy Mini Kit in 
accordance with the manufacturer’s instructions. Total RNA was transcribed using 
SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer’s 
instructions. Filtered pipette tips were used throughout to prevent contamination. cDNA 
samples were pre-warmed to 37°C. GoTaq Flexi DNA polymerase kit (Promega) was 
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used and kept on ice at all times. All PCR primers were obtained from MGW Biotech, 
dissolved in sterile water to a concentration of 100pmol/μl and dissolved for 8’ at 65°C 
with shaking. A mastermix containing 5xGreen GoTaq Flexi Buffer (1x final 
concentration), MgCl2 (1.5mM), GoTaq DNA polymerase (1U), dNTPs (0.25mM)(PCR 
nucleotide mix [Promega]), primers (0.5pmol/μl)(MGW Biotech) was made. Per 
sample, 1μl of DNA was dissolved in 24μl of mastermix and heated according to the 
type of PCR (see below) using an AB Applied Biosystems GeneAmp PCR System 
9700. All PCRs have a common initial heating phase of 94°C for 2min to activate the 
Taq polymerase and a final phase of 72°C for 7’ to complete extension of products and 
annealing of single-stranded complementary products. The PCR samples were 
subsequently stored at 4°C for up to 2 days or at -20°C until used. 
 
Mouse Prominin-1 
Primers: RT Prominin-1-F: 5’ GGA GCT GAC TTG AAT TGA GG 3’ 
 RT Prominin-1-R: 5’ ACC AAC ACC AAG AAC AAG GC 3’ 
 Actin-F:  5’ GAT GAC GAT ATC GCT GCG CTG GTC G 3’ 
 Actin-R:  5’ GCC TGT GGT ACG ACC AGA GGC ATA CAG 3’ 
Band: Prominin-1: 349bp 
 -actin:  1kb (internal control) 
Program: Denaturing:  940C 30’’ 
 Annealing:  600C 45’’ 35 cycles 
 Extension:  720C 45’’ 
 
The PCR samples were separated by agarose gel electrophoresis. 1.5%-2% Agarose 
(Sigma) was dissolved in 1x TAE buffer (Sigma) in the microwa#`	`\X		?		
ethidium bromide (Sigma) was added per 200ml of Agarose gel. The gel was poured 
into a mould and allowed to solidify. It was then transferred to a running chamber and 
filled with enough 1xTAE buffer to completely submerge the gel. 10μl of PCR samples 
were pipetted into the wells. 6μl of 100bp ladder (Promega) was loaded as a marker and 
the gel was run at 100V for ~1 hour. The bands were then visualised with a BioRad Gel 
Doc 1000 and QuantityOne software.  
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2.4.3 Protein extraction from neurospheres 
NS were collected in a 1.5ml Eppendorf tube and washed in PBS whilst kept on ice. All 
of the liquid was aspirated and 200μl RIPA buffer (50mM Tris pH: 7.4, Sigma; 1% 
Igepal, Fluka BioChemika; 0.25% Sodium Deoxycholate, Sigma; 150mM NaCl, Fisher 
Chemicals; 1mM EGTA, Sigma) containing Protease Inhibitor (1 tablet in 7ml RIPA 
buffer, Roche) was added to the neurospheres and left on ice for 20mins before either 
being mechanically homogenised by passing them through a 21g needle for immediate 
protein determination or transferred to a -800C freezer for storage. 
 
2.4.4 Protein determination assay 
Bovine serum albumin (BSA) standards of 0.0mgl/ml to 1.2mg/ml (in 0.2mg/ml 
increments) were prepared by diluting BSA (2mg/ml) with RIPA buffer. The NS 
homogenates were diluted 20-fold and 10-fold respectively with RIPA/PI. BCA protein 
assay reagent A and B (Pierce) were mixed in a 50:1 ratio and 200μl were pipetted into 
the wells of a 96-well plate. 10μl of each sample were added in duplicates and the plate 
was incubated at 37°C for 30’. The plate was then analysed using the Tecan Sunrise 
microplate reader with XFluor 4 software. The detection wavelength was set to 570nm 
with a reference of 690nm. The protein concentration of the NS sample homogenates 
was then back-calculated off the BSA standard curve. 
 
2.4.5 	
					 
0.75mm discontinuous “Laemmli” polyacrylamide gels were made up with 10% 
separating gel (dH2O, 10% Bis-acrylamide, separating gel buffer (0.38M Tris-base, 
1.4mM SDS, pH8.8), APS, TEMED) and 5% stacking gel (dH2O, 5% Bis-acrylamide, 
stacking gel buffer (0.13M Tris-base, 3.5mM SDS, traces of Bromphenolblue, pH6.8), 
APS, TEMED) for the wells. Prior to loading, the protein samples were made up to 
1.25mg/ml with dH2O, 1x XT sample buffer (BioRad) and 0.35M Dithiothreitol (DTT) 
to reduce the disulphide bridges. They were then boiled for 5’ at 95°C to denature the 
proteins. 10μl corresponding to 12.5μg of protein were loaded into each well. Two 
different protein markers were used, biotinylated protein ladder (Cell Signalling) and 
Precision Plus protein ladder (BioRad). Empty wells were loaded with 10μl 1x XT 
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sample buffer (BioRad) to ensure even running of the bands. The gel was then run at 
200V for ~35’ in ‘running buffer’ (250mM Tris, 1.92M Glycine, 1 % SDS). The 
stacking gel and any unused wells were then removed. 
Immobilon-P membrane (Millipore) and gel blotting paper (Schleicher & Schuell) were 
cut to match the gel size. The membrane was then dipped in 100% methanol for 15’’ 
washed in dH2O and equilibrated in cold ‘transfer buffer’ (dH2O, 20% methanol, 25mM 
Tris, 0.2M Glycine) for 15’. The gel, filter paper and two foam pads were also 
equilibrated in cold ‘transfer buffer’ for 15’. The blot was then assembled as follows: 1x 
foam pad, 2x filterpaper, equilibrated gel, Immobilon-P membrane, 2x filterpaper, 1x 
foam pad. A glass tube was used to gently roll air bubbles trapped in between the layers 
to prevent them interfering with the transfer of proteins. This was placed in a cassette 
and transferred to a mini-trans blot cell (BioRad) filled with cold ‘transfer buffer’. The 
cell was then run for 1h at 100V. The membrane was air-dried to improve protein 
binding, dipped in 100% methanol for 10’’ and air dried again. After drying the blot 
was washed in TBST (1mM Tris pH7.8, 0.1M NaCl, 0.05% Tween-20) and blocked 
overnight in 5% milkpowder (Marvel, Premier International Foods)/TBST (w/v) at 4°C 
on an orbital shaker. After washing, the blot was incubated overnight with primary 
antibody (see below) in 1% milkpowder/TBST at 4°C on an orbital shaker. Excess 
antibody was washed off with 3x rinses in TBST and the blot was incubated for 1h with 
horse radish peroxidase (HRP)-conjugated secondary antibody (see below)/1% 
milkpowder/TBST. Again, excess antibody was washed off with 3x rinses in TBST, and 
the blot was incubated with SuperSignal WestPico Chemiluminescent substrate (Pierce) 
to enhance the HRP signal. The bands were finally visualised with an Image Station 440 
(Kodak) with Kodak 1D v3.6 software. 
Antibodies: anti-CD133 (Prominin-1) (rabbit polyclonal, 1:500 [1μg/ml], Abcam 
ab66141), anti-	]	@	??	`[\@	{
	
$@	--actin 
(mouse monoclonal, 1:1000, Sigma A5441), goat anti-rabbit IgG-HRP (Sigma, A6667), 
goat anti-mouse IgG-HRP (Sigma, A9917). 
 
2.4.6 Semi-quantitative analysis of Western blot bands 
Using the KODAK 1D Image Analysis software package band areas of 814 pixels were 
assigned around each of the bands and set so that the peak of the intensity profiles fell 
centrally. The net intensity was then calculated as the sum of the background-subtracted 
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pixel intensity values within the band area defined. The corrected intensity was 
		]!				!	-actin Intensity)*1000. 
 
2.5 Magnetic/Fluorescence-Activated Cell Sorting 
 
2.5.1 Magnetic-activated cell sorting of neural stem cells into CD133-
negative and CD133-positive populations 
Neurospheres were collected and dissociated into single cells by complete aspiration of 
any media (including a wash of the cells in PBS) and incubation in 500μl (per half 
10cm plate) Accumax (Chemicon) for 45mins at 37C followed by mechanical 
dissociation. The Accumax was diluted out by transferral into NS medium at a ratio of 
1:3. The NSC-containing medium was then passed through a sterile 40μm nylon mesh 
to remove any multi-cell aggregates, collected and transferred onto ice. The MACS 
separation was achieved using the Miltenyi Biotec MiniMACS Starting Kit (130-090-
312), mouse anti-CD133 MicroBeads (130-092-33) and mouse anti-CD133-PE-
conjugated antibody in accordance with the manufacturer’s instructions. Keeping all the 
cells and reagents on ice the concentration of NSCs was adjusted to 1x107 per ml in NS 
medium. The cell suspension was centrifuged at 300g for 10 minutes at 40C and the 
supernatant was removed. The cell pellet was then re-suspended in 80l of MACS 
buffer (PBS pH7.2, 0.5% BSA, 2mM EDTA) per 107 cells and 20l of anti-CD133 
MicroBeads were also added per 107 cells. This suspension was then mixed and left to 
incubate for 15 minutes at 40C. 10l of mouse anti-CD133-PE conjugated staining 
antibody was then added to the suspension per 107 cells and left to incubate for 10 
minutes in the dark at 40C (in order to permit downstream FACS analysis). The cells 
were then washed by adding 1.5ml of MACS buffer per 107 cells, centrifugating them at 
300g for 10 minutes at 40C, removing the supernatant, and then re-suspending them in 
500l MACS buffer. An MS column was placed in the magnetic field of the MACS 
separation unit (magnet) and mounted on the MACS multistand. The column was 
prepared by running 500l of MACS buffer through it under gravity, ensuring that the 
column did not dry out, after which the 500l of cell suspension was subsequently 
applied. The unlabelled cells passed through the column, whilst the labelled cells were 
retained within the magnetic field, and collected in a 15ml falcon tube. The column was 
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then washed by running 500l of MACS buffer through it three times to fully elute the 
unlabelled cells. The total collected effluent represented the unlabelled CD133-negative 
NSC population. The column was then removed from the magnetic field of the MACS 
separation unit and placed over a separate 1.5ml Eppendorf collection tube. 1ml of 
MACS buffer was pipetted onto the column and immediately flushed through by 
applying a plunger in order to elute the magnetically labelled CD133-positive NSC 
population. This CD133-positive NSC fraction was obtained after passing the cells 
through a single column, rather than the manufacturer’s recommendation of two 
columns, because the further enrichment a second column provides was negligible when 
compared to its significant reduction in yield (~50%). However, as the yield of CD133-
negative NSCs from the MACS separation is relatively high we carried out this further 
enrichment by running those cells over a second MS column (using the same protocol as 
above) after re-labelling them with the MicroBeads and the antibody. The second 
CD133-negative/positive fractions eluted were respectively added to the first. The two 
cell fractions were then either used immediately for downstream experiments or 
transferred back into NS medium for subsequent culturing (Figure 57 and Figure 60). 
 
2.5.2 Fluorescence-activated cell sorting of neural stem cells into CD133-
negative and CD133-positive populations 
Neurospheres were collected and dissociated into single cells by complete aspiration of 
any media (including a wash of the cells in PBS) and incubation in 500μl (per half 
10cm plate) Accumax (Chemicon) for 45mins at 37C followed by mechanical 
dissociation. The Accumax was diluted out by transferral into NS medium at a ratio of 
1:3. The NSC-containing medium was then passed through a sterile 40μm nylon mesh 
to remove any multi-cell aggregates, collected and transferred onto ice. The cell 
suspension was then split into two tubes each containing a total of 1x107 cells in 1ml of 
NS medium. The cell suspensions were centrifugated at 300g for 10 minutes at 40C and 
the supernatants were removed. The cell pellets were re-suspended in 100l of MACS 
buffer per 107 cells and 10l of mouse anti-Prominin-1-PE conjugated staining antibody 
was added to the suspensions per 107 cells and left to incubate for 10 minutes in the 
dark at 40C. The cells were then washed by adding 1.5ml of MACS buffer per 107 cells, 
centrifuging them at 300g for 10 minutes at 40C, removing the supernatants, and re-
suspending them in 500l MACS buffer. The NSC-containing solutions were then split 
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into 10 tubes each containing an adjusted concentration of 2x106 cells in 1ml of MACS 
buffer and kept on ice. These samples were run through a high speed MoFlo XDP cell 
sorter (Beckman Coulter) with the gates set for FSC-SSC, FSC-Pulse Width, PE-
positive, and PE-negative in order to specifically sort viable and single PE-positive 
(CD133-positive) NSCs. The CD133-negative/positive fractions were eluted into NS 
medium on ice and their concentrations were calculated prior to being injected into the 
brains of recipient mice.  
 
2.5.3 Fluorescence-activated cell sorting analysis of neural stem cell CD133 
expression  
Neurospheres were collected and dissociated into single NSCs by complete aspiration of 
any media (including a wash of the cells in PBS) and incubation in 500μl (per half 
10cm plate) Accumax (Chemicon) for 45mins at 37C followed by mechanical 
dissociation. The Accumax was diluted out by transferral into NS medium at a ratio of 
1:3. The NSC-containing medium was then passed through a sterile 40μm nylon mesh 
to remove any multi-cell aggregates, collected and transferred onto ice. The 
concentration of the NSC-containing medium was adjusted to 1x107 cells in 1ml of NS 
medium. The cell suspension was centrifuged at 300g for 10 minutes at 40C and the 
supernatant was removed. The cell pellet was then resuspended in 100l of MACS 
buffer per 107 cells and 10l of mouse anti-Prominin-1-PE conjugated staining antibody 
was added to the suspension per 107 cells and left to incubate for 10 minutes in the dark 
at 40C. The cells were then washed by adding 1.5ml of MACS buffer per 107 cells, 
centrifuging them at 300g for 10 minutes at 40C, removing the supernatant, and 
resuspending them in 500l MACS buffer. The cell concentrations to be FACS 
analysed were adjusted to 1x106 cells/ml in MACS buffer and 1ml was run through a 
FACScalibur (Becton-Dickinson) flow cytometer using CellQuest software. A control 
population of unlabelled and unsorted NSCs were FACS-analysed in order to set a side 
scatter vs. forward scatter gate that would only allow the detection of viable and non-
aggregated single NSCs. The same population of cells was also used to set the M1 
fluorescence threshold for PE(CD133)-positivity to include a false-positive detection of 
~3%, which was then corrected to a 0% baseline. The expression intensity of CD133 
was then calculated as the integration of the fluorescence plot greater than the M1 
fluorescence threshold. 
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2.6 Immunostaining 
 
2.6.1 Paraffin immunohistochemistry 
Brains were fixed in 10% formaldehyde (formalin), processed through graded alcohols 
and xylene into paraffin wax (Tissue processor Tissue-Tek VIP or Vision Biosystem 
Peloris), then embedded in paraffin (LECA Tissue embedding station) and 3μm sections 
were taken and processed for staining after antigen retrieval by boiling for 2 minutes in 
citrate buffer and a 1 hour incubation in SuperBlock (Pierce): haematoxylin-eosin 
(H&E), anti--galactosidase (Cre-recombined cells; Chemicon AB1211, rabbit 
polyclonal, 1:500), anti-GFAP (glial fibrillary acidic protein; DAKO Z0334, rabbit 
polyclonal, 1:1000), anti-synaptophysin (neuronal synapse; Zymed 080130, rabbit 
polyclonal, prediluted), anti-NeuN (neuronal nuclei; Chemicon MAB377, mouse 
monoclonal, 1:2000), anti-Nestin (intermediate filament of neuroepithelial stem cells; 
BD Pharmingen 556309, mouse monoclonal IgG1, 1:100), anti-MAP2 (microtubule 
associated protein-2; Chemicon MAB3418, mouse monoclonal IgG1, 1:200), BrdU 
(proliferating cells; Abcam ab6326, rat monoclonal, 1:100), anti-Sox2 (embryonic stem 
cell transcription factor; Chemicon AB5603, rabbit polyclonal, 1:500), anti-Sox-9 
(neural crest cell transcription factor; National Institute for Medical Research – London, 
rabbit polyclonal, 1:200), anti-phospho-Histone H3 (proliferating cells; Cell Signaling, 
rabbit polyclonal, 1:50), anti-Olig2 (oligodendrocyte transcription factor 2; Abcam 
ab33427, rabbit polyclonal, 1:500), anti-EGFR (epidermal growth factor receptor; R&D 
Systems MAB1280, rat monoclonal IgG1, 1:500). All primary antibody incubations 
were for 1 hour at room temperature. Biotinylated secondary antibodies were incubated 
for 1 hour at room temperature, and visualisation was carried out using the horseradish 
peroxidase-conjugated streptavidin system with diaminobenzidine as a chromogen. 
All immunostaining was carried out using the automated Benchmark XT machine in 
accordance with the manufacturer’s guidelines. Analysis of the sections was performed 
under a Zeiss Axioskop 2 MOT microscope. Images were captured using a ColorView 
III digital camera with the AnalySIS software package. 
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2.6.2 Immunofluorescence staining 
Immunofluorescence was conducted on cells plated on coverslips, chamber slides (see 
sections 2.3.7 and 2.3.8), vibratome sections, and free-floating NS. Vibratome 
(Vibratome 1500, Vibratome Instruments # GS-044026) sections of 40-50um thickness 
were sectioned from formalin fixed, agarose-embedded and coronally orientated brains. 
The staining protocol was carried out on parafilm for coverslips, 24-well plates for 
vibratome sections, or in 1.5ml Eppendorf tubes for free-floating NS collected from 
culture. The cells were washed with PBS three times in between each protocol step. All 
cell containing media were permeabilised by incubation in 0.1% TritonX100 / PBS for 
10 minutes at room temperature. Non-specific binding to endogenous proteins was 
blocked by incubation in 0.1% BSA / PBS for 15 minutes (room temperature). Cells 
were then incubated with primary antibodies overnight at 40C: anti--galactosidase 
(Cre-recombined cells; Abcam ab616, rabbit polyclonal, 1:500), anti-GFAP (glial 
fibrillary acidic protein; Abcam ab4674, chicken polyclonal, 1:1000), anti-Nestin 
(intermediate filament of neuroepithelial stem cells; BD Pharmingen 556309, mouse 
monoclonal, 1:400), anti-Sox2 (embryonic stem cell transcription factor; Chemicon 
AB5603, rabbit polyclonal, 1:500), anti-CD133 (putative cancer stem cell marker; 
Abcam ab31448, rabbit polyclonal, 1:500), anti-MAP2 (microtubule associated protein-
2; Abcam ab5392, chicken polyclonal, 1:1000), anti-O4 (oligodendrocyte progenitor 
marker; Chemicon MAB345, mouse monoclonal IgM, 1:400), anti--tubulin 
(neuronal microtubule marker; Chemicon MAB1637, mouse monoclonal, 1:1000), anti-
GFP (green fluorescent protein; Abcam ab290, rabbit polyclonal, 1:500). Visualisation 
was achieved by incubation for 1 hour (protected from light) with directly conjugated 
Alexa Fluor secondary antibodies (Molecular Probes) carrying fluorochromes 488, 546, 
or 633nm. Hoechst 33342, a DNA-binding fluorescent molecule (405nm), was included 
in the secondary antibody incubation to achieve nuclear counterstaining. Secondary 
antibody only control stains were carried out by omitting the primary antibody 
incubation step in order to test for non-specific staining. All cell containing media were 
then mounted onto glass slides with coverslips (if required) using Dako fluorescent 
mounting medium. Sections were then left for 1hr for the mounting medium to set and 
imaged with either an AxioCam MRm camera mounted on a Zeiss Axioplan 2 
microscope using the Axiovision software or a Zeiss LSM510 META confocal laser 
scanning microscope with the LSM software. 
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2.6.3 Preparation of cytoblocks for paraffin immunohistochemistry 
Cytoblock is a method to embed cells in a wax-block that allows the cells to be cut into 
sections and processed for immunohistochemistry. NS or astrocytes were collected in 
1.5ml Eppendorf tubes, mixed 1:1 with 10% buffered formal saline (formalin) overnight 
at room temperature. A cytoblock kit (#74010159, Shandon) was used in accordance to 
the manufactures instructions. The resulting cytoblocks were processed in a tissue 
processor (Tissue-Tek VIP) and embedded in paraffin wax. Cytoblocks were cut with a 
nominal thickness of 3μm and were stained using the same antibodies and equipment 
referenced in section 2.3.4. Analysis of the cytoblock sections was performed under a 
Zeiss Axioskop 2 MOT microscope. Images were captured using a ColorView III 
digital camera with the AnalySIS software. 
 
2.7 Statistical Analysis 
For assays where multiple NSC genotypes were compared based on a single output (e.g. 
WST-1 proliferation assay, neurosphere size assay, neurosphere-forming clonogenicity 
assay, self-renewal assay) we used a one-way repeated measures ANOVA with a 
Bonferroni’s multiple comparison correction (*: P<0.05, **: P<0.01, ***: P<0.001). In 
cases where the number of repeated measures was not equal per group then a normal 
one-way ANOVA with a Bonferroni’s multiple comparison correction was used. 
For assays where multiple NSC genotypes were compared on multiple outputs (e.g. 
neurosphere differentiation assay) we used a two-way ANOVA with a Bonferroni’s 
multiple comparison correction (*: P<0.05, **: P<0.01, ***: P<0.001). 
When comparisons were made between multiple NSC genotypes each with more than 
one output (e.g. comparing the tumour latencies of in vitro recombined and engrafted 
NS versus in vivo recombined, derived in vitro and engrafted NS both within and 
between the different NSC genotypes), a two-way ANOVA with no repeated measures 
and a Bonferroni’s multiple comparison correction was used (*: P<0.05, **: P<0.01, 
***: P<0.001). 
When a direct comparison of a single output, and with matching data points, between 
two NSC genotypes was requi	]``					^
-/-; PTEN-/- vs. 
Rb-/-; p53-/- NS) a one-tailed paired Student’s t-Test was used (*: P<0.05). 
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When a direct comparison of a single output, but with unequal data points, between two 
NSC genotypes was required (e.g. mean tumour latency of PTEN-/-; p53-/- NS vs. PTEN-
/-; p53-/- TS) a two-tailed unpaired Student’s t-Test was used (*: P<0.05). 
*		*			=			]``		#`			$		
linear regression was used to determine the goodness of the fit (R2) and a two-tailed 
Pearson’s correlation test was used to measure the level of correlation (*: P<0.05, **: 
P<0.01, ***: P<0.001). 
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3 In Vitro Functional Characterisation of Neural Stem 
Cells Based on Genotype 
 
3.1 Introduction 
In vitro methods of studying neural stem cells (NSCs) are a valid complement to in vivo 
studies as they allow for the controlled analysis of NSC behaviour in a context-
dependent manner. One of the defining features of stem cells is their ability to self-
renew. Expansion of NSCs in vitro has enabled downstream analysis of their function, 
expression profile, and proteome (Maurer et al., 2004). This has led to the widespread in 
vitro analysis of both primary NSCs (Tropepe et al., 1999; Engstrom et al., 2002) and 
tumour cells (Ignatova et al., 2002; Hemmati et al., 2003; Singh et al., 2003) derived 
from the brains of mice and humans. Such previous research has focussed on the study 
of specific tumour cell subtypes, such as CD133+ glioblastoma cells (Liu et al., 2009). 
However, our model system generates multiple tumour types allowing for a functional 
comparison between multiple tumour cell subtypes. In addition, our model system also 
allows for a baseline functional comparison by using non-recombined NSCs as non-
tumour cell controls. 
By deriving SVZ NSCs from the brains of conditional knock-out adult mice we are able 
to generate primary in vitro cultures. These cultures can be expanded over serial 
passages in vitro (Conti and Cattaneo, 2010) allowing for downstream functional 
analysis of the NSCs with regards to their growth rate, multipotency, self-renewal, and 
mRNA expression profiles following inactivation of the TSGs Rb, p53, and PTEN. 
These in vitro expanded NSCs can then be engrafted into the brains of mice to examine 
their in vivo tumour hit rate, latency, and phenotype (addressed in Chapter Four). 
In this chapter we use this approach to address the following aims: 
 
Aims 
1. Verify that in vitro NSCs cultures contain the same SVZ NSCs that are targeted 
by i.c.v. Adenovirus-Cre administration. 
2. Characterise the effect of Rb, p53, and PTEN loss on the growth rate, self-
renewal, multipotency and biomarker expression of NSCs in vitro. 
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3. Examine whether the in vitro functional properties of NSCs correlate with in 
vivo tumour hit rate and/or latency. 
4. Identify surrogate markers of tumour phenotype. 
 
3.2 Materials and Methods 
Refer to the main materials and methods section (Chapter Two). 
 
3.3 Results and Discussion 
NSCs are possible candidates for brain tumour initiating cells (Sutter et al., 2007; Dirks, 
2008). Previous work has extensively verified the in vivo tumourigenicity of NSCs but 
less has been done to characterise their behaviour in vitro. Using our model system we 
aim to characterise the behavioural profile of NSCs with regards to their growth rate, 
self-renewal, and multipotency capabilities following inactivation of the TSGs Rb, p53, 
and PTEN. 
 
3.3.1 Cells derived from the subventricular zones of ROSA26RLox/Lox mice 
following intracerebroventricular Adenovirus-Cre become enriched in 
neurosphere cultures over serial passages 
In order to examine whether i.c.v. administration of Adenovirus-Cre targets NSCs, four 
separate cohorts (3-6 mice in each) of ~4 week old ROSA26RLox/Lox reporter mice 
(R26R) received injections. After an incubation period of seven days, NSC were 
prepared from the SVZ and expanded in vitro where they formed neurospheres. The 
proportion of NS that had been targeted by Adenovirus-Cre for recombination was then 
			?@	@	[@			
	-galactosidase staining (Figure 21). 
 
85 
 
 
Figure 21				
	-galactosidase-positive R26R NS increases over serial 
passages in vitro. (A) Each line (with their associated linear trendlines) on the graph represents an 
independent experiment in which NSCs (grown as NS) were derived from the brains of ROSA26RLox/Lox 
reporter mice 7 days post i.c.v. Adenovirus-Cre administration and grown as NS in vitro. The percentage 
of recombined NS was calculated at passages 0, 1, 2, 		
	=		-galactosidase staining and 
counting the positive NS. (B) Representative serial images taken at passages 0, 1, 2, and 3 for experiment 
	]	$					*			
	-galactosidase-positive R26R NS. 
The percentages given were generated from an average count taken from three randomly selected fields of 
vision captured through a 10x objective on a Zeiss Axiovert 200 microscope. 
 
*		]	$		-galactosidase-positive NS derived in four separate 
experiments was 12%, 1.7%, 5.8%, and 44.4% (Figure 21: A). Irrespective of the initial 
	@	*	
		-galactosidase-positive recombined NS increased in 
a linear manner when serially passaged. In the case of experiment four the percentage of 
-galactosidase-positive NS rose from 44.4% at passage zero to 97.2% by passage three 
(Figure 21: A). It is thought that only the most immature NSCs are capable of self-
renewal, although it has been suggested that the transiently amplifying neural progenitor 
cells can also form NS (Reynolds and Rietze, 2005). Therefore, only self-renewing 
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NSCs should be able to persist in a culture that is serially passaged. Our finding 
therefore suggests that in vitro NS cultures become enriched for NSCs and their 
transient amplifying progenies over serial passages. Experiment two (Figure 21: A, blue 
line) represents an experiment in which almost no SVZ NSCs were targeted by i.c.v. 
Adenovirus-	@			
			[	-galactosidase-
positive NS were identified in vitro. 
Neurospheres are a heterogeneous population of stem, transiently amplifying stem-like 
progenitor, and supporter cells (Ahmed, 2009). Over serial passages we would expect 
that the culture would become enriched for the self-renewing type B astrocytes and 
transiently amplifying type C progenitors of the SVZ. Assuming that a) i.c.v. 
administration of Adenovirus-Cre infects SVZ cells in a stochastic manner (four 
independent experiments generated four different starting percentages of recombined 
NS at passage 0), b) Adenovirus-Cre is not selective towards the type of cell it infects 
(Akagi et al., 1997)@		$	-galactosidase-positive ROSA26R-/- NSCs do not possess 
any growth advantage over their non-recombined NSC counterparts, we should expect 
				>		-galactosidase-#	!"		=*	*	-
galactosidase-positive NS after three passages in vitro. This was not the case, as shown 
by experiment four (Figure 21: A) in which the percentage of recombined NS was 
observed to reach 97% by passage 3. 
*				*			-galactosidase-positive NS had a slope that 
ranged from 15.6 to 28.4 across the viable experiments (Figure 21: Exp#1, 3, and 4). 
The relative similarity of these slopes suggests that the same mechanism is responsible 
for driving the increase. This mechanism can be explained by a phenomenon known as 
“NS aggregation” whereby NS in bulk culture can fuse together or even swap matter 
(Singec et al., 2006; Mori et al., 2007; Coles-Takabe et al., 2008). The blue colour of 
the recombined NSCs could drown out the colourless appearance of the non-
recombined NSCs when matter is aggregated or exchanged between NS. This would 
	*	!"		-galactosidase-positive could in fact be 50% positive and 50% 
#@		=		*			-galactosidase-positive NS in a linear 
fashion over serial passages. It would also explain why some NS exhibit patches of blue 
staining and why some NS of the same size appear to carry different shade depths of 
blue. 
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3.3.2 Intracerebroventricular administration of Adenovirus-Cre targets 
subventricular zone neural stem cells that are capable of self-renewal and 
are multipotent 
To specifically determine the self-renewal ability and to examine the multipotency of 
the cells constituting a NS culture we performed self-renewal and differentiation assays. 
Three separate cohorts (3-6 mice in each) of ~4 week old ROSA26RLox/Lox reporter mice 
(R26R) received injections and were left for four days prior to SVZ cell preparation and 
expansion in vitro. The NS were then dissociated into single cells and individually 
FACS-seeded into single wells of a 96-well plate (in accordance with the protocol given 
in section 3.2.1). The number of these cells, at passage one, that had self-renewed to 
form neurospheres after nine days was used to estimate what percentage of SVZ cells 
were capable of self-renewal and could be classed as NSCs. This percentage was then 
		|	=*	-galactosidase staining to calculate the original in vivo 
proportion of SVZ cells targeted by i.c.v. Adenovirus-Cre that were self-renewing NSCs 
(Figure 22). 
 
 
Figure 22: Table of the data generated from the three separate self-renewal assays conducted on 
SVZ cells, grown as NS in vitro, derived from the brains of ROSA26RLox/Lox control mice (R26R) 
four days post-i.c.v. Adenovirus-Cre administration. 
 
Across these three separate experiments, a total of 291 single cells were seeded into 
individual wells, from which 61 (21.8% +/- 2.3) self-renewed to form NS (Figure 22). 
Of these 61 self-renewing cells, 51 (17.4% +/- 1.7 of all single seeded cells) were 
	-galactosidase-positive (Figure 23: A, representative example). This 
suggests that 21.8% of SVZ cells were NSCs capable of self-renewal and that 17.4% of 
SVZ cells were self-renewing NSCs targeted by i.c.v. Adenovirus-Cre (i.e. i.c.v. 
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Adenovirus-Cre administration had a 80.8% +/- 7.4 success rate of targeting self-
renewing NSCs). The accepted architecture and cellular hierarchy of the SVZ predicts 
that type B astrocytes, thought to represent NSCs, represent a minority of the cell 
population (Doetsch et al., 1997). However, this relatively high percentage (21.8%) of 
self-renewing cells suggests that additional NSC subtypes may also possess the ability 
to self-renew, such as the transiently amplifying type C progenitors. 
 
 
Figure 23: I.c.v. Adenovirus-Cre administration targets self-renewing and multipotent SVZ NSCs 
that can be propagated in vitro. (A) Representative image series taken of the same NSC/NS over 9 days 
showing the monoclonal self-renewal ability of a single in vivo recombined NSC as it develops into a NS 
in vitro`	*	-galactosidase-positive stain at day 9 (Day 9, LacZ) demonstrates that Adenovirus-Cre 
administration targets these self-renewing SVZ NSCs. (B) Monoclonal NS generated from the self-
renewal assay were allowed to differentiate on glass slides for 3 days before their cells were examined for 
markers of NSCs (Nestin: C), astrocytes (GFAP: D), neurons (MAP2: E), and oligodendrocytes (O4: F). 
{	*	[		<@	-	-galactosidase. Blue: excitation at 405nm, green: excitation 
at 488nm, red: excitation at 546nm. Images were taken using a 63x objective with oil immersion on a 
Zeiss Axioplan 2 microscope and captured using a mounted AxioCam MRm camera and the Axiovision 
software. 
 
Individual monoclonal NS generated from the self-=	@	
				-
galactosidase staining, were then allowed to differentiate on laminin-coated glass 
chamber slides (Figure 23: B). These NS were observed to differentiate into glial, 
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neuronal, and oligodendrocytic lineages, demonstrating their multipotency (Figure 23: 
C-F). 
These experiments confirm that i.c.v. Adenovirus-Cre-mediated recombination targets 
self-renewing and multipotent SVZ NSCs that can be propagated in vitro. 
 
3.3.3 The combination and number of TSGs lost determines the growth 
rates and neurosphere-forming ability of neural stem cells in vitro 
The effect of inactivation of the TSGs Rb, p53, and PTEN on the in vitro growth rate of 
NSCs was determined by the WST-1 proliferation assay. This assay measures the 
cumulative mitochondrial activity (as a surrogate marker for growth) of NSCs at 0, 4, 6, 
and 8 hours after a 3 day incubation period. 
 
 
Figure 24: The growth rates of in vitro recombined Rb-/-; p53-/- ; PTEN-/-, Rb-/-; PTEN-/-, and PTEN-/-
; p53-/- NSCs (grown as NS) at passage 3 are significantly higher than that of non-recombined 
Adenovirus-GFP-infected NSCs. The growth rates of the Rb-/-; p53-/- NSCs and the single TSG 
knock-out Rb-/-, p53-/-, and PTEN-/- NSCs are not different to those of both the non-recombined-
untreated and Adenovirus-GFP-infected control NSC groups. Using the WST-1 assay the growth rate 
(y-axis) of NSCs (growing as NS) was measured at 0, 2, 4, and 8hrs (x-axis) after a 3 day incubation 
period. Growth rate of in vitro recombined Rb-/-; p53-/-; PTEN-/- (blue: n=3; 4.31 +/- 0.20; 8hrs) vs. Rb-/-; 
PTEN-/- (purple: n=3; 3.37 +/- 0.17; 8hrs) vs. PTEN-/-; p53-/- (red: n=3; 3.30 +/- 0.77; 8hrs) vs. Rb-/-; p53-/- 
(orange: n=3; 0.40 +/- 0.07; 8hrs) vs. Rb-/- (grey: n=2; 0.10 +/- 0.02; 8hrs) vs. p53-/- (grey: n=2; 0.28 +/- 
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0.03; 8hrs) vs. PTEN-/- (grey: n=2; 0.10 +/- 0.003; 8hrs) vs. non-recombined Adenovirus-GFP-infected 
(green: n=6; 0.14 +/- 0.05; 8hrs) vs. non-recombined untreated (grey: n=5) NSCs. Error bars: standard 
errors. ***: P<0.001 vs. GFP control at 8hrs (one-way ANOVA with Bonferroni’s multiple comparison 
correction). 
 
Two different controls were used for this experiment with the slightly decreased growth 
rate of the non-recombined Adenovirus-GFP-infected NSCs (Figure 24: green data set) 
compared to non-recombined untreated NSCs (Figure 24: grey data set), suggesting a 
possible effect of Adenovirus infection. This difference was not significant but to 
compensate for any possible Adenovirus-mediated effects the Adenovirus-GFP-infected 
control was used as the baseline control. The Rb-/-; p53-/-; PTEN-/- NSCs grew faster 
than the Rb-/-; PTEN-/- and PTEN-/-; p53-/- NSCs, all of which grew significantly faster 
than the Rb-/-; p53-/- NSCs which were found to grow at a statistically similar rate to the 
Rb-/- alone, p53-/- alone, PTEN-/- alone, and Adenovirus-GFP-infected NSCs. These 
results suggest that the growth rates of the different in vitro recombined NSC genotypes 
increase with the number of TSGs lost. The Rb-/-; p53-/- NSC growth rate appears to be a 
combination of the Rb-/- alone and p53-/- alone levels, and highlights a potential PTEN-
loss-mediated growth advantage. Interestingly, PTEN loss alone had no effect on the 
growth rate of NSCs but appeared to have a disproportionally large effect on increasing 
the growth rate of NSCs in which Rb or p53 had already been lost. For example, the Rb-
/-; PTEN-/- and PTEN-/-; p53-/- NSCs grew significantly faster than the Rb-/-; p53-/- NSCs, 
in which the additional loss of PTEN resulted in the Rb-/-; p53-/-; PTEN-/- genotype 
which had the fastest growth rate of all. This finding that PTEN loss alone is not 
sufficient to confer increased NSC proliferation contradicts the findings of other groups 
(Groszer et al., 2001; Stiles et al., 2004; Groszer et al., 2006). This discrepancy can be 
explained by several differences: (i) Groszer et al, 2001 used neural progenitor cells 
derived from brains of E14.5 or P0 mice whereas we used adult stem cells, and 
consequently (ii) loss of PTEN has different effects on neural progenitor populations 
than on adult NSC. 
Interestingly, as described in section 3.3.1 in vitro recombined and engrafted Rb-/-; p53-/- 
NS very rarely give rise to tumours (9.6%), suggesting that there is a correlation 
between in vitro growth rate and tumourigenicity. This potential correlation is addressed 
in section 3.3.5. 
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To further delineate the differential growth patterns of the NSC genotypes we used two 
additional assays. Firstly, the NS size assay (Figure 25) was used to measure the 
proliferative capacity of NSCs, and secondly, the NS-forming clonogenicity assay 
(Figure 26) was used, as an interpretation of the neurosphere formation assay originally 
described by Reynolds in 1992 (Reynolds and Weiss, 1992; Reynolds et al., 1992), to 
measure the NS-forming ability of NSCs. 
 
 
Figure 25: The Rb-/-; p53-/-; PTEN-/- NSCs at passage 3 form significantly larger NS than the rest of 
the experimental genotypes, all of which form NS of the same size as the Adenovirus-GFP-infected 
control NSCs. NSCs were seeded into NS medium and left to grow as NS for eight days before their 
diameters were measured using a Zeiss Axiovert 135 microscope and the Openlab 5 software package. 
NS size of non-recombined untreated (grey: n=11) vs. non-recombined Adenovirus-GFP-infected (green: 
n=11; 190.5 +/- 10.0) vs. in vitro recombined PTEN-/-; p53-/- (red: n=3; 211.3 +/- 14.8) vs. Rb-/-; p53-/- 
(orange: n=4; 216.9 +/- 9.2) vs. Rb-/-; p53-/-; PTEN-/- (blue: n=3; 280.1 +/- 18.2) vs. Rb-/-; PTEN-/- (purple: 
n=4; 208.2 +/- 11.7) vs. Rb-/- (grey: n=2; 187.5 +/- 7.0) vs. p53-/- (grey: n=2; 173.2 +/- 4.0) vs. PTEN-/- 
(grey: n=2; 187.3 +/- 3.2) NSCs. Error bars: standard errors. ***: P<0.001 vs. GFP control (one-way 
ANOVA with Bonferroni’s multiple comparison correction). 
 
The NS size assay confirmed our finding from the WST-1 assay, but was less apparent. 
The Rb-/-; p53-/-; PTEN-/- NSCs formed significantly larger NS than the rest of the 
experimental genotypes (P<0.001), from which the PTEN-/-; p53-/-, Rb-/-; p53-/- and Rb-/-; 
PTEN-/- NSCs appeared to form larger NS than the Rb-/- alone, p53-/- alone, PTEN-/- 
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alone, and Adenovirus-GFP-infected control NSCs, but did so in a statistically non-
significant manner (Figure 25). This suggests that either a) the NS size assay was not as 
sensitive as the WST-1 assay in delineating the proposed additive effect of additional 
TSG loss on growth rate advantage, or b) that the size of NS formed is not a suitable 
surrogate marker of growth rate. 
The growth rate of the Rb-/-; p53-/- NSCs was significantly lower than the other double 
knock-out genotypes, but they formed NS of a statistically similar size. This finding 
reinforces the earlier proposal that “the size of NS formed is not a suitable surrogate 
marker of growth rate”. 
In addition to growth rate, self-renewal is a key characteristic of NSCs. To see if the 
loss of the different combinations of TSGs had an effect on self-renewal we measured 
the NS-forming ability of the same NSC genotypes. 
 
 
Figure 26: All of the experimental NSC genotypes, with the exception of the Rb-/- and PTEN-/- 
NSCs, form significantly more NS at passage 3 than the Adenovirus-GFP-infected control NSCs. 
Interestingly, the p53-/- NSCs appear to form the most NS, but at a level that is not significantly 
more than the Rb-/-; p53-/- or Rb-/-; p53-/-; PTEN-/- NSCs. NSCs were seeded into NS medium and left 
to grow as NS for eight days before the number of NS formed was counted. NS size of non-recombined 
untreated (grey: n=6) vs. non-recombined Adenovirus-GFP-infected (green: n=6; 797.7 +/- 87.1) vs. in 
vitro recombined PTEN-/-; p53-/- (red: n=3; 1411.3 +/- 138.6) vs. Rb-/-; p53-/- (orange: n=4; 1750.5 +/- 
70.1) vs. Rb-/-; p53-/-; PTEN-/- (blue: n=3; 1617.3 +/- 127.2) vs. Rb-/-; PTEN-/- (purple: n=3; 1556.8 +/- 
131.2) vs. Rb-/- (grey: n=2; 1001.1 +/- 134.0) vs. p53-/- (grey: n=2; 1793.4 +/- 28.5) vs. PTEN-/- (grey: 
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n=2; 822.5 +/- 57.2) NSCs. Error bars: standard errors. *: P<0.05 vs. GFP control, **: P<0.01 vs. GFP 
control, ***: P<0.001 vs. GFP control (one-way ANOVA with Bonferroni’s multiple comparison 
correction). 
 
Unlike in the WST-1 and NS size assays (where the Rb-/-; p53-/-; PTEN-/- NSCs had the 
highest growth rates and formed the largest NS), the triple mutant Rb-/-; p53-/-; PTEN-/- 
NSCs formed similar numbers of NS compared to the PTEN-/-; p53-/-, Rb-/-; p53-/-, Rb-/-; 
PTEN-/-, and p53-/- NSCs, all of which formed significantly more NS than the 
Adenovirus-GFP-infected controls (Figure 26). The only similar finding from this NS-
forming clonogenicity assay (when compared to the WST-1 and NS size assays) was the 
lack of any statistically significant difference observed between the Rb-/- and PTEN-/- 
NSCs and the Adenovirus-GFP-infected controls. Whereas we suggested that a) the NS 
size assay might not be sensitive enough to delineate the proposed additive effect of 
additional TSG loss on growth advantage, or b) that the size of NS formed is not a 
suitable surrogate marker of growth rate, it appears that the number of NS formed can 
be used as a measure of delineating the growth patterns of the different NSC genotypes. 
However, these data do not match the growth data trends observed from the WST-1 
assay, as illustrated by the p53-/- NSCs forming the most significantly large (P<0.001) 
number of NS (1793.4 +/- 28.5), suggesting that different growth mechanisms were 
examined. A possible explanation is that the number of NS formed is a measure of self-
renewal and not of growth rate. However, it could also be argued that this NS-forming 
clonogenicity assay does not strictly measure the self-renewal ability of NSCs as single 
NSCs are not studied in isolation. In addition, the mass seeding of NSCs could mean 
that NS aggregation could occur, as previously described. To illustrate this point, the 
large number of NS formed by the p53-/- NSCs (Figure 26) could be as a result of their 
increased ability to self-renew following p53 loss (Meletis et al., 2006), and the small 
size of the NS formed (Figure 25) could be due to a low level of NS aggregation. In 
contrast, the comparatively larger but smaller number of NS formed by the Rb-/-; p53-/-; 
PTEN-/- NSCs may be due to increased NS aggregation. Transcriptionally inactive p53 
downregulates E-cadherin (calcium-dependent adhesion molecule) expression in the 
colon carcinoma cell line HCT116 (Roger et al., 2010) and may explain the low level of 
NS aggregation observed with p53-/- NSCs. For this reason we proposed that there may 
be a correlation between the number and size of the NS formed, which could be 
interpreted as a coefficient of NS aggregation. However, despite some instances of 
correlation (e.g. p53-/- and Rb-/-; p53-/-) the overall correlation between the NS size and 
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NS-forming clonogenicity for all the genotypes was not significant at R2=0.145 (data 
not shown). 
Taken together, the WST-1 proliferation assay (Figure 24), NS size assay (Figure 25), 
and NS-forming clonogenicity assay (Figure 26) were able to delineate the in vitro 
growth profiles of the different NSC genotypes. The WST-1 and NS size assays 
highlighted an additive effect of additional TSG loss on growth advantage, and a 
potential PTEN-loss-mediated growth advantage. And the NS-forming clonogenicity 
assay highlighted a similar additive effect but on the number of NS formed, and a 
potential relationship between p53 loss and reduced NS aggregation through the 
downregulation of cell adhesion molecules. However, we identified that the NS-forming 
clonogenicity assay could be measuring the self-renewal of NSCs rather than their 
outright growth rate, and that self-renewal can only be truly measured by studying 
single NSCs in isolation. As previously stated, NSCs can be defined by their self-
renewal and multipotency. To assess the self-renewal of our genetically modified NSC 
in vitro, we performed a self-renewal assay. 
 
3.3.4 In vitro recombined NSCs possess increased self-renewal in a 
genotype-dependent manner and with an additive effect of additional TSG 
loss 
We tested the primary and secondary in vitro self-renewal ability of all our NSC 
genotypes in order to characterise the effect of inactivating the TSGs Rb, p53, and 
PTEN. NS at passage two were dissociated into single cells (passage three), FACS-
seeded into 96-well plates, and incubated for nine days before the number of NS that 
formed were counted to assess the primary self-renewal ability. NS were then randomly 
selected, individually dissociated into single cells, and re-FACS-seeded into 96-well 
plates and left to assess the secondary self-renewal ability. The efficiency of the MoFlox 
XDP FACS machine at seeding single cells into single 96-well plate wells was verified 
at >99% and therefore no correction was applied to the self-renewal data. 
 
95 
 
 
Figure 27: All genotypes, with the exception of the Rb-/- and PTEN-/- NSCs, have a significantly 
increased self-renewal ability at passages 3 and 4 compared to the Adenovirus-GFP-infected 
control NSCs. Interestingly, increase in self-renewal appears to be an additive result of additional 
TSG loss, with the exception that the p53-/- NSCs possess a significantly elevated self-renewal 
ability. NS at passage 2 were dissociated into single NSCs and individually seeded, using a MoFlo XDP 
FACS machine, into single wells of a 96-well plate containing 200μl NS medium and left to grow for 
nine days before the number of NS formed was counted and interpreted as the primary self-renewal 
ability. The process was then repeated for a selection of these monoclonal NS, chosen at random, to 
assess the secondary self-renewal ability. Primary/secondary self-renewal of non-recombined 
Adenovirus-GFP-infected (green: n=2) vs. in vitro recombined Rb-/- (grey: n=2) vs. p53-/- (grey: n=2) vs. 
PTEN-/- (grey: n=2) vs. Rb-/-; p53-/- (orange: n=2) vs. PTEN-/-; p53-/- (red: n=2) vs. Rb-/-; PTEN-/- (purple: 
n=2) vs. Rb-/-; p53-/-; PTEN-/- (blue: n=2) NSCs. Primary self-renewal is shown as the solid bars and 
secondary self-renewal is shown as the paler-coloured bars on top of the primary self-renewal bars. Error 
bars: standard errors. *: P<0.05 vs. GFP control, **: P<0.01 vs. GFP control, ***: P<0.001 vs. GFP 
control (one-way repeated measures ANOVA with Bonferroni’s multiple comparison correction). 
 
Only the Rb-/- and PTEN-/- NSCs generated similar numbers of primary (21.3% +/- 0.8 
and 15.6% +/- 2.4) and secondary (41.5% +/- 2.1 and 31.1% +/- 1.3) self-renewing 
NSCs as the Adenovirus-GFP-infected controls (Figure 27). All of the double knock-out 
genotypes generated significantly more primary self-renewing NSCs (>30%) compared 
to GFP-infected non-recombined controls (21.0% +/- 1.2). The triple knock-out 
Rb/p53/PTEN NSCs showed the most significant increase of primary self-renewing 
cells (60.3% +/- 1.4), once again suggesting an additive effect of TSG loss on self 
renewal. Interestingly, the significantly increased number of primary self-renewing p53-
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/- NSCs (46.1% +/- 0.3) was as significant as the Rb-/-; p53-/-; PTEN-/- NSCs (P<0.001). 
This validates the same finding from the NS-forming clonogenicity assay (Figure 26).  
The secondary self-renewal patterns of significance remained similar to those observed 
with the primary self-renewal. However, the number of secondary self-renewing Rb-/-; 
p53-/- (88.9% +/- 1.05), PTEN-/-; p53-/- (76.1% +/- 1.05) and Rb-/-; PTEN-/- (71.8% +/- 
0.5) NSCs cells had increased to the same level as the p53-/- (73.7% +/- 0.25) and Rb-/-; 
p53-/-; PTEN-/- (94.4% +/- 1.3) NSCs (Figure 27). 
The increase in self-renewal upon p53 loss in NSC is in keeping with recent studies that 
p53 is a key determinant of the transcriptional activation of Nanog (Lin et al., 2005; 
Hong et al., 2009; Kawamura et al., 2009; Po et al., 2010; Zbinden et al., 2010). Nanog 
itself is an intrinsic determinant of stemness and self-renewal with its expression is 
downregulated upon differentiation (Mitsui et al., 2003; Boiani and Scholer, 2005; Pan 
and Thomson, 2007). In addition, Nanog is reactivated in glioma and prostate cancer 
cells (Clement et al., 2007; Jeter et al., 2009; Ji et al., 2009; Zbinden et al., 2010). Taken 
together, these studies confirm our finding that p53 loss has a significant effect on 
increasing the self-renewal of NSCs. It has been proposed that PTEN loss increases the 
in vitro self-renewal capacity of NSCs by enhancing G0 cell cycle exit (Groszer et al., 
2006). However, other groups did not verify this finding experimentally and have 
shown that PTEN loss alone is not sufficient to confer an increase in self-renewal but 
that the additional loss of p53 is required (Zheng et al., 2008). Also, downregulation of 
Rb has been correlated with increased self-renewal of mouse NSCs, but only as a result 
of Ink4a-Arf deletion (Molofsky et al., 2005). 
It therefore appears that only p53 loss has a direct effect on increasing the self-renewal 
capacity of NSCs and that additive effects of Rb and PTEN loss can only be seen, 
through indirect mechanisms, when both are lost together. The additive effect of 
additional TSG loss on increased growth (section 3.3.3) and self-renewal (Figure 27) 
suggests that these functional qualities may be indicators of in vivo tumourigenicity 
and/or tumour latency. 
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3.3.5 The in vitro growth rate of neural stem cells is a positive predictive 
indicator of in vivo tumour hit rate and an inverse predictive indicator of in 
vivo tumour latency 
In order to test whether the in vitro growth (Figure 24 and Figure 25) or self-renewal 
(Figure 27) properties of NSCs could be used as indicators of in vivo tumour hit rate 
and/or tumour latency we performed a multiple correlation analysis of the various data 
sets using data from the non-recombined Adenovirus-GFP-infected control, Rb-/-; p53-/-, 
PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NSCs (Figure 28). 
 
 
Figure 28:  Summary table of the correlation statistical analyses between the hit rate (in vivo 
tumour incidence), latency (in vivo tumour latency), WST-1 (growth assay), NS size (growth assay), 
and self-renewal data sets for the non-recombined Adenovirus-GFP-infected control, Rb-/-; p53-/-, 
PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NSCs. Linear regression was used to determine 
the goodness of the fit (R2), and a two-tailed Pearson’s correlation test was used to measure the level of 
correlation (*: P<0.05, ***: P<0.001). 
 
A statistically significant negative correlation was observed between the in vivo tumour 
hit rate and the in vivo tumour latency (R2=0.7741, P<0.05) (Figure 28). This implies 
that tumour development follows a stochastic model whereby the more aggressive and 
faster growing tumours carry a higher chance of development. If we also take into 
account the highly significant positive correlation between the in vivo tumour hit rate 
and the WST-1 in vitro growth rate data (R2=0.9924, P<0.001) we can revise this 
statement to read: those NSCs that exhibit the fastest growth rate in vitro possess the 
highest likelihood of generating tumours in vivo, and do so with the shortest latency. In 
other words, the in vitro growth rate of NSCs can be used as a positive predictive 
indicator of in vivo tumour hit rate. No correlation was observed between the NS size 
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and in vivo hit rate data (R2=0.4242). This further validates our earlier proposal that “the 
size of NS formed is not a suitable surrogate marker of growth rate” (section 3.3.3). 
 A significant positive correlation was also observed between the NS size and self-
renewal data (R2=0.9913, P<0.001). This finding suggests that NS size may indirectly 
infer self-renewal and supports our proposal “that there may be a correlation between 
the number and size of the NS formed, which could be interpreted as a coefficient of NS 
aggregation” (section 3.3.3). No significant correlations were observed between any of 
the other data sets. No significant correlation was observed between the NS-forming 
clonogenicity data and any of the other data sets, including self-renewal. The latter 
highlights the deficiency of using an NS-forming assay to infer self-renewal. 
 
3.3.6 Qualitative immunohistochemical biomarker analysis of in vitro 
recombined neurospheres yields few notable differences in expression levels 
Adenovirus-Cre-infected control RosaLox/Lox and in vitro recombined Rb-/-; p53-/-, PTEN-
/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NS were taken at passage three and 
prepared in cytoblocks for paraffin immunohistochemistry (sections 2.3.6 and 2.3.4) and 
qualitative biomarker expression analysis (Figure 29). 
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Due to the variable nature of staining intensity in cytoblocks, immunohistochemistry is 
only suitable for semiquantitative analysis. No opposites in expression patterns were 
observed between any of the NS genotypes, however, reductions of Olig2 expression in 
Rb-/-; p53-/- NS and of nestin expression in Rb-/-; PTEN-/- NS were observed. To improve 
this semiquantitative expression analysis we carried out immunofluorescence staining of 
NS grown as differentiating cells on coverslips. 
 
3.3.7 Expression of the biomarkers GFAP, Sox-2, and nestin by in vitro 
recombined and differentiated neurospheres are significantly altered in a 
genotype-dependent manner 
NS at passage three from our four double and triple knockout genotypes were plated 
onto laminin-coated glass coverslips and allowed to differentiate for five days. 
Following fixation, they were double-labelled with antibodies against GFAP and 
CD133 (Figure 30: A-E), Sox-2 and Nestin (Figure 30: F-$@	{[		-tubulin 
(Figure 30: K-O) and Hoechst 33342 (DAPI) was used as a nuclear counterstain. 
Adenovirus-GFP-infected NS fluoresce when excited by a 488nm laser, which can 
interfere with confocal microscopy image acquisition. For this reason, non-recombined 
untreated NS were used as the controls as no Adenovirus-mediated effect on the 
biomarker expression levels was observed (data not given). 
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Three differentiated NS (per stain per genotype) were randomly selected under the 
microscope, and a field of view that encompassed both the edge of the NS and the 
spreading of the cells was imaged using a Zeiss LSM510 META confocal laser 
scanning microscope with the LSM software. The number of cells that were positive for 
the marker of interest were counted from the three images (taken from 425μm x 425μm 
= 0.181mm2 fields of view), averaged, and expressed as a percentage against the total 
number of cells as measured by the number of Hoechst (or DAPI) positive nuclei 
(Figure 31 & Figure 32). This staining and counting was then repeated three times (to 
give an experimental n=3) using NS derived from separate cohorts of mice. Although an 
internal experimental control (PTENLox/Lox; p53Lox/Lox non-recombined untreated 
control) was used to allow for expression comparison between the genotypes, no 
positive or negative control was directly incorporated into the experimental design 
(antibody specificity was validated using paraffin immunohistochemistry but not 
immunofluorescence). For this reason, the results detailed in section 3.3.7 (Figure 30, 
Figure 31, Figure 32, Figure 33) should be considered with caution on the basis that the 
staining patterns have not been sufficiently controlled against non-specific antibody-
mediated effects. Positive controls could have taken the form of cell lines with known 
expression, and negative controls as knock-out cell lines. Additionally, incorporation of 
isotype controls would have enabled better (than secondary antibody only controls) 
control against: a) non-specific binding of the primary antibodies to cellular proteins, 
lipids, surface antigens (e.g. Fc receptors), and b) cellular autofluorescence.
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Figure 32: The expression of the biomarkers GFAP, CD133, Sox-2, and Nestin are significantly 
altered, in a genotype-dependent manner, following in vitro inactivation of the TSGs Rb, p53, and 
PTEN in differentiated neurospheres when compared against non-recombined untreated controls. 
The expression of MAP2 and -tubulin was respectively ubiquitous and absent across all the 
genotypes, and the Rb-/-; PTEN-/- glioblastoma-generating NS exhibits the most altered / unique 
expression profile when compared against the other in vitro recombined NS genotypes. Percentage 
of cells expressing the differentiation biomarkers GFAP, CD133, Sox-[@	!@	{[@		-tubulin 
from PTENLox/Lox; p53Lox/Lox non-recombined untreated control vs. Rb-/-; p53-/- vs. PTEN-/-; p53-/- vs. Rb-/-; 
PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS that were left to differentiate on laminin-coated glass coverslips for 5 
days before being fixed and immunofluorescently stained. Error bars: standard errors. *: P<0.05 vs. non-
recombined untreated control, **: P<0.01 vs. control, ***: P<0.001 vs. control (two-way ANOVA with 
Bonferroni’s multiple comparison correction). 
 
GFAP was observed to be expressed by significantly more cells in both the Rb-/-; PTEN-
/- (100% +/- 0: P<0.05) and Rb-/-; p53-/-; PTEN-/- (100% +/- 0: P<0.05) NS when 
compared against the non-recombined untreated control (83.1% +/- 1.8). CD133 was 
seen to be expressed by significantly more cells in the Rb-/-; p53-/- (95.0% +/- 2.7: 
P<0.001) and Rb-/-; PTEN-/- (65.3% +/- 6.7: P<0.01) NS, but by significantly less cells 
in the Rb-/-; p53-/-; PTEN-/- (25.0% +/- 4.8: P<0.001) NS when compared against the 
control (47.0% +/- 10.6) (Figure 32). The only change in Sox2 expression was observed 
with the Rb-/-; PTEN-/- (57.7% +/- 5.5: P<0.001) NS in which significantly less cells 
expressed Sox2 when compared against the control (98.0% +/- 1.3). Nestin was 
observed to be expressed by significantly more cells in the Rb-/-; p53-/- (60.5% +/- 5.5: 
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P<0.001), PTEN-/-; p53-/- (77.1% +/- 2.5: P<0.001), and Rb-/-; p53-/-; PTEN-/- (55.7% +/- 
7.9: P<0.05) NS when compared against the non-recombined untreated control (38.3% 
+/- 4.5). MAP2 was found to be expressed by 100% of the cells in both the non-
recombined control and all the in vitro 
	`	#@		-
tubulin expression was observed in any of the genotypes (Figure 32). 
As expected, the number of in vitro GFAP-expressing cells in PNET-generating Rb-/-; 
p53-/- NS was not significantly different from the control, in line with the fact that 
PNETs express GFAP at endogenously low levels (section 4.3.2). However, the PTEN-/-
; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NS predominantly generated high 
GFAP-expressing glioma, glioblastoma, and PNET + glioma tumours respectively 
following intracerebral engraftment, which all showed more GFAP-expressing cells in 
vitro. This correlation highlights the potential use of the in vitro NS differentiation 
expression profile as a predictor of the in vivo tumour expression profile. Additionally, 
this model system may possibly be used to manipulate (e.g. shRNA silencing) the in 
vitro differentiation expression profile to identify determining factors of tumour 
phenotype and identify therapeutic targets. A cellular pattern of CD133 staining was 
expected; in line with the in vivo staining pattern we observed (section 5.3.1). However, 
the pattern was overly granular and therefore probably a result of cross-reactivity with 
cellular debris. In chapter five we show that 12.5% of Rb-/-; p53-/-; PTEN-/- NSCs 
express CD133 whereas only 2.5% of wild-type untreated control NSCs express CD133 
(sections 5.3.2 and 5.3.3), a result not mirrored by the differentiation expression profile 
detailed here. Taken together, we believe that the CD133 staining was non-specific and 
subsequently void for analysis. As previously discussed, the incorporation of an isotype 
control into the experimental design would have effectively controlled against this 
outcome and allowed for a better understanding of the antibody reliability. Sox-2 is 
expressed by all the intrinsic brain tumours generated by our model, and also in human 
glioblastomas (Schmitz et al., 2007; Eschbacher et al., 2008). It has also been shown 
that miRNA silencing of Sox-2 in human glioblastoma-initiating cells reduces their 
proliferation and tumourigenicity in nude mice (Gangemi et al., 2009). A significant 
reduction of Sox-2-expressing cells was seen in the glioblastoma-generating Rb-/-; 
PTEN-/- NS; a result which contradicts the literature but suggests that the expression 
profile of differentiated NS may not always accurately predict the expression profile of 
the tumours they generate in vivo. Nestin is variably expressed across the different 
tumour phenotypes, but particularly strong immunoreactivity was seen in the 
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undifferentiated PNET tumours. Despite this, nestin expression is not restricted to 
undifferentiated tumours with expression also observed in high and low-grade 
malignant gliomas (Almqvist et al., 2002). MAP2, a marker of immature neurons, is 
highly expressed by all the intrinsic brain tumours generated by our model. This pattern 
of expression was not changed in the expression profile of the differentiated NS. The 
<			-tubulin positive cells highlights the fact that the in vitro differentiation 
conditions we used were not permissive to the generation of mature neurons and should 
be altered if required. However, the possibility that this observation was as a result of a 
lack of antibody specificity could have been effectively controlled aginst through the 
inclusion of a positive control into the experimental design. 
In addition to the number of positive cells, the expression intensity of the different 
markers across the genotypes was also graded. This was achieved by comparative 
confocal laser scanning imaging whereby the experimental genotype images were taken 
using identical imaging parameters as used for the control NS (Figure 33). 
 
 
Figure 33: The qualitative expression intensities of the differentiation biomarkers GFAP, CD133, 
Sox-2, Nestin, and MAP2 following in vitro inactivation of the TSGs Rb, p53, and PTEN correlate 
with the changes in the number of respective biomarker-expressing cells when compared against 
non-recombined untreated controls. Matrix of the expression intensity changes observed across the in 
vitro recombined Rb-/-; p53-/-, PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NS when compared 
against the PTENLox/Lox; p53Lox/Lox non-recombined untreated control. Red up-arrow: increased expression 
intensity, double red up-arrow: vastly increased expression intensity, blue down-arrow: decreased 
expression intensity, green dash: no change, grey dash: no expression observed. 
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The qualitative expression intensity levels of GFAP, Sox-2, and MAP2 were higher 
across all of the experimental genotypes. Interestingly, an increase in Sox-2 expression 
intensity was observed in the Rb-/-; PTEN-/- NS, despite having demonstrated a 
significantly reduced number of cells expressing Sox-2. Also, no change in the number 
of cells expressing MAP2 could be observed between any of the genotypes as the figure 
was always 100%. However, this expression intensity measurement method, highlighted 
a potential difference in MAP2 expression with the PTEN-/-; p53-/- and Rb-/-; p53-/-; 
PTEN-/- NS appearing to express it at a higher intensity than the Rb-/-; p53-/- and Rb-/-; 
PTEN-/- NS, despite 100% of the cells expressing MAP2 in all of the cases. The CD133 
expression intensity was disregarded due to its non-specific nature as previously 
described. The expression intensity of nestin was seen to be increased in the Rb-/-; p53-/-, 
PTEN-/-; p53-/-, and Rb-/-; p53-/-; PTEN-/- NS (Figure 33). These findings suggest that 
biomarker expression intensity correlates with the number of biomarker-expressing 
cells, but also highlights the potential of qualitative data in adding to quantitative data 
sets. However, in light of the lack of experimental controls within this design, as 
previously discussed, the deduced results from this immunofluorescence data should be 
taken with caution. 
 
3.3.8 Quantitative real-time PCR identifies differentially expressed cancer 
genes between genotypes 
Using the Cancer PathwayFinder RT2 Profiler PCR Superarray system we were able to 
examine the mRNA expression profiles of NSCs for 84 genes (representative of six 
cancer pathways) of NSCs. RNA was extracted from each of the Rb-/-; p53-/-, PTEN-/-; 
p53-/-, Rb-/-; p53-/-; PTEN-/-, and Rb-/-; PTEN-/- NS genotypes (n=2 for each, passage 2-5) 
to compare their mRNA expression profiles in the aim of identifying the effects of TSG 
loss in the different combinations. These profiles were corrected against RNA taken 
from Adenovirus-GFP-infected control NS (n=2, passage 3) and five housekeeping 
control genes. 
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Figure 34: Average mRNA expression fold changes (2(average )) and associated P-values for the 
full set of 84 experimental genes (and 5 additional housekeeping control genes: given at the bottom) 
examined. For each genotype the left-hand column represents the mRNA fold change and the right-hand 
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column represents the P-value. Gene (symbol) column colour key - orange: upregulated in all genotypes, 
red: upregulated in three genotypes, olive: upregulated in two genotypes, yellow: downregulated in three 
genotypes, green: single genotype differential expression. Fold change column colour key – blue font: 
<0.33, red font: >2. P-value column colour key – red font: P<0.05. Genotype fold change and P-value 
dual column colour key – highlighted blue box: dual-significant downregulation, highlighted orange box: 
dual-significant upregulation. 
 
Rb, p53, and PTEN were observed to be completely knocked-out with a fold change of 
0.00 (where 1.00 = no change) in all the corresponding genotypes in which they were 
lost, therefore validating the assay. In addition, it should be noted that no significant 
fold changes were observed in non-recombined Rb, p53, or PTEN genes as a 
compensation of the others being lost (Figure 34). Any significant up/downregulation of 
these 84 experimental genes was highlighted so that comparisons could be made 
between the different genotypes. Genes that were differentially expressed to a 
significant level were then used to generate a ‘hit list’ (Figure 35). 
 
 
Figure 35: Differentially expressed gene 'hit list'. For each genotype the left-hand coloum represents 
the mRNA fold change and the right-hand column represents the P-value. Gene (symbol) column colour 
key - orange: upregulated in all genotypes, red: upregulated in three genotypes, olive: upregulated in two 
genotypes, green: single genotype differential expression. Fold change column colour key – blue font: 
<0.33, red font: >2. P-value column colour key – red font: P<0.05. Genotype fold change and P-value 
dual column colour key – highlighted blue box: dual-significant downregulation, highlighted orange box: 
dual-significant upregulation. 
 
Previous work has shown that conditional knockout of TSGs in vivo results in the 
development of brain tumours whose phenotype is strongly influenced by genotype 
(Jacques et al., 2010). For example, the conditional in vivo knockout of Rb and p53 
resulted in the development of intrinsic tumours which phenotypically resembled human 
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primitive neuroectodermal-like tumours (PNETs), whereas the knockout of PTEN and 
p53 resulted in the development of gliomas. For this reason, the mRNA expression 
profiles of these two genotypes were compared. In in vitro cultures, the only 
significantly differentially expressed gene between those two genotypes was Mmp9 
(matrix metalloproteinase 9: 2.86-fold significant up-regulation in PTEN-/-; p53-/- vs. 
1.57-fold non-significant upregulation Rb-/-; p53-/-), which was relatively overexpressed 
in the PTEN-/-; p53-/- glioma-generating genotype. This was interesting as Mmp-9 has 
been shown to play a major role in the migration and invasion of tumour cells, with 
elevated Mmp-9 levels being associated with the enhanced progression of glioma in 
humans (Lakka et al., 2002). In addition, downregulation of Mmp-9 has been shown to 
inhibit the adhesion, migration and invasive potential of human glioma xenografts in 
nude mice. It is thought that this is achieved by downregulating integrins and associated 
signaling molecules (Veeravalli et al., 2010). These findings highlight Mmp-9 
expression as a potential correlate of glioma invasiveness (Figure 35). 
Other genes that were differentially expressed between the genotypes were S100a4 
(S100 calcium binding protein A4) with 17.85-fold upregulation in Rb-/-; PTEN-/- vs. 
non-significant upregulation in all other genotypes) and Timp1 (tissue inhibitor of 
metalloproteinase 1 with 42.36-fold significant upregulation in Rb-/-; PTEN-/- & 4.24-
fold significant upregulation in Rb-/-; p53-/-; PTEN-/- vs. non-significant upregulation in 
Rb-/-; p53-/- and PTEN-/-; p53-/-). These were interesting because they were 
up/downregulated to a particularly large extent in the Rb-/-; PTEN-/- glioblastoma-
generating genotype. In the case of S100a4, it is known that increased expression in rat 
C6 glioma cells correlates with the progression of low-grade astrocytic tumours to high-
grade glioblastomas, as well as increased migration throughout white matter in humans 
(Takenaga et al., 2007). This finding has also been verified in xenografted human 
glioblastoma cell lines and primary human glioma tissues, in addition to which S100a4-
expressing tumour cells were found to possess enhanced tumour-initiating capacity, 
self-renewal, and multipotency (Harris et al., 2008). Taken in combination with our 
findings, these data suggest S100a4 to be a potential marker of GICs. Timp1 is thought 
to be involved in tumour invasion, proliferation, and apoptosis across a range of 
different cancers. And it has been shown that a low Timp1 expression predicts longer 
overall survival in glioblastoma, but not grade II or III astrocytoma patients (Aaberg-
Jessen et al., 2008; Aaberg-Jessen et al., 2009). The decreased survival associated with 
increased Timp1 expression could be as a result of its anti-apoptotic effects preventing 
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chemo/radiotherapy-induced apoptosis. Timp1 may, therefore, represent a potential 
therapeutic target in the treatment of glioblastoma (Figure 35). 
Genes that were found to be consistently, overexpressed in all of our tumourigenic NSC 
genotypes were Cdkn2a (cyclin-dependent kinase inhibitor 2A: 3.52-11.59-fold 
significant upregulation across all genotypes), Met (Met proto-oncogene: upregulated 
across all genotypes with a 16.12-fold significant upregulation in Rb-/-; PTEN-/-), and 
Twist1 (Twist gene homolog1: 2.12-9.52-fold significant upregulation across all 
genotypes except Rb-/-; PTEN-/-). It has long been known that the Cdkn2a gene is lost or 
deleted in a wide variety of human tumours, including glioblastoma (Moulton et al., 
1995; Nobori et al., 1994). However, we observed an overexpression of Ckn2a in our 
model but propose that this is due to an overcompensation following the intrinsic loss of 
Rb, p53, and/or PTEN. Hence the Rb-/-; p53-/-; PTEN-/- NSC genotype demonstrated the 
largest overexpression. Met expression is strongly increased in glioblastomas, in which 
it is believed to promote tumour proliferation, migration, invasion, and angiogenesis. 
And based on this belief it has been shown that the in vivo growth of glioblastoma 
xenografts in nude mice is inhibited by intratumoural treatment with an anti-c-Met 
antibody (Martens et al., 2006). Considering that we found Met expression to be most 
significantly upregulated in the Rb-/-; PTEN-/- glioblastoma-generating genotype, we can 
be confident in our suggestion of Met as a therapeutic target in the treatment of 
glioblastoma. Twist1 has been shown to significantly increase the in vivo invasion of 
human glioblastoma cells following orthotopic xenotransplantation in nude mice. 
Inhibiting Twist1 has also been shown to decrease the invasion and growth of human 
glioblastoma cells in vitro (Mikheeva et al., 2010). Although Twist1 was not seen to be 
overexpressed in our Rb-/-; PTEN-/- glioblastoma-generating genotype, we propose that 
its consistent overexpression across the other genotypes is suggestive of a role in 
general tumour progression and cell migration (Figure 35). 
One anomaly can be seen in the downregulated expression of Vegfa (vascular 
endothelial growth factor A) in the Rb-/-; PTEN-/- glioblastoma-generating genotype. 
Vegfa is overexpressed in grade IV glioblastomas, particularly in areas surrounding 
necrosis (Johansson et al., 2002). However, the expression of the angiogenesis factor 
Vegfa is strongly correlated with the hypoxic conditions of in vivo environment. As 
such we believe that the relatively non-hypoxic conditions of in vitro cell culture 
effectively drive the downregulation of Vegfa (Figure 35). 
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Other genes found to be differentially expressed (to lesser degrees) between the 
different genotypes were Casp8, E2f1, Tnfrsf10b (most likely to be as a direct result of 
p53 loss), and Vegfb (Figure 35). 
 
3.4 Conclusion 
In this chapter we demonstrated that i.c.v. administration of Adenovirus-Cre targets 
self-renewing and multipotent SVZ NSCs that become enriched in neurosphere cultures 
over serial passages. This verified that the in vitro model system is an effective 
surrogate of the in vivo model system and allowed us to characterise the effect of Rb, 
p53, and PTEN loss on the growth rate, self-renewal, multipotency and biomarker 
expression of NSCs in vitro. The combination and number of TSGs lost was seen to 
determine the growth rates of NSCs in vitro, with an additive effect of additional TSG 
loss on increased growth rate. In vitro recombined NSCs also possessed increased self-
renewal in a genotype-dependent manner, in addition to possessing altered expression 
levels of GFAP, Sox-2, and nestin. We also identified that the in vitro growth rate, but 
not the in vitro self-renewal ability, of NSCs is a positive predictive indicator of in vivo 
tumour hit rate and an inverse predictive indicator of in vivo tumour latency. Finally, 
Mmp-9, S100a4, and Timp1 were identified as differentially expressed cancer genes 
between the NSC genotypes and hypothetical surrogate markers of tumour phenotype. 
We hypothesise that the different NSC genotypes possessed functional differences in 
growth rate, NS-forming ability, self-renewal, and differentiation expression profiles in 
vitro because they are composed of different NSC sub-populations with different 
functional properties. Cancer stem cells are dependent on their microenvironment 
(Calabrese et al., 2007) and we therefore hypothesise that the NSC sub-populations of 
the different genotypes exist in different states dependent on their in vitro or in vivo 
microenvironment. In the next chapter we aim to address this hypothesis and also 
examine a) whether these NSC states can be manipulated by switching between 
microenvironments and b) whether these states influence their in vivo tumour hit rate, 
latency, or phenotype. 
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3.5 Future Work 
Expansion of the sample numbers and/or number of genes tested across all of the 
functional assays would allow for a more robust analysis and the potential identification 
of additional in vitro predictive indicators of in vivo behaviour. In addition, the 
functional assay portfolio would benefit from the inclusion of multipotency profiles for 
the NSC genotypes. By studying the differentiation expression profiles of additional 
biomarkers (e.g. Sox-9, NeuN, Olig2 and an optimised CD133) we may elucidate 
further in vitro predictive indicators of in vivo behaviour. However, the methodological 
rigour of the differentiation analysis by immunofluorescence should be strengthened 
through the inclusion of positive and negative controls. The mRNA / cDNA expression 
analysis, although successful in identifying differentially expressed genes, would 
benefit from validation at the protein level by Western blot. 
Rather than correlating the functional properties of in vitro recombined NSCs directly to 
their behaviour in vivo, it would be interesting to observe the behaviour of the NSCs 
when grown in 3-D matrices as this may act as a better system for modelling in vivo 
behaviour without the need for lengthy in vivo studies. 
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4 Characterisation of the Brain Tumour Initiating Cell 
 
4.1 Introduction 
This chapter is separated into three parts, the first of which is covered by sections 4.3.1, 
4.3.2, and 4.3.3 in which we aim to confirm that the tumours generated by i.c.v. 
Adenovirus-Cre administration (section 1.7.2) were derived from SVZ NSCs and/or 
their immediate progeny. We aim to address this by deriving neurosphere cultures from 
the SVZs of RbLox/Lox; p53Lox/Lox, PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, and 
RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice and inducing recombination in vitro before 
engrafting these neurospheres into the brains of recipient mice to compare the tumour 
hit rate, latency, and phenotype profiles against those observed following i.c.v. 
Adenovirus-Cre administration. We also cultured and re-grafted ‘tumourspheres’ (TS) 
derived from a glioma generated by intracerebrally engrafted Rb-/-; p53-/- NS to examine 
whether the brain tumour initiating cell (BTIC) phenotype is maintained and refined 
through serial passages. 
Secondly, in section 4.3.4 we aim to address whether BTIC status can be refined to a 
specific SVZ NSC sub-type. We have previously demonstrated that i.c.v. Adenovirus-
CMV-Cre-mediated recombination of TSGs in cells of the SVZ NSC compartment 
results in the development of malignant brain tumours. However, the variability in 
tumour hit rate and phenotype suggests that we may not be exclusively targeting the 
BTIC population for recombination; plausible considering the widespread expression of 
the CMV promoter. Methods by which Cre-mediated recombination can be targeted 
within specific cell types or anatomical locations are commonly available. Nestin-Cre 
transgenic mouse lines were developed to study the effect of gene loss in nestin-
expressing stem cells during development whilst bypassing embryonic lethality (Betz et 
al., 1996). Using the same approach, cell-specific mutations have been achieved in 
Purkinje cells of the cerebellum and in the mid-hindbrain cerebellar region during 
development by expressing Cre-recombinase under the control of the L7 and Engrailed2 
promoters respectively (Barski et al., 2000; Song and Joyner, 2000). Here we use i.c.v. 
Adenovirus-GFAP-Cre administration to more specifically target the GFAP-expressing 
type B astrocytes of the SVZ (Garcia-Verdugo et al., 1998) for recombination. Using 
this approach we aim to address the relative contribution of the type B astrocytes to 
tumourigenesis. 
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Finally, in sections 4.3.5, 4.3.6, and 4.3.7 we aim to address whether the environment 
(in vivo versus in vitro) of the SVZ NSCs at the time of recombination has an influence 
on the tumour hit rate, latency, and/or phenotype profile for each of the different 
genotypes. The rationale being that in section 4.3.2 we highlight that some genotypes of 
in vitro recombined and intracerebrally engrafted NS do not recapitulate the tumour 
phenotypes seen following in vivo recombination of the same TSGs by i.c.v. 
Adenovirus-Cre administration. For example, in vivo recombination of Rb and p53 in 
RbLox/Lox; p53Lox/Lox mice resulted in the development of brain tumours, whereas in vitro 
recombined and engrafted Rb-/-; p53-/- NSCs did not generate tumours. The converse 
was observed with the RbLox/Lox; PTENLox/Lox genotype. We propose that such 
discrepancies could be because a) in vivo Adenovirus-Cre targets a cell population that 
is not present in vitro, and vice versa, or b) the act of deriving in vivo NSCs and putting 
them in culture alters the phenotype of the cells. In order to address these hypotheses, 
we will recombine NSCs in vivo by i.c.v. Adenovirus-Cre administration and then 
derive and expanded them in vitro at 2 weeks (early), 2 months (middle), or >3.5 
months (late) post-recombination. These NSCs will then be characterised in vitro and 
intracerebrally engrafted back into the brains of recipient mice to observe whether the 
hit rates, latencies, and phenotypes of the resulting brain tumours more closely resemble 
those generated by in vivo recombination or in vitro recombined and engrafted NS. 
Using this approach we aim to further characterise the in vivo tumourigenic 
transformation process and refine our knowledge of the BTIC. 
 
Aims 
1. Verify that brain tumour development following i.c.v. Adenovirus-Cre 
administration is initiated and driven by SVZ NSCs. 
2. Examine whether NSCs exist in the brain tumour bulk as brain tumour initiating 
cells (BTICs). 
3. Refine the BTIC to a more specific sub-type of SVZ NSC. 
4. Identify whether NSCs exist in different states dependent on their environment 
and whether these have altered tumour hit rates, latencies, and phenotype 
propensities. 
5. Functionally characterise these different states in vitro. 
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4.2 Materials and Methods 
Refer to the main materials and methods section (Chapter Two). 
 
4.3 Results and Discussion 
 
4.3.1 Inactivation of tumour suppressor genes in subventricular zone cells 
causes them to proliferate and migrate into the brain parenchyma where 
they generate tumours 
A cohort of five RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice received i.c.v. Adenovirus-Cre 
and were culled after 60 days (mean tumour latency: 101 days) with the aim of 
observing a developing tumour prior to clinical manifestation. 
 
 
Figure 36: SVZ cells targeted for inactivation of the TSGs Rb, p53 and PTEN proliferate and 
migrate away from the SVZ into the brain parenchyma where they generate tumours. 
Representative images of a RbLox/Lox; p53Lox/Lox; PTENLox/Lox mouse 60 days post-i.c.v. Adenovirus-Cre 
					-galactosidase and GFAP with a Hoechst 33342 (DAPI) 
counterstain (A,B). Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 546nm. 
Images were taken using a 10x (inset: 20x) objective on a Zeiss LSM510 META confocal laser scanning 
microscope with the LSM software. Scale bar: 100μm (main images) or 50μm (inset). 
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{	?				
		-galactosidase-positive recombined cells, including 
the GFAP-expressing type B astrocytes, could be seen in the SVZ (Figure 36: A, inset). 
These recombined cells were proliferating and migrating laterally away from the SVZ 
into the brain parenchyma where we would expect them to generate a PNET tumour 
after a mean latency of 101 days. This highlights that the highly proliferative cells 
responsible for forming the bulk of brain tumours can originate from the SVZ. 
 
4.3.2 In vitro recombined and intracerebrally engrafted neurospheres 
derived from the subventricular zone neural stem cell compartment 
recapitulate the tumour phenotype observed following 
intracerebroventricular Adenovirus-Cre administration 
Neurosphere cultures derived from the SVZs of adult mice contain self-renewing and 
multipotent NSCs (sections 3.3.1 and 3.3.2). To confirm that the intrinsic primary brain 
tumours generated by i.c.v. Adenovirus-Cre administration were derived from SVZ 
NSCs we generated neurosphere cultures from the brains of RbLox/Lox; p53Lox/Lox, 
PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, and RbLox/Lox; p53Lox/Lox; PTENLox/Lox 
mice and induced recombination in vitro after 15-30 days (passage 1) by infecting them 
with Adenovirus-`	??	
	]	
	-galactosidase staining) of 
the NS was achieved across all of the genotypes. These in vitro recombined NSCs 
(growing as neurospheres) demonstrated a genotype-dependent increase in growth rate 
and self-renewal (sections 3.3.3 and 3.3.4). After an additional 2-4 passages (10-40 
days) in culture, these NS were engrafted into the striata of a total of 113 non-
recombined LoxP mutant mice of matched genetic backgrounds in 14 separate 
experiments. The viability of the NS was confirmed by examining their cellular 
morphology (haematoxylin and eosin staining: data not shown) using the cytoblock 
procedure for paraffin immunohistochemistry (Error! Reference source not found.). 
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9.6% of in vitro recombined Rb-/-; p53-/- NS (n=52; 4x PNET, 1x PNET + glioma), 
79.0% of PTEN-/-; p53-/- NS (n=19; 8x glioma, 6x oligoastrocytoma, 1xPNET), 70.6% 
of Rb-/-; PTEN-/- NS (n=17; 11x glioblastoma, 1x glioblastoma + oligoastrocytoma), and 
96.0% of Rb-/-; p53-/-; PTEN-/- NS (n=25; 13x PNET + glioma, 6x PNET, 3x 
oligoastrocytoma, 1x glioma, 1x oligodendroglioma) generated intrinsic brain tumours 
following intracerebral engraftment (Figure 38). 
 
 
Figure 38: Summary of the experimental results (including ‘n’ number, mean tumour latency, hit 
rate, and predominant tumour phenotype) from the i.c.v. administration of Adenovirus-Cre in 
RbLox/Lox; p53Lox/Lox, PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, and RbLox/Lox; p53Lox/Lox; 
PTENLox/Lox mice and the intracerebral engraftment of in vitro recombined NS derived from the 
same mice. 
 
The tumour latencies following in vitro recombined NS engraftment were shorter than 
the respective i.c.v. Adenovirus-Cre-induced tumour latencies across all of the 
genotypes. The in vitro recombined NS spend 10-40 days in culture before being 
engrafted, this time may therefore account for the observed reduction in latency. This 
suggests that the in vivo tumourigenic process that takes place prior to clinical tumour 
manifestation (e.g. acquisition of further mutations) is not delayed by in vitro culturing. 
The tumour latency of the PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NS 
were significantly shorter than the Rb-/-; p53-/- NS. As with the i.c.v. Adenovirus-Cre-
induced tumours, the Rb-/-; p53-/-; PTEN-/- genotype generated tumours in the shortest 
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time, which was also significantly less than that of the PTEN-/-; p53-/- NS-induced 
tumour latency (Figure 39). 
 
 
Figure 39: The genotype of the in vitro recombined NS determines the latency of tumour formation. 
Box and whiskers plot showing the mean tumour formation latency +/- 95% confidence intervals with 
min and max data points. *: P<0.05 vs. Rb-/-; p53-/- NS, **: P<0.005 vs. Rb-/-; p53-/- NS, ***: P<0.001 vs. 
Rb-/-; p53-/- NS, ###: P<0.001 vs. illustrated comparison (one-way ANOVA with Bonferroni’s multiple 
comparison correction). 
 
As demonstrated by Figure 38, the tumours generated from the engraftment of in vitro 
recombined NS generally appeared to be phenocopies of those tumours generated by 
i.c.v. Adenovirus-Cre administration (Figure 40). 
 
  
12
3 
 
 
Fi
gu
re
 4
0:
 T
he
 p
he
no
ty
pe
 o
f i
nt
ri
ns
ic
 b
ra
in
 tu
m
ou
rs
 g
en
er
at
ed
 fo
llo
w
in
g 
in
tr
ac
er
eb
ra
l e
ng
ra
ftm
en
t o
f i
n 
vi
tro
 r
ec
om
bi
ne
d 
ne
ur
os
ph
er
es
 is
 d
ep
en
de
nt
 o
n 
th
e 
co
m
bi
na
tio
n 
of
 T
SG
s i
na
ct
iv
at
ed
. R
ep
re
se
nt
at
iv
e 
im
ag
es
 ta
ke
n 
fr
om
 tu
m
ou
rs
 g
en
er
at
ed
 fo
llo
w
in
g 
in
tra
ce
re
br
al
 (i
n 
th
e 
st
ria
tu
m
) e
ng
ra
ftm
en
t o
f i
n 
vi
tro
 re
co
m
bi
ne
d 
R
b-
/- ;
 p
53
-/-
 (A
,E
,I,
M
), 
PT
EN
-
/- ;
 p
53
-/-
 (B
,F
,J,
N
), 
R
b-
/- ;
 P
TE
N
-/-
 (C
,G
,K
,O
), 
an
d 
R
b-
/- ;
 p
53
-/-
; P
TE
N
-/-
 (D
,H
,L
,P
) N
S.
 T
he
 tu
m
ou
rs
 w
er
e 
st
ai
ne
d 
fo
r h
ae
m
at
ox
yl
in
 a
nd
 e
os
in
 (A
-D
), 
G
FA
P 
(E
-H
), 
sy
na
pt
op
hy
si
n 
(I
-L
), 
an
d 
O
lig
2 
(M
-P
) t
o 
as
si
st
 in
 th
e 
cl
as
si
fic
at
io
n 
of
 th
ei
r p
he
no
ty
pe
. I
n 
th
e 
ca
se
 o
f t
he
 R
b-
/- ;
 p
53
-/-
 N
S 
tu
m
ou
r (
A
,E
,I,
M
), 
th
e 
w
el
l-d
em
ar
ca
te
d 
m
or
ph
ol
og
ic
al
 a
pp
ea
ra
nc
e 
of
 th
e 
tu
m
ou
r 
w
as
 su
gg
es
tiv
e 
of
 P
N
ET
 b
ut
 th
e 
ex
pr
es
sio
n 
pr
of
ile
 w
as
 c
ou
nt
er
-in
tu
iti
ve
ly
 fo
un
d 
to
 b
e 
G
FA
P-
ne
ga
tiv
e 
(E
), 
sy
na
pt
op
hy
si
n-
ne
ga
tiv
e 
(I
), 
an
d 
O
lig
2-
po
si
tiv
e 
(M
). 
Th
e 
R
b-
/- ;
 P
TE
N
-/-
 
N
S-
in
du
ce
d 
gl
io
bl
as
to
m
a 
(C
,G
,K
,O
) w
as
 id
en
tif
ie
d 
by
 p
al
is
ad
in
g 
ne
cr
os
is
 a
nd
 v
as
cu
la
r p
ro
fil
er
at
io
n 
(C
, i
ns
et
). 
Im
ag
es
 w
er
e 
ta
ke
n 
us
in
g 
a 
C
ol
or
V
ie
w
 II
I d
ig
ita
l c
am
er
a 
m
ou
nt
ed
 o
n 
a 
Ze
is
s A
xi
os
ko
p 
2 
M
O
T 
m
ic
ro
sc
op
e 
w
ith
 a
 1
0x
 m
ag
ni
fic
at
io
n 
(4
0x
 fo
r i
ns
et
) a
nd
 u
si
ng
 th
e 
A
na
ly
SI
S 
so
ftw
ar
e 
pa
ck
ag
e.
124 
 
The Rb-/-; p53-/- NS generated tumours that morphologically resembled human PNETs 
due to being well-demarcated and containing closely packed, undifferentiated cells that 
often appeared in rosette formations (Figure 40: A). However, these ‘PNETs’ were 
GFAP-negative, synaptophysin-negative, and Olig2-positive (Figure 40: E,I,M). PNETs 
are usually classified by their GFAP-negative, synaptophysin-positive, and Olig2-
negative profile as observed with the PNET component of the Rb-/-; p53-/-; PTEN-/- NS-
induced tumour (Figure 40: H,L,P). Notably, three of the four PNETs generated by the 
Rb-/-; p53-/- NS (of which the representative image is one) grew around the 4th ventricle 
in the cerebellum. It may therefore be the case that the Rb-/-; p53-/- NS were mistakenly 
delivered to the cerebellum where they were influenced by extrinsic factors to develop 
into medulloblastoma-like tumours (Hambardzumyan et al., 2008). Although the PTEN-
/-; p53-/- NS generated more gliomas than oligoastrocytomas, the proportion of 
oligoastrocytomas had risen from those observed following i.c.v. Adenovirus-Cre 
administration. These oligoastrocytomas were identified by their monomorphic and 
diffuse appearance in addition to their GFAP-positivity, synaptophysin-negativity, and 
their high level of Olig2-positivity (Figure 40: F,J,N) (Ligon et al., 2004). The absence 
of vascular proliferation and necrosis was indicative of a lower-grade oligoastrocytoma, 
but their high cellularity suggests that they are anaplastic (Figure 40: B) (Louis et al., 
2007). The Rb-/-; PTEN-/- NS generated tumours that resembled human glioblastoma, 
identified by their infiltrative nature and the presence of vascular proliferation (Figure 
40: C, inset), giant cells, palisading necrosis, and high cellularity (Louis et al., 2007). In 
addition, they were found to weakly express both GFAP (Figure 40: G) (Wilhelmsson et 
al., 0 AD) and Olig2 (Figure 40: O) (Mokhtari et al., 2005), as well as being 
synaptophysin-negative (Figure 40: K). The predominant phenotype of the tumours 
resulting from i.c.v. Adenovirus-Cre administration in RbLox/Lox; p53Lox/Lox; PTENLox/Lox 
mice shifted from PNET (39 out of 42) to a PNET + glioma biphasic phenotype (13 out 
of 24) following engraftment of Rb-/-; p53-/-; PTEN-/- NS (Figure 40: D). The PNET 
component of this tumour was identified as previously described and the glioma 
component was identified by their infiltrative appearance, the patterning of small dense 
nuclei (Figure 40: D), and their GFAP-positive (Figure 40: H), synaptophysin-negative 
(Figure 40: L) and Olig2-positive (Figure 40: P) expression profile (Louis et al., 2007). 
The shift to a bi-phasic tumour phenotype with an increased glial presence suggests that 
a wider variety of BTIC populations are present in the in vitro environment than in vivo. 
However, the general phenocopy trend observed between the in vitro recombined and 
engrafted NS tumours and the i.c.v. Adenovirus-Cre-induced tumours supports the 
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hypothesis that intrinsic brain tumours are derived from cells of the SVZ stem / 
progenitor cell compartment (Rietze and Reynolds, 2006) and also suggests that the act 
of deriving NSCs in vitro does not significantly alter their phenotype. Despite this, 
differences were observed in the Rb-/-; p53-/- and Rb-/-; PTEN-/- NSC genotypes. 
Interestingly, in vivo i.c.v. Adenovirus-Cre recombination in RbLox/Lox; p53Lox/Lox mice 
resulted in the development of brain tumours in 27.6% of mice, whereas in vitro 
recombined and engrafted Rb-/-; p53-/- NSCs generated tumours with a vastly decreased 
hit rate of 9.6%. This suggests that either a) in vivo Adenovirus-Cre could be targeting a 
cell population that is not present in vitro, or that b) the act of deriving in vivo NSCs and 
putting them in culture alters the phenotype of the cells. We hypothesise that the 
inactivation of Rb and p53 in an SVZ NSC can result in the tumourigenic 
transformation of the cell, but that this transformation is facilitated by the in vivo SVZ 
microenvironment of the cell. Conversely, whereas i.c.v. administration of Adenovirus-
Cre in RbLox/Lox; PTENLox/Lox mice did not result in the development of any intrinsic 
brain tumours, in vitro recombined and engrafted Rb-/-; PTEN-/- NS generated tumours 
with a hit rate of 70.6%. This suggests that only the in vitro neurosphere culture 
environment is permissive to tumourigenesis following inactivation of the TSGs Rb and 
PTEN. 
 
4.3.3 Tumourspheres derived from brain tumour biopsies recapitulate the 
original phenotype over serially engraftments 
Tumourspheres (TS) were derived from a glioma that was clinically presenting 333 days 
post-engraftment of in vitro recombined PTEN-/-; p53-/- NS. The TS were expanded in 
vitro for 10 passages and re-grafted back into the brains of 9 recipient mice (Figure 41). 
 
 
Figure 41: Overview of the experimental procedure used to serially derive and engraft 
tumourspheres (TS). 
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The engrafted PTEN-/-; p53-/- TS generated intrinsic brain tumours with a 100% hit rate 
and a mean latency of 91.6 days +/- 5.25; an increase from a hit rate of 79.0% and a 
significant reduction (P<0.005; two-tailed unpaired Student’s t-Test) from a mean 
latency of 149.8 days +/- 15.4 (Figure 42).
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The increased hit rate and reduced latency suggests that the tumour bulk contains a 
purified, or increased, number of BTICs. In addition, the original glioma phenotype was 
recapitulated in all 9 of the recipient mice (Figure 43). 
 
 
Figure 43: TS derived from a PTEN-/-; p53-/- NS-induced glioma recapitulate the phenotype when 
re-grafted into the brains of recipient mice. Representative images taken from tumours identified as 
diffusely infiltrating gliomas generated following intracerebral engraftment of in vitro recombined PTEN-
/-; p53-/- NS (A) and PTEN-/-; p53-/- TS (B) derived from a PTEN-/-; p53-/- NS-induced glioma. Images 
were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 
10x magnification and using the AnalySIS software package. 
 
These high-grade gliomas were identified by their diffusely infiltrating cells with a 
biphasic pattern of small dense and larger vesicular nuclei, and by the presence of 
micro-vascular proliferation (Louis et al., 2007). These findings suggest that NSC-like 
TS-forming cells reside within the tumour bulk and are a class of BTIC that it is 
maintained in a tumourigenic state and committed to the glial phenotypic lineage. 
 
4.3.4 The GFAP-expressing type B astrocytes of the subventricular zone 
are a class of brain tumour initiating cell 
We have previously shown (Chapter One) that i.c.v Adenovirus-CMV-Cre-mediated 
recombination of the TSGs Rb, p53, and PTEN in cells of the SVZ NSC compartment 
result in the genotype-dependent development of brain tumours. To assess the relative 
tumourigenic contribution of the GFAP-expressing type B astrocytes (Doetsch et al., 
1999) we delivered i.c.v. Adenovirus-GFAP-Cre (Adenovirus-Cre under the control of 
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the GFAP promoter) into a total of 91 mice, of all the double and triple TSG LoxP 
genotypes, in 11 separate experiments (Figure 44). 
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I.c.v. administration of Adenovirus-GFAP-Cre resulted in the development of tumours 
with comparable genotype-dependent phenotypic profiles, tumour hit rates, and tumour 
latencies to i.c.v. Adenovirus-CMV-Cre administration (Figure 45). 
 
 
Figure 45: Summary of the experimental results (including ‘n’ number, mean tumour latency, hit 
rate, and predominant tumour phenotype) from the i.c.v. administration of Adenovirus-CMV-Cre 
and Adenovirus-GFAP-Cre in RbLox/Lox; p53Lox/Lox, PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, 
and RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice. 
 
I.c.v. Adenovirus-CMV-Cre administration resulted in the development of intrinsic 
brain tumours in: 27.6% (mean latency: 274 days) of RbLox/Lox; p53Lox/Lox mice (n=98; 
22x PNET, 4x glioma, 1x PNET + glioma), 25.6% (mean latency: 225 days) of 
PTENLox/Lox; p53Lox/Lox mice (n=121; 28x glioma, 3x oligoastrocytoma), 0% of 
RbLox/Lox; PTENLox/Lox mice (n=18), and 50.0% (mean latency: 101 days) of RbLox/Lox; 
p53Lox/Lox; PTENLox/Lox mice (n=84; 39x PNET, 2x glioma, 1x PNET + glioma) (Figure 
45). In comparison, i.c.v. Adenovirus-GFAP-Cre administration resulted in the 
development of intrinsic brain tumours in: 3.8% (mean latency: 290 days) of RbLox/Lox; 
p53Lox/Lox mice (n=26; 1x PNET), 33.3% (mean latency: 230 days) of PTENLox/Lox; 
p53Lox/Lox mice (n=24; 8x glioma), 0% of RbLox/Lox; PTENLox/Lox mice (n=14), and 
44.4% (mean latency: 147 days) of RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice (n=27; 5x 
PNET, 3x glioma, 2x PNET + glioma) (Figure 45). The similar tumour profiles 
observed following Adenovirus-GFAP-Cre and Adenovirus-CMV-Cre recombination 
suggests that the GFAP-expressing type B astrocytes of the SVZ are an influential class 
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of brain tumour initiating cell (BTIC). However, the RbLox/Lox; p53Lox/Lox mice 
demonstrated a reduced tumour hit rate when administered with Adenovirus-GFAP-Cre 
compared against Adenovirus-CMV-Cre. This suggests that either a) in the case of 
PNETs there are other SVZ cells that contribute towards tumourigenesis, hence a 
reduction in hit rate when only the type B astrocytes are targeted, and/or b) inactivation 
of the TSGs Rb and p53 in GFAP-expressing type B astrocytes shifts their cellular 
signature to a state in which they are less tumourigenic. In addition, RbLox/Lox; 
p53Lox/Lox; PTENLox/Lox mice administered with Adenovirus-GFAP-Cre exhibited a 
significantly longer mean tumour latency (P<0.05; two-tailed unpaired Student’s t-Test) 
and a reduced number of PNETs, suggesting that the PNET BTIC may have been 
depleted by inactivation of Rb and p53 and that additional PTEN inactivation meant that 
more gliomas (with longer latencies) were allowed to develop. 
 
4.3.5 Subventricular zone neural stem cells targeted for recombination in 
vivo exhibit the same in vitro growth rate, but reduced in vitro self-renewal, 
when compared against their in vitro recombined counterparts 
It is our hypothesis that NSCs exist in different states, with different functional 
properties, relative to their environment (in vitro versus in vivo). We hypothesise that 
these different states may be the cause of the discrepancy observed between the hit rates 
of tumours generated from i.c.v. Adenovirus-Cre administration in RbLox/Lox; p53Lox/Lox 
mice (24.8%) versus in vitro recombined and engrafted Rb-/-; p53-/- NS (9.6%), when all 
the other in vitro recombined NS genotypes exhibited increase tumour hit rates (section 
4.3.2). To this end, we expanded our model system to allow the characterisation of 
NSCs in these different in vitro and in vivo states. 
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Figure 46: Schematic overview of the model systems used to characterise NSCs targeted for 
tumourigenic recombination in their in vitro (middle schematic) and in vivo (bottom schematic) 
states. 
 
To define the functional properties of the NSCs in their hypothetically different states 
we used the WST-1 proliferation assay to measure the cumulative mitochondrial 
activity (as a surrogate marker of in vitro growth rate) of passage three Rb-/-; p53-/- 
NSCs at 0, 4, 6, and 8 hours after a 3 day incubation period (Figure 47). The assay was 
used to compare the growth rates of in vitro recombined Rb-/-; p53-/- NSCs and in vivo 
recombined RbLox/Lox; p53Lox/Lox NSCs derived and grown in vitro at 2 weeks, 2 months 
and 4.5 months post-i.c.v. Adenovirus-Cre administration. All of the in vivo recombined 
!"		=	
#		
	??	-galactosidase-positive (recombined) by 
passage two, therefore accounting for any non-recombined NSC interference. 
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Figure 47: The growth rates of passage three in vitro recombined Rb-/-; p53-/- NS, in vivo 
recombined RbLox/Lox; p53Lox/Lox NSCs derived and grown as NS in vitro at 2 weeks, 2 months and 
4.5 months post-i.c.v. Adenovirus-Cre administration, and non-recombined Adenovirus-GFP-
infected are all statistically the same. Using the WST-1 assay the growth rate (y-axis) of NSCs 
(growing as NS) was measured at 0, 2, 4, and 8hrs (x-axis) after a 3 day incubation period. Growth rate of 
in vitro recombined Rb-/-; p53-/- (orange: n=3) vs. in vivo recombined RbLox/Lox; p53Lox/Lox NSCs derived 
and grown as NS in vitro at 2 weeks, 2 months and 4.5 months post-i.c.v. Adenovirus-Cre administration 
(brown: n=2 each) vs. non-recombined Adenovirus-GFP-infected (green: n=6) NS. Error bars: standard 
errors. No statistical difference observed between any of the NS growth rates at 8hrs (one-way ANOVA 
with Bonferroni’s multiple comparison correction). 
 
No statistical difference was observed between any of the Rb-/-; p53-/- NS, regardless of 
the cellular environment at the time of recombination (in vitro versus in vivo) and the 
length of in vivo Adenovirus-Cre incubation (Figure 47). Also, no statistical difference 
was observed between any of the Rb-/-; p53-/- NS and the non-recombined Adenovirus-
GFP-infected control NS. The in vivo recombined and derived in vitro NS appeared to 
possess a slower growth rate than the in vitro recombined NS, but this could be due to 
variability in the health of the cells prior to the assay. These data suggest that the 
cellular environment of NSCs at the time of recombination is not correlated to a change 
in growth rate. Therefore, despite identifying the in vitro growth rate of in vitro 
recombined NSCs as a positive predictive indicator of in vivo tumour hit rate (section 
3.3.5), this concept cannot be applied to the environment-driven NSC state hypothesis. 
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We also performed a monoclonal self-renewal assay in the aim of elucidating a 
functional difference between the NSCs of different environmental origins. The non-
recombined Adenovirus-GFP-infected NSC control and in vitro Adenovirus-Cre-
recombined Rb-/-; p53-/- NSCs, as analysed in section 3.3.4, are supplied for baseline 
comparison purposes. Against these we compared the primary and secondary self-
renewal abilities of in vivo Adenovirus-Cre-recombined and derived in vitro (after 3 
days) Rb-/-; p53-/- NSCs, in vitro Adenovirus-GFAP-Cre-recombined Rb-/-; p53-/- NSCs, 
and in vivo Adenovirus-GFAP-Cre-recombined and derived in vitro (after 3 days) Rb-/-; 
p53-/- NSCs (Figure 48). 
 
 
Figure 48: Illustration of the experimental paradigm used to evaluate the self-renewal ability of in 
vitro recombined Rb-/-; p53-/- NSCs vs. in vivo Adenovirus-Cre-recombined and derived in vitro 
(after 3 days) Rb-/-; p53-/- NSCs vs.  in vitro Adenovirus-GFAP-Cre-recombined Rb-/-; p53-/- NSCs 
vs. in vivo Adenovirus-GFAP-Cre-recombined and derived in vitro (after 3 days) Rb-/-; p53-/- NSCs. 
 
NS at passage two were dissociated into single cells (passage three), FACS-seeded into 
96-well plates, and incubated for nine days before the number of NS that formed were 
counted to assess the primary self-renewal ability. NS were then randomly selected, 
individually dissociated into single cells, and re-FACS-seeded into 96-well plates and 
left to assess the secondary self-renewal ability. The efficiency of the MoFlox XDP 
FACS machine at seeding single cells into single 96-well plate wells was verified at 
>99% and therefore no correction was applied to the self-renewal data. 
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Figure 49: Only the in vitro recombined Rb-/-; p53-/- NSCs, regardless of the cell targeted, 
demonstrated a significantly increased primary self-renewal ability over the Adenovirus-GFP-
infected control NSCs with significance achieved by all of the NSC groups at the secondary self-
renewal phase. NS at passage 2 were dissociated into single NSCs and individually seeded, using a 
MoFlo XDP FACS machine, into single wells of a 96-well plate containing 200μl NS medium and left to 
grow for nine days before the number of NS formed was counted and interpreted as the primary self-
renewal ability. The process was then repeated for a selection of these monoclonal NS, chosen at random, 
to assess the secondary self-renewal ability. Primary/secondary self-renewal of non-recombined 
Adenovirus-GFP-infected (green: n=2) vs. in vitro Adenovirus-Cre-recombined Rb-/-; p53-/- (orange: n=2) 
vs. in vivo Adenovirus-Cre-recombined and derived in vitro (after 3 days) Rb-/-; p53-/- NSCs (orange: 
n=2), in vitro Adenovirus-GFAP-Cre-recombined Rb-/-; p53-/- NSCs (orange: n=2), and in vivo 
Adenovirus-GFAP-Cre-recombined and derived in vitro (after 3 days) Rb-/-; p53-/- NSCs (orange: n=2). 
Primary self-renewal is shown as the solid bars and secondary self-renewal is shown as the paler-coloured 
bars on top of the primary self-renewal bars. Error bars: standard errors. *: P<0.05 vs. GFP control, **: 
P<0.01 vs. GFP control, ***: P<0.001 vs. GFP control, #: P<0.05 between highlighted groups (one-way 
repeated measures ANOVA with Bonferroni’s multiple comparison correction). 
 
For primary self-renewal, only the number of in vitro Adenovirus-Cre-recombined Rb-/-; 
p53-/- NSCs (34.8% +/- 1.0) and in vitro Adenovirus-GFAP-Cre-recombined Rb-/-; p53-/- 
NSCs (32.5% +/- 1.3) were observed to be significantly different from the Adenovirus-
GFP-infected control (21.0% +/- 1.2) (Figure 49). At the secondary self-renewal stage, 
significance against the Adenovirus-GFP-infected control was achieved by all of the Rb-
/-; p53-/- NSC groups. Fewer in vivo recombined and derived primary NSCs appeared to 
self-renew when compared against their corresponding in vitro recombined NSCs, and a 
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significant reduction was observed with the in vivo Adenovirus-GFAP-Cre-recombined 
and derived in vitro (after 3 days) Rb-/-; p53-/- NSCs (19.8% +/- 0.3). This suggests that, 
despite not demonstrating a difference in their in vitro growth rate, Rb-/-; p53-/- NSCs in 
their SVZ in vivo environment are functionally different from their in vitro recombined 
counterparts in that they possess a reduced self-renewal ability. No correlation was 
observed between the self-renewal ability of in vitro recombined NSCs and their in vivo 
tumour hit rate following engraftment (section 3.3.5), so a reduction in the self-renewal 
ability of in vivo recombined and derived in vitro NSCs should not be considered a 
potential predictive indicator of reduced in vivo tumour hit. Instead, the reduction in 
self-renewal could be interpreted as an indication that NSCs exist in different states 
dependent on their environment, and that these different states can be discriminated by 
their functional profiles. 
 
4.3.6 The environment of subventricular zone neural stem cells at the time 
of recombination influences in vivo tumour hit rate and latency but with 
little effect on phenotype 
To examine the in vivo tumour hit rate of NSCs recombined in vivo and derived in vitro 
we i.c.v. injected multiple mouse cohorts with Adenovirus-Cre before deriving NS at 
early (2 weeks), intermediate (2 months), or late (>3.5 months) time points. These NS 
were expanded in vitro for 2-8 passages and intracerebrally engrafted into the striata of 
a total of 86 non-recombined mice of the same genetic background in 10 separate 
experiments. Mice were left for up to 449 days post-engraftment before the experiment 
was terminated (Figure 50). 
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These data were combined with the in vitro recombined and engrafted NS data to 
generate a tumour incident plot comparing the trends between cell genotype, cell 
recombination environment, tumour latency, and tumour phenotype (Figure 51). 
 
 
Figure 51: Incidence plot of the tumours generated from the intracerebral engraftment of Rb-/-; 
p53-/-, Rb-/-; PTEN-/-, PTEN-/-; p53-/- and Rb-/-; p53-/-; PTEN-/- NS recombined in vitro (circles) or in 
vivo and derived after 2 weeks (diamonds), 2 months (hexagons), and 4.5 months (triangles). Axis: 
tumour latency (days). 
 
The incident plot highlights the differences between the hit rates, latencies, and 
phenotypes of the tumours generated by the different engrafted NS genotypes. 
Interestingly, it also highlights a clear difference within the different NS genotypes 
based on the environment of the NSCs at the time of recombination (Figure 52). 
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Figure 52: Summary of the experimental results (including ‘n’ number, mean tumour latency, hit 
rate, and predominant tumour phenotype) from the i.c.v. administration of Adenovirus-CMV-Cre 
and Adenovirus-GFAP-Cre in RbLox/Lox; p53Lox/Lox, PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, 
and RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice in addition to the results from the intracerebral 
engraftment of in vitro recombined NS and in vivo recombined and derived in vitro NS derived from 
the same mice. 
 
Intracerebral engraftment of in vivo recombined and derived in vitro NS (regardless of 
time prior to in vitro derivation) resulted in an intrinsic tumour hit rate of 45.8% for Rb-
/-; p53-/- NS (n=48; 14x PNET/glioma, 4x glioma, 3x PNET, 1x oligoastrocytoma), 
33.3% for PTEN-/-; p53-/- NS (n=9; 2x oligoastrocytoma, 1x glioma), 0% of Rb-/-; 
PTEN-/- NS (n=11), and 33.3% of Rb-/-; p53-/-; PTEN-/- NS (n=18; 4x PNET, 2x PNET + 
glioma) (Figure 52). Notably, the tumour hit rates and latencies following engraftment 
of the in vivo recombined and derived in vitro NS appeared to more closely resemble 
those following i.c.v. Adenovirus-Cre administration rather than engraftment of in vitro 
recombined NS. For example, in vitro recombined and engrafted Rb-/-; PTEN-/- NS 
generated tumours with a 70.6% hit rate and 116 day latency whereas both i.c.v. 
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Adenovirus-Cre administration in RbLox/Lox; PTENLox/Lox mice and in vivo recombined, 
derived in vitro and engrafted Rb-/-; PTEN-/- NS failed to generate a single brain tumour 
(Figure 52). A similar trend was observed with the in vivo recombined, derived in vitro 
and engrafted PTEN-/-; p53-/- and Rb-/-; p53-/-; PTEN-/- NS, which demonstrated hit rates 
(both 33.3%) that more closely resembled the 25.6-33.3% and 44.4-50% respectively 
achieved with i.c.v. Adenovirus-Cre. In addition, the tumour latencies of the same in 
vivo recombined, derived in vitro and engrafted NS were significantly longer (P<0.05 
and P<0.001 respectively; two-tailed unpaired Student’s t-Test) than following 
engraftment of their in vitro recombined counterparts. However, despite these 
differences in tumour hit rate and latency, the tumour phenotypes remained comparable. 
This suggests that the environment of the NSC at the time of recombination influences 
the in vivo tumour hit rate of the NSCs but has no effect on the phenotype. In the case of 
the PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- genotypes, NSCs 
recombined in an in vitro environment possess the greatest tumourigenicity (highest hit 
rate and shortest latency). We propose that this is either because a) the number of BTICs 
is at its greatest in the in vitro environment, or b) the NSCs exist in an altered and more 
tumourigenically susceptible state in vitro. 
The one exception to this rule is the Rb-/-; p53-/- NS genotype, for which NSCs 
recombined in the in vitro environment were less tumourigenic (albeit non-significantly 
for tumour latency: P>0.05; two-tailed unpaired Student’s t-Test) than their in vivo 
recombined, derived in vitro and engrafted NS (Figure 52). However, when the tumour 
latencies of the in vivo recombined, derived in vitro and engrafted NS are broken down 
based on the length of time prior to derivation (2 weeks vs. 2 months vs. >3.5 months) a 
significant difference was observed between the 2 week and the >3.5 months groups 
(Figure 53). 
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Figure 53: In vivo recombined and derived in vitro after 2 weeks Rb-/-; p53-/- NS generate brain 
tumours with a significantly shorter latency following engraftment than when derived after >3.5 
months. Mean and standard error plot with all the data points showing the in vivo tumour latency. **: 
P<0.001 vs. illustrated comparison (one-way ANOVA with Bonferroni’s multiple comparison 
correction). 
 
The tumour latencies of the in vivo recombined NS derived after 2 weeks were not 
significantly different from those of the in vitro recombined NS but a trend could be 
observed between increased tumour latency and an increase in the length of time before 
in vitro derivation. The tumour hit rates of the in vivo recombined NS derived after 2 
weeks, 2 months, and >3.5 months were 56.3%, 75.0%, and 36.0% respectively. No 
statistically significant correlation, exclusive or inclusive of the in vitro recombined and 
engrafted NS data set, was observed between the length of time before derivation and 
tumour hit rate (P>0.05; two-tailed Pearson test). We propose that the observed increase 
in tumour latency with increased time between in vivo recombination and in vitro 
derivation may be as a result of micro-dissecting different populations of transformed 
SVZ cells. In addition, the fact that an elevated hit rate (36.0-75.0% versus 27.6% with 
i.c.v. Adenovirus-Cre) was observed with in vivo recombined Rb-/-; p53-/- NSCs that 
were derived in vitro and engrafted back into the brains of mice suggests that the 
hypothetical in vivo state of Rb-/-; p53-/- NSCs is maintained in transition from in vivo to 
the in vitro environment. In section 4.3.1 we identified that after 2 months (60 days) the 
SVZ cells targeted for recombination had proliferated and begun to migrate away from 
the SVZ. It is possible that the SVZ micro-dissections performed at the 2 week time 
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points captures the greatest number of recombined tumourigenic SVZ NSCs before this 
proliferation and migration occurs. And that after 3.5 months, the majority of the 
tumourigenic SVZ cells had migrated away from the SVZ leaving a depleted pool 
available for capture by micro-dissection. This hypothesis implies that tumour latency is 
dependent on tumourigenic cell load. In turn, this would suggest that leaving in vivo 
recombined and derived in vitro NS in culture for longer would result in a greater 
number of tumourigenic NSCs as they out-compete the other cells. This was the case 
with NSCs derived after 2 weeks that had tumour hit rates of 28.6% and 77.8% after 4 
and 8 passages in culture respectively (Figure 50). However, both cultures were 100% 
-galactosidase-#			@	=**		*	*	-galactosidase 
staining is not sensitive enough in determining the proportion of recombined cells or 
that recombined SVZ cells can exist with different grades of tumourigenicity. 
 
4.3.7 In vivo recombined, derived in vitro and engrafted Rb-/-; p53-/- 
neurospheres reproducibly generate a novel tumour resembling a small cell 
glioblastoma highlighting a potential influence of neural stem cell 
environment on lineage specificity 
In vivo recombined and derived in vitro Rb-/-; p53-/- NS were engrafted into the brains of 
recipient mice as described in section 4.3.6. Whereas the predominant tumour 
phenotype generated by tumourigenic NSCs of the PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and 
Rb-/-; p53-/-; PTEN-/- genotypes remained relatively constant, regardless of 
recombination environment, in vivo recombined and derived in vitro Rb-/-; p53-/- NSCs 
reproducibly gave rise to a novel tumour phenotype following engraftment. I.c.v. 
Adenovirus-Cre administration in RbLox/Lox; p53Lox/Lox mice had a 27.6% tumour hit rate 
of which 81.5% were PNETs. I.c.v. Adenovirus-GFAP-Cre administration in RbLox/Lox; 
p53Lox/Lox mice had a 3.8% tumour hit rate of which 100% were PNETs. In vitro 
recombined and engrafted Rb-/-; p53-/- NS had a tumour hit rate of 9.6% of which 80% 
were PNETs. However, in vivo recombined, derived in vitro and engrafted Rb-/-; p53-/- 
NS had a hit rate of 45.8% of which only 13.6% were PNETs but 63.6% were a novel 
glioma-like tumour with some PNET characteristics (Figure 54). 
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Figure 54: In vivo recombined, derived in vitro and engrafted Rb-/-; p53-/- NS reproducibly generate 
a novel glioblastoma-like tumour with some undifferentiated neuronal characteristics, regardless of 
the time between in vivo recombination and derivation in vitro. Representative images taken from 
tumours generated following intracerebral (in the striatum) engraftment of in vivo recombined and 
derived in vitro after 2 weeks (A,C,E,G,I) or 2 months (B,D,F,H,J) Rb-/-; p53-/- NS. The tumours were 
stained for haematoxylin and eosin (A,B), GFAP (C,D), nestin (E,F), synaptophysin (G,H), and Olig2 
(I,J) to assist in the classification of their phenotype. The tumours were often bi-phasic with some areas 
morphologically resembling a PNET (A, left side of image) but that were always synaptophysin-negative 
(G). Areas of GFAP-positivity (D, left side of image) were suggestive of a glial or astro/oligodendroglial 
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phenotype but counter-intuitively those areas were Olig2-negative (J, left side of image). The nestin-
positivity of all the tumours (E,F) confirmed their undifferentiated state. Images were taken using a 
ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x magnification 
and using the AnalySIS software package. 
 
Typically, PNETs appear well-demarcated with closely packed and undifferentiated 
cells positive for synaptophysin, and often appearing in rosette formations (Louis et al., 
2007). These particular tumours contained foci that matched this description (Figure 54: 
A, left half of image), but were always synaptophysin-negative (Figure 54: G,H). These 
undifferentiated cells also contained elongated nuclei, little cytoplasm (Figure 54: B, 
right side of image), and were GFAP-negative (Figure 54: D, right side of image). 
Rhythmic monomorphic astroglial-like patterning was also observed in some foci 
(Figure 54: A, right side of image), but these were also GFAP-negative (Figure 54: C). 
In addition, all of the tumours were Olig2-positive (Figure 54: I,J) except in areas of 
highly infiltrative GFAP-positive cells (Figure 54: J, left side of image); suggestive of a 
glioblastoma-like phenotype (Louis et al., 2007). Taken together, unlike the typical 
pleomorphic appearance of conventional glioblastomas, these particular tumours 
contained undifferentiated neuronal-like foci that were more indicative of a small cell 
astrocytoma / glioblastoma phenotype (Perry et al., 2004; Pina-Oviedo et al., 2006). 
This phenotype, novel to our model and unique to the Rb-/-; p53-/- genotype, highlights a 
potential effect of the NSC recombination environment on tumourigenic lineage-
specificity. 
 
4.4 Conclusion 
In this chapter we demonstrated that brain tumourigenesis is initiated and driven by 
SVZ NSCs by showing that a) i.c.v. Adenovirus-Cre recombination of TSGs in the SVZ 
causes cells to proliferate and migrate into the brain parenchyma where they generate 
tumours, and b) NSCs derived from the SVZ of adult mice and grown / recombined in 
vitro generate tumours that recapitulate the i.c.v. Adenovirus-Cre-induced phenotypes 
following intracerebral engraftment. Neurosphere-forming stem-like cells were 
observed to exist in the brain tumour bulk, as brain tumour initiating cells (BTICs), and 
were found to remain committed to a specific phenotype / lineage over serial 
engraftments. We hypothesise that these committed BTICs are the progeny of the SVZ 
NSCs targeted for recombination. To trace the origins of these committed BTICs we 
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used i.c.v. Adenovirus-GFAP-Cre to target only the GFAP-expressing type B astrocytes 
of the SVZ for recombination in the aim of examining their relative contribution to 
tumourigenesis. Using this approach we identified that targeting only the type B 
astrocytes of the SVZ for recombination induced the same patterns of tumour hit rate, 
latency, and phenotype as seen following non-specific targeting of all SVZ cells. This 
suggests that the type B astrocytes represent an SVZ class of BTIC. Interestingly, we 
revealed that the environment of SVZ NSCs (in vivo versus in vivo) at the time of 
recombination influences in vivo tumour hit rate and latency, but with little effect on 
phenotype. In addition, SVZ NSCs targeted for recombination in vivo were found to 
possess the same in vitro growth rate as their in vitro recombined counterparts, but 
exhibited reduced self-renewal. We therefore propose that the cellular environment of 
NSCs influences the states and ratios of different NSC sub-populations, and that these 
states determine their tumourigenic profile. This cell phenotype-based model of 
identifying BTICs complements the work of Clement et al, who have also pursued 
marker-independent identification of BTICs (Clement et al., 2010). 
Despite this, the majority of research has focussed on identifying BTICs based on their 
marker expression profile. To this end, CD133 was identified (Singh et al., 2003; Singh 
et al., 2004) and has been widely studied / disputed for its potential as a marker of 
BTICs (Bao et al., 2006; Clement et al., 2009; Facchino et al., 2010; Nishide et al., 
2009). In the next chapter we aim to examine the roll of CD133 expression and its 
potential as a marker of BTICs in our model of tumourigenesis. 
 
4.5 Future Work 
Expansion of the sample numbers across all of the in vivo experiments would allow for 
a more robust analysis of tumour hit rate, latency, and phenotype correlates. BTICs 
from the bulk of a tumour were serially engrafted through only one passage but were 
found to generated tumours with an increased hit rate and significantly reduced latency. 
By serially engrafting these BTICs through further passages we could derive a purified 
and highly tumourigenic primary cell line, which we could use to conduct a 
comprehensive functional characterisation in addition to identifying markers of BTICs. 
Ideally, this would be done for all the cell genotypes and all the different tumour 
phenotypes that they can induce. The concept of environment influencing NSC state 
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was devised by primarily using Rb-/-; p53-/- NSCs. Repeating the experiment for all of 
the genotypes would provide additional insight into this concept. 
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5 Investigating CD133 (Prominin-1) as a Marker of Brain 
Tumour Initiating Cells 
 
5.1 Introduction 
The cancer stem cell hypothesis states that only a small sub-population of cells within a 
tumour is tumourigenic. There is a large body of literature implicating the cell surface 
protein CD133 (Prominin-1) as both a marker of organ-specific adult stem cells and 
cancer stem cells. This association was first comprehensively characterised in colon 
cancer stem cells (Ricci-Vitiani et al., 2007; O'Brien et al., 2007; Singh et al., 2003) but 
continues to be debated (Shmelkov et al., 2008; Clement et al., 2009). The study of 
CD133 as a marker of cancer stem cells has expanded across a range of cancers 
including haematopoietic (Vercauteren and Sutherland, 2001), kidney (Florek et al., 
2005), ovarian (Ferrandina et al., 2008), prostate (Vander Griend et al., 2008), lung 
(Eramo et al., 2008), and brain (Singh et al., 2003; Singh et al., 2004). The study of 
CD133 as a marker of brain cancer stem cells, or brain tumour initiating cells (BTICs), 
is the most widely studied field in which CD133-positive cells represent a radio-
resistant and aberrantly proliferating population of glioma BTICs (Bao et al., 2006). 
However, subsequent contradictory studies in which CD133-negative glioma cells have 
been found to form tumours (Wang et al., 2008) have precluded definitive verfication of 
CD133 as a marker of BTICs. Little is known about the functional properties of murine 
CD133-positive cells both in vitro and in vivo, and using our model system we aim to 
address this knowledge gap. 
In this chapter we use a combination of magnetic-activated cell sorting (MACS) and 
fluorescence-activated cell sorting (FACS) to sort NSCs into their respective CD133-
negative (CD133-) and CD133-positive (CD133+) populations. Using these methods we 
aim to characterise the influence of CD133 expression on the in vitro functional 
properties and in vivo tumour hit rates, latencies, and phenotype propensities of NSCs. 
 
Aims 
1. Verify that SVZ NSCs express CD133 both in vivo and in vitro. 
2. Characterise the CD133 expression pattern in wild-type and recombined 
tumourigenic NSCs. 
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3. Characterise the functional differences of tumourigenic CD133+ and CD133- 
NSCs in vitro. 
4. Characterise the in vivo tumour hit rates, latencies, and phenotype propensities 
of tumourigenic CD133+ and CD133- NSCs and assess whether CD133 
expression can be used as a predictive indicator. 
5. Identify novel markers of BTICs. 
 
5.2 Materials and Methods 
Refer to the main materials and methods (Chapter Two). 
 
5.3 Results 
 
5.3.1 CD133 is expressed by subventricular zone neural stem cells targeted 
by intracerebroventricular Adenovirus-GFP administration in vivo and by 
neurospheres in vitro 
Adenovirus-GFP was administered i.c.v. into the brains of five wild-type RosaLox/Lox 
mice, which were left for five days before being culled and their brains taken for 
immunohistochemistry. 50μm thick vibratome sections of the SVZ were stained for 
CD133, GFAP, and GFP to observe whether CD133 is expressed by GFAP-positive 
SVZ NSCs in vivo, and whether Adenovirus-GFP administration targets these CD133-
expressing cells. 
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Figure 55: CD133 is expressed by SVZ cells, including GFAP-positive type B NSCs, and also by 
cells targeted for Adenovirus-GFP-infection. Representative images of the RosaLox/Lox wild-type SVZ 5 
days post-i.c.v. Adenovirus-GFP administration immunofluorescently stained for GFAP and CD133 
(A,B), or GFP and CD133 (C,D) with a Hoechst 33342 (DAPI) counterstain. Blue: excitation at 405nm, 
green: excitation at 488nm, red: excitation at 546nm. Images were taken using a 20x objective on a Zeiss 
LSM510 META confocal laser scanning microscope with the LSM software. 
 
The SVZ of RosaLox/Lox mice was found to contain some GFAP-positive NSCs that co-
expressed CD133 (Figure 55: A,B). This suggests that CD133 can also be expressed by 
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the GFAP-positive type B astrocytes of the SVZ (Doetsch et al., 1997). In addition, 
CD133 expression was observed by some ependymal cells and some GFAP-negative 
cells residing within the SVZ NSC niche, possibly including the transiently amplifying 
type C progenitor cells (Doetsch et al., 1999). Adenovirus-GFP-infected cells could be 
seen throughout the SVZ at five days post-i.c.v. administration, some of which were 
also CD133-positive (Figure 55: C,D). This confirms that i.c.v. Adenovirus 
administration targets CD133-expressing cells of the SVZ. An E14.5 mouse embryo 
was used as the positive control for this CD133 antibody (data not shown) on the basis 
that cells within both the developing brain and the kidneys are known expressors of 
CD133 (Miraglia et al., 1997; Corbeil et al., 1998). In addition, non-neurogenic brain 
parenchyma was used as the negative control. 
To observe whether these CD133-positive SVZ cells survive SVZ micro-dissection and 
maintain their expression in vitro, we immunofluorescently stained free-floating NS 
(passage 3) generated from RosaLox/Lox control mice for CD133 and compared their 
expression against in vitro recombined Rb-/-; p53-/-; PTEN-/- NS (passage 4). 
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Figure 56: CD133 is expressed by both GFAP-positive/negative NS cells in vitro, with little 
immunofluorescent difference discernable between non-recombined RosaLox/Lox and in vitro 
recombined Rb-/-; p53-/-; PTEN-/- NS. (A,C) Representative images of RosaLox/Lox wild-type NS (passage 
3) derived 5 days post-i.c.v. Adenovirus-GFP administration immunofluorescently stained for GFAP and 
CD133. (B,D) Representative images of in vitro recombined Rb-/-; p53-/-; PTEN-/- NS (passage 4) 
immunofluorescently stained for GFAP and CD133. All images include a Hoechst 33342 (DAPI) 
counterstain. Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 546nm. Images 
were taken using a 40x objective under oil immersion on a Zeiss LSM510 META confocal laser scanning 
microscope with the LSM software. 
 
The RosaLox/Lox NS contained CD133-positive cells that were both GFAP-positive and 
negative, suggesting that the CD133-positive SVZ NSCs observed in vivo are included 
in ex vivo microdissection and maintain their expression in vitro (Figure 56: A,C). It has 
been proposed that CD133 is a marker of brain tumour initiating cells (Singh et al., 
2004; Singh et al., 2003), however, no real difference in the level or pattern of CD133 
expression was observed between the tumourigenic in vitro recombined Rb-/-; p53-/-; 
PTEN-/- NS (Figure 56: B,D) and the non-tumourigenic RosaLox/Lox NS. The proportion 
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of CD133-positive NS cells in vitro was large in comparison to the proportion observed 
in vivo and suggests that the in vitro microenvironment may preserve NSCs in an 
undifferentiated CD133-positive state. However, it is more likely to be indicative of 
non-specific staining caused by antibody trapping. Therefore, to accurately measure the 
proportion of CD133-positive cells we used single cell magnetic/fluorescence-activated 
cell sorting (MACS / FACS) and FACS analysis. 
 
5.3.2 Wild-type neural stem cells equilibrate CD133 expression in vitro 
Before studying the expression levels of CD133 in tumourigenic NSCs it is we verified 
the baseline pattern of CD133 expression in non-recombined NSCs. Non-recombined 
PTENLox/Lox; p53Lox/Lox NSCs (passage four) were used as wild-type NSCs and were 
MACSorted into CD133- and CD133+ populations (Figure 57). 
 
 
Figure 57: Schematic of the paradigm used for the MACSorting of non-recombined wild-type 
PTENLox/Lox; p53Lox/Lox NSCs into CD133- and CD133 + populations in vitro. PTENLox/Lox; p53Lox/Lox 
NS were split into single cells and labelled with mouse anti-CD133 magnetic MicroBeads and mouse 
anti-Prominin-1-PE-conjugated antibody for MACSeparation and downstream FACS analysis 
respectively. The NSCs were run through a MACS column and the CD133-/+ fractions were eluted into 
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two separate containers. The CD133+ fraction was sampled or added to NS medium and left for two 
passages. The CD133- fraction was re-labelled with anti-CD133 MicroBeads and run through a second 
MACS column for further purification before being sampled or added to NS medium and left for two 
passages. 
 
A sample of unlabelled and unsorted NSCs was FACS-analysed in order to set the side 
scatter vs. forward scatter gate to only permit detection of viable and non-aggregated 
NSCs (Figure 58: A). The same population of cells was also used to set the M1 
fluorescence threshold for positivity to include a false-positive detection of 2.8%, which 
was then corrected to a 0% baseline (Figure 58: B). The CD133-labelled NSCs were 
observed to contain 2.5% CD133+ve cells prior to being sorted (Figure 58: C). 
Immediately after MACSorting, the CD133- and CD133+ populations were found to 
contain 2.2% (Figure 58: D) and 47.9% (Figure 58: E) CD133+ cells respectively, and 
altered levels of 8.28% (Figure 58: F) and 6.92% (Figure 58: G) CD133+ cells after two 
passages. However, it should be noted that only side-scatter versus forward-scatter, and 
propidium iodide (data not shown), gating measures were taken to correct against non-
specific staining of the CD133 antibody (as a result of cellular debris / aggregates and 
apoptotic cells). Therefore, without the inclusion of an isotype control it is possible that: 
a) non-specific binding of the CD133 antibody to cellular proteins, lipids, surface 
antigens (e.g. Fc receptors), and b) cellular autofluorescence, could have contributed to 
the observed fluorescence. For this reason, the results described here should be 
interpreted with caution. 
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Figure 58: The level of CD133 expressed by MACSorted wild-type PTENLox/Lox; p53Lox/Lox NSCs 
returns to equilibrium after two passages in vitro. (A) The FACS side scatter vs. forward scatter gate 
of detection was set to detect viable non-aggregated NSCs. An unlabelled and unsorted population of 
NSCs was used as the baseline control (B) against which the (C) labelled but unsorted, (D) MACSorted 
CD133- passage 0, (E) MACSorted CD133+ passage 0, (F) MACSorted CD133- passage 2  (G) 
MACSorted CD133+ passage 2 NSC populations were shown to contain 2.5%, 2.2%, 47.9%, 8.28%, and 
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6.92% CD133+ cells respectively. Purple curve: unlabelled control, green curve: overlay of labelled 
fraction. 
 
The setting of a false-positive detection rate of 2.8% represents a technical limitation of 
FACS analysis as it is arbitrarily set. If inaccurate we could not be certain that a 
hypothetically 100% pure population of CD133- cells was in fact 100% pure. This could 
compromise the in vivo grafting experiments in which 100% purity of CD133-/+ cells is 
desired. In addition, the low shift in fluorescence intensity (Figure 58: C,E; ~0.5 log 
units) of CD133-positive cells is suggestive of weak expression, and makes accurate 
separation difficult. However, this could be addressed by using the more precise method 
of FACSorting. An additional source of error is highlighted by in Figure 58: E which 
shows the lack of a peak in the CD133+ population. This might suggest that the range of 
CD133 expression is particularly large but the lack of a peak is more indicative of the 
fact that we could only analyse a low number of 65,000 cells due to receiving a very 
small yield. This low yield of 131,000 CD133+ cells in total makes downstream 
analysis difficult. Despite this, the 21-fold difference in the proportion of CD133+ cells 
obtained in the CD133- and CD133+ fractions mean that a viable comparison of their 
functional properties is possible. 
Interestingly, after being cultured for two passages post-sorting, the CD133 expression 
profile of the negative and positive populations had both altered. The number of CD133 
expressing cells in the CD133- population increased from 2.2% to 8.28%, and 
conversely, the number of CD133+ cells in the CD133+ population reduced from 47.9% 
to 6.92%. This implies that wild-type NSCs equilibrate CD133 expression in vitro and 
that this change can take as little as two passages (~20 days). We hypothesise that the 
CD133-/+ NSCs may reach the original level of 2.5% CD133+ cells if left for additional 
passages. Interestingly, the elevation in the number of CD133+ NSCs observed in the 
CD133- fraction after two passages is suggestive of expression overcompensation. 
Alternatively, it may be possible that the MACSorting event altered the behavioural of 
the NSCs by placing a slight selection pressure on them, resulting in a distorted (>2.5%) 
CD133 expression equilibrium. This would suggest that CD133+ cells are more capable 
of surviving this selection pressure, much in the same way that they have also been 
shown to be more capable of surviving radiation (Bao et al., 2006). 
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To validate the CD133 expression overcompensation of the CD133- NSCs after two 
passages the level of CD133 RNA expression level was measured in parallel by reverse 
transcriptase PCR (rt-PCR). 
 
 
Figure 59: The expression level of CD133 RNA by MACSorted CD133- NSCs is seen to increase 
after 2 passages in vitro. Reverse transcriptase-PCR of CD133 RNA expression in unsorted vs. CD133-
ve (P0) vs. CD133-ve (P2) neurospheres. The unsorted control cells and the P0 MACSorted CD133- cells 
exhibited similar titration patterns and 1:25 dilution band visibility, thus mirroring the FACS analysis 
finding (2.5% unsorted vs. 2.2% P0). After two passages in vitro this level of CD133 RNA expression 
was seen to increase, as shown by the RNA band visibility in the 1:125 dilution, once again mirroring the 
FACS analysis finding of increased CD133 protein expression (8.28%). 
 
The FACS analysis showed that the CD133- (P0) population contained 2.2% CD133+ 
cells (Figure 58: D), similar to the 2.5% observed in the original unsorted population 
(Figure 58: C). This finding was mirrored at the RNA expression level as shown by the 
rt-PCR in which no difference could be observed between the same two populations 
(Figure 59: Unsorted vs. CD133- P0). The slight band seen in the 1:125 dilution of the 
unsorted cells but not the CD133- (P0) population may represent the 0.31% difference 
in CD133 expression observed in the FACS analysis. Interestingly, the correlation 
between the patterns of CD133 expression at the protein (FACS) and RNA (rt-PCR) 
levels suggests that they possess a 1:1 ratio. After two passages the CD133- population 
exhibited an increased level of CD133 as illustrated by the strong bands in the 1:5, 1:25, 
and 1:125 dilution lanes (Figure 59). This finding correlates with the FACS data that 
showed the expression of CD133 to rise from 2.2% (P0) to 8.28% (P2) (Figure 58: D,F). 
This experiment was repeated using in vitro recombined NSCs to characterise the effect 
of tumourigenic transformation on CD133 expression. 
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5.3.3 Tumourigenic transformation of NSCs alters the pattern of CD133 
expression in vitro 
As the the genotype that produced tumours with the shortest latency, Rb-/-; p53-/-; PTEN-
/- NSCs were chosen as the tumourigenic NSCs. In vitro recombined Rb-/-; p53-/-; PTEN-
/- NSCs were taken at passage seven and MACSorted into CD133- and CD133+ 
populations (Figure 60). 
 
 
Figure 60: Schematic of the paradigm used for the MACSorting of tumourigenically transformed 
Rb-/-; p53-/-; PTEN-/- NSCs into CD133- and CD133 + populations in vitro. Rb-/-; p53-/-; PTEN-/- NS 
were split into single cells and labelled with mouse anti-CD133 magnetic MicroBeads and mouse anti-
Prominin-1-PE-conjugated antibody for MACSeparation and downstream FACS analysis respectively. 
The NSCs were run through a MACS column and the CD133-/+ fractions were eluted into two separate 
containers. The CD133+ fraction was sampled or added to NS medium and left for two passages. The 
CD133- fraction was re-labelled with anti-CD133 MicroBeads and run through a second MACS column 
for further purification, after which the secondary yield of CD133+ NSCs were added to the primary 
yield, before being sampled or added to NS medium and left for two passages. 
 
162 
 
A false-positive detection of 3.0% was set as the baseline. Prior to sorting, the 
tumourigenic NSCs were found to contain 12% CD133+ cells (Figure 61: A), a notable 
increase over the 2.5% observed in the wild-type NSCs (Figure 58: C). Over serial 
passages both populations of the CD133- and CD133+ NSCs were once again observed 
to reach an equilibrium, but at a vastly different rate to the non-tumourigenic NSCs. 
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Figure 61: In vitro recombined and tumourigenic Rb-/-; p53-/-; PTEN-/- NSCs have an increased level 
of CD133 expression vs. wild-type NSCs which takes longer to equilibrate following MACSorting 
into CD133-/+ populations. FACS analysis showing the level of CD133 expression in Rb-/-; p53-/-; 
PTEN-/- NSCs prior to, and at zero, two, eight, and 11 passages after MACSorting. (A) The endogenous 
expression of CD133 in Rb-/-; p53-/-; PTEN-/- NSCs is 12%. Rb-/-; p53-/-; PTEN-/- NSCs were MACSorted 
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into CD133- and CD133+ populations that respectively contained 0% and 25.1% at passage 0 (B) to 22% 
(C) and 57.3% (D) after two passages, 6% (E) and 28.2% (F) after eight passages, and 4.3% (G) and 10% 
(H) after 11 passages. (A,C-H) Purple curve: unlabelled control, green curve: overlay of labelled fraction. 
(B) Red curve: MACSorted CD133- P0 fraction, purple curve: underlay of labelled but unsorted fraction, 
green curve: underlay of MACSorted CD133+ P0 fraction. 
 
The number of CD133 expressing cells for the CD133- and CD133+ MACSorted 
populations respectively changed from 0% and 25.1% (Figure 61: B) at passage 0 
(immediately after sorting) to 22% (Figure 61: C) and 57.3% (Figure 61: D) after two 
passages, 6% (Figure 61: E) and 28.2% (Figure 61: F) after eight passages, and 4.3% 
(Figure 61: G) and 10% (Figure 61: H) after 11 passages. This suggests that 
tumourigenic NSCs possess an altered rate of CD133 expression equilibration, 
potentially because of CD133 expression-associated functional differences. To validate 
this finding protein samples were extracted from NS at post-MACSorting passages one 
and seven. Passage one and seven NS were chosen, rather than passage two and eight 
NS, because the passage one and seven NS were dissociated into single NSCs which 
were then immediately FACS-analysed to give the results given as P2 and P8 (Figure 
61: C-F). We hypothesised that the number of CD133-expressing cells could change by 
the time 12 day old NS at passage two and eight were ready to be sampled, and 
concluded that the 12 day old passage one and seven NS were more representative of 
the single passage two and eight NSCs that were FACS-analysed. For comparison 
purposes, a protein sample was also taken from single NSCs at passage eight to examine 
the effect of NS dissociation on detection of the surface antigen CD133. Such surface 
antigens are exposed to the action of the protease-based dissociation chemical. 
 
 
Figure 62: The reduction of CD133 intensity observed from the CD133+ (P1 NS) band to the 
CD133+ (P7 NS) band mirrors the reduction in CD133 expression observed from the FACS-
analysis shown in Figure 61 (percentage CD133+ expression given). Western blot for CD133 
expression in the MACSorted CD133+ Rb-/-; p53-/-; PTEN-/- NSCs at one, seven, and eight passages post-
sort. The CD133+ (P8 NSCs) band appears less intense than that of the P7 NS, from which they were 
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derived, suggesting that NS-NSC dissociation reduces CD133 expression. The percentages associated 
with bands 1 and 2 are the respective proportions of CD133+ cells as measured in parallel by FACS . 
 
FACS analysis of the CD133+ Rb-/-; p53-/-; PTEN-/- NSCs at passages two and eight 
post-MACSorting showed that the number of CD133+ cells had reduced from 57.3% to 
28.2% (Figure 61). This reduction was validated by Western blot which showed a 
similar reduction in expression (Figure 62). Interestingly, the CD133+ (P8 NSCs), 
which were derived from the P7 NS, appear to exhibit an even lower level of CD133 
expression. Using the KODAK 1D Image Analysis Software we have been able to 
quantify these changes. 
 
 
Figure 63: Table of the corrected CD133 expression intensities for each of the Western blot 
MACSorted CD133+ fraction bands in Figure 62. The corrected CD133 band intensities support and 
confirm the reduction in CD133 expression observed in the CD133+ population over serial passages, as 
originally shown in Figure 61 by FACS analysis. The net intensity was calculated as the sum of the 
background-subtracted pixel intensity values within the band area defined. The corrected intensity was 
calculated as (Net 			!	-actin Intensity)*1000. 
 
The semi-quantitative analysis of these bands confirms that we can indeed see a 
reduction in the CD133 expression of MACSorted CD133+ cells between the P1 NS 
and the P7 NS. In addition, the 48.2% reduction in CD133 expression obtained from the 
Western blot (Figure 63: Band 1 vs. band 2) matches the 50.8% reduction obtained from 
the FACS analysis (Figure 61). Interestingly, the act of dissociating NS into single 
NSCs caused a reduction in CD133 expression of 45.3% (a reduction in corrected 
intensity from 48.28 to 26.43) (Figure 63). This suggests that a ~45% overestimation in 
CD133 protein expression is observed by Western blot if representative NS are used 
instead of the single NSCs used for FACS-analysis. In addition, it appears that CD133 
expression increases temporally over the ~12 days of a passage, otherwise a 45% 
dissociation-based reduction in CD133 expression would translate into the observed 
10% equilibrium having been achieved at passage five instead of passage 11. 
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The CD133+ NSCs isolated from the MACSort were only 25.1% pure when compared 
to the 47.9% purity achieved with the wild-type NSCs, despite an elevated baseline 
endogenous expression of 12%. This level of 25.1% CD133 expression in the CD133+ 
population was generated from a larger yield of cells with a better defined fluorescence 
peak. However, the unsorted but labelled NSCs exhibited an extended skew of 
fluorescence covering an entire log unit on the upper boundary of their FACS plot 
(Figure 64: B). This will have resulted in the setting of an artificially high M1 
fluorescence threshold and a subsequent underestimation of the level of CD133 
expression. Therefore, the 25.1% proportion of CD133+ cells may have been closer to 
the 57.3% observed after two passages (Figure 61: D). This may explain the presence of 
an overcompensation of the number of CD133+ cells after two passages by a population 
whose expression of CD133 was expected to decrease. However, from the side scatter 
vs. forward scatter plot (Figure 64: A) for the unsorted NSCs it can be seen that the cells 
lacked distinct populations and that the cellular debris (SSC-H <300, FSC-H<300) 
merged into the gated viable population. This may explain the skewed fluorescence of 
the NSCs as some auto-fluorescent debris will have been included in the viable cell gate 
and whose could have intensified the output of the fluorescent Phycoerythrin (PE) dye. 
 
 
Figure 64: An excess of cellular debris and a lack of distinct populations interferes with selecting a 
viable population gate and results in a skewed fluorescence plot. FACS plots illustrating the gate of 
detection set for MACSorting the Rb-/-; p53-/-; PTEN-/- NSCs. (A) The side-scatter (SSC-H) vs. forward-
scatter (FSC-H) FACS plot highlights the lack of distinct populations of cells within the sample being 
analysed, hence the difficult setting of a gate of detection which is likely to have included cellular debris. 
(B) This inclusion of this debris may adversely interact with the viable NSCs and/or the antibody to cause 
the fluorescence skew observed in the unsorted population. 
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Previously we showed that it took two passages for wild-type MACSorted CD133-/+ 
NSCs to reach a CD133 expression equilibrium of ~7.5% (Figure 58). In contrast, the 
Rb-/-; p53-/-; PTEN-/- CD133- NSCs took eight passages to return to an equilibrium of 
6% and the CD133+ NSCs were still only approaching a hypothesised equilibrium of 
10% after 11 passages (Figure 65). 
 
 
Figure 65: FACS analysis of CD133 expression in NSCs over serial passages following MACSorting 
for CD133-/+ shows that both populations of wild-type NSCs return to a CD133 expression 
equilibrium after two passages whereas in vitro recombined and tumourigenic Rb-/-; p53-/-; PTEN-/- 
NSCs take up to 11 passages. A line plot of the percentage of NSCs expressing CD133 post-
MACSorting (y-axis) over serial passages (x-axis). 
 
The Rb-/-; p53-/-; PTEN-/- CD133- and CD133+ NSC population equilibrations have 
trend line slopes of -2.1 and -5.2 respectively (ignoring the overcompensation observed 
between passages zero and two). The increased negative slope (faster rate of 
equilibration) of the CD133+ population may be caused by a functional quality, or 
alternatively the mechanism of equilibration could be entirely expression-dependent 
with the increased CD133+ equilibration a consequence of higher initial expression. 
The latter is difficult to explain as the wild-type CD133+ NSCs had the highest rate of 
equilibration (Figure 65: Pale blue line, slope: -20.5). We therefore hypothesise that the 
different equilibration rates are determined by functional differences. This study was 
repeated using a second population of Rb-/-; p53-/-; PTEN-/- NSCs from which only the 
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CD133+ population was isolated. This repeat population of the tumourigenic NSCs 
were found to contain 13.8% CD133+ cells (data not shown), therefore validating the 
previously acquired figure of 12%. 
 
 
Figure 66: FACS analysis of CD133 expression in a repeat population of MACSorted CD133+ Rb-/-; 
p53-/-; PTEN-/- NSCs shows that the observed CD133 expression equilibration is a reproducible 
effect (up to passage 4). A line plot of the percentage of NSCs expressing CD133 post-MACSorting (y-
axis) over serial passages (x-axis). 
 
The repeat Rb-/-; p53-/-; PTEN-/- CD133+ NSCs exhibited an equilibration slope of -2.93 
(Figure 66), which is different from the previously observed slope of -5.2 and is in fact 
more similar to the CD133- NSC equilibration slope of -2.1. This suggests that variation 
in the health of the cells influences the equilibration rate. No CD133 expression 
overcompensation was observed in the repeat CD133+ NSCs, which began with a 
remarkably high purity of 82.9% (Figure 66). This highlights that a) the MACSorting 
technique has an inherent variability most likely based on NSC health state, and b) the 
observed overcompensation of CD133 expression in the Rb-/-; p53-/-; PTEN-/- CD133+ 
NSCs (Figure 61: B,D) was indeed an anomalous finding caused by an underestimation 
of the initial level of CD133 expression. 
Interestingly, as seen with the wild-type NSCs, the expression of CD133 by the CD133- 
Rb-/-; p53-/-; PTEN-/- NSCs was observed to overcompensate from 0% CD133+ cells at 
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passage 0 to 22% after two passages (Figure 61: C). It is possible that the lower starting 
CD133 expression level of 0% drove an exacerbated overcompensation. The CD133 
expression equilibria attained by the Rb-/-; p53-/-; PTEN-/- CD133-/+ (4.3%/10%) NSCs 
after 11 passages are lower than the starting level of expression (12%), with the 
converse being true for the wild-type NSCs. This reinforces our earlier suggestion that 
the level of CD133 expression in the CD133-/+ wild-type NSCs would have reduced 
further over additional passages. For this reason, it is difficult to state that the CD133 
expression equilibrium to which NSCs reset themselves following MACSorting is 
different from the resting equilibrium observed in unsorted control NSCs. We do, 
however, propose that in vitro recombined Rb-/-; p53-/-; PTEN-/- NSCs possess an 
elevated basal level of CD133 expression as well as an altered pattern of CD133 
expression when compared to wild-type controls, most likely as a result of functional 
changes brought about by tumourigenic transformation. In addition, the presence of an 
equilibrium implies that CD133 expression is regulated by the NSC microenvironment. 
To test the hypothesis that CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs possess different 
functional characteristics we examined their growth rate and NS-forming ability in 
vitro. 
 
5.3.4 CD133 expression influences growth rate but not the NS-forming 
ability of tumourigenic NSCs in vitro 
Our findings suggest that in vitro recombination of Rb, p53, and PTEN alters CD133 
expression as Rb-/-; p53-/-; PTEN-/- NS possessed a higher proportion of CD133+ NSCs 
(12%) than wild-type NSCs (2.5%). Also, more passages were needed by Rb-/-; p53-/-; 
PTEN-/- NS to reach an equilibrium of ~7.5% CD133+ cells. We hypothesise that these 
alterations in CD133 expression are as a result of acquired / induced functional property 
changes in the NSCs. In an attempt to elucidate these behavioural differences in vitro 
we assayed MACSorted CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs for their growth rate 
(WST-1 assay) and NS-forming ability (NS size and NS-forming clonogenicity assay). 
Using the WST-1 assay we measured the mitochondrial activity (as a surrogate marker 
of growth rate) of NSCs at 0, 2, 4, and 8 hours after a 3 day incubation period. 
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Figure 67: CD133-/+ NSCs appear to have a reduced growth rate at 2 passages post-MACSorting 
which corrects back to the level exhibited by the unsorted controls after 4 passages. The difference 
observed between the CD133- and CD133+ NSC populations after 2 passages also disappears after 
4 passages, suggesting a normalisation or equilibration. Using the WST-1 assay the growth rate (y-
axis) of NSCs (growing as NS) was measured at 0, 2, 4, and 8hrs (x-axis) after a 3 day incubation period. 
Growth rate of in vitro recombined Rb-/-; p53-/-; PTEN-/- NSCs at 2 (block lines) and 4 (dotted lines) 
passages post-MACSorting for CD133- (pink: n=2) / CD133+ (blue: n=2) vs. unsorted controls (dark 
blue: n=3) vs. non-recombined Adenovirus-GFP-infected controls (green: n=6). Error bars: standard 
errors. ***: P<0.001 vs. Rb-/-; p53-/-; PTEN-/- NSCs at 8hrs, #: P<0.05 (one-way ANOVA with 
Bonferroni’s multiple comparison correction). 
 
After two passages, the unsorted control Rb-/-; p53-/-; PTEN-/- NSCs grew significantly 
faster than the MACSorted CD133+ cells, which also grew significantly faster than their 
CD133- counterparts (Figure 67). All of these cells grew significantly faster than the 
non-tumourigenic Adenovirus-GFP-infected control NSCs. After four passages the 
growth rate of both the MACSorted CD133-/+ cells had increased to a statistically 
similar rate as the unsorted controls, and the difference between the CD133+ and 
CD133- had disappeared. We have already shown that CD133+ Rb-/-; p53-/-; PTEN-/- 
NSCs have a faster equilibration rate than their CD133- counterparts, and attributed this 
difference to a hypothesised functional difference. That difference is illustrated by these 
findings from passage two in which the CD133+ NSCs are observed to have a faster 
growth rate than the CD133- NSCs. Interestingly, this difference had disappeared as the 
growth rates of both the CD133-/+ NSCs had returned to normal levels after four 
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passages, a passage number at which the equilibration of CD133 expression was still in 
progress (Figure 65). 
As an indicator of NS-forming ability we measured the size of the NS formed by the 
NSCs when left in culture for eight days. 
 
 
Figure 68: MACSorted Rb-/-; p53-/-; PTEN-/- CD133-/+ NSCs appear to form smaller NS than their 
unsorted counterparts after 2 passages, but NS of the same size after 4 passages. The difference 
observed between the CD133- and CD133+ NSC populations after 2 passages also disappears after 
4 passages, suggesting a normalisation or equilibration. NSCs were seeded into NS medium and left to 
grow as NS for eight days before their diameters were measured using an Axiovert 135 microscope 
(Zeiss) and the Openlab 5 software package. NS size of non-recombined Adenovirus-GFP-infected 
controls (green: n=11) vs. in vitro recombined unsorted Rb-/-; p53-/-; PTEN-/- NSC controls (dark blue: 
n=3) vs. Rb-/-; p53-/-; PTEN-/- NSCs MACSorted for CD133- (pink: n=2) and CD133+ (blue: n=2) cells at 
passage 2 vs. Rb-/-; p53-/-; PTEN-/- NSCs MACSorted for CD133- (pale pink: n=2) and CD133+ (pale 
blue: n=2) cells at passage 4. Error bars: standard errors. *: P<0.05 vs. GFP control, **: P<0.01 vs. GFP 
control (one-way ANOVA with Bonferroni’s multiple comparison correction). 
 
The NS size assay confirmed the growth-difference observed in the WST-1 assay, but 
was less marked. In this assay the unsorted control Rb-/-; p53-/-; PTEN-/- NSCs formed 
the significantly largest NS (Figure 68). And although the MACSorted CD133+/- NSCs 
at passage two appeared to form smaller NS than the Rb-/-; p53-/-; PTEN-/- NSCs, this 
difference was in fact non-significant. In addition, no significant difference was 
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observed between the size of the CD133+ and CD133- NS at passage two. However, the 
passage four CD133+/- NS were significantly larger than the controls. This suggests 
that there is also a CD133 expression-related equilibration in NS-forming ability. The 
reductions in growth rate and NS-forming ability of the CD133- and CD133+ NSCs at 
passage (from the unsorted Rb-/-; p53-/-; PTEN-/- NSCs) were less significant in the case 
of the NS size assay than the WST-1 assay (~15% and ~7% vs. ~60% and 40% 
respectively). However, both assays confirm the functional differences of the unsorted, 
CD133+ and CD133- NSCs. 
In addition, an NS-forming clonogenicity assay was used to measure the NS-forming 
ability of the same CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs. 
 
 
Figure 69: MACSorting for CD133-/+ NSCs has no effect on the NS-forming ability of the cells as 
no significant difference can be observed between any of the CD133-/+ populations and the 
unsorted control. NSCs were seeded in medium and left to grow for eight days before the number of NS 
formed was counted. NS-forming ability of non-recombined Adenovirus-GFP-infected controls (green: 
n=6) vs. in vitro recombined unsorted Rb-/-; p53-/-; PTEN-/- NSC controls (dark blue: n=3) vs. Rb-/-; p53-/-; 
PTEN-/- NSCs MACSorted for CD133- (pink: n=2) and CD133+ (blue: n=2) cells at passage 2 vs. Rb-/-; 
p53-/-; PTEN-/- NSCs MACSorted for CD133- (pale pink: n=2) and CD133+ (pale blue: n=2) cells at 
passage 4. Error bars: standard errors. **: P<0.01 vs. GFP control (one-way ANOVA with Bonferroni’s 
multiple comparison correction). 
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The unsorted Rb-/-; p53-/-; PTEN-/- NSCs and MACSorted CD133+/- NSCs at passage 
two and four all had significantly increased NS-forming abilities when compared 
against the Adenovirus-GFP-infected control NSCs (Figure 69). Despite previously 
showing an interaction between CD133 expression and growth rate, no statistical 
difference was observed between the CD133 expression profile and NS-forming ability 
of the unsorted versus CD133+/- Rb-/-; p53-/-; PTEN-/- NSCs. Previous studies support 
this lack of functional difference between CD133+ and CD133- NSCs (Clement et al., 
2009). 
Previously we disregarded that the equilibration rate is CD133 expression-dependent as 
the wild-type CD133+ NSCs, despite having a comparable level of CD133 expression 
(post-MACSorting) to their tumourigenic counterparts, exhibited the fastest 
equilibration rate of all. However, we hypothesise that MACSorting for CD133 
expression may select for a specific sub-population of NSCs. There are at least three 
sub-populations of NSCs in the SVZ, each with different functional properties (Doetsch 
et al., 1997). If we assume that NSCs exist as a heterogeneous population in vitro, 
MACSorting for CD133-/+ NSCs may essentially be purifying for specific NSC sub-
populations, which could be delineated by their functional properties in vitro. 
{#@	*	*#	*=	*			=	
					
hypoxic conditions (Matsumoto et al., 2009), indicating that CD133 expression may be 
a reflection of NSCs environmental conditions and provide no insight into NSC sub-
type classification. This latter suggestion would mean that the increased CD133 
expression and reduced rate of CD133 equilibration observed following tumourigenic 
transformation was a manifestation of tumourigenic NSCs being more resistant to in 
vitro hypoxia, and therefore exhibiting less response in the form of downregulated 
CD133 expression. Or that CD133 expression correlates with hypoxia resistance and 
that tumourigenic Rb-/-; p53-/-; PTEN-/- NSCs therefore have a higher endogenous level 
of CD133 expression when compared to wild-type NSCs. This hypothesis would mean 
that only the survival rates of CD133-/+ NSCs in hypoxic conditions should be different 
and that the in vivo tumourigenic capacity of isolated CD133- and CD133+ Rb-/-; p53-/-; 
PTEN-/- NSCs should be the same. To test this hypothesis we examined the in vivo 
tumour hit rates, latencies, and phenotype propensities of intracerebrally engrafted 
CD133- and CD133+ Rb-/-; p53-/-; PTEN-/- NSCs. 
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5.3.5 In vivo engraftment of CD133+ versus both CD133- and unsorted Rb-
/-; p53-/-; PTEN-/- NSCs results in the preferential development of 
gliomas 
Both MACS and FACS methods were used to isolate Rb-/-; p53-/-; PTEN-/- CD133- and 
CD133+ NSCs. It was previously mentioned (section 5.3.2) that MACSorting may not 
be sensitive enough for the purpose of in vivo cell grafting experiments as the purity of 
the CD133-/+ populations cannot be guaranteed. For the purposes of distinguishing the 
different in vivo properties of CD133- and CD133+ NSCs in vivo it could be argued that 
100% purities are required for both populations to be grafted. The two methods of 
separation were compared to test this hypothesis. 
 
 
Figure 70: FACSorting NSCs for CD133 achieves greater CD133-/+ isolate purities than 
MACSorting. FACS plots showing the CD133-/+ NSC purities achieved using MACSorting (A,B) and 
FACSorting (C,D). Side-scatter vs. forward-scatter FACS plot of the MACSorted (A) and FACSorted (C) 
NSCs showing the gated regions of detection. Fluorescence FACS plots of the CD133- (purple) and 
CD133+ (green) NSCs showing that the purities of the MACSorted (B) isolates are 87.2% and 82.9% 
respectively, whereas those of the FACSorted (D) are both >99%. 
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The purities of the MACSorted CD133- and CD133+ isolates were 87.2% and 82.9% 
respectively (data not shown). In comparison, FACSorting Rb-/-; p53-/-; PTEN-/- NSCs 
for CD133- /+ populations achieved an impressive >99% purity in both cases (Figure 
70). The first MACSorting experiment used two pooled cohorts of mice (n=16) 
separately grafted with unsorted Rb-/-; p53-/-; PTEN-/- NS as the controls. The second 
FACSorting experiment used the same controls but with an additional cohort of mice 
(n=8) grafted with dissociated but unsorted Rb-/-; p53-/-; PTEN-/- single NSCs.
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No real difference was observed in the phenotype of intracerebral tumours generated 
from engrafted Rb-/-; p53-/-; PTEN-/- single NSCs or NS (Figure 71). The only difference 
between these two control sets was that the single NSCs appeared to have longer tumour 
latencies. However, we propose that this is due to lower numbers of cells being injected 
(~217,600) than with the NS controls (~690,000 and ~1.38x106). For the purpose of the 
analysis, both of these control sets were pooled to create a single cohort of 24 controls. 
Interestingly, there appeared to be minimal difference between the results of the MACS 
and FACSorted CD133-/+ cells in terms of both tumour phenotype and latency. Both 
sets of MACS and FACSorted CD133+ NSCs gave rise to only pure gliomas after 200 
and 127 days respectively (Figure 71). And the CD133- cells even gave rise to identical 
oligoastrocytomas at the same 61 day latency with both sorting methods. The only 
difference was that MACSorted CD133- NSCs appeared to have a higher tumour hit 
rate with the additional tumours coming after longer incubations and with a tendency to 
the PNET or PNET + glioma phenotypes (a similar effect as observed with the 
controls). It could be that the ratio of CD133+ to CD133- NSCs in the MACSorted 
CD133- (87.2% pure) population more closely resembled that of the controls than that 
of the FACSorted CD133-  (>99% pure) population. Or that more cells (~1.8x106) were 
injected following MACSorting than FACSorting (~460,714). In light of only minor 
differences, both sets of MACS and FACSorted NSCs have been pooled for the analysis 
into a single cohort for the mice injected with CD133- NSCs (n=12, excludes 4x time-
culls) and another for those injected with CD133+ NSCs (n=6). The trends between cell 
profile, tumour latency period, and tumour phenotype are illustrated in an incidence plot 
(Figure 72). 
 
 
Figure 72: Incidence plot of the tumours generated from the intracerebral engraftment of Rb-/-; 
p53-/-; PTEN-/- NS/NSCs vs. MACS/FACSorted CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs. Axis: tumour 
latency (days). 
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The grafted Rb-/-; p53-/-; PTEN-/- NSC/NS controls had a tumour hit rate of 95.8% with 
23 out of the 24 mice exhibiting an intrinsic brain tumour after a mean latency of 85 
days (Figure 71 and Figure 72). Of these 23 tumours, the most predominant phenotype 
was PNET + glioma (n=12: mean latency = 83 days), followed by PNET (n=6: mean 
latency = 95 days), oligoastrocytoma (n=3: mean latency = 74 days), oligodendroglioma 
(n=1: mean latency = 109 days), and glioma (n=1: mean latency = 51 days). 
Interestingly, many of the tumours presented features of both PNETs and gliomas after 
the same latency. This goes against our previous finding that gliomas appear to develop 
after a much longer latency than PNETs. One possible explanation is that the in vitro 
generated Rb-/-; p53-/-; PTEN-/- NSC populations contain multiple lineage populations of 
tumourigenic BTICs, and that mice carrying purely glioma BTICs survive considerably 
longer as the progression of the glioma is slower. The grafted CD133- NSCs had an 
intrinsic brain tumour hit rate of 41.7% (5 out of 12) with a mean latency of 79 days and 
a phenotypic profile of oligoastrocytoma (n=2: mean latency = 61 days), PNET + 
glioma (n=2: mean latency = 90 days), and PNET (n=1: mean latency = 95 days). In 
comparison, the grafted CD133+ NSCs had an intrinsic brain tumour hit rate of 33.3% 
with a much increased mean latency of 164 days and a phenotypic profile of solely 
glioma (n=2: mean latency = 164 days). These findings suggest that a) 
MACS/FACSorted CD133- and CD133+ Rb-/-; p53-/-; PTEN-/- NSCs have a reduced 
tumourigenic capacity when compared to the unsorted controls (or that the 
MACS/FACSorting procedure reduces the viability of the cells prior to grafting), b) 
obtaining 100% purity of CD133-/+ NSCs prior to grafting may not be strictly 
necessary to achieving meaningful results, c) increased expression of CD133 may be 
associated with an increased presence of a glioma-specific BTIC population (in Rb-/-; 
p53-/-; PTEN-/- NSCs), d) CD133- NSCs can in fact be tumourigenic in vivo, and share a 
similar tumour phenotype profile to the unsorted controls.
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Figure 73: Intracerebral engraftment of unsorted control Rb-/-; p53-/-; PTEN-/- NSCs/NS results in 
the development of a wide range of tumour phenotypes (predominantly PNET + Glioma) with a 
high hit rate of 95.8% and a mean latency of 85 days. Immunohistochemical analysis of the intrinsic 
brain tumour profile following the intracerebral grafting of unsorted control Rb-/-; p53-/-; PTEN-/- 
NSCs/NS. Representative tumours were taken from the each of the PNET, Glioma, Oligodendroglioma,  
PNET + Glioma, and Oligoastrocytoma phenotypes observed and stained for H&E (A-E), GFAP (F-J), 
synaptophysin (K-O), and olig2 (P-T). Images were taken using a ColorView III digital camera mounted 
on a Zeiss Axioskop 2 MOT microscope with a 10x objective and using the AnalySIS software package. 
Scale bar: 150m. 
 
Tumours were classified as PNETs following the identification of a GFAP- / 
synaptophysin+ / olig2-/+ expression profile often associated with the presence of giant 
cells and a well-demarcated but disorganised and dense cell arrangement (Figure 73: 
A,F,K,P). Conversely, gliomas possess a GFAP+ / synaptophysin- / olig2+ profile and 
are more diffusely distributed in addition to being highly infiltrative (Figure 73: 
B,G,L,Q). The PNET + glioma tumours contained aspects of both phenotypes, often 
next to one another in a tumour mass (Figure 73: D,I,N,S). The single 
oligodendroglioma was so classified in accordance with the presence of its “fried egg” 
cellular appearance and a GFAP-/+ / synaptophysin - / olig2+ expression profile (Figure 
73: C,H,M,R). And finally, the oligoastrocytomas appear very similar to the gliomas but 
with a reduced expression of GFAP (Figure 73: E,J,O,T). 
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Figure 74: Intracerebral engraftment of MACSorted CD133- Rb-/-; p53-/-; PTEN-/- NSCs results in 
the development of a variety of tumours (predominantly PNET + Glioma) with a mean latency of 
79 days, both similar to that of the unsorted controls, but with a lower hit rate of 41.7%. 
Intracerebral engraftment of MACSorted CD133+ Rb-/-; p53-/-; PTEN-/- NSCs results in the 
development of solely gliomas with a vastly increased mean latency of 164 days and an equally low 
hit rate of 33.3%.  Immunohistochemical analysis of the brain tumour profile resulting from the 
intracerebral grafting of MACS/FACSorted CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs. Representative 
tumours were taken from the each of the PNET, PNET + Glioma, and Oligoastrocytoma phenotypes 
observed with the CD133- grafted NSCs, in addition to the Glioma phenotype observed with the CD133+ 
grafted NSCs, and stained for H&E (A-E), GFAP (F-J), synaptophysin (K-N), and olig2 (O-R). Images 
were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 
10x or 20x (insets) objective and using th	{""	=	<`	"	
	\?X			
		?	X		` 
 
The tumour phenotypes were classified as above, but interestingly, fewer phenotypes 
were observed following the engraftment of MACS/FACSorted CD133-/+ NSCs. In 
particular, the CD133+ NSCs were observed to only generate gliomas irrespective of 
the sorting method. The MACSorted CD133+ NSCs gave rise to a classical glioma with 
highly mitotic and infiltrative cells (Figure 74: D) possessing a GFAP+ / synaptophysin- 
/ olig2+ profile. On the other hand, the FACSorted CD133+ NSCs also gave rise to a 
glioma, but one that grew extracranially and with an infiltrative fibroblastic component 
(Figure 74: J). The CD133- grafted cells generated tumours and did so with a 
phenotypic profile similar to that of the unsorted controls. These findings suggest that 
an alteration of the CD133 expression away from its equilibrium to either a purely 
CD133- or CD133+ status reduces in vivo tumour hit rate by up to ~60%. However, this 
may be due to the MACS / FACSorting process altering the viability of NSCs prior to 
engraftment. Interestingly, CD133+ Rb-/-; p53-/-; PTEN-/- NSCs appear to have a 
propensity towards generating gliomas. To validate this finding we performed a 
Western blot for CD133 in order to correlate its expression against the in vivo tumour 
hit rates, latencies, and phenotype propensities of the four double and triple knock-out 
NSC genotypes (PTEN-/-; p53-/-, Rb-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/-). 
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5.3.6 In vitro CD133 expression by tumourigenic NS does not correlate with 
either in vivo tumour hit rate or latency 
Protein samples were collected from each of the four different in vitro recombined NSC 
genotypes (PTEN-/-; p53-/-, Rb-/-; p53-/-, Rb-/-; PTEN-/-, Rb-/-; p53-/-; PTEN-/-) and a 
CD133 western blot was performed (Figure 75) to compare their relative expression 
levels (n=3 for each). The NSC passage number of the samples varied between three 
and five (and 10 in the case of the NS derived from a PTEN-/-; p53-/- tumoursphere-
induced glioma sample).  
 
 
Figure 75: In vitro CD133 protein expression of tumourigenic NS varies both within and between 
genotypes. Western blot of CD133 (_<$		-actin (42kDa) expression in PTEN-/-; p53-/- vs. Rb-/-; 
p53-/- vs. Rb-/-; PTEN-/- vs.Rb-/-; p53-/-; PTEN-/- NS (n=3 for each genotype), with associated passage 
numbers and the results of any corresponding in vivo engraftment studies. Two additional samples (NS 
grown from a PTEN-/-; p53-/- NS-induced glioma and NS derived from the brains of a cohort of RbLox/Lox; 
PTENLox/Lox mice six months after having had received an intracerebroventricular injection of Adeno-Cre) 
were included on the blot for preliminary comparison purposes. 
 
The net (relative) intensities of the CD133 bands were semi-quantitatively measured 
	*	#	-actin bands as baseline controls. Corrected CD133 intensities 
were then generated for comparative analysis purposes (Figure 76). No correlation 
between passage number and CD133 expression was observed. 
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The corrected CD133 intensities were grouped by genotype (the two additional non-
basic genotype samples were omitted from this grouping) to examine the intra- and 
inter-genotype expression profile of tumourigenic NSCs (Figure 77). 
 
 
Figure 77: There are no statistically significant differences in the levels of CD133 expressed by 
PTEN-/-; p53-/- vs. Rb-/-; p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS in vitro. A bar chart 
	*						]					-actin 
intensity, *1000) expressed (y-axis) by each of the four genotypes of tumourigenic NS in vitro (x-axis). 
Error bars: standard errors. No significance difference observed between any of the groups (one-way 
ANOVA with Bonferroni’s multiple comparison correction). 
 
No statistical differences were observed between any of the genotypes, with the 
exception of the Rb-/-; p53-/-; PTEN-/- genotype, and large variations in CD133 
expression levels were observed within each of the genotypes (Figure 77). It is possible 
that a significant difference between two of the groups may be achieved with a sample 
number greater than three, and the inclusion of an internal control would allow for an 
absolute comparison. However, the size of the intra-genotype variability (PTEN-/-; p53-/-
: 111.38, band 2 vs. 988.17, band 3) suggests that either a) CD133 protein expression in 
vitro is influenced more strongly by environmental conditions (e.g. culture conditions, 
general cellular health) than by the tumourigenic profile of the cells (combination of 
TSGs lost), and/or b) the cellular composition of NS is highly heterogeneous and 
CD133 expression may not need to be 100% representative of all the NSCs within the 
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NS in order to see a CD133-correlated effect on tumour hit rate, latency, and phenotype. 
The latter suggestion is difficult to address as it assumes that there are subclasses of 
CD133+ NSCs. 
To address whether in vitro CD133 expression correlates with in vivo tumour hit rate, 
latency, and phenotype we compared the CD133 expression data of the Western blot 
samples with their respective in vivo grafting data and visualised the correlation on a 
bubble plot of mean in vivo tumour latency (y-axis) vs. CD133 expression (x-axis) vs. in 
vivo tumour hit rate (z-axis: bubble size). It should be noted that limited in vivo grafting 
data was available from the samples selected for the western blot (n=1 per genotype). 
 
 
Figure 78: There appears to be a correlation between increased in vitro CD133 expression of NS 
and a propensity towards generating glial tumours in vivo, but no correlation between CD133 
expression and tumour hit rate or latency. Each bubble represents a single in vivo grafting experiment 
encompassing a cohort of 6-13 mice with the phenotype given being the predominant tumour phenotype 
generated and plotted according to in vivo tumour latency (y-axis) vs. CD133 expression (x-axis) vs. in 
vivo tumour hit rate (z-axis: bubble size). 
 
These data show that the tumour phenotypes found at the high CD133-expression (right) 
side of the plot are glial tumours and suggests that there may be some correlation 
between in vitro CD133 expression and a propensity towards generating a glial tumour 
in vivo (Figure 78), as previously suggested. The Rb-/-; p53-/- PNET tumour phenotype 
illustrated (in full pink) was actually not the predominant phenotype expressed with ‘no 
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tumour’ being found in 66% of the mice injected with cells. Additional sample numbers 
would be required to conduct a robust correlation analysis between CD133 expression 
and in vivo tumour hit rate as all four of the other plotted in vivo graft experiment 
tumour phenotypes possessed a 100% tumour hit rate. To address this, in section 5.3.8 
we repeat the Western blot experiment using only samples for which there was 
associated in vivo grafting data and incorporating an internal control (non-recombined 
NS). 
 
5.3.7 In vitro 	?	
@	KK"	XY			[@	
correlate with CD133 expression but does not correlate with either in 
vivo tumour hit rate or latency 
{	
			\``		ion levels have been shown to inversely 
correlate with those of CD133 by downregulating it in response to hypoxic conditions 
(Matsumoto et al., 2009). This suggests that tumourigenic NS expressing high levels of 
CD133 may be more resistant to hypoxia and possess increased in vivo survival and 
tumour hit rate. Here we used the same samples as for the CD133 Western blot in 
section 5.3.6 to perform a para		
			]Figure 79). 
 
 
Figure 79: In vitro 		?		KK"	XY	[	
	<n and between 
genotypes. Western blot of 	][?<$		-actin (42kDa) expression in PTEN-/-; p53-/- vs. Rb-/-; 
p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS (n=3 for each genotype), with associated passage 
numbers and the results of any corresponding in vivo engraftment studies. Two additional samples (NS 
grown from a PTEN-/-; p53-/- NS-induced glioma and NS derived from the brains of a cohort of RbLox/Lox; 
PTENLox/Lox mice six months after having had received an intracerebroventricular injection of Adeno-Cre) 
were included on the blot for preliminary comparison purposes. 
 
*		]#$			*		
	=	-quantitatively measured 
us	*	#	-	
		
	`				
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were then generated for comparative analysis purposes (Figure 80). No correlation 
be=		
				=	
#` 
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*				=		
		]*	=		-
basic genotype samples were omitted from this grouping) to examine the intra- and 
inter-genotype expression profile of tumourigenic NSCs (Figure 81). 
 
 
Figure 81: Only Rb-/-; PTEN-/- vs. Rb-/-; p53-/- NS in vitro have a statistically significant difference in 
	[			?\	{	
	*		*						
]					-actin intensity, *1000) expressed (y-axis) by each of the four genotypes of 
tumourigenic NS (n=3 for each) in vitro (x-axis). Error bars: standard errors. *: P<0.05 (one-tailed paired 
Student’s t-Test). No significance difference observed between any of the groups using a one-way 
ANOVA with Bonferroni’s multiple comparison correction). 
 
As seen with the CD133 expression data, each of the genotypes possessed a large 
			#		*	#			@	*	#	*	
need for a sample size greater than three. However, whereas no statistically significant 
differences in CD133 expression were observed between any of the genotypes, a 
		]?`?$		=	
#	
=	*			
of Rb-/-; PTEN-/- and Rb-/-; p53-/- NS in vitro (Figure 81). Interestingly, the same two 
genotypes were the closest to exhibiting a statistically significant difference (p=0.071) 
in CD133 expression. The correlation between the expression levels of the CD133 and 
	=		
		*			*	]Figure 82). 
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Figure 82: Expression of CD133 by in vitro recombined Rb-/-; p53-/-; PTEN-/- tumourigenic NS 
[@		<		?\	A scatter plot of CD133 expression (y-$			
expression (x-axis), for each of the four genotypes of tumourigenic NS (n=3 for each), in the form of 
corrected intensities as measured semi-quantitatively from Western blots run using the same samples in 
parallel. The data points from the different genotypes are colour coded in accordance with the key. The 
correlation coefficient of the two data sets (R2 = 0.4617) was significant (P<0.05). Linear regression was 
used to determine the goodness of the fit (R2), and a two-tailed Pearson test was used to measure the level 
of correlation (*: P<0.05). 
 
CD133 was f		
		#					]Figure 
81$`	*		#	*							<		` On this 

@	=		*			 of the Western blot samples with the 
same in vivo grafting data used for CD133 in order to elucidate any potential 
correlations between in vitro 			in vivo tumour hit rate, latency, and 
phenotype. The results were once again visualised on a bubble plot of mean in vivo 
tumour latency (y-$	#`			]-axis) vs. in vivo tumour hit rate (z-axis: 
bubble size). 
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Figure 83: No correlations were observed between in vitro 	?		XY		in vivo 
tumourigenicity (hit rate), in vivo tumour latency, or in vivo tumour phenotype. Each bubble 
represents a single in vivo grafting experiment encompassing a cohort of 6-13 mice with the phenotype 
given being the predominant tumour phenotype generated and plotted according to in vivo tumour latency 
(y-$	#`			]-axis) vs. in vivo tumour hit rate (z-axis: bubble size). 
 
No correlations were observed between the in vitro 				in vivo 
tumour hit rate, latency, or phenotype (Figure 83). Only the PTEN-/-; p53-/- NS, which 
predominantly generated oligodendrogliomas, were observed to express the expected 
#		]=$	#			]Figure 83$`	*@	*	#			
expressed by the Rb-/-; PTEN-/- NS was equally high as it was for CD133, suggesting 
that glioblastoma-generating NS may have aberrantly functioning hypoxia-response 
*	=*
	*											
both proteins remain highly expressed. Taken together our data suggests a more 
	*@	*			#	@		
=			
CD133 expression. In addition, although our data did not identify any correlation 
between the expression o	*					in vivo tumour hit rate, CD133 
remains a potential marker of hypoxia resistance. 
Although much focus has been directed towards CD133 as a marker, and potential 
target, of glioblastoma-initiating cells (GICs) it has been shown that shRNA knock 
down of HIF-		*				*			-renewal in 
vitro and their invasion in vivo (Mendez et al., 2010). This suggests that HIF-		
represent a more promising therapeutic target in the treatment of glioblastoma. 
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5.3.8 Glioblastoma-initiating cells appear to exhibit increased CD133 
expression in vitro 
Protein samples were collected from five different NSC genotypes (controls vs. PTEN-/-
; p53-/-, Rb-/-; p53-/-, Rb-/-; PTEN-/-, Rb-/-; p53-/-; PTEN-/-) and a CD133 western blot was 
performed to compare their relative expression levels (n=2 for each) (Figure 84). The 
NSC passage number of the samples varied between two and five and no correlation 
was observed with CD133 expression. 
 
 
Figure 84: In vitro CD133 protein expression of tumourigenic NS has a high degree of genotype-
independent variability but appears to be a predictor of glioblastoma development. Western blot of 
	]_<$		-actin (42kDa) expression in non-recombined Adenovirus-GFP-infected control 
vs. PTEN-/-; p53-/- vs. Rb-/-; p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS (n=2 for each genotype), 
with associated passage numbers and the results (hit rate and predominant tumour phenotype) of 
corresponding in vivo engraftment studies. 
 
The net (relative) intensities of the CD133 bands were semi-quantitatively measured 
	*	#	-actin bands as baseline controls. Corrected CD133 intensities 
were then generated for comparative analysis purposes (Figure 85). 
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The corrected CD133 intensities were grouped by genotype to examine the intra- and 
inter-genotype expression profile of tumourigenic NSCs. As we have previously 
demonstrated, the tumourigenic NS samples reproducibly gave rise to the same 
predominant tumour phenotype within each genotype. The one exception being the Rb-/-
; PTEN-/- genotype for which only one of the in vivo grafting experiments gave rise to 
the development of tumours (glioblastoma). 
 
 
Figure 86: There are no statistically significant differences in the levels of CD133 expressed by non-
recombined Adenovirus-GFP-infected controls vs. PTEN-/-; p53-/- vs. Rb-/-; p53-/- vs. Rb-/-; PTEN-/- 
vs. Rb-/-; p53-/-; PTEN-/- NS in vitro (n=2 for each genotype). A bar chart comparing the grouped 
				]					-actin intensity, *1000) expressed (y-
axis) by each of the five genotypes of tumourigenic NS in vitro (x-axis). Error bars: standard errors. No 
significance difference observed between any of the groups (one-way ANOVA with Bonferroni’s 
multiple comparison correction). 
 
No statistically significant differences were observed in the level of CD133 expression 
between any of the in vitro NS genotypes being examined (including non-recombined 
Adenovirus-GFP-infected controls) (Figure 86). The genotype sample sizes were 
limited to two by the restriction of only using samples for which there was associated in 
vivo grafting data. In the case of the PTEN-/-; p53-/- and Rb-/-; p53-/- NS genotypes the 
internal variation in CD133 expression was minimal, whereas it was too large for a 
comparative analysis in the control, Rb-/-; PTEN-/- and Rb-/-; p53-/-; PTEN-/- genotypes. 
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The variation in the Rb-/-; PTEN-/- genotype is because only one of the two NS samples 
gave rise to tumours following intracerebral engraftment. Interestingly, these in vivo 
tumourigenic Rb-/-; PTEN-/- NS generated glioblastomas with a 100% hit rate. Their 
level of CD133 expression was measured at a corrected intensity of 81.35 (the highest 
recorded across all the samples) versus the 34.01 (second lowest across all the 
experimental samples) measured from the Rb-/-; PTEN-/- NS that generated no tumours 
(Figure 85). This validates the similar finding from sections 5.3.5 and 5.3.6 that in vitro 
CD133 expression may be a marker of glioma initiating cells. 
The large variation observed within the control group raises the question of sample 
validity. The Western blot bands (Figure 84) themselves are valid, but the variation 
from a CD133 expression corrected intensity of 71.78 (control sample 1: Band #1) to 
9.00 (control sample 2: Band #2) suggests that either a) Band #1 was caused by a 
sample or technical anomaly, or as previously proposed (section 5.3.6) b) CD133 
protein expression in vitro is influenced more strongly by environmental conditions 
(e.g. culture conditions, general cellular health) than by the tumourigenic profile of the 
cells (combination of TSGs lost). The findings from sections 5.3.2 and 5.3.3 showed 
that in vitro recombined and tumourigenic NS were found to contain 12% CD133+ cells 
versus 2.5% in non-recombined controls. Ignoring control sample 1 (Band #1), this 
expected ~5-fold increase in CD133 expression from the controls to the Rb-/-; p53-/-; 
PTEN-/- NS was observed. 
These findings suggest that in vitro CD133 expression is strongly influenced by 
environmental conditions which must be carefully controlled for if CD133 its potential 
as a marker of glioblastoma initiating cells is to be examined. 
In an attempt to draw out any further correlations between in vitro CD133 expression 
and in vivo tumour hit rate, latency, and phenotype we once again plotted the Western 
blot data on a bubble plot of mean in vivo tumour latency (y-axis) vs. CD133 expression 
(x-axis) vs. in vivo tumour hit rate (z-axis: bubble size). 
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Figure 87: CD133 is most strongly expressed in vitro by NS that generate glioblastoma 
(glioblastoma) tumours following intracerebral engraftment, but no correlation was observed 
between CD133 expression and tumour hit rate or latency. Each bubble represents a single in vivo 
grafting experiment encompassing a cohort of 6-13 mice with the phenotype given being the predominant 
tumour phenotype generated and plotted according to in vivo tumour latency (y-axis) vs. CD133 
expression (x-axis) vs. in vivo tumour hit rate (z-axis: bubble size). The in vivo engraftment data for the 
Rb-/-; p53-/- NS is included for comparison purposes despite predominantly generating no tumours. 
 
Despite generating few tumours in vivo, the Rb-/-; p53-/- NS possessed a high relative 
expression of CD133 in vitro (Figure 87). This finding confirms the lack of a correlation 
between in vitro CD133 expression and tumour hit rate. Also, no correlation was 
observed between CD133 expression and tumour latency, as shown by the two Rb-/-; 
p53-/-; PTEN-/- NS grafting cohorts which expressed vastly different levels of CD133 in 
vitro despite having indistinguishable tumour profiles (Figure 87). The only finding 
validated by this visualisation was the trend between a high relative expression of 
CD133 in vitro and a propensity towards generating a glioblastoma tumour in vivo. 
 
5.4 Conclusion 
In this chapter we demonstrated that CD133 is expressed in vivo by the same SVZ 
NSCs that generate tumours following i.c.v. Adenovirus-Cre-mediated recombination of 
TSGs. In addition, this in vivo expression of CD133 was maintained by the SVZ NSCs 
when grown as NS in vitro. Interestingly, we identified that only 2.5% of wild-type 
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NSCs express CD133, a similar proportion to that seen with colon cancer cells (Ricci-
Vitiani et al., 2007), but that this proportion rose to 12% following tumourigenic 
transformation (to Rb-/-; p53-/-; PTEN-/-  NSCs). This is the first model system to suggest 
a causative link between elevated CD133 expression and early neoplastic transformation 
(pre-tumour development). Additionally, it is also the first model to identify that CD133 
possesses a dynamic expression equilibrium in vitro, seemingly governed by an 
interaction between the functional properties of the NSCs and their health state / 
microenvironment. Both wild-type and tumourigenic NSCs were found to possess a 
similar CD133 expression equilibrium of ~7.5%, but the rate of equilibration for the 
tumourigenic NSCs was notably slower (11 passages) than for the wild-type NSCs (2 
passages). It was thought that this could have been as a result of a functional differences 
between wild-type and tumourigenic and/or CD133+ and CD133- NSCs, and indeed we 
found that CD133 expression positively correlates with the in vitro growth rate (but not 
the NS-forming ability) of tumourigenic NSCs. However, the variability in the 
equilibration rates observed versus the highly reproducible in vitro growth rates 
suggests that the CD133 expression equilibrium is influenced most strongly by NSC 
health state and culture conditions. The contribution of such variable influencers to 
CD133 expression may account for the ambiguity surrounding the status of CD133 as a 
marker of BTICs, as seen in the literature (Bao et al., 2006; Shmelkov et al., 2008; 
Griguer et al., 2008). Nevertheless we are able to report that in vitro recombined Rb-/-; 
p53-/-; PTEN-/- NSCs possess an elevated basal level of CD133 expression and an 
altered pattern of CD133 expression when compared to wild-type controls, and that 
further work is required to deduce the functional characteristics governing the level of 
CD133 expression and its rate of equilibration. In contrast to reports in the literature that 
CD133- cells do not represent the BTIC (Bao et al., 2006) we found that CD133- NSCs 
generated tumours following intracerebral engraftment, and did so with a tumour profile 
(hit rate, latency, phenotype) that was similar to non-sorted tumourigenic NSCs. 
Although no correlation was observed between NSC CD133 expression and in vivo 
tumour hit rate or latency, a potential correlation was identified between elevated 
expression and a propensity towards generating glial, or more specifically glioblastoma, 
tumours. This finding supports the widespread documentation of CD133 as a marker of 
the glioblastoma cancer stem cell (Singh et al., 2003; Murat et al., 2008). In addition, 
we originally proposed that a part of the functional difference between CD133- and 
CD133+ NSCs may be hypoxia-related and that CD133+ NSCs may be more resistant 
to the in vivo environment and subsequently possess an increased tumour hit rate. 
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However, we in fact saw that CD133-/+ NSCs possessed comparable tumour hit rates 
(41.7% and 33.3%) following in vivo engraftment. To this end, we validated the status 
					<			
	deduced that the relationship is not a 
basic inverse correlation as high levels of both proteins were observed in glioblastoma-
generating NS, suggestive of aberrantly functioning hypoxia-response mechanisms. 
The majority of research has focussed on the origins of BTICs as neural stem or 
progenitor cells (Zaidi et al., 2009), however, in the next chapter we address whether 
terminally differentiated astrocytes can contribute to the development of brain tumours. 
 
5.5 Future Work 
The methodological rigour of the MACS / FACS studies should be strengthened 
through the inclusion of isotype controls into the experimental design. Only Rb-/-; p53-/-; 
PTEN-/- NSCs were FACS analysed for their level of CD133 expression. By repeating 
this analysis, along with an equilibration rate analysis, for all the other NSC genotypes it 
would allow us to assess the effect of TSG loss on CD133 expression in addition to 
allowing a more robust comparison between CD133 expression and in vivo tumour 
phenotype. A full in vitro functional characterisation of these additional genotypes 
would also allow us to examine whether the functional effects of CD133 expression are 
genotype-dependent. NSC self-renewal and multipotency assays should be included in 
the in vitro functional assay portfolio to examine the effect of CD133 expression of the 
two defining qualities of NSCs. Finally, the correlations analysis between CD133 
expression and in vivo tumour hit rate and latency were based on a maximum sample 

		[`	*		#
		
*						
that any statistical analyses were underpowered. It is therefore necessary to significantly 
increase those sample numbers to allow for a more robust and viable analysis. 
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6 The Relative Contribution of Terminally Differentiated 
Astrocytes to the Development of Brain Tumours 
 
6.1 Introduction 
The majority of research has focussed on the role of neural stem, neural progenitor, and 
stem-like cells (Zaidi et al., 2009) and less is understood about the relative contribution 
of mature cell types to the development of intrinsic brain tumours. Knocking-out the 
cell cycle regulator genes Ink4a-Arf and constitutively activating the EGF receptor in 
mature murine glial cells causes them to develop into high-grade gliomas (Bachoo et al., 
2002). It is also possible that other differentiated cell types such as oligodendrocytes 
and neurons could possess the same ability. These models have extrinsically induced 
neoplastic transformation by the loss-of-function of TSGs and the incorporation of 
oncogenic factors. It is believed that this approach drives astrocytes to de-differentiate 
towards a stem-like tumourigenic cell type. It is therefore extremely difficult to attribute 
any in vivo tumourigenesis observed specifically to a terminally differentiated whose 
cellular signature will no longer be recognisable when compared to its original form. In 
section 1.8 we laid out the aim of addressing whether brain tumour initiating cells 
(BTICs) could originate from terminally differentiated cells such as astrocytes, 
however, such a process should be thought of as two-step considering that mature 
astrocytes may be able to de-differentiate into stem-like / progenitor cells, but it is only 
these stem-like / progenitor cells (regardless of origin) that have the ability to develop 
into BTICs. 
Using our model system we set out to confirm whether terminally differentiated 
astrocytes are targeted for recombination by intracerebral Adenovirus-Cre 
administration, and to test the hypothesis of whether these mature astrocytes can 
undergo neoplastic transformation and contribute to tumourigenesis. 
 
Aims 
1. Verify whether i.c.v. Adenovirus-Cre administration targets terminally 
differentiated astrocytes, outside of the SVZ, for TSG recombination. 
2. Assess whether TSG loss in terminally differentiated astrocytes induces a 
transformation in function and/or differentiation state of the cells. 
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3. Examine whether these hypothetically transformed astrocytes can generate 
tumours in vivo.  
 
6.2 Materials and Methods 
Refer to the main materials and methods (Chapter Two). 
 
6.3 Results 
 
6.3.1 Intracerebroventricular Adenovirus-Cre administration targets 
terminally differentiated astrocytes for recombination 
In verify whether terminally differentiated astrocytes are susceptible to Adenovirus-
mediated infection we injected Adenovirus-GFP into the cortices of wild-type C57/Bl6 
mice and culled them after 7 days. The sub-cortical region, into which the Adenovirus-
GFP was delivered, was found to have a high number of GFAP-positive mature 
astrocytes, a large proportion of which were also positive for GFP (Figure 88). 
 
 
Figure 88: Mature astrocytes are targeted for infection by intracerebral Adenovirus-GFP 
administration. (A) Representative image showing the presence of both mature astrocytes (red) and 
Adenovirus-GFP infected cells (green). (B) Mature astrocytes can be targeted for Adenovirus-mediated 
recombination, as shown here by the colocalisation of the mature astrocytic marker GFAP with GFP at 7 
days following intracerebral Adenovirus-GFP administration. DAPI: Hoechst nuclear staining, aGFP: 
GFP protein detected using an anti-GFP antibody, GFAP: glial fibrilliary acidic protein for the detection 
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of mature astrocytes, aGFP + GFAP: colocalisation of aGFP + GFAP). Blue: excitation at 405nm, green: 
excitation at 488nm, red: excitation at 546nm. Images were taken using a 20x objective on a Zeiss 
Axioplan 2 microscope and captured using a mounted AxioCam MRm camera and the Axiovision 
software. 
 
The colocalisation of GFAP and GFP staining highlights that GFAP-positive mature 
astrocytes were targeted for infection by Adenovirus-GFP (Figure 88). This suggests 
that if Adenovirus-Cre were to diffuse into the brain parenchyma following i.c.v. 
administration it would target mature astrocytes for TSG recombination. 
To validate this suggestion we retrospectively analysed the brains of 12 RbLox/Lox; 
p53Lox/Lox, 7 RbLox/Lox; p53Lox/Lox; PTENLox/Lox, and 5 PTENLox/Lox; p53Lox/Lox mice that 
received i.c.v. Adenovirus-Cre injections but that had survived more than twice the 
*		*			`			=*		" 	-galactosidase 
immunoreactivity were used for the analysis, as this would suggest that the Adenovirus-
Cre injection had missed the lateral ventricles and targeted an ectopic (striatum, cortex, 
corpus callosum, hippocampus) region of the brain. These ectopic regions were then 
examined to see whether recombination had occurred in terminally differentiated cell 
types. 
 
 
Figure 89: Ectopic injection of Adenovirus-Cre recombines grey and white matter astrocytes and 
hippocampal neurons in vivo. ^#			
	-galactosidase-positive astrocytes 
(A-C) and neurons (D) in the cortex + corpus callosum (A,C), striatum (B), and hippocampus (D) of 
RbLox/Lox; p53Lox/Lox (A), RbLox/Lox; p53Lox/Lox; PTENLox/Lox (B,C), and  PTENLox/Lox; p53Lox/Lox mice. CC: 
corpus callosum. Images were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 
MOT microscope with a 20x objective and using the AnalySIS software package. 
203 
 
 
-galactosidase-positive recombination was found in both grey (cortex and striatum) 
and white (corpus callosum) matter astrocytes in the brains of RbLox/Lox; p53Lox/Lox and 
RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice (Figure 89: A-C). In addition, mature neurons of 
the hippocampus were observed to have been targeted for recombination in 
PTENLox/Lox; p53Lox/Lox mice (Figure 89: D). Despite this, none of the brains examined 
exhibited any sign of neoplasms. This suggests that mature astrocytes and neurons, 
outside of the SVZ, may not contribute towards tumourigenesis. However, unless we 
	*				-galactosidase in all the brains of mice which did 
develop tumours, then we cannot be sure that mature astrocytes do not contribute 
towards tumourigenesis as the occurrence may be extremely low. 
 
6.3.2 In vitro recombination of Rb, p53, and PTEN in terminally 
differentiated astrocytes induces a functional transformation 
As it is difficult to trace the origin of a neural progenitor / stem-like cell back to a 
terminally differentiated astrocyte in vivo, we devised an in vitro model system that 
allowed us to functionally characterise the effects of Rb, p53, and PTEN loss in fully 
differentiated astrocytes. To this end, astrocytes were derived from post-natal day 2-5 
mice carrying the same LoxP genotypes as previously used. Rb, p53, and PTEN were 
then conditionally knocked-out in these astrocytes by in vitro recombination with 
Adenovirus-Cre. We propose the following four hallmark features the astrocytes must 
exhibit for them to be considered ‘neoplastically transformed’: 
1. Increased growth rate and/or a loss of senescence; 
2. Loss of contact inhibition (i.e. the ability of cells to grow over the top of one 
another in a disorganised fashion in vitro); 
3. Loss of adhesion dependence (i.e. the ability of cells to grow as free-floating 
aggregates in vitro, or metastisise in vivo); 
4. Capable of in vivo tumourigenesis. 
 
In order to address point one we characterised the effect inactivation of the TSGs Rb, 
p53, and PTEN had on the in vitro growth rate of astrocytes by using the WST-1 
proliferation assay to measure their cumulative mitochondrial activity (as a surrogate 
marker of growth rate) at 0, 4, 6, and 8 hours after a 2 day incubation period. 
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Figure 90: The growth rates of in vitro recombined Rb-/-; p53-/-; PTEN-/-, PTEN-/-; p53-/-, Rb-/-, and 
p53-/- astrocytes at passage 3 are significantly higher than that of non-recombined Adenovirus-
GFP-infected control astrocytes. The Rb-/-; p53-/-, Rb-/-; PTEN-/-, and PTEN-/- astrocytes also grew 
significantly faster than the Adenovirus-GFP-infected control astrocytes but to a lower degree than the 
other genotypes. There was no significant difference in growth between any of the experimental 
genotypes. Using the WST-1 assay the growth rate (y-axis) of astrocytes at passage 3 was measured at 0, 
2, 4, and 8hrs (x-axis) after a 2 day incubation period. Growth rate of in vitro recombined Rb-/-; p53-/-; 
PTEN-/- (blue: n=3) vs. PTEN-/-; p53-/- (red: n=3) vs. Rb-/-; p53-/- (orange: n=3) vs. Rb-/-; PTEN-/- (purple: 
n=3) vs. Rb-/- (grey: n=2) vs. p53-/- (grey: n=2) vs. PTEN-/- (grey: n=2) vs. non-recombined untreated 
(grey: n=11) vs. non-recombined Adenovirus-GFP-infected (green: n=8) astrocytes. Error bars: standard 
errors. *: P<0.05 vs. GFP control at 8hrs, ***: P<0.001 vs. GFP control at 8hrs (one-way ANOVA with 
Bonferroni’s multiple comparison correction). 
 
As with the NSC WST-1 assay, a decreased growth rate the non-recombined 
Adenovirus-GFP-infected astrocytes (Figure 90: green data set) was observed when 
compared against the non-recombined untreated NSCs (Figure 90: grey data set), and 
highlighted a potential Adenovirus-mediated reduction on growth. However, this 
difference was not significant (as with the NSC WST-1 assay) and the Adenovirus-
GFP-infected astrocytes were used as the control group for the purpose of statistical 
analysis. All of the experimental genotypes, regardless of the number of TSGs lost, 
exhibited a significantly increased growth rate over the controls. The Rb-/-; p53-/-; 
PTEN-/- (3.10 +/- 0.59; 8hrs), PTEN-/-; p53-/- (3.10 +/- 0.81; 8hrs), Rb-/- (3.45 +/- 0.26; 
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8hrs) and p53-/- (3.66 +/- 0.36; 8hrs) astrocytes demonstrated the most significant 
(P<0.001) increase in growth rate over the Adenovirus-GFP-infected controls (0.95 +/- 
0.11) (Figure 90). And the Rb-/-; p53-/- (2.36 +/- 0.08; 8hrs), Rb-/-; PTEN-/- (2.34 +/- 
0.17; 8hrs) and PTEN-/- (2.70 +/- 0.01; 8hrs) astrocytes also demonstrated a significant 
increase in growth rate (P<0.05) over the controls, but to a lesser extent than the other 
experimental genotypes. Despite this, no significant difference was observed between 
any of the experimental genotypes. Overall, the in vitro recombined astrocytes 
possessed a similar genotype-dependent growth rate profiles as the NSCs (section 
3.3.3), but with two notable exceptions. Firstly, the single knock-out astrocyte 
genotypes all exhibited increased growth rates over the controls, and in the case of Rb-/- 
and p53-/- even greater than the double knock-out Rb-/-; p53-/- and Rb-/-; PTEN-/- 
genotypes. This contradicts the previously proposed additive effect of additional TSG 
loss on in vitro growth rate. However, after passage one in culture (prior to the WST-1 
assay), immediately following in vitro recombination, the single knock-out astrocytes 
were observed to grow even slower than the controls. As a result, the single knock-out 
astrocytes had to be kept in culture for a significantly extended period of up to four 
months rather than the typical two weeks for them to reach the passage requirement for 
the WST-1 assay. After passage two the single knock-out astrocytes began to grow 
more quickly and we propose that this was as a result of acquiring additional mutations 
in genes / pathways outside of those targeted for recombination. This acquired growth 
advantage is therefore not directly representative of the TSGs targeted for 
recombination. The second difference observed between the growth rate profiles of the 
astrocytes and the NSC was that the Rb-/-; p53-/- astrocytes exhibited a significant 
increase over the controls, suggesting that the mechanisms governing growth rate may 
be different between astrocytes and NSCs. However, the increase in Rb-/-; p53-/- 
astrocyte growth rate was only double that of the control; the same relative increase as 
observed with the Rb-/-; p53-/- NSCs. 
Taken together, these findings verify that inactivation of the TSGs Rb, p53, and PTEN 
in astrocytes confers an increased growth rate. To confirm that these astrocytes were 
also immortalised, we kept Rb-/-; p53-/- astrocytes in culture for 75 passages without 
observing any signs of senescence. 
Point two was addressed by observing in vitro recombined astrocytes in their normal 
culture conditions. And point three was addressed by plating in vitro recombined 
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astrocytes into pro-mitogenic NSC medium to observe whether they could grow in a 
similar manner to neurospheres. 
 
 
Figure 91: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes appear to transform as shown by 
their loss of contact inhibition as they are observed to grow over the top of one another (A), and loss 
of adhesion dependence as they are observed to grow as free-floating NS-like aggregates when 
plated as a single cells (B). 
 
Recombined Rb-/-; p53-/-; PTEN-/- astrocytes were observed to grow in a disorganised 
non-uniform manner in vitro (Figure 91: A). Rather than growing as an adherent 
monolayer that arrests upon confluence the astrocytes had lost their contact inhibition 
and grew over the top of one another and even formed aggregated buds in areas of high 
density. In some cases these buds were observed to detach from the plates and grow as 
free-floating aggregates. In addition, astrocytes plated in NSC medium were observed to 
grow non-adherently as free-floating NS-like aggregates termed “astrospheres” (Figure 
91: B). These astrospheres could be serially passaged (an indirect measure of self-
renewal), suggesting that they could represent de-differentiated astrocytes with stem-
like properties. 
 
6.3.3 In vitro recombination of Rb, p53, and PTEN appears to shift mature 
astrocytes towards a de-differentiated phenotype 
In sections 6.3.1 and 6.3.2 we suggested that terminally differentiated astrocytes could 
become tumourigenic by first de-differentiating into neural progenitor / stem-like cells, 
as originally proposed by Laywell et al in 2000 (Laywell et al., 2000). We 
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immunofluorescently stained astrocytes (passage three) grown on glass coverslips for 
GFAP and nestin to examine the effect of TSG loss on their expression profile. 
 
 
Figure 92: The number of astrocytes expressing the differentiation biomarkers GFAP and nestin 
appears to reduce after in vitro recombination of the TSGs Rb, p53, and PTEN; suggestive of an 
altered phenotype. Representative images of RbLox/Lox; p53Lox/Lox; PTENLox/Lox non-recombined untreated 
control (A,D,G) vs.  Rb-/-; p53-/-; PTEN-/-  (B,E,H) vs. Rb-/- (C,F,I) astrocytes at passage three that were 
left to grow on laminin-coated glass coverslips for 5 days before being fixed and immunofluorescently 
dual-stained for GFAP and nestin (A-C) with the individual GFAP (D-F) and nestin (G-I) stains also 
given. All cells were counterstained with Hoechst 33342 (DAPI). Blue: excitation at 405nm, green: 
excitation at 488nm, red: excitation at 546nm. Images were taken Zeiss AxioCam MRm camera mounted 
on a Zeiss Axioplan 2 microscope using a 20x objective and the Axiovision software. 
 
The majority of non-recombined untreated RbLox/Lox; p53Lox/Lox; PTENLox/Lox astrocytes 
at passage three expressed GFAP and/or nestin (Figure 92: A,D,G), with co-expression 
also observed in the majority of the cells. However, fewer in vitro recombined Rb-/-; 
p53-/-; PTEN-/- astrocytes expressed GFAP and/or nestin, and co-expression was also 
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seen in less cells (Figure 92: B,E,H). This suggests that in vitro recombination of Rb, 
p53, and PTEN alters the expression profile of astrocytes. It is difficult to verify 
whether this altered expression profile corresponds to an altered de-differentiated 
phenotype, as the decreased number of GFAP-expressing cells suggests de-
differentiation away from the astrocytic lineage but the reduced number of nestin-
expressing cells suggests a progression towards a more differentiated cell phenotype 
(Vescovi et al., 1993). For this reason, additional markers of differentiation are required 
to verify this hypothetical de-differentiation. To illustrate the reduced growth crate of 
single knock-out astrocytes immediately following in vitro recombination, we included 
Rb-/- astrocytes in the analysis. Firstly, the overall number of viable cells observed at 
five days post-plating was less than both the control and Rb-/-; p53-/-; PTEN-/- astrocytes. 
And secondly, the number of cells expressing GFAP and/or nestin had almost 
disappeared (Figure 92: C,F,I). 
To verify whether the Rb-/-; p53-/-; PTEN-/- astrocytes were driven to a de-differentiated 
state we trypsinised confluent passage three astrocytes from in vitro culture and studied 
the expression of a range of different biomarkers using the cytoblock paraffin 
immunohistochemistry format.
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The Rb-/-; p53-/-; PTEN-/- astrocytes appeared to possess an atypical morphology when 
compared to the non-recombined untreated controls, as shown by their shrunken and 
more spherical cellular appearance (Figure 93: K vs. A). As expected the Rb-/-; p53-/-; 
PTEN-/- 	=	-galactosidase-positive (Figure 93: N vs. D) and exhibited 
increased proliferation as demonstrated by their phospho-Histone H3 immunoreactivity 
(Figure 93: O vs. E). As a verification of the earlier immunofluorescence finding, in 
vitro recombination of Rb, p53, and PTEN appeared to cause a reduction in the number 
of nestin-expressing cells with a reduction also observed in the strength of its expression 
(Figure 93: M vs. C). However, despite previously suggesting that the number of 
GFAP-expressing cells was lower in the Rb-/-; p53-/-; PTEN-/- astrocytes (as measured by 
immunofluorescence), here we observed a comparative pattern and level of GFAP to the 
control (Figure 93: L vs. B). Comparable levels of expression were also observed with 
the putative stem cell marker Sox-9 (Figure 93: Q vs. G) and the differentiated neuronal 
markers synaptophysin (Figure 93: S vs. I) and NeuN (Figure 93: T vs. J). However, a 
notable increase was observed in the level and number of cells expressing the stem cell 
marker Sox-2 (Figure 93: P vs. F) with an associated reduction in the level of MAP2 
expression (Figure 93: R vs. H). Nestin is not an undisputable marker of de-
differentiated cells as a reduction in its expression may be due to TSG loss rather than 
de-differentiation, and chromosomal loss of the nestin locus is possible. 
Taking all of these findings into account, it appears that in vitro recombination of the 
TSGs Rb, p53, and PTEN shifts mature astrocytes towards a high Sox-2 and low 
nestin/MAP2-expressing de-differentiated phenotype. 
 
6.3.4 In vitro recombined and engrafted astrocytes do not give rise to 
tumours and degenerate by four weeks 
To address the fourth criterion of neoplastic transformation we grafted in vitro 
recombined astrocytes into the striata of non-recombined mice of the same genetic 
background. Engraftment of at least 105 in vitro recombined astrocytes into 48 immune-
competent mice (11 received Rb-/-; PTEN-/- astrocytes, 9 received Rb-/-; p53-/- astrocytes, 
14 received Rb-/-; p53-/-; PTEN-/- astrocytes, 6 received p53-/- astrocytes, and 8 received 
Rb-/- astrocytes) of the same genetic background did not result in a single viable tumour 
when the mice were left for up to 307 days post-engraftment (Figure 94). 
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This long-term finding led us to design and conduct a short-term study in the aim of 
tracking the short-term fate of engrafted astrocytes. Rb-/-; p53-/-; PTEN-/- astrocytes were 
used for this purpose as, like the NSCs, they possessed the highest in vitro growth rate. 
1x106 in vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes were grafted into the striata of 
14 immune-competent mice of the same genetic background with time-culls (n=3 for 
each) performed at one, two, four, and six weeks post-engraftment, and the remaining 
mice (n=2) being left for long-term analysis (Figure 95). 
 
 
Figure 95: Schematic of the short-term astrocyte engraftment experiment indicating the number of 
Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into the striata of 14 mice and the planned time culls (n=3 
for each) at 1, 2, 4, and 6 weeks post-engraftment (the 2 remaining mice were left for a long-term 
assessment). 
 
Two mice were culled after 8 days due to the onset of clinical symptoms. These mice 
were found to be suffering from hydrocephalus, presumably caused by some of the cells 
being deposited in the lateral ventricles and causing a blockage to the circulation of 
cerebral spinal fluid. Grafted astrocytes were detectable, as localized foci proximal to 
the graft site, up to two weeks post-engraftment (Figure 96: A,B). Their viability was 
demonstrated by their positive staining for BrdU (Figure 96: D, E), a synthetic 
nucleoside that is incorporated into the newly synthesized DNA of actively 
replicating/proliferating cells. However, by two weeks there was a decrease in the 
number of viable astrocytes associated with the graft site as shown by the reduced BrdU 
(Figure 96	@	¤$		-galactosidase (Figure 96: G, H) positivity. By four weeks the 
area that was previously occupied by the grafted astrocytes had been completely 
replaced by fibrous connective tissue (Figure 96: C). The complete degeneration and 
clearance of these proliferating astrocytes was validated by the negative BrdU (Figure 
96	$		-galactosidase (Figure 96: I) stains of the graft site. 
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Figure 96: In vitro recombined and engrafted Rb-/-; p53-/-; PTEN-/- astrocytes do not give rise to 
tumours and degenerate by 4 weeks. Representative images taken from each time point showing that 
grafted astrocytes were detectable up to two weeks post-engraftment (A,B). After 1 week the grafted 
astrocytes were highly positive for ¢¥	]$		-galactosidase (G). However, by 2 weeks there was a 
decrease in the number of proliferating grafted astrocytes as shown by the combined reduced number of 
¢¥	]¤$		-galactosidase (H) positive cells. By four weeks the grafted astrocytes had been 
completely cleared from the area (C, F, I). Images were taken using a ColorView III digital camera 
mounted on a Zeiss Axioskop 2 MOT microscope with a 2.5x magnification (A-C) or a 6.3x 
magnification (D-I) and using the AnalySIS software package. Scale bar: A-C, 700m and D-I, 275m. 
 
These findings suggest that, despite their functional transformation in vitro, terminally 
differentiated astrocytes do not contribute to in vivo tumourigenesis in our model. 
Previous studies by other groups in which astrocytes were found to be capable of 
tumourigenesis all used immune-compromised mice (Bachoo et al., 2002; Lee et al., 
2008b). It is therefore possible that by engrafting these cells into the brains of immune-
competent mice we were less likely to observe astrocytic tumourigenesis due to an 
immune-mediated response against the cells. For this reason, repeated the experiment 
but engrafted the Rb-/-; p53-/-; PTEN-/- astrocytes into the striata of immune-deficient 
nude mice. 
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6.3.5 In vitro recombined astrocytes engrafted into immune-deficient nude 
mice do not give rise to tumours but persist as non-proliferating cells within 
the graft site for over 5 weeks 
5x105 in vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes were grafted into the striata of 
11 immune-deficient nude mice with time-culls (n=3 for each) performed at two and 
four weeks, and with the remaining mice being left for the long-term (n=5) to see if any 
tumours would develop (Figure 97). 
 
 
Figure 97: Schematic of the astrocyte engraftment experiment indicating number of Rb-/-; p53-/-; 
PTEN-/- astrocytes engrafted into the striata of 11 nude mice and the planned time culls at 2 (n=3) 
and 4 weeks (n=3) post-engraftment, with the remaining 5 mice left for long-term assessment. 
 
The experiment was terminated after five weeks due to the remaining five long-term 
mice exhibiting clinical symptoms of behavioural incapacitation and extrinsic tumours 
of the skull. Grafted astrocytes were detectable, as localized foci proximal to the graft 
site, up to five weeks post-engraftment (Figure 98: A-C). Their viability and identity 
was confirmed up to two weeks by their positive staining for BrdU (Figure 98: D) and 
-galactosidase (Figure 98: G). However, by four and five weeks there was a decrease 
in the number of proliferating grafted astrocytes associated as shown by the reduced 
number of BrdU-positive cells in the graft site (Figure 98: E, F). Despite no longer 
proliferating, the grafted astrocytes were observed to persist within the graft site after 
#	=<		#	
	*	#		-galactosidase (Figure 98: I). 
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Figure 98: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into the striata of nude 
mice do not give rise to tumours but are observed to persist as non-proliferating cells after 5 weeks. 
Representative images taken from each time point showing that grafted astrocytes were detectable up to 
five weeks post-engraftment (A-C). After 2 weeks the grafted astrocytes were positive for BrdU (D) and 
-galactosidase (G). By 4 and 5 weeks there was a decrease in the number of proliferating transplanted 
astrocytes as shown by the reduced number of BrdU-positive cells (E,F). These grafted astrocytes, 
**		@	*		
			=	
#				-galactosidase-positive 
cells (I). Images were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT 
microscope with a 2.5x magnification (A-C) or a 6.3x magnification (D-I) and using the AnalySIS 
software package. Scale bar: A-C, 700m and D-I, 275m. 
 
Astrocytes were cleared from the graft site by four weeks in immune-competent mice, 
whereas they persisted in immune-deficient nude mice. This finding supports the 
hypothesis of an immune-mediated degeneration and clearance of the astrocytes in 
immune-competent mice. Despite this, this additional experiment provided no evidence 
to suggest that terminally differentiated astrocytes could be contribute to 
tumourigenesis. However, as previously stated, a number of mice exhibited large 
tumours of the skull over the course of the experiment. All five of the long-term mice, 
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and one of the two week time-cull mice, had to be culled due to the development of 
these tumours. 
 
 
Figure 99: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into nude mice can give 
rise to extrinsic tumours of the skull after 2 weeks. -galactosidase-positive grafted astrocytes (C) were 
observed to generate a highly proliferating (B) extrinsic tumour mass (A). Images were taken using a 
ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 1.6x magnification 
(A) or a 2.5x magnificatio	]¢@$			*	{""	=	<`	"	
	{@	_??X		¢-
@	\?X` 
 
In the two week time-cull mouse a large well-demarcated tumour cell mass was found 
to be mechanically infiltrating into the brain (Figure 99: A). The cells were identified as 
grafted astrocytes by the fact that they were highly proliferative (Figure 99: B) and 
#		-galactosidase (Figure 99: C). The pathology of the tumour was identified 
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as a large spindle cell tumour from an H&E stain of a skull fragment viewed under high 
power magnification in which the infiltration zone could be observed (Figure 100). 
 
 
Figure 100: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into the brains of nude 
mice can give rise to large spindle cell tumours within the skull after 2 weeks. Images were taken 
using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x 
magnification and using the AnalySIS software package. Scale bar: 175m. 
 
However, these tumours cannot be considered as intrinsic brain tumours as they develop 
extrinsically and intrude into the brain parenchyma. 
 
6.3.6 In vitro recombined Rb-/-; p53-/- astrocytes grown as NS-like 
“astrospheres” behaviourally resemble their neural stem cell 
counterparts but do not give rise to tumours 
As previously mentioned, astrocytes are usually cultured adherently in the presence of 
fetal calf serum. However, astrocytes plated in pro-mitogenic NSC medium were 
observed to grow non-adherently as free-floating aggregates we termed “astrospheres” 
(Figure 91). These astrospheres could be serially passaged (an indirect measure of self-
renewal), suggesting that they could represent de-differentiated astrocytes with stem-
like properties. To characterise the functional changes associated with this 
transformation we measured the in vitro growth rate (WST-1 assay) and aggregate-
forming ability (AS size and AS-forming clonogenicity assays) of Rb-/-; p53-/- 
astrospheres. No statistical comparisons could be made between the different cell types 
in each of these assays as the astrosphere sample size was only one.
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In vitro recombined Rb-/-; p53-/- astrospheres exhibited a growth rate that was similar to 
that of the adherently grown Rb-/-; p53-/- astrocytes rather than the NSCs, despite being 
grown in NSC medium (Figure 101: A). This finding suggests that despite being 
transformed into a stem-like state, the Rb-/-; p53-/- astrospheres retain the intrinsic 
growth properties of their astrocytic origin. Whereas the Rb-/-; p53-/- NS displayed a 
relatively low growth rate with a correlated reduction in tumourigenicity in vivo, we 
propose that the increased growth rate of the Rb-/-; p53-/- astrospheres could be an 
indicator of the ability to form tumours in vivo. The Rb-/-; p53-/- astrospheres exhibited 
similar aggregate-forming abilities of Rb-/-; p53-/- NSC counterparts as they were 
observed to develop into spheres of a similar size (Figure 101: B) and with a similar 
overall number (Figure 101: C). 
To test whether these stem-like astrospheres could form tumours in vivo we conducted a 
short-term study whereby we engrafted in vitro recombined Rb-/-; p53-/- astrospheres 
into the striata of 5 immune-competent mice with time-culls at 11 days and 2 months 
(Figure 102). 
 
 
Figure 102: Schematic of the astrosphere engraftment experiment whereby Rb-/-; p53-/- astrospheres 
were engrafted into the striata of 5 immune-competent mice with time-culls planned at 11 days 
(n=3) and 2 months (n=2) post-engraftment. 
 
Two mice were found dead at day one post-engraftment, caused by acute hydrocephalus 
as a result of accidentally injecting the astrospheres into the lateral ventricles. For this 
reason, only a single mouse was time-culled after 11 days. 
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Figure 103: In vitro recombined Rb-/-; p53-/- astrospheres engrafted into the striata of immune-
competent mice do not give rise to tumours and are cleared by 2 months. Representative images 
taken from each time point showing that grafted astrospheres were detectable up to 11 days post-
engraftment (A-D) but had been cleared by 2 months (E-$`	{			*	-galactosidase-positive 
grafted astrospheres (B) were still viable in the graft site (C: black arrows) and were GFAP-negative (D). 
By 2 months there was no evidence of any viable grafted astrospheres (E-G) despite verification of a 
successful graft as shown by the reactive astrocytosis circumventing the injection tract (H). Images were 
taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 2.5x 
magnification (A-C) or a 6.3x magnification (D-I) and using the AnalySIS software package. Scale bar: 
A-@	_??X		-@	[_\X` 
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A cell mass with atypical morphology was identified within the striatum at 11 days 
post-engraftment (Figure 103	{$`	*		=	#		-galactosidase (Figure 
103: B) and BrdU (Figure 103: C), confirming their status as viable proliferating cells 
derived from the grafted astrospheres. Interestingly, the astrospheres cells within the 
graft site were observed to be GFAP-negative (Figure 103: D). This mirrored the 
finding in section 6.3.3 that in vitro recombination caused Rb-/-; p53-/- astrocytes to de-
differentiate to a GFAP-negative/nestin-negative phenotype and suggests that this 
hypothetical de-differentiation is maintained in vivo. By two months post-engraftment 
there was little evidence of any surviving Rb-/-; p53-/- astrospheres, despite a successful 
engraftment as verified by the high level of reactive astrocytosis observed along the 
injection tract (Figure 103: H). No atypical (Figure 103: E) or BrdU-positive 
proliferating cells (Figure 103	$@				=	-galactosidase-positive cells (Figure 
103: F) were identified along the injection tract. This suggests that by two months the 
astrospheres had been completely broken down into single cells and cleared from the 
brain leaving a glial scar (Figure 103: H). It should be noted, however, that Rb-/-; p53-/- 
NSCs also failed (in the majority of cases) to generate tumours in vivo. For this reason, 
repeats of this experiment with other genotypes (e.g. Rb-/-; p53-/-; PTEN-/-) may provide 
a more rigorous model system. 
Taken together, the results of the various in vivo engraftment studies suggest that 
terminally differentiated astrocytes, regardless of the combination of TSGs lost and of 
their differentiation state, do not contribute to in vivo tumour development. 
 
6.4 Conclusion 
In this chapter we demonstrated that i.c.v. Adenovirus-Cre administration targets 
terminally differentiated astrocytes, outside of the SVZ, for recombination. Such 
recombination and loss of the TSGs Rb, p53, and PTEN in these mature astrocytes was 
shown to induce a) a functional transformation to cells with an increased in vitro growth 
rate, a loss of contact inhibition, and a loss of adhesion dependence, and b) a phenotypic 
transformation to a de-differentiated stem-like state. Despite these transformations, we 
showed that terminally differentiated astrocytes, regardless of the combination of TSGs 
lost, did not contribute to in vivo tumour development in our model system. This 
immune-competency of the mice receiving the intracerebral astrocytes engraftments had 
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no effect on this result, despite the identification of an immune-mediated degeneration 
and clearance of engrafted astrocytes in immune-competent mice. 
 
6.5 Future Work 
The sample numbers for the astrocyte grafting experiments were 14 and 11 for the 
immune-competent and immune-deficient mice respectively. These sample numbers 
should be expanded to rule out the possibility that astrocytic in vivo tumourigenesis has 
a <4% rate of occurrence. In addition, the in vivo grafting experiments should be 
repeated for all of the experimental genotypes to assess whether there is a genotype-
dependent influence. Rb-/-; p53-/- astrocytes were used to generate astrospheres to test 
their in vivo tumourigenicity despite Rb-/-; p53-/- NSCs possessing a low tumour hit rate 
of 9.6%. This low tumour hit rate of the Rb-/-; p53-/- may have impeded the chance of 
observing in vivo tumour formation with engrafted Rb-/-; p53-/- astrospheres. For this 
reason, the astrosphere grafting experiment should be repeated with either all the 
genotypes or the at least the genotypes that carried the highest in vivo tumour hit rate for 
the NS grafting experiments (e.g. Rb-/-; p53-/-; PTEN-/-: 96%). Also, additional repeats of 
the astrosphere in vitro functional characterisation experiments would allow for 
statistical analysis (the sample number used was n=1). It would also be interesting to see 
if the RNA and protein expression profiles of the transformed stem-like astrocytes more 
closely resembles that of NSCs or the original terminally differentiated astrocytes. To 
this end, the pattern of CD133 expression (as examine in Chapter Five) in transformed 
astrocytes could be examined. 
  
224 
 
7 Summary and Conclusion 
Brain tumours represent one of the most devastating pathologies of the central nervous 
system. Their diagnosis, especially in the case of WHO grade IV glioblastoma, often 
carries a poor prognosis. In order to develop effective therapeutic treatment regimens it 
is essential to identify the cell type from which brain tumours arise, and to define the 
cellular and molecular events that occur during tumourigenesis. A variety of human 
tumours, such as those of the haematopoietic system, have well defined cells of origin. 
However, the BTIC is less well defined, and little is known about how the genetic 
changes observed in established tumours influence their functional and phenotypic 
profiles. In addition, relatively few markers of the BTIC cell have been identified, and 
all are still debated. Brain tumours commonly exhibit cellular characteristics typical of 
highly undifferentiated cells, a quality that first led to the implication of NSCs in 
tumour formation. There is growing evidence that BTICs are derived from cells of the 
neural stem cell compartment. Despite this, the relative contribution of terminally 
differentiated cell types (e.g. astrocytes and oligodendrocytes) to the formation of brain 
tumours has been widely studied (Holland et al., 1998b; Bachoo et al., 2002). The aim 
of our work was to a) characterise the in vitro functional profiles of tumourigenic neural 
stem cells (based on the combination of tumour suppressor genes inactivated), b) refine 
the origin and characterise the profile of the brain tumour initiating cell, c) identify 
and/or validate markers of brain tumour initiating cells, and d) assess the relative 
contribution of terminally differentiated astrocytes to the development of brain tumours. 
These aims were designed to achieve a better understanding of both the genetic and 
cellular processes driving brain tumour initiation. 
 
7.1 Brain tumours originate from adult neural stem/progenitor cells 
of the subventricular zone and their genotype influences tumour 
hit rate, latency, and phenotype 
We have shown that intrinsic brain tumours can arise from cells of the subventricular 
zone (SVZ) neural stem cell compartment in mice (Figure 11, Figure 13, Figure 14). By 
conditionally inactivating tumour suppressor genes in this compartment we induced 
neoplastic transformation and formation of tumours. The tumours generated in our 
model correlated with the combination of genetic mutations (Figure 12). Specifically, 
inactivating Rb and p53 led to the development of well demarcated primitive embryonal 
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tumours with evidence of neuronal differentiation, similar to human primitive 
neuroectodermal tumours (PNETs). The additional loss of PTEN did not alter the 
differentiation of the tumours, but it was associated with a significantly reduced latency 
and change in the tumour architecture in terms of increased cellular migration. In 
contrast, deletion of PTEN and p53 resulted in the development of diffusely infiltrative 
glial tumours, similar to high grade human gliomas and best corresponding to anaplastic 
oligoastrocytomas. Instead, combined inactivation of Rb and PTEN in the SVZ did not 
result in the development of any tumours. We hypothesise that the events which succeed 
the initial genetic lesion may play a role in determining the tumour phenotype, and may 
account for the variability observed in the tumour genotype-phenotype correlation. In 
epithelial tumours, there are well-described morphologically recognisable precursor 
lesions that correlate with specific early genetic abnormalities (Miller et al., 2005). In 
contrast, no such abnormalities have yet been identified in the CNS. In our model, 
tumours develop after a reproducible latency dependent on genotype. Mice in which all 
three TSGs Rb, p53, and PTEN are conditionally knocked out exhibit a reduced tumour 
latency (Figure 12: S), because it will take less time for them to accrue additional 
mutations to reach the tumourigenic threshold. This paradigm provides an excellent 
model to identify precursor lesions of the SVZ (Figure 12: A,B,C + Figure 13) and the 
sequence of pathways that may be mutated during oncogenesis. Despite major advances 
in identifying mutations, chromosomal abnormalities and activated pathways for many 
of the human brain tumours, the known genetic abnormalities only account for a 
minority of the tumours analysed and would therefore provide a highly subjective form 
of analysis (Collins, 2002; Louis et al., 2007). Whilst there are superficial differences 
between the murine tumours generated in our model and their proposed human 
equivalents, pathways relevant for human brain tumours were also dysregulated in the 
corresponding murine tumours. For example, while in our model of glioma formation 
Rb loss was not the primary genetic lesion, alteration of the Ink4a/Arf pathway may 
have lead to an inactivation of Rb function. Interestingly, our data indicates a novel role 
for Rb (loss) in driving tumour development towards the PNET phenotype. However, 
Rb (or more specifically its inhibition) may play a role in glioma progression as CDK4, 
a kinase that phosphorylates and inactivates Rb, is upregulated in glioma (Wiedemeyer 
et al., 2010). However, discrepancies remain between the genotype-phenotype 
mechanisms proposed in our model when compared to those of others. For example, in 
a glioma model Wang et al  demonstrated a loss of p16/Ink4a in GFAP-expressing 
precursor cells as a result of p53 mutation (Wang et al, 2009), whereas we found a 
226 
 
significant upregulation of Cdkn2a (refer to section 3.3.8) following the same genetic 
insult. However, it is possible that deletion of p53 (prior to the development of glioma 
in our model) results in the upregulation of p19/Arf and subsequent inhibition of Mdm2, 
in an effort to stabilize and re-activate p53 (Tao and Levine, 1999). The involvement of 
the Rb pathway at a later stage in our glioma model underlines the importance of the 
sequence of mutations in determining the tumour phenotype. Our results suggest that 
CNS tumourigenesis is a process where genetic mutations and activation of particular 
pathways determine the phenotype of the tumour. 
 
7.2 The in vitro functional profile of neural stem cells is influenced 
by genotype and can be used as a predictive indicator of in vivo 
tumour hit rate and latency 
We have shown that i.c.v. administration of Adenovirus-Cre targets self-renewing and 
multipotent cells in the SVZ niche. The combination and number of TSGs lost in these 
NSCs determines their in vitro growth rates, with a growth rate that is proportional to 
the number of tumour suppressor genes inactivated. Tumourigenic NSCs show 
increased self-renewal, in a genotype-dependent manner, as well as altered expression 
levels of GFAP, Sox-2, and nestin. The in vitro growth rate, but not the in vitro self-
renewal ability, of NSCs corresponds to in vivo tumour hit rate (initiation) and an 
inversely correlates to in vivo tumour latency. 
We hypothesise that the different NSC genotypes show functional differences in vitro 
because they are composed of NSC sub-populations with different functional profiles. It 
is known that cancer stem cells are dependent on their microenvironment (Calabrese et 
al., 2007), and we therefore hypothesise that the in vitro or in vivo microenvironment of 
NSCs influences their functional profile and ability to initiate tumour development. 
 
7.3 The cellular environment of neural stem cells at the time of 
tumour suppressor gene inactivation influences their in vivo 
tumourigenic profile 
We demonstrated that brain tumourigenesis is initiated and driven by SVZ NSCs: a) 
i.c.v. Adenovirus-Cre-mediated recombination of TSGs in the SVZ causes cells to 
proliferate and migrate into the brain parenchyma where they generate tumours, and b) 
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NSCs derived from the SVZ of adult mice, expanded and recombined in vitro generate 
tumours following intracerebral engraftment that recapitulate the i.c.v. Adenovirus-Cre-
induced phenotypes. Cells with the ability to self-renew were observed in the brain 
tumour bulk and probably represent BTICs. These cells were found to remain 
committed to a specific phenotype / lineage over serial engraftments. We hypothesise 
that these committed BTICs are the progeny of genetically targeted cells in the SVZ. To 
trace the origins of these committed BTICs we used i.c.v. Adenovirus-GFAP-Cre to 
target only the GFAP-expressing type B astrocytes of the SVZ for recombination in 
order to examine if they produce a similar or identical tumour phenotype. Using this 
approach we identified that targeting only the type B astrocytes of the SVZ for 
recombination induced similar tumour incidences, latencies, and histological 
phenotypes as seen following CMV-driven expression of Cre in SVZ cells. This 
suggests that the GFAP-expressing type B astrocytes of the SVZ are key contributors to 
the formation of brain tumours in our model. However, in the case of PNETs it was 
found that there was a reduction in incidence when only the type B astrocytes were 
targeted; suggesting that other SVZ cells (e.g. transient-amplifying progenitor cells) can 
contribute towards tumourigenesis. In addition, RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice 
injected with Adenovirus-GFAP-Cre exhibited a significantly longer mean tumour 
latency and a reduced number of PNETs, suggesting that targeting the GFAP-expressing 
type B cells induces a differentiaiotn toward glial lieages. 
Interestingly, we observed that the environment of SVZ NSCs (in vivo versus in vivo) at 
the time of recombination influences in vivo tumour hit rate and latency, but has limited 
effect on the phenotype. In vivo i.c.v. Adenovirus-Cre-mediated recombination in 
RbLox/Lox; p53Lox/Lox mice resulted in the development of brain tumours in 27.6% of 
mice, whereas in vitro recombined and engrafted Rb-/-; p53-/- NSCs generated tumours 
with a reduced incidence of 9.6%. This suggests that in vivo Adenovirus-Cre targets a 
cell type that is not present in vitro, and that Rb-/-; p53-/- NSCs preferentially transform 
into a tumourigenic state in the in vivo SVZ microenvironment. Conversely, whereas 
i.c.v. administration of Adenovirus-Cre in RbLox/Lox; PTENLox/Lox mice did not result in 
the development of intrinsic brain tumours, in vitro recombined and engrafted Rb-/-; 
PTEN-/- NS generated tumours with a hit rate of 70.6%. This suggests that, following 
inactivation of the TSGs Rb and PTEN, the transformed and tumourigenic cells only 
exist in the in vitro neurosphere culture environment. In addition, SVZ NSCs targeted 
for recombination in vivo had the same in vitro growth rate as their in vitro recombined 
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counterparts, but reduced self-renewal. We also found that tumour latency is dependent 
on the number of cells injected and that increased passage number results in an 
increased tumour incidence of grafts. 
NSCs and their progeny alter their function to match that of the local microenvironment, 
for example, NSCs that are introduced into the mammary epithelium niche adopt the 
function of intrinsic mammary epithelial cells (Booth et al., 2008). We propose that a 
similar mechanism of environmental influence affects the function and properties of 
NSCs, and that these properties subsequently determine their ability to initiate tumour 
development. 
 
7.4 Increased CD133 expression by tumourigenic neural stem cells 
appears to correlate with a propensity towards generating 
glioblastoma, but not the in vivo tumour hit rate or latency 
We demonstrated that CD133 is expressed by the same SVZ NSCs (e.g. GFAP-positive 
type B astrocytes of the SVZ) that generate tumours following recombination of TSGs 
by i.c.v. Adenovirus-Cre administration. Only 2.5% of wild-type NSCs were found to 
express CD133, and they possessed a CD133 expression equilibrium of 6.92-8.28% to 
which they return after only two passages following purification to either CD133- or 
CD133+ isolates. In comparison, 12% of tumourigenic NSCs expressed CD133, and 
although these tumourigenic NSCs possessed a similar CD133 expression equilibrium 
(4.3-10%) their rate of equilibration was reduced from two passages to 11 passages. At 
a functional level, CD133 expression positively correlates with the in vitro growth rate 
of tumourigenic NSCs but not their NS-forming ability. In contrast to some reports in 
the literature that CD133- cells do not represent the BTIC (Bao et al., 2006) we found 
that CD133- NSCs also generated tumours following intracerebral engraftment, and did 
so with a tumour profile (hit rate, latency, phenotype) that was similar to non-sorted 
tumourigenic NSCs. Also, contrary to suggestions in the literature, sorted CD133-/+ 
NSC isolate purities as low as 82.9% were adequate for observing a difference in their 
in vivo tumourigenic profiles. Although no correlation was observed between NSC 
CD133 expression and in vivo tumour hit rate or latency, a potential correlation was 
identified between elevated expression and a propensity towards generating 

`		@	=	#		 a surrogate marker of CD133 but found 
that their relationship is not the basic inverse correlation as previously thought. High 
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levels of both proteins were observed in glioblastoma-generating NS, hypothetically as 
a result of aberrantly functioning hypoxia-response mechanisms. For example, others 
*#	*=	*			=	
					*		
(Matsumoto et al., 2009), indicating that CD133 expression may be a reflection of NSC 
environmental conditions / hypoxia resistance and provide no insight into NSC sub-type 
classification. It therefore appears that a) CD133 protein expression in vitro is 
influenced more strongly by environmental conditions (e.g. culture conditions, general 
cellular health) than by the tumourigenic profile of the cells (combination of TSGs lost), 
and b) the cellular composition of NS is highly heterogeneous and CD133 expression 
may not need to be 100% representative of all the NSCs within the NS in order to see a 
CD133-correlated effect on tumour hit rate, latency, and phenotype. 
 
7.5 Terminally differentiated astrocytes do not contribute to brain 
tumour formation 
Brain tumours are classified according to morphological and/or immunophenotypic 
resemblance of the tumour cells to terminally differentiated cells of the brain, e.g. 
astrocytomas or oligodendrogliomas are characterised by expression profiles similar to 
those of astrocytes or oligodendrocytes (Louis et al., 2007). This classification was 
based on the original thinking that brain tumours arose from these mature cell types. 
However, since the discovery of neural stem cells, the focus of research into the BTIC 
has shifted onto neural stem, neural progenitor, and stem-like cells (Zaidi et al., 2009; 
Kondo, 2006). Despite this, several studies have shown that terminally differentiated 
astrocytes can be (extrinsically) transformed into a de-differentiated and tumourigenic 
stem-like state. This has been achieved using a variety of methods including: a) ectopic 
overexpression of the (proto)oncogenes H-RasV12 and K-Ras (Lee et al., 2008b; Ding et 
al., 2001; Uhrbom et al., 2005), SV40 T/t-Ag (Rich et al., 2001; Blouw et al., 2003), 
human telomerase catalytic subunit (hTERT) (Sonoda et al., 2001), and epidermal 
growth factor receptor (EGFR) (Bachoo et al., 2002); b) deletion of the Ink4-Arf tumour 
suppressor gene (Uhrbom et al., 2005; Holland et al., 1998b; Bachoo et al., 2002); or c) 
deletion of the hypoxia-responsive transcription factor HIF-				@	*	
angiogenic vascular endothelial growth factor (VEGF) (Blouw et al., 2003). 
However, it should be noted that such model systems are different to our paradigm in 
that they all include ectopic overexpression of oncogenes. We believe that these model 
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systems do not accurately replicate tumourigenesis as the ectopic overexpression of H-
RasV12, SV40 T/t-Ag, and hTERT can convert almost any normal cell into a tumour-
initiating cancer cells (MacKenzie et al., 2002). For example, H-RasV12 p53-/- astrocytes 
exhibit increased proliferation and are tumourigenic in vivo (Lee et al., 2008b). Ras is a 
G-protein that is activated by guanine exchange factors (GEFs) and is responsible for 
the coupling of growth factor receptors to downstream mitogenic activators involved in 
cell proliferation, differentiation, and survival. Mutations in the Ras family of genes Ras 
are present in 20-30% of all human cancers, and in many cell types overexpression of 
H-Ras results in loss of growth control and neoplastic transformation (Omerovic et al., 
2007). For this reason, we believe that H-Ras overexpression drives the tumourigenic 
transformation of mature astrocytes in a way that does not accurately model the true in 
vivo process, hence the vastly reduced tumour latencies observed with such model 
systems when compared against our own. It may be possible to oncogenically de-
differentiate mature astrocytes into stem-like / progenitor cells, but only these stem-like 
/ progenitor cells (regardless of origin) should be thought of as BTICs and not the 
orginal astrocytes. 
It has been suggested that a) in vitro and in vivo targeting of astrocytes selects for a less 
mature astrocytic cell with enhanced growth and differential potential, and b) in vitro 
culturing of astrocytes, only possible from neonatal brains, includes astrocytes capable 
of cell divisions (Stiles and Rowitch, 2008). In our model, we: a) use a model system 
with no ectopically-induced overexpression of oncogenes, b) derive astrocytes from the 
brains of post-natal mice, and c) investigate whether ectopic recombination of the TSGs 
in astrocytes of non-neurogenic brain regions (e.g. cortex, striatum, hippocampus) can 
result in tumour formation. 
To this end, we demonstrated that i.c.v. Adenovirus-Cre administration targets 
terminally differentiated astrocytes, outside of the SVZ, for recombination. Loss of the 
TSGs Rb, p53, and PTEN in terminally differentiated astrocytes induced transformation 
to de-differentiated cells with increased in vitro growth rate, loss of contact inhibition, 
and loss of adhesion dependence. Despite these transformations, we showed that 
terminally differentiated astrocytes, regardless of the combination of TSGs lost, were 
unable to form tumours in our model system. 
Using a model system that resembles our own, Xiao et al have demonstrated that 
ectopic inactivation of Rb and PTEN in terminally differentiated astrocytes results in the 
development of high-grade astrocytomas (Xiao et al., 2002). However, this model 
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system used truncated, but still oncogenic, SV40 T antigen expressed under the GFAP 
promoter to inactivate pRb; meaning that the tumourigenic effect was both ectopically 
induced, and could not be discriminated from a GFAP-expressing type B astrocyte stem 
cell-mediated effect. Other groups have also used TSG inactivation / loss to study the 
role of mature astrocytes in tumourigenesis, with most focussing on the INK4a and 
ARF genes. INK4a and ARF are TSGs whose proteins, p16INK4a and p14/p19ARF, are 
regulators of the Rb and p53 pathways respectively. Homozygous deletion of the 
INK4a-ARF locus is one of the most frequent mutations in human glioblastoma (Liggett 
and Sidransky, 1998) and a variety of experiments have shown that INK4a-ARF loss in 
mature astrocytes transforms them into a tumourigenic state. However, once again these 
experiments combine INK4a-ARF  inactivation with overexpression of oncogenic 
factors such as EGFR, platelet-derived growth factor (PDGF), Akt, and K-Ras (Bachoo 
et al., 2002; Tchougounova et al., 2007; Weiss et al., 2003; Holland et al., 1998a; 
Holland et al., 1998b). Not all experiments have found that (supposedly) mature 
astrocytes can contribute to tumourigenesis; with the same end result as our model 
Holland et al found that in vivo overexpression of activated Ras and Akt in terminally 
differentiated astrocytes of non-neurogenic regions does not transform them into 
tumourigenic cells (Holland et al., 2000). 
 
7.6 A novel model of genotype/microenvironment-dependent 
tumourigenesis 
Our model system suggests that there is a causative link between tumour genotype and 
fate determination, with the combination of initial genetic mutations (TSG loss) strongly 
influencing both the hit rate and the phenotype of the resulting brain tumours. Although 
a variety of mouse models have independently been used to model glioma, PNET, or 
medulloblastoma tumours in isolation (refer to section 1.6: Table 1), we show here that 
cells of the same compartment are capable of forming all these tumour types, depending 
on the combination of induced genetic mutations, in a single and intra-comparable 
model. However, as the SVZ stem cell compartment is known to contain at least three 
functionally different sub-populations of NSCs (Doetsch et al., 1997), we hypothesise 
that these may be differentially susceptible to any given combination of oncogenic 
signals. For example, in our model in vivo recombination of Rb and p53 in all cells of 
the SVZ NSC compartment resulted in the development of PNETs with a 27.6% hit 
rate, however, the same genetic lesion targeted to only the GFAP-expressing type B 
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astrocytes of the same compartment resulted in the almost complete abolishment of any 
tumour development (3.8% hit rate). This hypothesis of a ‘NSC subtype functional 
profile – genetic lesion’ inter-dependency as a key determinant of tumour phenotype is 
supported by the histological reproducibility of the tumours seen in our model across a 
range of other models. For example, Zheng et al have also shown that GFAP-cre-
mediated inactivation of PTEN and p53 in neural progenitor cells results in the 
development of malignant astrocytomas (Zheng et al, 2008). 
In order to explain this proposed relationship between NSC subtype functional profile 
and genetic mutation combination we believe there are three primary hypotheses 
requiring consideration: 
 
(i) The SVZ NSC compartment contains pre-committed glial / neuronal BTIC 
subtypes that produce the distinct tumour phenotypes regardless of the 
combination of genetic mutations. This hypothesis is difficult to disprove from an 
in vivo perspective as controlling against variation in cell-targeting-specificity 
provides many challenges. However, using our model system we were able to 
isolate cells from the same in vivo locale and create parallel in vitro cultures 
where the only difference between them was combination of induced genetic 
mutations. Using this approach we were able to delineate in vitro functional 
differences as well as in vivo differences in tumour development hit rate, latency, 
and phenotype propensity as a direct consequence of the combination of genetic 
mutations.  
(ii) The SVZ NSC compartment contains a single BTIC that is responsible for 
producing all tumour phenotypes and does so as a direct consequence of the 
combination of genetic mutations. However, this hypothesis does not adequately 
explain the variability of tumour hit rate, latency, and phenotype observed in our 
mode system unless we attribute all of this to a microenvironment-mediated 
effect. 
(iii) The SVZ NSC compartment contains multiple functionally different BTIC subtypes 
(neural stem/progenitor cell subtypes) that are predisposed to particular 
differentiation lineages when presented with specific oncogenic signals. 
Considering that all SVZ NSC subtypes are non-preferentially targeted in our 
model, this would mean that loss of Rb (in any combination context) would confer 
a growth advantage to neuronal progenitors (perhaps by ctransforming them into a 
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neuroblast type A cell phenotype) and drive the tumour down a PNET lineage. 
Conversely, loss of PTEN and p53 would only take effect on glial-committed 
progenitors and therefore result in the preferential development of glioma with 
variable oligodendroglial features. This would also explain why the loss of all 
three TSGs primarily results in the development of PNETs but with some gliomas 
after longer latencies and the occasional bi-phasic PNET + glioma phenotype. 
This is because despite the loss of Rb some glial-committed progenitors would 
respond to the loss of PTEN and p53 and develop into gliomas in parallel to the 
PNETs. 
 
Taking all our findings into account (Figure 104), we believe hypothesis (iii) to be the 
most accurate. However, most hypotheses of tumourigenesis (including this one) 
describe tumour phenotype as a direct result of tumour cell lineage specificity (Huse 
and Holland, 2010; Zaidi et al., 2009; Laks et al., 2010; Vescovi et al., 2006; 
Fomchenko and Holland, 2005; Oliver and Wechsler-Reya, 2004). In light of our novel 
finding that the environment of SVZ NSCs (in vivo versus in vivo) at the time of 
recombination influences their in vivo tumour hit rate and latency but with limited effect 
on the phenotype (Figure 104), we propose that microenvironment should constitute an 
additional variable to produce the following hypothesis (iv): 
 
(iv) The SVZ NSC compartment contains multiple BTIC subtypes (neural 
stem/progenitor cell subtypes) that are predisposed to particular differentiation 
lineages when presented with specific oncogenic signals, but whose tumourigenic 
permissiveness and functional profile is influenced by their microenvironment.  
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Figure 104: Environment-dependent tumourigenesis. This schematic of the results depicted in Figure 
52 illustrates the influence NSC environment at the time of tumour suppressor gene inactivation has on 
the ability of NSCs to initiate tumour development. Arrow thickness indicates in vivo tumour hit rate. 
Blue arrows: tumour development from i.c.v. Adenovirus-Cre-mediated in vivo recombination of the 
indicated genotype. Green arrows: tumour development from in vitro recombined and engrafted NSCs of 
the indicated genotype. Orange arrows: tumour development from in vivo recombined, derived in vitro 
and engrafted NSCs of the indicated genotype. 
 
The three-layered schematic (Figure 104) highlights the in vivo tumour hit rate and 
phenotype observed for each of the NSC genotypes depending on the cellular 
microenvironment at the time of gene inactivation. For example, in vitro recombined 
Rb-/-; PTEN-/- NSCs efficiently generate glioblastomas with a high hit rate, whilst no 
tumours form after in vivo recombination. Our studies suggest that BTICs can possess a 
varying range of tumour-initiating abilities dependent on genotype and cellular 
microenvironment. 
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7.7 Impact of Work on Brain Tumour Diagnosis and Treatment 
In order to understand the histogenesis of brain tumour development and develop 
effective therapeutic treatment regimens it is important to identify the “cell of origin” 
from which brain tumours arise, and to define the cellular and molecular events that 
occur during tumourigenesis. A variety of animal models (refer to section 1.6) have 
been used to further our understanding of the genetic basis of CNS tumourigenesis, 
however, the cell of origin for most CNS tumours remains only indirectly inferred or 
unknown. Our research has added significant weight to the argument that neural 
stem/progenitor cells of the SVZ neurogenic niche can become a class of brain tumour 
initiating cell (BTIC) capable of generating multiple phenotypes. The similarities 
between normal adult NSCs and BTICs have been discussed in detail (refer to section 
1.3.2 and 1.4.1). We also defined a causative link between the genotype (initial genetic 
lesion) of BTICs and the phenotype of the tumours they produce. The additional 
research we have done into this genotype-phenotype relationship has added to our 
understanding of fate determination during tumourigenesis. As a result, we have 
identified that fate determination can be a contextually-relevant event whereby NSCs 
can give rise to an array of BTIC sub-types based on the interaction between their 
genetic / functional profile and their microenvironment. We used spatial and temporal 
cell isolation techniques (intrinsic to our model system) and comparative functional 
profiling to delineate these BTIC sub-types and subsequently deduce that they possess 
different tumourigenic and phenotypic propensities. We therefore propose that the 
efficacy of single signalling pathway therapeutics (e.g. gene therapy) as a post-
symptomatic treatment option will remain limited and highly variable, and that the 
focus of treatment research should lie with concomitant therapies (e.g. the incorporation 
of temozolomide into established chemo/radiotherapy treatment regimes for glioma). 
The pre-clinical success seen with antiangiogenic therapies (Calabrese et al., 2007) 
supports this argument and we believe that therapies targeting the tumour 
microenvironment hold significant potential. In summary, the potential therapeutic 
implication of defining the BTIC is enormous as: a) treatments that specifically target 
tumour growth would minimising the cytotoxic side-effects seen with traditional 
chemo/radiotherapy, and b) defining the aetiology of tumourigenesis would foster a 
greater understanding of how to prevent tumour formation and recurrence. 
Perhaps the greatest potential of our model system is in its potential contribution to the 
diagnosis and management of brain tumours. The ability of the model to genetically 
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control the production of a range of different tumours means that we have been able to 
use comparative expression profiling to identify differentially expressed signalling 
pathways implicated in tumour fate determination. We aim to continue this research to 
identify and validate novel diagnostic markers and potential therapeutic targets with 
known correlates to tumour hit rate, latency, phenotype propensity, and treatment 
resistance. 
 
7.8 Future Work 
Detailed below are several additional experiments that could be carried out to further 
test the hypotheses generated in the course of this research program. 
 
7.8.1 Investigation of the relative contribution of neural stem cells from 
other neurogenic niches to tumourigenesis 
Our research has focussed on the role that SVZ NSCs play in tumourigenesis of the 
CNS. It could be examined if stem/progenitor cells from other niches (e.g. NSCs of the 
subgranular zone within the dentate gyrus of the hippocampus (Seri et al., 2001)) are 
capable of forming brain tumours. 
 
7.8.2 Specifically target tumour suppressor gene inactivation in other 
neural stem cell sub-types 
We reported results from specifically targeting TSG inactivation in the GFAP-
expressing type B astrocytes of the SVZ. By using Adenovirus-Cre expressed under the 
control of different promoters such as CD133, the orphan nuclear receptor TLX (Shi et 
al., 2004)@		^	(Jackson et al., 2006) it could be investigated whether cell 
populations expressing specific markers give rise to distinct brain tumour phenotypes. 
 
7.8.3 Investigate the relative contribution of other cell types to brain 
tumour formation 
We demonstrated that terminally differentiated astrocytes do not contribute to in vivo 
tumour development in our model system. Using the same approach it could be 
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investigated whether oligodendrocytes, neurons, and ependymal cells could contribute 
to brain tumour formation. 
 
7.8.4 Analyse tumour samples generated from our mouse model to identify 
markers that correlate with in vivo tumour hit rate, latency, and 
phenotype 
By using a combination of cDNA microarray and laser capture micro-dissection it is 
possible to analyse brain tumour samples generated from our model for markers of in 
vivo tumour hit rate, latency, and phenotype. Such markers could then be used to assist 
in the delineation of BTICs and ultimately as targets for the therapeutic treatment of 
brain tumours (e.g. antibody-assisted chemotherapy). 
 
7.8.5 Compare murine and human brain tumours 
By carrying out an in vitro functional characterisation, in addition to profiling the in 
vivo tumourigenic properties of human brain tumour samples, as we did for mouse 
BTICs, it will be possible to identify similarities between the two systems. These 
correlates could then be used to translate our findings into a human-relevant context as 
well as identifying which aspects of the mouse model system can be extrapolated to the 
human condition. 
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10 Appendix 
Table 1: Summary table of established animal models of CNS tumourigenesis………………………….41 
Figure 1: Stem cell compartment hierarchy. S: neural stem cell, P1: early transient-amplifying progenitor 
cell, P2: late transient-amplifying progenitor cell, T: terminally differentiated cell. .................................. 20
Figure 2: Anatomical location of NSCs in the adult mouse brain (adapted from (Sutter et al., 2007). (1) 
The subventricular zone (SVZ) of the rostral portion of the lateral ventricles. (2) The subcallosal zone 
(SCZ) found between the corpus callosum and the hippocampus, and the subgranular zone (SGZ) within 
the dentate gyrus of the hippocampus. (3) Between the internal granular layer (IGL) and the white matter 
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Figure 3: Hierarchical cellular organisation of the subventricular zone in the adult mouse. (A) Coronal 
cross-section of the mouse brain: NSCs (shown as blue circles) are located in the SVZ and can undergo 
neoplastic transformation resulting in the development of a brain tumour (shown as red circles). (B) 
Differentiation hierarchy of the NSC sub-classes within the SVZ. (C) Schematic representation of the 
spatial organisation of the NSC sub-classes within the SVZ (Alvarez-Buylla and Lim, 2004). (D) H&E 
stain of the wild-type mouse SVZ depicting the spatial organisation of the NSC sub-classes. H&E image 
was taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 
40x objective and using the AnalySIS software package. E: ependymal cells, A: Type A neuroblasts, B: 
Type B astrocytes, C: Type C transient-amplifying progenitor cells, LV: lateral ventricles. .................... 24
Figure 4: A schematic representation of the (a) stochastic vs. (b) hierarchical model of tumourigenesis 
(adapted from (Vescovi et al., 2006). The stochastic model proposes that all tumour cells can sustain the 
growth of a tumour whereas the hierarchical model proposes that only a small subset of tumour cells 
possess this ability. ..................................................................................................................................... 27
Figure 5: Schematic representation of the cancer stem cell hypothesis. According to the hierarchical 
model, only a small subset of tumour cells has the ability, as cancer stem cells, to drive tumour 
repopulation following surgical resection and chemo/radiotherapy. The phenotype of the repopulated 
tumour does not always perfectly recapitulate that of the original tumour. ............................................... 28
Figure 6: Generation of knock-out mice. Embryonic stem (ES) cells are derived from the blastocyst inner 
cell mass and expanded in vitro. The required genetic material (gene) is then introduced into the ES cells, 
along with the neomycin resistance gene (NeoR), by homologous recombination. The in vitro culture is 
then treated with neomycin to positively select those ES cells containing the required genetic material, 
which are then transplanted back into the inner cell mass of a blastocyst. This blastocyst is then implanted 
in a surrogate mother who produces chimaeric (mice that developed from both genetically manipulated 
and normal ES cells) offspring. These chimaeras are then crossed against one another to achieve germline 
transmission so that the artificially inserted genetic material is expressed by all cells of the body (used 
with permission from Pedro Cuadrado). .................................................................................................... 43
Figure 7: Cre-mediated recombination of the stop codon in between the LoxP sites results in the 
expression 	£ @	=**		
		
	-galactosidase staining. ................................................... 46
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Figure 8: Schematic of the experimental procedure used to achieve in vivo recombination of the TSGs. 
I.c.v. administration of Adenovirus-Cre targets SVZ cells for LoxP site recombination and subsequent 
TSG loss. .................................................................................................................................................... 47
Figure 9: Schematic of the experimental procedure used for the derivation and generation of in vitro 
recombined NSCs and astrocytes. NSCs (A) and astrocytes (B) are derived from the SVZ or cortices, 
respectively of mice and grown in vitro. Prior to splitting for passage two these cells are separated into 
three treatment groups: untreated, Adenovirus-GFP-infected (control), and Adenovirus-Cre-recombined 
(experimental). They are then further expanded to allow for functional characterisation and testing of their 
tumourigenicity through intracerebral engraftment. ................................................................................... 48
Figure 10: R26R mice given an intra-cerebroventricular (i.c.v.) injection of Adenovirus-Cre exhibit a 
reproducible pattern of recombination in the 4-5 cell thick periventricular layer that includes the SVZ and 
ependymal layer (A,B). These cells include NS-			#	
	*	-galactosidase-
positivity (D). An equivalent population of cells was targeted in control wild-type mice injected with 
Adenovirus-GFP (C) (adapted from (Jacques et al., 2010). ....................................................................... 49
Figure 11: The GFP-expression of infected SVZ cells was observed to co-localise with GFAP (A,C) and 
nestin (B,D), suggesting that Adenovirus infection targets the NSCs of the SVZ (adapted from (Jacques et 
al., 2010). Representative images of R26R wild-type SVZ 7 days post-i.c.v. Adenovirus-GFP 
administration immunofluorescently stained for  GFP and GFAP (A-C) or nestin (B,D) with a Hoechst 
33342 (DAPI) counterstain. Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 
546nm. Images were taken using a 10x objective on a Zeiss LSM510 META confocal laser scanning 
microscope with the LSM software. ........................................................................................................... 50
Figure 12: In vivo recombination of NSCs induces tumour formation. The development of 
microneoplasias were observed in the RbLox/Lox; p53Lox/Lox (A), RbLox/Lox; p53Lox/Lox; PTENLox/Lox (B), and 
PTENLox/Lox; p53Lox/Lox (C) genotypes at 112, 104, and 126 days post i.c.v. Adenovirus-Cre administration 
respectively. Fully developed large intrinsic tumours were observed to develop in the same genotypes 
(D,E,F) at 194, 182, and 209 days respectively, with means of 190, 95, and 210 (S). In the case of the 
RbLox/Lox; p53Lox/Lox genotype the tumour appeared to clinically resemble that of a PNET (G,J,M,P), this 
was also the case for the RbLox/Lox; p53Lox/Lox; PTENLox/Lox genotype (H,K,N,Q). However, the 
PTENLox/Lox; p53Lox/Lox genotype appeared to give rise to a glioma-like tumour (I,L,O,R) (adapted from 
(Jacques et al., 2010). ................................................................................................................................. 52
Figure 13: In vivo inactivation of TSGs results in the development of small neoplastic lesions in the SVZ 
prior to tumour formation. The location of precursor lesions from 14x Rb-/-; p53-/-, 6x Rb-/-; p53-/-; PTEN-/-
, and 14x PTEN-/-; p53-/- were identified using haematoxylin and eosin paraffin immunohistochemistry 
and schematically plotted to verify their origin. ......................................................................................... 54
Figure 14: In vitro recombined and engrafted NS generate tumours. As with i.c.v. Adenvirus-Cre 
administration, in vitro recombined Rb-/-; p53-/-; PTEN-/- NS were observed to generate synaptophysin-
positive (G) and GFAP-negative (I) PNET-like tumours (A,C,E) whereas the PTEN-/-; p53-/- NS were 
observed to generate synaptophysin-negative (H) and GFAP-positive (J) glioma-like tumours (B,D,F) 
(adapted from (Jacques et al., 2010). .......................................................................................................... 55
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Figure 15: Bregma coordinates of the brain region microdissected for lateral ventricle acquisition. ........ 62
Figure 16: Coronal schematic showing the two lateral SVZ-containing lateral ventricle regions (yellow) 
targeted for microdissection. Black line: first plane used to trim tissue, dashed red line: second plane used 
to trim tissue, green lines: third planes used to trim tissue. ........................................................................ 62
Figure 17: 95% of NSCs used for single cell sorting (self-renewal assay) were viable. Representative 
DAPI fluorescence (y-axis) vs. side scatter (x-axis) FACS plot of a NSC sample used for single cell 
sorting into individual wells of a 96-well plate using a MoFlo XDP FACS machine. ............................... 68
Figure 18: Schematic representation of the primary and secondary phases of the self-renewal assay 
protocol. ..................................................................................................................................................... 69
Figure 19: All samples that passed the NanoDrop purity test were found to have high quality non-
degraded rRNA. (A) Representative BioAnalyzer electropherogram of a total RNA sample taken from in 
vitro neurospheres showing well-defined sharp peaks for both the 18S and 28S ribosomal RNA. (B) 
Sharp pseudo-agarose gel electrophoresis bands demonstrate minimal degradation. ................................ 71
Figure 20: Two-step cycling program used to run the Mouse Cancer PathwayFinder RT2 Profiler PCR 
Superarray on the ABI 7500 FAST Real-Time PCR System. .................................................................... 72
	[	*			
	-galactosidase-positive R26R NS increases over serial 
passages in vitro. (A) Each line (with their associated linear trendlines) on the graph represents an 
independent experiment in which NSCs (grown as NS) were derived from the brains of ROSA26RLox/Lox 
reporter mice 7 days post i.c.v. Adenovirus-Cre administration and grown as NS in vitro. The percentage 
of recombined NS was calculated at passa	?@	@	[@			
	=		-galactosidase staining and 
counting the positive NS. (B) Representative serial images taken at passages 0, 1, 2, and 3 for experiment 
	]	$					*			
	-galactosidase-positive R26R NS. 
The percentages given were generated from an average count taken from three randomly selected fields of 
vision captured through a 10x objective on a Zeiss Axiovert 200 microscope. ......................................... 85
Figure 22: Table of the data generated from the three separate self-renewal assays conducted on SVZ 
cells, grown as NS in vitro, derived from the brains of ROSA26RLox/Lox control mice (R26R) four days 
post-i.c.v. Adenovirus-Cre administration. ................................................................................................ 87
Figure 23: I.c.v. Adenovirus-Cre administration targets self-renewing and multipotent SVZ NSCs that can 
be propagated in vitro. (A) Representative image series taken of the same NSC/NS over 9 days showing 
the monoclonal self-renewal ability of a single in vivo recombined NSC as it develops into a NS in vitro. 
*	-galactosidase-positive stain at day 9 (Day 9, LacZ) demonstrates that Adenovirus-Cre 
administration targets these self-renewing SVZ NSCs. (B) Monoclonal NS generated from the self-
renewal assay were allowed to differentiate on glass slides for 3 days before their cells were examined for 
markers of NSCs (Nestin: C), astrocytes (GFAP: D), neurons (MAP2: E), and oligodendrocytes (O4: F). 
{	*	[		<@	-	-galactosidase. Blue: excitation at 405nm, green: excitation 
at 488nm, red: excitation at 546nm. Images were taken using a 63x objective with oil immersion on a 
Zeiss Axioplan 2 microscope and captured using a mounted AxioCam MRm camera and the Axiovision 
software. ..................................................................................................................................................... 88
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Figure 24: The growth rates of in vitro recombined Rb-/-; p53-/- ; PTEN-/-, Rb-/-; PTEN-/-, and PTEN-/-; p53-
/- NSCs (grown as NS) at passage 3 are significantly higher than that of non-recombined Adenovirus-
GFP-infected NSCs. The growth rates of the Rb-/-; p53-/- NSCs and the single TSG knock-out Rb-/-, p53-/-, 
and PTEN-/- NSCs are not different to those of both the non-recombined-untreated and Adenovirus-GFP-
infected control NSC groups. Using the WST-1 assay the growth rate (y-axis) of NSCs (growing as NS) 
was measured at 0, 2, 4, and 8hrs (x-axis) after a 3 day incubation period. Growth rate of in vitro 
recombined Rb-/-; p53-/-; PTEN-/- (blue: n=3; 4.31 +/- 0.20; 8hrs) vs. Rb-/-; PTEN-/- (purple: n=3; 3.37 +/- 
0.17; 8hrs) vs. PTEN-/-; p53-/- (red: n=3; 3.30 +/- 0.77; 8hrs) vs. Rb-/-; p53-/- (orange: n=3; 0.40 +/- 0.07; 
8hrs) vs. Rb-/- (grey: n=2; 0.10 +/- 0.02; 8hrs) vs. p53-/- (grey: n=2; 0.28 +/- 0.03; 8hrs) vs. PTEN-/- (grey: 
n=2; 0.10 +/- 0.003; 8hrs) vs. non-recombined Adenovirus-GFP-infected (green: n=6; 0.14 +/- 0.05; 8hrs) 
vs. non-recombined untreated (grey: n=5) NSCs. Error bars: standard errors. ***: P<0.001 vs. GFP 
control at 8hrs (one-way ANOVA with Bonferroni’s multiple comparison correction). ........................... 89
Figure 25: The Rb-/-; p53-/-; PTEN-/- NSCs at passage 3 form significantly larger NS than the rest of the 
experimental genotypes, all of which form NS of the same size as the Adenovirus-GFP-infected control 
NSCs. NSCs were seeded into NS medium and left to grow as NS for eight days before their diameters 
were measured using a Zeiss Axiovert 135 microscope and the Openlab 5 software package. NS size of 
non-recombined untreated (grey: n=11) vs. non-recombined Adenovirus-GFP-infected (green: n=11; 
190.5 +/- 10.0) vs. in vitro recombined PTEN-/-; p53-/- (red: n=3; 211.3 +/- 14.8) vs. Rb-/-; p53-/- (orange: 
n=4; 216.9 +/- 9.2) vs. Rb-/-; p53-/-; PTEN-/- (blue: n=3; 280.1 +/- 18.2) vs. Rb-/-; PTEN-/- (purple: n=4; 
208.2 +/- 11.7) vs. Rb-/- (grey: n=2; 187.5 +/- 7.0) vs. p53-/- (grey: n=2; 173.2 +/- 4.0) vs. PTEN-/- (grey: 
n=2; 187.3 +/- 3.2) NSCs. Error bars: standard errors. ***: P<0.001 vs. GFP control (one-way ANOVA 
with Bonferroni’s multiple comparison correction). .................................................................................. 91
Figure 26: All of the experimental NSC genotypes, with the exception of the Rb-/- and PTEN-/- NSCs, 
form significantly more NS at passage 3 than the Adenovirus-GFP-infected control NSCs. Interestingly, 
the p53-/- NSCs appear to form the most NS, but at a level that is not significantly more than the Rb-/-; 
p53-/- or Rb-/-; p53-/-; PTEN-/- NSCs. NSCs were seeded into NS medium and left to grow as NS for eight 
days before the number of NS formed was counted. NS size of non-recombined untreated (grey: n=6) vs. 
non-recombined Adenovirus-GFP-infected (green: n=6; 797.7 +/- 87.1) vs. in vitro recombined PTEN-/-; 
p53-/- (red: n=3; 1411.3 +/- 138.6) vs. Rb-/-; p53-/- (orange: n=4; 1750.5 +/- 70.1) vs. Rb-/-; p53-/-; PTEN-/- 
(blue: n=3; 1617.3 +/- 127.2) vs. Rb-/-; PTEN-/- (purple: n=3; 1556.8 +/- 131.2) vs. Rb-/- (grey: n=2; 
1001.1 +/- 134.0) vs. p53-/- (grey: n=2; 1793.4 +/- 28.5) vs. PTEN-/- (grey: n=2; 822.5 +/- 57.2) NSCs. 
Error bars: standard errors. *: P<0.05 vs. GFP control, **: P<0.01 vs. GFP control, ***: P<0.001 vs. GFP 
control (one-way ANOVA with Bonferroni’s multiple comparison correction). ....................................... 92
Figure 27: All genotypes, with the exception of the Rb-/- and PTEN-/- NSCs, have a significantly increased 
self-renewal ability at passages 3 and 4 compared to the Adenovirus-GFP-infected control NSCs. 
Interestingly, increase in self-renewal appears to be an additive result of additional TSG loss, with the 
exception that the p53-/- NSCs possess a significantly elevated self-renewal ability. NS at passage 2 were 
dissociated into single NSCs and individually seeded, using a MoFlo XDP FACS machine, into single 
wells of a 96-well plate containing 200μl NS medium and left to grow for nine days before the number of 
NS formed was counted and interpreted as the primary self-renewal ability. The process was then 
repeated for a selection of these monoclonal NS, chosen at random, to assess the secondary self-renewal 
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ability. Primary/secondary self-renewal of non-recombined Adenovirus-GFP-infected (green: n=2) vs. in 
vitro recombined Rb-/- (grey: n=2) vs. p53-/- (grey: n=2) vs. PTEN-/- (grey: n=2) vs. Rb-/-; p53-/- (orange: 
n=2) vs. PTEN-/-; p53-/- (red: n=2) vs. Rb-/-; PTEN-/- (purple: n=2) vs. Rb-/-; p53-/-; PTEN-/- (blue: n=2) 
NSCs. Primary self-renewal is shown as the solid bars and secondary self-renewal is shown as the paler-
coloured bars on top of the primary self-renewal bars. Error bars: standard errors. *: P<0.05 vs. GFP 
control, **: P<0.01 vs. GFP control, ***: P<0.001 vs. GFP control (one-way repeated measures ANOVA 
with Bonferroni’s multiple comparison correction). .................................................................................. 95
Figure 28:  Summary table of the correlation statistical analyses between the hit rate (in vivo tumour 
incidence), latency (in vivo tumour latency), WST-1 (growth assay), NS size (growth assay), and self-
renewal data sets for the non-recombined Adenovirus-GFP-infected control, Rb-/-; p53-/-, PTEN-/-; p53-/-, 
Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NSCs. Linear regression was used to determine the goodness of 
the fit (R2), and a two-tailed Pearson’s correlation test was used to measure the level of correlation (*: 
P<0.05, ***: P<0.001). .............................................................................................................................. 97
Figure 29: Only the PNET-generating Rb-/-; p53-/- NS showed an expression profile different from all 
other in vitro recombined NS genotypes and controls. Representative images taken from cytoblocks of 
Adenovirus-Cre-infected control RosaLox/Lox (A1-A12) vs. Rb-/-; p53-/- (B1-B12), PTEN-/-; p53-/- (C1-
C12), Rb-/-; PTEN-/- (D1-D12), and Rb-/-; p53-/-; PTEN-/- (E1-E12) NS stained for haematoxylin-eosin, 
{@	@	-galactosidase, phospho-Histone H3, Sox-2, Sox-9, MAP2, synaptophysin, and NeuN, 
Olig2, and EGFR. Images were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 
2 MOT microscope with a 5x magnification and using the AnalySIS software package. ......................... 99
Figure 30: The expression of differentiation biomarkers varies significantly, and in a genotype-dependent 
manner, following in vitro inactivation of the TSGs Rb, p53, and PTEN. Representative images of 
PTENLox/Lox; p53Lox/Lox non-recombined untreated control (A,F,K) vs.  Rb-/-; p53-/- (B,G,L) vs. PTEN-/-; 
p53-/- (C,H,M) vs. Rb-/-; PTEN-/- (D,I,N) vs. Rb-/-; p53-/-; PTEN-/- (E,J,O) NS that were left to differentiate 
on laminin-coated glass coverslips for 5 days before being fixed and immunofluorescently dual-stained 
for GFAP and CD133 (A-E), Sox-2 and Nestin (F-$@	{[		-tubulin (K-O), and Hoechst 33342 
(DAPI: A-O). Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 546nm. Images 
were taken using a 20x objective on a Zeiss LSM510 META confocal laser scanning microscope with the 
LSM software. .......................................................................................................................................... 101
Figure 31: Table of results of the counts (n=3), their averages, and the expression intensities recorded for 
all the differentiation biomarkers across all the different genotypes. ....................................................... 103
Figure 32: The expression of the biomarkers GFAP, CD133, Sox-2, and Nestin are significantly altered, 
in a genotype-dependent manner, following in vitro inactivation of the TSGs Rb, p53, and PTEN in 
differentiated neurospheres when compared against non-recombined untreated controls. The expression of 
{[		-tubulin was respectively ubiquitous and absent across all the genotypes, and the Rb-/-; 
PTEN-/- glioblastoma-generating NS exhibits the most altered / unique expression profile when compared 
against the other in vitro recombined NS genotypes. Percentage of cells expressing the differentiation 
biomarkers GFAP, CD133, Sox-[@	!@	{[@		-tubulin from PTENLox/Lox; p53Lox/Lox non-
recombined untreated control vs. Rb-/-; p53-/- vs. PTEN-/-; p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- 
NS that were left to differentiate on laminin-coated glass coverslips for 5 days before being fixed and 
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immunofluorescently stained. Error bars: standard errors. *: P<0.05 vs. non-recombined untreated 
control, **: P<0.01 vs. control, ***: P<0.001 vs. control (two-way ANOVA with Bonferroni’s multiple 
comparison correction). ............................................................................................................................ 104
Figure 33: The qualitative expression intensities of the differentiation biomarkers GFAP, CD133, Sox-2, 
Nestin, and MAP2 following in vitro inactivation of the TSGs Rb, p53, and PTEN correlate with the 
changes in the number of respective biomarker-expressing cells when compared against non-recombined 
untreated controls. Matrix of the expression intensity changes observed across the in vitro recombined Rb-
/-; p53-/-, PTEN-/-; p53-/-, Rb-/-; PTEN-/-, and Rb-/-; p53-/-; PTEN-/- NS when compared against the 
PTENLox/Lox; p53Lox/Lox non-recombined untreated control. Red up-arrow: increased expression intensity, 
double red up-arrow: vastly increased expression intensity, blue down-arrow: decreased expression 
intensity, green dash: no change, grey dash: no expression observed. ..................................................... 106
Figure 34: Average mRNA expression fold changes (2(average )) and associated P-values for the full 
set of 84 experimental genes (and 5 additional housekeeping control genes: given at the bottom) 
examined. For each genotype the left-hand column represents the mRNA fold change and the right-hand 
column represents the P-value. Gene (symbol) column colour key - orange: upregulated in all genotypes, 
red: upregulated in three genotypes, olive: upregulated in two genotypes, yellow: downregulated in three 
genotypes, green: single genotype differential expression. Fold change column colour key – blue font: 
<0.33, red font: >2. P-value column colour key – red font: P<0.05. Genotype fold change and P-value 
dual column colour key – highlighted blue box: dual-significant downregulation, highlighted orange box: 
dual-significant upregulation. ................................................................................................................... 108
Figure 35: Differentially expressed gene 'hit list'. For each genotype the left-hand coloum represents the 
mRNA fold change and the right-hand column represents the P-value. Gene (symbol) column colour key 
- orange: upregulated in all genotypes, red: upregulated in three genotypes, olive: upregulated in two 
genotypes, green: single genotype differential expression. Fold change column colour key – blue font: 
<0.33, red font: >2. P-value column colour key – red font: P<0.05. Genotype fold change and P-value 
dual column colour key – highlighted blue box: dual-significant downregulation, highlighted orange box: 
dual-significant upregulation. ................................................................................................................... 109
Figure 36: SVZ cells targeted for inactivation of the TSGs Rb, p53 and PTEN proliferate and migrate 
away from the SVZ into the brain parenchyma where they generate tumours. Representative images of a 
RbLox/Lox; p53Lox/Lox; PTENLox/Lox mouse 60 days post-i.c.v. Adenovirus-Cre administration 
				-galactosidase and GFAP with a Hoechst 33342 (DAPI) counterstain 
(A,B). Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 546nm. Images were 
taken using a 10x (inset: 20x) objective on a Zeiss LSM510 META confocal laser scanning microscope 
with the LSM software. Scale bar: 100μm (main images) or 50μm (inset). ............................................ 116
Figure 37: Summary table of the experimental details of all the mice that received intracerebral injections 
of in vitro recombined NS (#: experiment analysed, but not performed, by the reporter). ...................... 120
Figure 38: Summary of the experimental results (including ‘n’ number, mean tumour latency, hit rate, and 
predominant tumour phenotype) from the i.c.v. administration of Adenovirus-Cre in RbLox/Lox; p53Lox/Lox, 
PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, and RbLox/Lox; p53Lox/Lox; PTENLox/Lox mice and the 
intracerebral engraftment of in vitro recombined NS derived from the same mice. ................................ 121
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Figure 39: The genotype of the in vitro recombined NS determines the latency of tumour formation. Box 
and whiskers plot showing the mean tumour formation latency +/- 95% confidence intervals with min and 
max data points. *: P<0.05 vs. Rb-/-; p53-/- NS, **: P<0.005 vs. Rb-/-; p53-/- NS, ***: P<0.001 vs. Rb-/-; 
p53-/- NS, ###: P<0.001 vs. illustrated comparison (one-way ANOVA with Bonferroni’s multiple 
comparison correction). ............................................................................................................................ 122
Figure 40: The phenotype of intrinsic brain tumours generated following intracerebral engraftment of in 
vitro recombined neurospheres is dependent on the combination of TSGs inactivated. Representative 
images taken from tumours generated following intracerebral (in the striatum) engraftment of in vitro 
recombined Rb-/-; p53-/- (A,E,I,M), PTEN-/-; p53-/- (B,F,J,N), Rb-/-; PTEN-/- (C,G,K,O), and Rb-/-; p53-/-; 
PTEN-/- (D,H,L,P) NS. The tumours were stained for haematoxylin and eosin (A-D), GFAP (E-H), 
synaptophysin (I-L), and Olig2 (M-P) to assist in the classification of their phenotype. In the case of the 
Rb-/-; p53-/- NS tumour (A,E,I,M), the well-demarcated morphological appearance of the tumour was 
suggestive of PNET but the expression profile was counter-intuitively found to be GFAP-negative (E), 
synaptophysin-negative (I), and Olig2-positive (M). The Rb-/-; PTEN-/- NS-induced glioblastoma 
(C,G,K,O) was identified by palisading necrosis and vascular profileration (C, inset). Images were taken 
using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x 
magnification (40x for inset) and using the AnalySIS software package. ................................................ 123
Figure 41: Overview of the experimental procedure used to serially derive and engraft tumourspheres 
(TS). ......................................................................................................................................................... 125
Figure 42: Summary table of the experimental details of all the mice that received intracerebral injections 
of TS derived from a glioma generated by in vitro recombined and engrafted PTEN-/-; p53-/- NS. ......... 127
Figure 43: TS derived from a PTEN-/-; p53-/- NS-induced glioma recapitulate the phenotype when re-
grafted into the brains of recipient mice. Representative images taken from tumours identified as diffusely 
infiltrating gliomas generated following intracerebral engraftment of in vitro recombined PTEN-/-; p53-/- 
NS (A) and PTEN-/-; p53-/- TS (B) derived from a PTEN-/-; p53-/- NS-induced glioma. Images were taken 
using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x 
magnification and using the AnalySIS software package. ....................................................................... 128
Figure 44: Summary table of the experimental details of all the LoxP mutant mice that received i.c.v. 
Adenovirus-GFAP-Cre (#: experiment analysed, but not performed, by the reporter). ........................... 131
Figure 45: Summary of the experimental results (including ‘n’ number, mean tumour latency, hit rate, and 
predominant tumour phenotype) from the i.c.v. administration of Adenovirus-CMV-Cre and Adenovirus-
GFAP-Cre in RbLox/Lox; p53Lox/Lox, PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, and RbLox/Lox; p53Lox/Lox; 
PTENLox/Lox mice. ..................................................................................................................................... 132
Figure 46: Schematic overview of the model systems used to characterise NSCs targeted for tumourigenic 
recombination in their in vitro (middle schematic) and in vivo (bottom schematic) states. ..................... 134
Figure 47: The growth rates of passage three in vitro recombined Rb-/-; p53-/- NS, in vivo recombined 
RbLox/Lox; p53Lox/Lox NSCs derived and grown as NS in vitro at 2 weeks, 2 months and 4.5 months post-
i.c.v. Adenovirus-Cre administration, and non-recombined Adenovirus-GFP-infected are all statistically 
the same. Using the WST-1 assay the growth rate (y-axis) of NSCs (growing as NS) was measured at 0, 
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2, 4, and 8hrs (x-axis) after a 3 day incubation period. Growth rate of in vitro recombined Rb-/-; p53-/- 
(orange: n=3) vs. in vivo recombined RbLox/Lox; p53Lox/Lox NSCs derived and grown as NS in vitro at 2 
weeks, 2 months and 4.5 months post-i.c.v. Adenovirus-Cre administration (brown: n=2 each) vs. non-
recombined Adenovirus-GFP-infected (green: n=6) NS. Error bars: standard errors. No statistical 
difference observed between any of the NS growth rates at 8hrs (one-way ANOVA with Bonferroni’s 
multiple comparison correction). ............................................................................................................. 135
Figure 48: Illustration of the experimental paradigm used to evaluate the self-renewal ability of in vitro 
recombined Rb-/-; p53-/- NSCs vs. in vivo Adenovirus-Cre-recombined and derived in vitro (after 3 days) 
Rb-/-; p53-/- NSCs vs.  in vitro Adenovirus-GFAP-Cre-recombined Rb-/-; p53-/- NSCs vs. in vivo 
Adenovirus-GFAP-Cre-recombined and derived in vitro (after 3 days) Rb-/-; p53-/- NSCs. .................... 136
Figure 49: Only the in vitro recombined Rb-/-; p53-/- NSCs, regardless of the cell targeted, demonstrated a 
significantly increased primary self-renewal ability over the Adenovirus-GFP-infected control NSCs with 
significance achieved by all of the NSC groups at the secondary self-renewal phase. NS at passage 2 were 
dissociated into single NSCs and individually seeded, using a MoFlo XDP FACS machine, into single 
wells of a 96-well plate containing 200μl NS medium and left to grow for nine days before the number of 
NS formed was counted and interpreted as the primary self-renewal ability. The process was then 
repeated for a selection of these monoclonal NS, chosen at random, to assess the secondary self-renewal 
ability. Primary/secondary self-renewal of non-recombined Adenovirus-GFP-infected (green: n=2) vs. in 
vitro Adenovirus-Cre-recombined Rb-/-; p53-/- (orange: n=2) vs. in vivo Adenovirus-Cre-recombined and 
derived in vitro (after 3 days) Rb-/-; p53-/- NSCs (orange: n=2), in vitro Adenovirus-GFAP-Cre-
recombined Rb-/-; p53-/- NSCs (orange: n=2), and in vivo Adenovirus-GFAP-Cre-recombined and derived 
in vitro (after 3 days) Rb-/-; p53-/- NSCs (orange: n=2). Primary self-renewal is shown as the solid bars 
and secondary self-renewal is shown as the paler-coloured bars on top of the primary self-renewal bars. 
Error bars: standard errors. *: P<0.05 vs. GFP control, **: P<0.01 vs. GFP control, ***: P<0.001 vs. GFP 
control, #: P<0.05 between highlighted groups (one-way repeated measures ANOVA with Bonferroni’s 
multiple comparison correction). ............................................................................................................. 137
Figure 50: Summary table of the experimental details of all the mice that received intracerebral injections 
of in vivo recombined and derived in vitro NS (#: experiment analysed, but not performed, by the 
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Figure 51: Incidence plot of the tumours generated from the intracerebral engraftment of Rb-/-; p53-/-, Rb-/-
; PTEN-/-, PTEN-/-; p53-/- and Rb-/-; p53-/-; PTEN-/- NS recombined in vitro (circles) or in vivo and derived 
after 2 weeks (diamonds), 2 months (hexagons), and 4.5 months (triangles). Axis: tumour latency (days).
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Figure 52: Summary of the experimental results (including ‘n’ number, mean tumour latency, hit rate, and 
predominant tumour phenotype) from the i.c.v. administration of Adenovirus-CMV-Cre and Adenovirus-
GFAP-Cre in RbLox/Lox; p53Lox/Lox, PTENLox/Lox; p53Lox/Lox, RbLox/Lox; PTENLox/Lox, and RbLox/Lox; p53Lox/Lox; 
PTENLox/Lox mice in addition to the results from the intracerebral engraftment of in vitro recombined NS 
and in vivo recombined and derived in vitro NS derived from the same mice. ........................................ 143
Figure 53: In vivo recombined and derived in vitro after 2 weeks Rb-/-; p53-/- NS generate brain tumours 
with a significantly shorter latency following engraftment than when derived after >3.5 months. Mean 
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and standard error plot with all the data points showing the in vivo tumour latency. **: P<0.001 vs. 
illustrated comparison (one-way ANOVA with Bonferroni’s multiple comparison correction). ............ 145
Figure 54: In vivo recombined, derived in vitro and engrafted Rb-/-; p53-/- NS reproducibly generate a 
novel glioblastoma-like tumour with some undifferentiated neuronal characteristics, regardless of the time 
between in vivo recombination and derivation in vitro. Representative images taken from tumours 
generated following intracerebral (in the striatum) engraftment of in vivo recombined and derived in vitro 
after 2 weeks (A,C,E,G,I) or 2 months (B,D,F,H,J) Rb-/-; p53-/- NS. The tumours were stained for 
haematoxylin and eosin (A,B), GFAP (C,D), nestin (E,F), synaptophysin (G,H), and Olig2 (I,J) to assist 
in the classification of their phenotype. The tumours were often bi-phasic with some areas 
morphologically resembling a PNET (A, left side of image) but that were always synaptophysin-negative 
(G). Areas of GFAP-positivity (D, left side of image) were suggestive of a glial or astro/oligodendroglial 
phenotype but counter-intuitively those areas were Olig2-negative (J, left side of image). The nestin-
positivity of all the tumours (E,F) confirmed their undifferentiated state. Images were taken using a 
ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x magnification 
and using the AnalySIS software package. .............................................................................................. 147
Figure 55: CD133 is expressed by SVZ cells, including GFAP-positive type B NSCs, and also by cells 
targeted for Adenovirus-GFP-infection. Representative images of the RosaLox/Lox wild-type SVZ 5 days 
post-i.c.v. Adenovirus-GFP administration immunofluorescently stained for GFAP and CD133 (A,B), or 
GFP and CD133 (C,D) with a Hoechst 33342 (DAPI) counterstain. Blue: excitation at 405nm, green: 
excitation at 488nm, red: excitation at 546nm. Images were taken using a 20x objective on a Zeiss 
LSM510 META confocal laser scanning microscope with the LSM software. ....................................... 153
Figure 56: CD133 is expressed by both GFAP-positive/negative NS cells in vitro, with little 
immunofluorescent difference discernable between non-recombined RosaLox/Lox and in vitro recombined 
Rb-/-; p53-/-; PTEN-/- NS. (A,C) Representative images of RosaLox/Lox wild-type NS (passage 3) derived 5 
days post-i.c.v. Adenovirus-GFP administration immunofluorescently stained for GFAP and CD133. 
(B,D) Representative images of in vitro recombined Rb-/-; p53-/-; PTEN-/- NS (passage 4) 
immunofluorescently stained for GFAP and CD133. All images include a Hoechst 33342 (DAPI) 
counterstain. Blue: excitation at 405nm, green: excitation at 488nm, red: excitation at 546nm. Images 
were taken using a 40x objective under oil immersion on a Zeiss LSM510 META confocal laser scanning 
microscope with the LSM software. ......................................................................................................... 155
Figure 57: Schematic of the paradigm used for the MACSorting of non-recombined wild-type 
PTENLox/Lox; p53Lox/Lox NSCs into CD133- and CD133 + populations in vitro. PTENLox/Lox; p53Lox/Lox NS 
were split into single cells and labelled with mouse anti-CD133 magnetic MicroBeads and mouse anti-
Prominin-1-PE-conjugated antibody for MACSeparation and downstream FACS analysis respectively. 
The NSCs were run through a MACS column and the CD133-/+ fractions were eluted into two separate 
containers. The CD133+ fraction was sampled or added to NS medium and left for two passages. The 
CD133- fraction was re-labelled with anti-CD133 MicroBeads and run through a second MACS column 
for further purification before being sampled or added to NS medium and left for two passages. .......... 156
Figure 58: The level of CD133 expressed by MACSorted wild-type PTENLox/Lox; p53Lox/Lox NSCs returns 
to equilibrium after two passages in vitro. (A) The FACS side scatter vs. forward scatter gate of detection 
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was set to detect viable non-aggregated NSCs. An unlabelled and unsorted population of NSCs was used 
as the baseline control (B) against which the (C) labelled but unsorted, (D) MACSorted CD133- passage 
0, (E) MACSorted CD133+ passage 0, (F) MACSorted CD133- passage 2  (G) MACSorted CD133+ 
passage 2 NSC populations were shown to contain 2.5%, 2.2%, 47.9%, 8.28%, and 6.92% CD133+ cells 
respectively. Purple curve: unlabelled control, green curve: overlay of labelled fraction. ....................... 158
Figure 59: The expression level of CD133 RNA by MACSorted CD133- NSCs is seen to increase after 2 
passages in vitro. Reverse transcriptase-PCR of CD133 RNA expression in unsorted vs. CD133-ve (P0) 
vs. CD133-ve (P2) neurospheres. The unsorted control cells and the P0 MACSorted CD133- cells 
exhibited similar titration patterns and 1:25 dilution band visibility, thus mirroring the FACS analysis 
finding (2.5% unsorted vs. 2.2% P0). After two passages in vitro this level of CD133 RNA expression 
was seen to increase, as shown by the RNA band visibility in the 1:125 dilution, once again mirroring the 
FACS analysis finding of increased CD133 protein expression (8.28%). ................................................ 160
Figure 60: Schematic of the paradigm used for the MACSorting of tumourigenically transformed Rb-/-; 
p53-/-; PTEN-/- NSCs into CD133- and CD133 + populations in vitro. Rb-/-; p53-/-; PTEN-/- NS were split 
into single cells and labelled with mouse anti-CD133 magnetic MicroBeads and mouse anti-Prominin-1-
PE-conjugated antibody for MACSeparation and downstream FACS analysis respectively. The NSCs 
were run through a MACS column and the CD133-/+ fractions were eluted into two separate containers. 
The CD133+ fraction was sampled or added to NS medium and left for two passages. The CD133- 
fraction was re-labelled with anti-CD133 MicroBeads and run through a second MACS column for 
further purification, after which the secondary yield of CD133+ NSCs were added to the primary yield, 
before being sampled or added to NS medium and left for two passages. ............................................... 161
Figure 61: In vitro recombined and tumourigenic Rb-/-; p53-/-; PTEN-/- NSCs have an increased level of 
CD133 expression vs. wild-type NSCs which takes longer to equilibrate following MACSorting into 
CD133-/+ populations. FACS analysis showing the level of CD133 expression in Rb-/-; p53-/-; PTEN-/- 
NSCs prior to, and at zero, two, eight, and 11 passages after MACSorting. (A) The endogenous 
expression of CD133 in Rb-/-; p53-/-; PTEN-/- NSCs is 12%. Rb-/-; p53-/-; PTEN-/- NSCs were MACSorted 
into CD133- and CD133+ populations that respectively contained 0% and 25.1% at passage 0 (B) to 22% 
(C) and 57.3% (D) after two passages, 6% (E) and 28.2% (F) after eight passages, and 4.3% (G) and 10% 
(H) after 11 passages. (A,C-H) Purple curve: unlabelled control, green curve: overlay of labelled fraction. 
(B) Red curve: MACSorted CD133- P0 fraction, purple curve: underlay of labelled but unsorted fraction, 
green curve: underlay of MACSorted CD133+ P0 fraction. .................................................................... 163
Figure 62: The reduction of CD133 intensity observed from the CD133+ (P1 NS) band to the CD133+ 
(P7 NS) band mirrors the reduction in CD133 expression observed from the FACS-analysis shown in 
Figure 61 (percentage CD133+ expression given). Western blot for CD133 expression in the MACSorted 
CD133+ Rb-/-; p53-/-; PTEN-/- NSCs at one, seven, and eight passages post-sort. The CD133+ (P8 NSCs) 
band appears less intense than that of the P7 NS, from which they were derived, suggesting that NS-NSC 
dissociation reduces CD133 expression. The percentages associated with bands 1 and 2 are the respective 
proportions of CD133+ cells as measured in parallel by FACS . ............................................................. 164
Figure 63: Table of the corrected CD133 expression intensities for each of the Western blot MACSorted 
CD133+ fraction bands in Figure 62. The corrected CD133 band intensities support and confirm the 
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reduction in CD133 expression observed in the CD133+ population over serial passages, as originally 
shown in Figure 61 by FACS analysis. The net intensity was calculated as the sum of the background-
subtracted pixel intensity values within the band area defined. The corrected intensity was calculated as 
]!				!	-actin Intensity)*1000. ............................................................................... 165
Figure 64: An excess of cellular debris and a lack of distinct populations interferes with selecting a viable 
population gate and results in a skewed fluorescence plot. FACS plots illustrating the gate of detection set 
for MACSorting the Rb-/-; p53-/-; PTEN-/- NSCs. (A) The side-scatter (SSC-H) vs. forward-scatter (FSC-
H) FACS plot highlights the lack of distinct populations of cells within the sample being analysed, hence 
the difficult setting of a gate of detection which is likely to have included cellular debris. (B) This 
inclusion of this debris may adversely interact with the viable NSCs and/or the antibody to cause the 
fluorescence skew observed in the unsorted population. ......................................................................... 166
Figure 65: FACS analysis of CD133 expression in NSCs over serial passages following MACSorting for 
CD133-/+ shows that both populations of wild-type NSCs return to a CD133 expression equilibrium after 
two passages whereas in vitro recombined and tumourigenic Rb-/-; p53-/-; PTEN-/- NSCs take up to 11 
passages. A line plot of the percentage of NSCs expressing CD133 post-MACSorting (y-axis) over serial 
passages (x-axis). ..................................................................................................................................... 167
Figure 66: FACS analysis of CD133 expression in a repeat population of MACSorted CD133+ Rb-/-; p53-
/-; PTEN-/- NSCs shows that the observed CD133 expression equilibration is a reproducible effect (up to 
passage 4). A line plot of the percentage of NSCs expressing CD133 post-MACSorting (y-axis) over 
serial passages (x-axis). ............................................................................................................................ 168
Figure 67: CD133-/+ NSCs appear to have a reduced growth rate at 2 passages post-MACSorting which 
corrects back to the level exhibited by the unsorted controls after 4 passages. The difference observed 
between the CD133- and CD133+ NSC populations after 2 passages also disappears after 4 passages, 
suggesting a normalisation or equilibration. Using the WST-1 assay the growth rate (y-axis) of NSCs 
(growing as NS) was measured at 0, 2, 4, and 8hrs (x-axis) after a 3 day incubation period. Growth rate of 
in vitro recombined Rb-/-; p53-/-; PTEN-/- NSCs at 2 (block lines) and 4 (dotted lines) passages post-
MACSorting for CD133- (pink: n=2) / CD133+ (blue: n=2) vs. unsorted controls (dark blue: n=3) vs. 
non-recombined Adenovirus-GFP-infected controls (green: n=6). Error bars: standard errors. ***: 
P<0.001 vs. Rb-/-; p53-/-; PTEN-/- NSCs at 8hrs, #: P<0.05 (one-way ANOVA with Bonferroni’s multiple 
comparison correction). ............................................................................................................................ 170
Figure 68: MACSorted Rb-/-; p53-/-; PTEN-/- CD133-/+ NSCs appear to form smaller NS than their 
unsorted counterparts after 2 passages, but NS of the same size after 4 passages. The difference observed 
between the CD133- and CD133+ NSC populations after 2 passages also disappears after 4 passages, 
suggesting a normalisation or equilibration. NSCs were seeded into NS medium and left to grow as NS 
for eight days before their diameters were measured using an Axiovert 135 microscope (Zeiss) and the 
Openlab 5 software package. NS size of non-recombined Adenovirus-GFP-infected controls (green: 
n=11) vs. in vitro recombined unsorted Rb-/-; p53-/-; PTEN-/- NSC controls (dark blue: n=3) vs. Rb-/-; p53-/-
; PTEN-/- NSCs MACSorted for CD133- (pink: n=2) and CD133+ (blue: n=2) cells at passage 2 vs. Rb-/-; 
p53-/-; PTEN-/- NSCs MACSorted for CD133- (pale pink: n=2) and CD133+ (pale blue: n=2) cells at 
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passage 4. Error bars: standard errors. *: P<0.05 vs. GFP control, **: P<0.01 vs. GFP control (one-way 
ANOVA with Bonferroni’s multiple comparison correction). ................................................................. 171
Figure 69: MACSorting for CD133-/+ NSCs has no effect on the NS-forming ability of the cells as no 
significant difference can be observed between any of the CD133-/+ populations and the unsorted control. 
NSCs were seeded in medium and left to grow for eight days before the number of NS formed was 
counted. NS-forming ability of non-recombined Adenovirus-GFP-infected controls (green: n=6) vs. in 
vitro recombined unsorted Rb-/-; p53-/-; PTEN-/- NSC controls (dark blue: n=3) vs. Rb-/-; p53-/-; PTEN-/- 
NSCs MACSorted for CD133- (pink: n=2) and CD133+ (blue: n=2) cells at passage 2 vs. Rb-/-; p53-/-; 
PTEN-/- NSCs MACSorted for CD133- (pale pink: n=2) and CD133+ (pale blue: n=2) cells at passage 4. 
Error bars: standard errors. **: P<0.01 vs. GFP control (one-way ANOVA with Bonferroni’s multiple 
comparison correction). ............................................................................................................................ 172
Figure 70: FACSorting NSCs for CD133 achieves greater CD133-/+ isolate purities than MACSorting. 
FACS plots showing the CD133-/+ NSC purities achieved using MACSorting (A,B) and FACSorting 
(C,D). Side-scatter vs. forward-scatter FACS plot of the MACSorted (A) and FACSorted (C) NSCs 
showing the gated regions of detection. Fluorescence FACS plots of the CD133- (purple) and CD133+ 
(green) NSCs showing that the purities of the MACSorted (B) isolates are 87.2% and 82.9% respectively, 
whereas those of the FACSorted (D) are both >99%. .............................................................................. 174
Figure 71: Summary table of all the in vivo intracerebral grafting experiments performed with in vitro 
recombined Rb-/-; p53-/-; PTEN-/- NS/NSCs (controls) and MACS/FACSorted Rb-/-; p53-/-; PTEN-/- 
CD133- and CD133+ NSCs (#: micrograph taken of this tumour for the histology panel)……………..176 
Figure 72: Incidence plot of the tumours generated from the intracerebral engraftment of Rb-/-; p53-/-; 
PTEN-/- NS/NSCs vs. MACS/FACSorted CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs. Axis: tumour latency 
(days). ....................................................................................................................................................... 177
Figure 73: Intracerebral engraftment of unsorted control Rb-/-; p53-/-; PTEN-/- NSCs/NS results in the 
development of a wide range of tumour phenotypes (predominantly PNET + Glioma) with a high hit rate 
of 95.8% and a mean latency of 85 days. Immunohistochemical analysis of the intrinsic brain tumour 
profile following the intracerebral grafting of unsorted control Rb-/-; p53-/-; PTEN-/- NSCs/NS. 
Representative tumours were taken from the each of the PNET, Glioma, Oligodendroglioma,  PNET + 
Glioma, and Oligoastrocytoma phenotypes observed and stained for H&E (A-E), GFAP (F-J), 
synaptophysin (K-O), and olig2 (P-T). Images were taken using a ColorView III digital camera mounted 
on a Zeiss Axioskop 2 MOT microscope with a 10x objective and using the AnalySIS software package. 
Scale bar: 150m. ..................................................................................................................................... 180
Figure 74: Intracerebral engraftment of MACSorted CD133- Rb-/-; p53-/-; PTEN-/- NSCs results in the 
development of a variety of tumours (predominantly PNET + Glioma) with a mean latency of 79 days, 
both similar to that of the unsorted controls, but with a lower hit rate of 41.7%. Intracerebral engraftment 
of MACSorted CD133+ Rb-/-; p53-/-; PTEN-/- NSCs results in the development of solely gliomas with a 
vastly increased mean latency of 164 days and an equally low hit rate of 33.3%.  Immunohistochemical 
analysis of the brain tumour profile resulting from the intracerebral grafting of MACS/FACSorted 
CD133-/+ Rb-/-; p53-/-; PTEN-/- NSCs. Representative tumours were taken from the each of the PNET, 
PNET + Glioma, and Oligoastrocytoma phenotypes observed with the CD133- grafted NSCs, in addition 
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to the Glioma phenotype observed with the CD133+ grafted NSCs, and stained for H&E (A-E), GFAP 
(F-J), synaptophysin (K-N), and olig2 (O-R). Images were taken using a ColorView III digital camera 
mounted on a Zeiss Axioskop 2 MOT microscope with a 10x or 20x (insets) objective and using the 
{""	=	<`	"	
	\?X					?	X		` .......................... 182
Figure 75: In vitro CD133 protein expression of tumourigenic NS varies both within and between 
`		
			]_<$		-actin (42kDa) expression in PTEN-/-; p53-/- vs. Rb-/-; 
p53-/- vs. Rb-/-; PTEN-/- vs.Rb-/-; p53-/-; PTEN-/- NS (n=3 for each genotype), with associated passage 
numbers and the results of any corresponding in vivo engraftment studies. Two additional samples (NS 
grown from a PTEN-/-; p53-/- NS-induced glioma and NS derived from the brains of a cohort of RbLox/Lox; 
PTENLox/Lox mice six months after having had received an intracerebroventricular injection of Adeno-Cre) 
were included on the blot for preliminary comparison purposes. ............................................................ 183
Figure 76: Summary table of all the samples used to generate the western blot (Figure 75) along with their 
genotype, in vivo 		]	
$@	=			-actin intensities, corrected CD133 
intensities, and genotype group averages with standard errors. ............................................................... 184
Figure 77: There are no statistically significant differences in the levels of CD133 expressed by PTEN-/-; 
p53-/- vs. Rb-/-; p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS in vitro. A bar chart comparing the 
					]					-actin intensity, *1000) 
expressed (y-axis) by each of the four genotypes of tumourigenic NS in vitro (x-axis). Error bars: 
standard errors. No significance difference observed between any of the groups (one-way ANOVA with 
Bonferroni’s multiple comparison correction). ........................................................................................ 185
Figure 78: There appears to be a correlation between increased in vitro CD133 expression of NS and a 
propensity towards generating glial tumours in vivo, but no correlation between CD133 expression and 
tumour hit rate or latency. Each bubble represents a single in vivo grafting experiment encompassing a 
cohort of 6-13 mice with the phenotype given being the predominant tumour phenotype generated and 
plotted according to in vivo tumour latency (y-axis) vs. CD133 expression (x-axis) vs. in vivo tumour hit 
rate (z-axis: bubble size). ......................................................................................................................... 186
Figure 79: In vitro 					!"	#	
*	=*		
=	
`		
			][?<$		-actin (42kDa) expression in PTEN-/-; p53-/- vs. Rb-/-; 
p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS (n=3 for each genotype), with associated passage 
numbers and the results of any corresponding in vivo engraftment studies. Two additional samples (NS 
grown from a PTEN-/-; p53-/- NS-induced glioma and NS derived from the brains of a cohort of RbLox/Lox; 
PTENLox/Lox mice six months after having had received an intracerebroventricular injection of Adeno-Cre) 
were included on the blot for preliminary comparison purposes. ............................................................ 187
Figure 80: Summary table of all the samples used to generate the western blot given in Figure 79 along 
with their genotype, in vivo grafting data (if applicabl$@	=			-actin intensities, corrected 
	@				#	=*		` .................................................... 189
Figure 81: Only Rb-/-; PTEN-/- vs. Rb-/-; p53-/- NS in vitro have a statistically significant difference in the 
#			`	{	
	*		*						]	
				-actin intensity, *1000) expressed (y-axis) by each of the four genotypes of 
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tumourigenic NS (n=3 for each) in vitro (x-axis). Error bars: standard errors. *: P<0.05 (one-tailed paired 
Student’s t-Test). No significance difference observed between any of the groups using a one-way 
ANOVA with Bonferroni’s multiple comparison correction). ................................................................. 190
Figure 82: Expression of CD133 by in vitro recombined Rb-/-; p53-/-; PTEN-/- tumourigenic NS inversely 
	=*		expression. A scatter plot of CD133 expression (y-$				
(x-axis), for each of the four genotypes of tumourigenic NS (n=3 for each), in the form of corrected 
intensities as measured semi-quantitatively from Western blots run using the same samples in parallel. 
The data points from the different genotypes are colour coded in accordance with the key. The correlation 
coefficient of the two data sets (R2 = 0.4617) was significant (P<0.05). Linear regression was used to 
determine the goodness of the fit (R2), and a two-tailed Pearson test was used to measure the level of 
correlation (*: P<0.05). ............................................................................................................................ 191
Figure 83: No correlations were observed between in vitro 			!"		in vivo 
tumourigenicity (hit rate), in vivo tumour latency, or in vivo tumour phenotype. Each bubble represents a 
single in vivo grafting experiment encompassing a cohort of 6-13 mice with the phenotype given being 
the predominant tumour phenotype generated and plotted according to in vivo tumour latency (y-axis) vs. 
		]-axis) vs. in vivo tumour hit rate (z-axis: bubble size). ............................................ 192
Figure 84: In vitro CD133 protein expression of tumourigenic NS has a high degree of genotype-
independent variability but appears to be a predictor of glioblastoma development. Western blot of 
	]_<$		-actin (42kDa) expression in non-recombined Adenovirus-GFP-infected control 
vs. PTEN-/-; p53-/- vs. Rb-/-; p53-/- vs. Rb-/-; PTEN-/- vs. Rb-/-; p53-/-; PTEN-/- NS (n=2 for each genotype), 
with associated passage numbers and the results (hit rate and predominant tumour phenotype) of 
corresponding in vivo engraftment studies. .............................................................................................. 193
Figure 85: Summary table of all the samples used to generate the western blot (Figure 84) along with their 
genotype, in vivo 		]	
$@	=			-actin intensities, corrected CD133 
intensities, and genotype group averages with standard errors. ............................................................... 194
Figure 86: There are no statistically significant differences in the levels of CD133 expressed by non-
recombined Adenovirus-GFP-infected controls vs. PTEN-/-; p53-/- vs. Rb-/-; p53-/- vs. Rb-/-; PTEN-/- vs. Rb-
/-; p53-/-; PTEN-/- NS in vitro (n=2 for each genotype). A bar chart comparing the grouped corrected 
			]					-actin intensity, *1000) expressed (y-axis) by 
each of the five genotypes of tumourigenic NS in vitro (x-axis). Error bars: standard errors. No 
significance difference observed between any of the groups (one-way ANOVA with Bonferroni’s 
multiple comparison correction). ............................................................................................................. 195
Figure 87: CD133 is most strongly expressed in vitro by NS that generate glioblastoma (glioblastoma) 
tumours following intracerebral engraftment, but no correlation was observed between CD133 expression 
and tumour hit rate or latency. Each bubble represents a single in vivo grafting experiment encompassing 
a cohort of 6-13 mice with the phenotype given being the predominant tumour phenotype generated and 
plotted according to in vivo tumour latency (y-axis) vs. CD133 expression (x-axis) vs. in vivo tumour hit 
rate (z-axis: bubble size). The in vivo engraftment data for the Rb-/-; p53-/- NS is included for comparison 
purposes despite predominantly generating no tumours. ......................................................................... 197
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Figure 88: Mature astrocytes are targeted for infection by intracerebral Adenovirus-GFP administration. 
(A) Representative image showing the presence of both mature astrocytes (red) and Adenovirus-GFP 
infected cells (green). (B) Mature astrocytes can be targeted for Adenovirus-mediated recombination, as 
shown here by the colocalisation of the mature astrocytic marker GFAP with GFP at 7 days following 
intracerebral Adenovirus-GFP administration. DAPI: Hoechst nuclear staining, aGFP: GFP protein 
detected using an anti-GFP antibody, GFAP: glial fibrilliary acidic protein for the detection of mature 
astrocytes, aGFP + GFAP: colocalisation of aGFP + GFAP). Blue: excitation at 405nm, green: excitation 
at 488nm, red: excitation at 546nm. Images were taken using a 20x objective on a Zeiss Axioplan 2 
microscope and captured using a mounted AxioCam MRm camera and the Axiovision software. ......... 201
Figure 89: Ectopic injection of Adenovirus-Cre recombines grey and white matter astrocytes and 
hippocampal neurons in vivo`	^#			
	-galactosidase-positive astrocytes 
(A-C) and neurons (D) in the cortex + corpus callosum (A,C), striatum (B), and hippocampus (D) of 
RbLox/Lox; p53Lox/Lox (A), RbLox/Lox; p53Lox/Lox; PTENLox/Lox (B,C), and  PTENLox/Lox; p53Lox/Lox mice. CC: 
corpus callosum. Images were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 
MOT microscope with a 20x objective and using the AnalySIS software package. ................................ 202
Figure 90: The growth rates of in vitro recombined Rb-/-; p53-/-; PTEN-/-, PTEN-/-; p53-/-, Rb-/-, and p53-/- 
astrocytes at passage 3 are significantly higher than that of non-recombined Adenovirus-GFP-infected 
control astrocytes. The Rb-/-; p53-/-, Rb-/-; PTEN-/-, and PTEN-/- astrocytes also grew significantly faster 
than the Adenovirus-GFP-infected control astrocytes but to a lower degree than the other genotypes. 
There was no significant difference in growth between any of the experimental genotypes. Using the 
WST-1 assay the growth rate (y-axis) of astrocytes at passage 3 was measured at 0, 2, 4, and 8hrs (x-axis) 
after a 2 day incubation period. Growth rate of in vitro recombined Rb-/-; p53-/-; PTEN-/- (blue: n=3) vs. 
PTEN-/-; p53-/- (red: n=3) vs. Rb-/-; p53-/- (orange: n=3) vs. Rb-/-; PTEN-/- (purple: n=3) vs. Rb-/- (grey: 
n=2) vs. p53-/- (grey: n=2) vs. PTEN-/- (grey: n=2) vs. non-recombined untreated (grey: n=11) vs. non-
recombined Adenovirus-GFP-infected (green: n=8) astrocytes. Error bars: standard errors. *: P<0.05 vs. 
GFP control at 8hrs, ***: P<0.001 vs. GFP control at 8hrs (one-way ANOVA with Bonferroni’s multiple 
comparison correction). ............................................................................................................................ 204
Figure 91: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes appear to transform as shown by their loss 
of contact inhibition as they are observed to grow over the top of one another (A), and loss of adhesion 
dependence as they are observed to grow as free-floating NS-like aggregates when plated as a single cells 
(B). ........................................................................................................................................................... 206
Figure 92: The number of astrocytes expressing the differentiation biomarkers GFAP and nestin appears 
to reduce after in vitro recombination of the TSGs Rb, p53, and PTEN; suggestive of an altered 
phenotype. Representative images of RbLox/Lox; p53Lox/Lox; PTENLox/Lox non-recombined untreated control 
(A,D,G) vs.  Rb-/-; p53-/-; PTEN-/-  (B,E,H) vs. Rb-/- (C,F,I) astrocytes at passage three that were left to 
grow on laminin-coated glass coverslips for 5 days before being fixed and immunofluorescently dual-
stained for GFAP and nestin (A-C) with the individual GFAP (D-F) and nestin (G-I) stains also given. All 
cells were counterstained with Hoechst 33342 (DAPI). Blue: excitation at 405nm, green: excitation at 
488nm, red: excitation at 546nm. Images were taken Zeiss AxioCam MRm camera mounted on a Zeiss 
Axioplan 2 microscope using a 20x objective and the Axiovision software. ........................................... 207
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Figure 93: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes appear to an increased expression of Sox-
2, and in a greater number of cells, but a reduced expression of nestin and MAP2; suggestive of a de-
differentiated phenotype. Representative images taken from cytoblocks of non-recombined untreated 
RbLox/Lox; p53Lox/Lox; PTENLox/Lox (A-J) vs. Rb-/-; p53-/-; PTEN-/- (K-T) astrocytes stained for haematoxylin-
	]{@¡$@	{	]¢@£$@		]@$@	-galactosidase (D,N), phospho-Histone H3 (E,O), Sox-2 (F,P), 
Sox-9 (G,Q), MAP2 (H,R), synaptophysin (I,S), and NeuN (J,T). Images were taken using a ColorView 
III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x magnification and using 
the AnalySIS software package. ............................................................................................................... 209
Figure 94: Table outlining the parameters and results for all the in vitro recombined astrocytes engrafted 
into the brains of recipient mice. .............................................................................................................. 212
Figure 95: Schematic of the short-term astrocyte engraftment experiment indicating the number of Rb-/-; 
p53-/-; PTEN-/- astrocytes engrafted into the striata of 14 mice and the planned time culls (n=3 for each) at 
1, 2, 4, and 6 weeks post-engraftment (the 2 remaining mice were left for a long-term assessment). ..... 213
Figure 96: In vitro recombined and engrafted Rb-/-; p53-/-; PTEN-/- astrocytes do not give rise to tumours 
and degenerate by 4 weeks. Representative images taken from each time point showing that grafted 
astrocytes were detectable up to two weeks post-engraftment (A,B). After 1 week the grafted astrocytes 
=	**	#		¢¥	]$		-galactosidase (G). However, by 2 weeks there was a decrease in 
the number of proliferating grafted astrocytes as shown by the combined reduced number of BrdU (E) 
	-galactosidase (H) positive cells. By four weeks the grafted astrocytes had been completely cleared 
from the area (C, F, I). Images were taken using a ColorView III digital camera mounted on a Zeiss 
Axioskop 2 MOT microscope with a 2.5x magnification (A-C) or a 6.3x magnification (D-I) and using 
the AnalySIS software package. Scale bar: A-C, 700m and D-I, 275m. ............................................. 214
Figure 97: Schematic of the astrocyte engraftment experiment indicating number of Rb-/-; p53-/-; PTEN-/- 
astrocytes engrafted into the striata of 11 nude mice and the planned time culls at 2 (n=3) and 4 weeks 
(n=3) post-engraftment, with the remaining 5 mice left for long-term assessment. ................................. 215
Figure 98: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into the striata of nude mice do 
not give rise to tumours but are observed to persist as non-proliferating cells after 5 weeks. Representative 
images taken from each time point showing that grafted astrocytes were detectable up to five weeks post-
engraftment (A-$`	{	[	=<	*			=	#		¢¥	]$		-galactosidase 
(G). By 4 and 5 weeks there was a decrease in the number of proliferating transplanted astrocytes as 
shown by the reduced number of BrdU-positive cells (E,F). These grafted astrocytes, although not 
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#				-galactosidase-positive cells (I). 
Images were taken using a ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT 
microscope with a 2.5x magnification (A-C) or a 6.3x magnification (D-I) and using the AnalySIS 
software package. Scale bar: A-C, 700m and D-I, 275m. .................................................................... 216
Figure 99: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into nude mice can give rise to 
			*	<		[	=<`	-galactosidase-positive grafted astrocytes (C) were observed 
to generate a highly proliferating (B) extrinsic tumour mass (A). Images were taken using a ColorView III 
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digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 1.6x magnification (A) or a 2.5x 
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Figure 100: In vitro recombined Rb-/-; p53-/-; PTEN-/- astrocytes engrafted into the brains of nude mice can 
give rise to large spindle cell tumours within the skull after 2 weeks. Images were taken using a 
ColorView III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 10x magnification 
and using the AnalySIS software package. Scale bar: 175m. ............................................................... 218
Figure 101: In vitro recombined Rb-/-; p53-/- astrocytes grown as astrospheres exhibit a growth rate similar 
to their adherently grown astrocytic counterparts but form astrospheres of a similar size and number to 
their neurosphere counterparts. (A) WST-1 assay:  Astrospheres were dissociated at passage two and the 
single cells were seeded at 6x104 cells/well into a 96-well plate containing NS medium and the 
proliferative index (y-axis) was measured at 0, 2, 4, and 8hrs (x-axis) after a 3 day incubation period. (B) 
NS/astrosphere size assay: Astrospheres were dissociated at passage two and the single cells were seeded 
at 0.5x106 cells/well into a 6-well plate containing NS medium and left to grow as astrospheres for eight 
days before their diameters were measured using a Zeiss Axiovert 135 microscope and the Openlab 5 
software package. (C) NS/astrosphere-forming clonogenicity assay: Astrospheres were dissociated at 
passage two and the single cells were seeded at 0.5x106 cells/well into a 6-well plate containing NS 
medium and left to grow as astrospheres for eight days before the number of astrospheres formed were 
counted. Cell genotypes and ‘n’ numbers supplied on graphs. Error bars: standard errors. ..................... 219
Figure 102: Schematic of the astrosphere engraftment experiment whereby Rb-/-; p53-/- astrospheres were 
engrafted into the striata of 5 immune-competent mice with time-culls planned at 11 days (n=3) and 2 
months (n=2) post-engraftment. ............................................................................................................... 220
Figure 103: In vitro recombined Rb-/-; p53-/- astrospheres engrafted into the striata of immune-competent 
mice do not give rise to tumours and are cleared by 2 months. Representative images taken from each 
time point showing that grafted astrospheres were detectable up to 11 days post-engraftment (A-D) but 
had been cleared by 2 months (E-$`	{			*	-galactosidase-positive grafted astrospheres (B) 
were still viable in the graft site (C: black arrows) and were GFAP-negative (D). By 2 months there was 
no evidence of any viable grafted astrospheres (E-G) despite verification of a successful graft as shown 
by the reactive astrocytosis circumventing the injection tract (H). Images were taken using a ColorView 
III digital camera mounted on a Zeiss Axioskop 2 MOT microscope with a 2.5x magnification (A-C) or a 
6.3x magnification (D-I) and using the AnalySIS software package. Scale bar: A-@	_??X		-I, 
[_\X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Figure 104: Environment-dependent tumourigenesis. This schematic of the results depicted in Figure 52 
illustrates the influence NSC environment at the time of tumour suppressor gene inactivation has on the 
ability of NSCs to initiate tumour development. Arrow thickness indicates in vivo tumour hit rate. Blue 
arrows: tumour development from i.c.v. Adenovirus-Cre-mediated in vivo recombination of the indicated 
genotype. Green arrows: tumour development from in vitro recombined and engrafted NSCs of the 
indicated genotype. Orange arrows: tumour development from in vivo recombined, derived in vitro and 
engrafted NSCs of the indicated genotype. .............................................................................................. 234
 
